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SUMMARY

At the requests of the Belmont Department of Health, community residents, and in response to a 
legislative directive, the Community Assessment Program (CAP) of the Massachusetts 
Department of Public Health (MDPH), Bureau of Environmental Health conducted an evaluation 
of possible environmental exposures and cancer in relation to the Cambridge Plating Company, 
an active electroplating facility which has been in operation at 39 Hittinger Street in Belmont, 
Massachusetts since 1968. This project was conducted under a cooperative agreement with the 
Agency for Toxic Substances and Disease Registry (ATSDR) for MDPH to conduct health 
assessments in Massachusetts. 
The investigation reviews available environmental data for the Cambridge Plating site and 
considers potential ways that people may come into contact with chemicals from the facility.  
The evaluation also looks at the pattern of cancer in Belmont and surrounding communities, 
focusing on residential neighborhoods near Cambridge Plating.  Six cancer types were evaluated 
in this investigation: cancers of the kidney, liver, lung and bronchus, and pancreas as well as 
leukemia and non-Hodgkin’s lymphoma (NHL).  Using data from the Massachusetts Cancer 
Registry, rates for these cancer types were calculated for the town of Belmont as a whole and for 
the census tracts (CT) that comprise the town, with a particular focus on CT 3572, where 
Cambridge Plating is located, and the adjacent CT 3571.  In addition, this report provides cancer 
incidence analyses for the surrounding communities of Arlington, Cambridge, and Watertown.  
Appendix A of the report presents more detailed information about the occurrence of cancer in 
all four communities as well as in relation to other locations of potential environmental concern.  
Available information about risk factors related to the development of cancer was also 
considered. In general, most of the six cancer types evaluated in relation to Cambridge Plating 
occurred near or below the rates expected for Belmont CTs 3571, 3572, and the town of Belmont 
as a whole during the 18-year time period, 1982–1999.  With some exceptions, cancer incidence 
in the surrounding communities of Arlington, Cambridge, and Watertown was also near or below 
expected rates. 
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A number of potential exposure pathways exist, in particular potential exposure to historical air 
emissions from Cambridge Plating.  Contaminants of potential concern at the facility include 
past emissions of trichloroethylene (TCE) and chromium.  No ambient air sampling data are 
available, however, to determine whether air emissions from the facility have existed in the 
surrounding neighborhoods and/or the extent to which they might have contributed to cancer or 
noncancer health effects reported by residents in this area.  It is possible that some neighborhood 
residents have experienced irritant health effects associated with air emissions from the facility.  
However, it is important to note that some individuals, particularly those with pre-existing 
conditions such as asthma and allergies, may experience irritant reactions that would not 
necessarily impact the general population similarly.  There were no completed exposure 
pathways for area residents in relation to Cambridge Plating. 
Sampling conducted previously at the Cambridge Plating site identified some contamination of 
groundwater and subsurface soil on the site.  No available information suggests that 
contaminants such as volatile organic compounds (VOCs), polycyclic aromatic hydrocarbons, 
and metals detected at levels above health-based comparison values in groundwater and soil pose 
a health threat to individuals living in neighborhoods adjacent to the facility under present 
conditions. For example, the groundwater beneath the site is not a source of drinking water, and 
it is unlikely that residents would come into contact with subsurface soil on the property since 
the majority of the site is paved.  Based on the available environmental data reviewed, 
concentrations of VOCs detected in groundwater samples collected down-gradient and close to 
the site boundary near Hittinger Street are below levels expected to result in indoor air impacts in 
nearby homes. Based on recent site investigations, including additional characterization of 
groundwater conditions and flow patterns, it is not expected that residents north of the site along 
Channing Road would have opportunities for exposure to levels of VOCs in indoor air that could 
present a health risk. 
Based on criteria established by ATSDR, the Cambridge Plating site would be classified as 
posing an Indeterminate Public Health Hazard in the past and No Apparent Public Health Hazard 
in the present and future. No ambient air sampling data exist; therefore, it cannot be determined 
whether people living near the Cambridge Plating site were at risk of exposure to air emissions 
(such as TCE or chromium) from the facility in the past.  However, based on a review of 
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available environmental data, analysis of possible exposure pathways, and an evaluation of the 
pattern of cancer in the area surrounding the facility, results do not suggest that a common factor 
(environmental or nonenvironmental) played a major role in the incidence of cancer in Belmont 
census tracts 3571 and 3572, in the town of Belmont as a whole, or in the surrounding 
communities during the 18-year time period, 1982–1999. 
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 I. INTRODUCTION AND STATEMENT OF ISSUES 
At the request of the Belmont Department of Health, community residents, and in response to a 
legislative directive, the Community Assessment Program (CAP) in the Bureau of 
Environmental Health of the Massachusetts Department of Public Health (MDPH), conducted an 
evaluation of cancer incidence in Belmont, Massachusetts, and the surrounding communities of 
Cambridge, Arlington, and Watertown.  This project was conducted under a cooperative 
agreement with the Agency for Toxic Substances and Disease Registry (ATSDR) for MDPH to 
conduct health assessments in Massachusetts.  This evaluation was initiated because of 
community concerns about possible environmental exposure and cancer in relation to the 
Cambridge Plating Company, an electroplating facility located at 39 Hittinger Street in Belmont.  
The facility has been in operation since 1968 and has been known by a variety of names during 
its history; the current electroplating operation at the site is Purecoat North, LLC.  For the 
purposes of this report, however, all electroplating operations at 39 Hittinger Street will be 
referred to as Cambridge Plating. 
This report evaluates the potential for exposure related to chemicals used at or emitted from 
Cambridge Plating and also provides a review of several types of cancer in Belmont and the 
surrounding communities of Cambridge, Arlington, and Watertown, with a particular focus on 
Belmont census tracts (CT) 3572 and 3571.  Cambridge Plating is located in CT 3572, and CT 
3571 is an adjacent census tract that is near the facility (shown in Figure 1).  Appendix A of the 
report provides more detailed information about the occurrence of cancer in all four communities 
as well as in relation to other locations of potential environmental concern.  In addition, available 
information about risk factors, including environmental factors, related to the development of 
cancer was considered. To evaluate concerns about potential exposure to hazardous substances 
from the Cambridge Plating site, MDPH contacted the Massachusetts Department of 
Environmental Protection (MDEP) and the U.S. Environmental Protection Agency (EPA) to 
obtain and review available environmental information for the facility. 
Cancer rates were evaluated for the town of Belmont and the census tracts that comprise the 
town and for Cambridge, Arlington, and Watertown for the years 1982–1999, the time period for 
which the most recent and complete cancer incidence data were available from the 
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Massachusetts Cancer Registry (MCR) at the initiation of this analysis.  Belmont is divided into 
eight smaller geographic areas or census tracts (CTs).  A census tract is a smaller geographic 
subdivision of a city or town designated by the U.S. Census Bureau.  Because age group and 
gender specific population information is required to calculate incidence rates, the census tract is 
the smallest geographic area for which cancer rates can be accurately calculated.  Belmont CT 
3572, where Cambridge Plating is located, comprises an area of 0.6 square miles and has a total 
population of 3,204 (U.S. Census Bureau 2000).  Census tract 3571, which is adjacent, has an 
area of 0.8 square miles and a population of 4,148. Figure 1 shows the location of Cambridge 
Plating and the boundaries of CTs 3571 and 3572. 
The results of this descriptive analysis can be useful in identifying cancer patterns or trends in a 
geographic context, may help determine whether a common cause or etiology is possible, and 
can serve to identify areas where further public health investigations or actions may be 
warranted. Descriptive analyses may also indicate that an excess of known risk factors 
associated with a disease, such as environmental exposures, exists in a certain geographic area.  
This descriptive analysis of cancer incidence data cannot be used to establish a causal link 
between a particular risk factor (either environmental or nonenvironmental) and the development 
of cancer. In addition, this analysis cannot determine the cause of cancer for any one individual. 
The purpose of this evaluation is (1) to report the findings of the patterns of cancer in Belmont 
(with particular focus on CTs 3571 and 3572) and in the surrounding communities of 
Cambridge, Arlington and Cambridge and (2) to evaluate the findings in the context of the 
available environmental information related to Cambridge Plating to determine whether 
recommendations for further public health action are needed. 
II. OBJECTIVES 
The specific objectives of this investigation were as follows: 
•	 To evaluate the extent to which contamination at or emissions from the Cambridge Plating 
facility could result in exposure to people in the area and whether adverse health effects 
would be possible if exposure occurred. 
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•	 To review the incidence of six cancer types in the town of Belmont and the surrounding 
communities of Cambridge, Arlington, and Watertown, with a particular focus on CTs 3571 
and 3572 in Belmont. 
•	 To evaluate the geographic distribution of individuals diagnosed with cancer in the four 
communities and see if there are any patterns in particular areas of the communities or in 
areas of potential environmental concern. 
•	 To review descriptive information available from the Massachusetts Cancer Registry for 
individuals diagnosed with cancer in the four communities, to see if there are any particular 
characteristics related to known or suspected risk factors, including environmental factors, 
for developing these diseases. 
•	 To discuss possible exposure pathways related to Cambridge Plating and the results of the 
cancer incidence evaluation in the context of the available scientific and medical literature on 
cancer and contaminants of concern to determine whether further investigation or public 
health action is warranted. 
III. BACKGROUND AND COMMUNITY ENVIRONMENTAL CONCERNS 
Community environmental concerns related to Cambridge Plating Company have focused 
specifically on historical air emissions as well as groundwater and soil contamination identified 
on the property. Residents have expressed concerns about cancer and several non-cancer health 
outcomes including upper respiratory irritation, nausea, and headaches.  In addition, complaints 
about odors and noise have been reported by individuals residing near the facility (Belmont 
Health Department 2003a; 2003c).  In order to address these community concerns, the MDPH 
contacted the Massachusetts Department of Environmental Protection (MDEP) Metro/Northeast 
Regional Office and the U.S. Environmental Protection Agency (EPA) Region 1 to obtain and 
review available environmental information pertaining to Cambridge Plating. 
Cambridge Plating is located at 39 Hittinger Street in Belmont, Massachusetts (see Figure 2). 
This site is located in census tract 3572 (shown in Figure 1).  Since 1968, electroplating 
operations have been conducted at the site (Coler and Colantonio 2002a). A number of other 
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commercial and industrial activities are reported to have occurred at the site before the 
electroplating operations began. One company used the site to produce concrete burial vaults 
and bricks (Coler and Colantonio 2002a).  Historical operations reported at or near the 
Cambridge Plating site include a clay mining operation and, in the early 1900s, an open burning 
town dump (Coler and Colantonio 2002a). 
Cambridge Plating is regulated for air emissions, sewage discharge, on-site storage of hazardous 
waste, and transport of hazardous waste off the site for disposal.  There have been several spills 
or accidental releases reported and investigated at the Cambridge Plating facility during the 
company’s years of operation; a partial drum spill of muriatic acid in 1980; a tank overfill of 
diesel fuel in 1982; and, in 1983, the discovery of soil contaminated with diesel fuel from a 
former underground storage tank (Paragon Environmental Services 1996).  Some fires have also 
been reported at the site, including an indoor office fire on March 15, 1998, and a fire in the 
wastewater treatment system area on May 25, 2002 (Coler and Colantonio 1998c; EPA Region 1 
2003a). 
In 1989, the detection of an apparent release of unspecified hazardous materials on a portion of 
the property resulted in regulatory actions that required subsurface environmental sampling to 
establish the extent of contamination.  Site investigations that included sampling of on-site soil 
and groundwater were completed in 1996 and 2002.  More recently, soil contaminated with 
chromium discovered in a portion of the property adjacent to the Massachusetts Bay 
Transportation Authority (MBTA) railroad tracks resulted in a site investigation of this area in 
May/June 2003 (Coler and Colantonio 2003a).  In addition, in response to an MDEP 
requirement, an investigation of groundwater and soil gas was conducted at the site in January 
2004 (Coler and Colantonio 2004).  Additional investigations of groundwater and on-site surface 
soil were conducted in response to an MDEP requirement in 2005 (OHI 2005).  Off-site surface 
soil sampling was conducted by MDEP in 2007 (MDEP 2007).  The available environmental 
data from these investigations, along with information provided by EPA, were considered in this 
public health assessment. 
Within the immediate vicinity of the Cambridge Plating facility there are a range of land uses.  
To the north, Cambridge Plating is abutted by the MBTA commuter rail tracks and by residential 
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and commercial properties beyond the tracks.  To the east are Brighton Street and a convenience 
store, a gas station, and a small business park.  A residential neighborhood is located south of the 
facility and to the west there are school playing fields and a school parking lot.  The Belmont 
High School building is approximately 500 feet away. 
Cambridge Plating is located within the Mystic River Watershed and is not located within a 
potentially productive aquifer (Coler and Colantonio 2002a).  Nearby surface water bodies 
include Clay Pit Pond, which is in front of Belmont High school; Blair Pond, which is behind the 
commercial buildings on Brighton Street to the east; and Little Pond, which is a fifth of a mile 
north of the site (locations are shown in Figure 2). 
The public health assessment titled “Evaluation of Environmental Concerns and Cancer 
Incidence in Belmont and Surrounding Communities, Middlesex County, Massachusetts, 1982– 
1999” was released on October 20, 2005, for a public comment period ending on December 15, 
2005. Public comments were received by the MDPH and are addressed in Appendix E and 
Appendix F. 
IV. REVIEW OF ENVIRONMENTAL SAMPLING DATA 
To address concerns about possible environmental exposures associated with Cambridge Plating, 
MDPH reviewed information from several reports on file with MDEP and EPA, as well as the 
Toxics Release Inventory (TRI) data available from EPA.  Available environmental sampling 
data were reviewed, and a screening evaluation was conducted to identify substances that need to 
be considered for further analysis to determine whether they may be of potential health concern.  
The screening analysis identifies maximum concentrations of contaminants detected in various 
types of environmental media (i.e., air, soil, water) and compares these concentrations to health-
based comparison values established by ATSDR (ATSDR 2003a, 2003b).  If an ATSDR 
comparison value was not available for a specific chemical, the maximum detected concentration 
of that chemical was compared to risk-based concentrations (RBCs) developed by EPA Region 3 
(Hubbard 2000) or the applicable groundwater or soil standards established by MDEP (MDEP 
2003b), in that order. For compounds detected in groundwater, maximum concentrations were 
also compared with state or federal drinking water standards. 
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The ATSDR comparison values are specific concentrations of a chemical for air, soil, or water 
that are used by health assessors to identify environmental contaminants that require further 
evaluation. These comparison values are developed on the basis of health guidelines and 
assumed exposure situations that represent conservative estimates of human exposure.  Chemical 
concentrations detected in environmental media at levels that are lower than their comparison 
values are not likely to pose a health threat.  However, the fact that a chemical concentration is 
detected in environmental media at a level above a comparison value does not necessarily mean 
that a person who comes into contact with that concentration will be harmed.  If the 
concentration of a chemical is greater than the appropriate comparison value, the potential for 
exposure to the chemical is further evaluated to determine whether exposure is occurring and 
whether health effects might be possible as a result of that exposure.  The factors related to 
exposure that are unique to the specific situation under investigation need to be considered to 
determine whether adverse health effects from a chemical of concern are plausible. 
ATSDR has identified levels of metals and polyaromatic hydrocarbons (PAHs) that are 
considered normal for soil in urban and suburban communities.  The United States Geological 
Society (USGS) has also identified measurements for levels of metals that are considered typical 
for soil in the eastern United States (Shacklette and Boerngen 1984).  These levels are called 
background levels and are used along with comparison values for both metals and PAHs in this 
analysis. 
A. Soil 
Soil sampling has been conducted at the Cambridge Plating site for a variety of reasons, ranging 
from environmental sampling associated with specific releases of contaminants to environmental 
sampling for more comprehensive site investigations.  The majority (n = 18) of the samples were 
collected from soil between 2 to 8 feet below the ground surface.  Typically, surface soil samples 
are taken from the top 0–3 inches of soil. This is of particular interest when evaluating possible 
exposure as it is more likely that individuals would have more frequent contact with surface soil 
than with deeper soils.  However, the soil samples for Cambridge Plating, with the exception of 
samples collected for chromium analysis, were not collected from soil shallower than 2 feet in 
depth. 
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The maximum value for each contaminant for which environmental data were available from the 
file review was compared to the appropriate screening value.  Analysis of the on-site soil 
samples found arsenic, chromium, trichloroethylene, and a range of polycyclic aromatic 
hydrocarbons (PAHs) at levels above relevant comparison values (see Table 1).  Sampling 
locations are shown in Figure 3. The information reviewed indicated that no off-site soil 
sampling was conducted. 
Arsenic was detected in five of eight soil samples collected at Cambridge Plating.  The 
maximum concentration of 44 milligrams per kilogram (mg/kg) was detected in soil sampling 
conducted during excavation activities for the installation of a new loading dock in 1994.  
However, subsequent sampling of soil in the same area found lower levels of arsenic.  Based on 
the information reviewed, it is unclear whether excavated soils were removed from the site.  In 
the other four samples with elevated levels of arsenic, the levels ranged from 5.1 mg/kg to 7.6 
mg/kg. Although all five detected arsenic concentrations exceed ATSDR’s cancer risk 
evaluation guide (CREG) for arsenic in soil of 0.5 mg/kg, all of the levels detected are within the 
range of typical background concentrations for soil in the eastern United States (ATSDR 1993; 
Shacklette and Boerngen 1984). Table 1 shows the maximum concentrations of contaminants 
detected in the on-site soil samples. 
Elevated levels of total chromium were detected in on-site soil during sampling conducted in 
response to a release identified in an approximate 450-square foot area of the property located 
north of the building abutting the MBTA railroad tracks.  The maximum concentration of total 
chromium (32,000 mg/kg) was detected in a composite soil sample collected 3 to 5 feet below 
ground surface in this area. Total chromium was detected in 25 of the soil samples from this 
area; concentrations exceeded the reference media evaluation guide (RMEG) value for childhood 
exposure to chromium VI (200 mg/kg) nine times and for adult exposure to chromium VI 
(2,000 mg/kg) three times. There are no ATSDR comparison values for total chromium in soil so 
RMEGs for chromium VI, which is the most toxic form of chromium, were used as comparison 
values. 
Because chromium VI, the hexavalent form of chromium, is a carcinogen, soil samples collected 
from the area north of the building were also analyzed for chromium VI.  The maximum 
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concentration of chromium VI (210 mg/kg) was detected in subsurface soil, approximately at or 
below the ATSDR comparison values (see Table 1).  Chromium levels identified in subsurface 
soils from other areas of the site were well below comparison values.  Sampling of surface soil in 
this area (discussed in detail below) indicates that both total chromium and hexavalent chromium 
levels are approximately at or below the ATSDR comparison values. 
In November 2005, Cambridge Plating submitted surface soil sampling results for both total 
chromium and chromium VI in response to a requirement by the Massachusetts Department of 
Environmental Protection (MDEP) (OHI 2005).  Ten additional on-site locations were sampled, 
including three locations along Hittinger Street, three along the MBTA railroad tracks, two along 
the fence adjacent to the baseball field, and two along Brighton Street.  These locations were 
required by MDEP based on air emissions modeling results indicating that areas of maximum 
impact would be located on the site; this modeling was done in order to select reasonably 
conservative sampling locations (J. Miano, MDEP, personal communication, 2006).  All OHI 
samples were collected from surface soils at depths between 0 and 6 inches and analyzed for 
both total and hexavalent forms of chromium.  As previously mentioned, surface soil samples are 
of particular interest when evaluating possible exposure as it is more likely that individuals 
would have more frequent contact with surface soil than with the deeper soils discussed above.  
Total chromium was detected in all ten surface soil samples at concentrations ranging from 23 to 
220 mg/kg (OHI 2005).  The maximum detected concentration of total chromium was below the 
RMEG value for adult exposure to chromium VI (2,000 mg/kg) and similar to the RMEG value 
for childhood exposure to chromium VI (200 mg/kg) (ATSDR comparison values for total 
chromium were not available, so comparison values for chromium VI were used).  Chromium VI 
was detected in one of the ten surface soil samples at 1.2 mg/kg (OHI 2005), which is well below 
both the adult and child RMEG values for chromium VI.   
In June 2007, in response to a request from the community and a MDPH recommendation in the 
Cambridge Plating Public Health Assessment report released for public comment in 2005, the 
MDEP sampled surface soil at off-site locations near Cambridge Plating to confirm the results of 
air emissions modeling and to determine if elevated levels of chromium were present in off-site 
soil. The seven off-site samples were located near the tennis courts and ball field east of the 
facility, near residences north of the facility, near the intersection of Hittinger and Baker Streets 
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south of the facility, and at three locations along Brighton Street northwest, west, and southwest 
of the facility (Figure 4).  Chromium VI (hexavalent) was not detected in any of the seven off-
site surface soil samples (MDEP 2007).  Total chromium was detected in all seven samples at 
concentrations ranging from 12 to 46 mg/kg, but were well below ATSDR comparison values for 
chromium VI (MDEP 2007).  These concentrations were also below concentrations of total 
chromium considered typical for soil in the eastern United States (1-1,000 mg/kg) (Shacklette 
and Boerngen 1984). 
The maximum level of benzo(a)pyrene (11 mg/kg) detected exceeds the ATSDR soil CREG of 
0.1 mg/kg.  There are a number of other PAHs that exceed EPA’s risk-based concentrations 
(RBCs). RBCs were used because there are no ATSDR comparison values for these compounds.  
However, the majority of PAH compounds detected (benzo(a)anthracene, benzo(b)fluoranthene, 
and indeno(1,2,3-cd)pyrene) were within the range of typical background concentrations for 
urban soil. Because PAHs are by-products of incomplete combustion processes, they have been 
reported to be associated with previous land uses in this area, such as brick making and an open-
burn dumpsite (Coler and Colantonio 2002a). 
B. Groundwater 
There are 17 monitoring wells at the Cambridge Plating site that have been used to collect 
groundwater samples on several different occasions. Groundwater at the site is between 3 and 7 
feet below the surface (Coler and Colantonio 2004).  At some of these wells, arsenic, 
trichloroethylene (TCE), cis-1,2-dichloroethene, vinyl chloride, and PAHs have been detected at 
levels above drinking water comparison values (Table 2 and Figure 3).  However, groundwater at 
the Cambridge Plating site is not used as a drinking water supply, and all of Belmont is serviced 
with municipal water.  The information reviewed does not indicate that any groundwater 
sampling has been conducted off the site. 
There is little historical groundwater sampling of volatile organic compounds (VOCs) for the 
majority of monitoring wells at the site, and no specific time trends are apparent.  Elevated levels 
of TCE and cis-1,2-dichloroethene (cis-1,2–DCE) have been consistently detected in samples 
collected from wells located west of the main building and down-gradient from the locations of 
floor drains and sump tanks in the facility (monitoring wells CC-105 and MW-03 – see Figure 
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3). Under an agreement with MDEP, a quarterly monitoring program for these two wells is 
currently in place to help determine whether the site represents a current source of TCE and cis­
1,2-DCE to groundwater (Coler and Colantonio 2002b).  The maximum groundwater 
concentrations of TCE (49,800 micrograms per liter [µg/L]) and cis-1,2 DCE (8,150 µg/L) were 
detected in monitoring well MW-03 during a 2004 sampling event (Coler and Colantonio 2004).  
Both concentrations exceed EPA’s RBCs for drinking water (ATSDR comparison values were 
not available). Groundwater concentrations measured during sampling in 2005 showed lower 
levels of both TCE (360 µg/L) and cis-1,2 DCE (4,500 µg/L) in monitoring well MW-03, but 
both concentrations continue to exceed the EPA’s RBCs for drinking water (OHI 2005).  Vinyl 
chloride was detected in three out of ten monitoring wells sampled and the maximum 
concentration of vinyl chloride (1,200 µg/L) was detected above the CREG value for drinking 
water (0.03 µg/L) in monitoring well MW-03 in September 2005.  The source of these elevated 
VOC levels has not been determined, although both cis-1,2–DCE and vinyl chloride are known 
breakdown products of TCE (ATSDR 1997). Depths to groundwater in monitoring wells MW­
03 and CC-105 wells during 2002–2004 sampling ranged from 5.95 feet–6.69 feet and 3.41 feet– 
4.18 feet, respectively (Coler and Colantonio 2004). 
While TCE and cis-1,2, DCE were detected at much lower levels in monitoring well CC-2, 
which is located closer to the property boundary near Hittinger Street, the maximum 
concentration of TCE detected in this well (380 µg/L in 2000) exceeds available drinking water 
comparison values (Coler and Colantonio 2002a).  Vinyl chloride was not detected in this well.  
Monitoring well CC-2 is located approximately 160 feet south of monitoring well MW-03 (refer 
to Figure 3). 
Additionally, in an Interim Deadline letter dated May 20, 2005, MDEP required that Cambridge 
Plating Company obtain a groundwater sample from beneath the floor in the TCE degreasing 
area or boiler room in order to investigate the source of elevated levels of VOCs at the loading 
dock on the southern side of the building (MDPH 2005b).  The groundwater sample was taken 
10 feet below the floor of the degreasing area by OHI Engineering, Inc.  The sample had 
detections of TCE (15 µg/L), cis-1,2 DCE (20 µg/L), and vinyl chloride (5 µg/L) (OHI 2005).   
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C. Air Emissions 
Cambridge Plating first submitted an application for an air quality emissions permit to the MDEP 
Bureau of Waste Prevention (BWP) in 1982 and the most recent permit was submitted in 1995 
(MDEP 1982, 1995). The major sources of air emissions at the facility have been two solvent 
degreasers and a hard chrome-plating bath (MDEP 1995).  However, routine stack sampling is 
not required under the air-permitting program and no ambient air sampling data are available for 
the neighborhood areas in the immediate vicinity of the facility. 
A review of data reported in EPA’s Toxics Release Inventory (TRI) was conducted.  The TRI is 
a reporting system that estimates the annual releases of toxic chemicals to the environment.  The 
system evolved from the Emergency Planning and Community Right-to-Know Act.  Businesses 
are required to report the locations and quantities of chemicals stored on a site to state and local 
agencies to help communities prepare to respond to potential chemical spills and emergency 
releases (EPA 2005). Although TRI annual release estimates cannot be used to specifically 
evaluate whether individuals living near the Cambridge Plating site are actually at risk of 
exposure to air emissions, the information can be helpful when evaluating the pattern of cancer 
in the residential areas surrounding the facility and the possibility that environmental factors may 
have played a role. 
Review of available TRI data for Cambridge Plating for the years 1987–2005 indicates that 
fugitive emissions (emission from sources other than stacks or vents) of TCE were highest in the 
late 1980s. The maximum TCE emissions (66,960 pounds) were reported for the year 1989.  
Annual TCE emissions fluctuated between approximately 14,000 and 19,000 pounds in the 
intervening years, with another peak in emissions reported for the year 1996 (58,500 pounds).  
TRI emissions data indicate that TCE was last released from the facility in 2003 when fugitive 
TCE emissions at Cambridge Plating were 11,638 pounds (EPA 2005).  Currently, air emissions 
of TCE have been eliminated because TCE is no longer being used at the facility (Belmont 
Department of Health 2004a, U.S. EPA Region 1 2005).  Other compounds reported to the TRI 
as being emitted to air from the Cambridge Plating facility at some point during the years for 
which TRI data were available included hydrochloric acid, nickel compounds, nitric acid, 
sodium hydroxide solution, and sulfuric acid (see Table 3). 
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While not reported in TRI data, air permit applications and the presence of a hard chromium- 
electroplating process at the facility indicate that Cambridge Plating has also been a source of 
hexavalent chromium air emissions (MDEP 1995).  Although there is no information on what 
time chromium-electroplating operations began at the facility, it was reported that the “hard 
chrome” tank was installed in 1969 (Cambridge Plating 2001).  On the basis of the permit 
information reviewed, the hard chromium electroplating process area was located toward the 
back portion of the building (away from Hittinger Street) and the stack height associated with 
this process was reported to be 20 feet above the ground surface (MDEP 1995).  According to 
the 1995 permit, stack emissions of chromium were reported to be 0.007 tons per year (MDEP 
1995). 
According to EPA Region 1, the applicable air regulations for chromium came into effect for 
Cambridge Plating in 1995.  While some form of air pollution control was probably in place 
prior to that, previous emissions and/or controls of chromium from the facility are unknown 
(EPA Region 1 2003b). In 2002, Cambridge Plating undertook an agreement with EPA to 
completely close the chromium-electroplating portion of its operations (EPA Region 1 2003b, 
2002b). As a result, chromium air emissions associated with the use of this process ended in 
December 2002.  While a “chromating” process is still in operation, it is not heated and air 
emissions are not expected (EPA Region 1 2005).   
V. EVALUATION OF POTENTIAL COMMUNITY EXPOSURE PATHWAYS 
An evaluation of potential pathways of exposure was conducted to help evaluate whether 
emissions or releases at the Cambridge Plating facility could be affecting the health of residents 
in the surrounding neighborhood in the present, could affect the health of residents in the future, 
or could have affected the health of residents in the past.  A person must first be exposed to a 
chemical before any potential adverse health effects can result.  Five conditions must be present 
for exposure to a chemical to occur.  First, there must be a source of the chemical.  Second, an 
environmental medium must be contaminated by either the source or by chemicals transported 
away from the source.  Third, there must be a location where a person can potentially come into 
contact with the contaminated medium.  Fourth, there must be a means by which the 
contaminated medium could enter a person’s body, such as ingestion, inhalation, or dermal 
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absorption. Fifth, there must be a population to be exposed. Even if a person is exposed to a 
chemical, it doesn’t mean that the person will be harmed.  For a person to be harmed by 
exposure, the chemical must actually reach the target organ susceptible to the toxic effects 
caused by that particular substance at a sufficient dose and for a sufficient exposure time for an 
adverse health effect to occur (ATSDR 1993). 
A completed exposure pathways exists when all of the five conditions previously described are 
present. A potential exposure pathway exists when one or more of the five elements is missing 
or uncertain and indicates that exposure could have occurred in the past, may be occurring in the 
present, or could occur in the future. An exposure pathway can be eliminated if at least one of 
the five elements is missing and will not likely be present in the future.  Refer to Table 4 for a 
summary of exposure pathways discussed in this section.   
A. Exposure to Soil 
Most of the Cambridge Plating site is covered by asphalt or concrete (Coler and Colantonio 
2002a; Paragon Environmental Services 1996), so it is unlikely that residents who live nearby 
will be exposed to soil from the site.  In addition, the facility is still in active industrial use; 
therefore, it is unlikely that non-employees would be accessing the site extensively.  Reports in 
the Belmont Health Department files indicate that young adults have trespassed on the 
Cambridge Plating property in the past; specifically, there was an incidence of youth climbing on 
the roof of the building (Belmont Department of Health 2003a, 2003c).  It is possible that 
individuals who trespassed near a portion of the property abutting the MBTA railroad tracks 
could have had infrequent contact with chromium in soil before the chromium contamination 
was discovered and access restricted by a fence. Assuming that an older child trespassed on this 
area of the site in the past and incidentally ingested the maximum concentration of total 
chromium detected in soil samples collected between 0 and 4 feet below ground surface (3,900 
mg/kg), for 1 day per week for 26 weeks over 5 years, the level would be below EPA’s chronic 
Reference Doses for both Chromium III and Chromium VI (ATSDR Minimal Risk Levels and 
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U.S. EPA cancer slope factors were not available for total chromium)1. Therefore, it is unlikely 
that individuals who might have trespassed in this area of the site would have had sufficient 
exposure to result in health effects. 
In the 2005 public comment release of the public health assessment titled “Evaluation of 
Environmental Concerns and Cancer Incidence in Belmont and Surrounding Communities, 
Middlesex County, Massachusetts, 1982–1999,” the MDPH recommended additional surface soil 
sampling and analysis for chromium to determine those areas most impacted by chromium 
deposition in the past. Air modeling was conducted by the MDEP during 2006.  The model used 
meteorological conditions, stack emission rate, and other model inputs to predict the relative 
distribution of chromium that might be present in soils in the vicinity of Cambridge Plating due 
to stack emissions and deposition.  Based on the modeling, which used regional data for values 
such as wind speed and wind directions, MDEP predicted that the areas with the highest 
concentrations of chromium would likely be located on the site. 
As part of Phase II assessment work at the Cambridge Plating site, MDEP required that ten 
specific locations around the perimeter of the property be sampled to determine levels of 
chromium in surface soils.  The November 2005 sampling locations were chosen by MDEP 
based on air emissions modeling results which indicated that areas of maximum impact would be 
located on the site. An analysis of the soil sampling data indicated that the chromium levels 
present in the on-site surface soil were low and are unlikely to result in adverse health effects in 
nearby residents (see Section IV-A). 
To further confirm and validate the results of air emissions modeling in regards to off-site 
conditions, in June 2007, the MDEP sampled surface soil at off-site locations near Cambridge 
Plating. Concentrations of chromium measured at off-site areas were below both ATSDR 
comparison values and concentrations considered typical for soil in the eastern United States.  
Noncancer Effects Exposure Factor = (1 day/week) (26 weeks/year) (5 years) = 0.07 
  (5 years) (365 days/year) 
Maximum total chromium detected in samples collected at depths from 0 to 4 feet = 3,900 mg/kg 
Noncancer Effects Exposure Dose = (3900 mg/kg) (200 mg/day) (0.07) (1 kg/106 mg) = 1.6 x 10-3 mg/kg/day
     35 kg 
EPA’s Chronic Rfd (Chromium III) = 1.5 mg/kg/day 
EPA’s Chronic Rfd (Chromium VI) = 3 x 10-3 mg/kg/day 
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Therefore, chromium in off-site soil is unlikely to result in adverse health effects in nearby 
residents. 
Workers at the site who are involved with electroplating activities are unlikely to be exposed to 
soil beneath the site. Although it is possible that workers who visit the site for construction or 
excavation activities (such as undertaking soil borings for the purposes of environmental analysis 
or removing or replacing underground storage tanks) may be exposed in the future, such 
activities are likely to be undertaken using proper health and safety precautions to minimize 
exposure potential. 
A source of concern to nearby residents has been the Cambridge Plating facility’s history of non­
compliance with wastewater limits and discharge to the sewer (Belmont Department of Health 
2003c). Although the sewer pipe that runs along Hittinger Street was cracked in the past, it is 
currently reported to be in good condition (Belmont Department of Community Development 
2003) and revealed no evidence of damage or leakage (OHI 2005).  It is possible that wastewater 
discharged to the sewer from this facility resulted in some contamination of surrounding soils 
and possibly groundwater in the vicinity of any cracks.  It is unlikely, however, that residents of 
this area would be exposed to such contamination because the potentially impacted soils are 
located beneath the ground surface and, as stated previously, groundwater in this area is not a 
source of drinking water. 
B. Exposure to Groundwater 
A recent groundwater elevation study showed a generally southern groundwater flow direction 
on the eastern portion of the facility and a southwesterly flow on the western side of the facility.  
Groundwater at the site is between 3 and 7 feet below the surface (Coler and Colantonio 2004).  
The highest levels of VOC contamination detected in groundwater are in monitoring wells MW­
03 and CC-105, which are west of the Cambridge Plating buildings (Figure 3).  VOC 
concentrations detected in groundwater are much lower closer to the southern property boundary 
near Hittinger Street, but the concentrations of TCE detected in the most westerly monitoring 
well (CC-2) were also elevated above available drinking water comparison values (MCL = 5 
µg/L). Specifically, TCE was detected in groundwater samples from well CC-2 at 380 µg/L, 200 
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µg/L, and 162 µg/L during the years 2000, 2003, and 2004, respectively (Coler and Colantonio 
2002; 2004). 
The groundwater wells sampled at Cambridge Plating are for monitoring purposes only, and no 
one drinks water from these wells.  All residential properties in the town of Belmont are supplied 
with drinking water from the Massachusetts Water Resources Authority, and there are no known 
private drinking water wells (MWRA 2003; Belmont Department of Health 2003b).  Because 
groundwater in this area is not being used as a source of drinking water, ingestion is not a 
possible route of exposure for residents. 
C. Exposure to Indoor Air 
Data currently available for VOCs in groundwater indicate that the highest levels of TCE and 
1,2-DCE were detected west of the Cambridge Plating building and on the site (monitoring wells 
CC-105 and MW-03), and that levels closer to the southern site boundary near Hittinger Street 
were lower but still elevated above drinking water comparison values.  Volatilization of VOCs to 
indoor air in nearby homes would be possible if groundwater is shallow and VOCs are present in 
groundwater beneath homes at sufficient concentrations. 
To evaluate whether the levels of TCE detected in groundwater at the site could contaminate 
indoor air in nearby residences, MDPH asked ATSDR to run a model incorporating site-specific 
information on groundwater, soil, and housing for the area surrounding the facility (ATSDR 
2003c). ATSDR used information on the predicted groundwater flow direction at the Cambridge 
Plating site, the depth to contamination, the type of soil, and the typical size and age of nearby 
homes and applied the Johnson-Ettinger mathematical model to determine what concentrations 
of TCE in groundwater would result in indoor air concentrations of TCE at levels above health-
based comparison values for air exposure.  Modeling results indicated that the potential for a 
vapor intrusion exposure pathway could exist when TCE is present in groundwater at 
concentrations greater that 12,800 µg/L (ATSDR 2003c).  With the exception of monitoring 
wells MW-03 and CC-105 located west of the Cambridge Plating building, TCE was detected 
below the groundwater concentration at which a vapor intrusion exposure pathway would be of 
potential concern at the site. In particular, the concentrations of TCE detected in groundwater 
monitoring well CC-2 located down-gradient and closer to the site boundary near Hittinger Street 
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were 380 µg/L and lower; therefore, it is unlikely that persons living near this area of the site are 
being exposed to TCE in indoor air at levels of health concern. 
Because of the historical levels of VOCs detected in groundwater wells and uncertainties 
associated with the direction of groundwater flow at the site, MDEP required Cambridge Plating 
to evaluate whether VOCs in groundwater are resulting in soil gas that could impact nearby 
residences along Hittinger Street (MDEP 2003a).  Results of groundwater sampling from this 
investigation showed that levels similar to those detected in monitoring wells MW-03 and CC­
105 are not widespread and do not appear to be migrating off the site (Coler and Colantonio 
2004). Soil gas sampling conducted both adjacent to the building and closer to Hittinger Street 
indicated that VOCs in soil gas decrease significantly in sampling locations closer to the property 
boundary. This investigation also applied a dilution attenuation factor of 1,000 to measured 
VOC soil gas concentrations as a screening approach to estimate possible indoor air 
concentrations (Coler and Colantonio 2004).  None of the estimated VOC indoor air 
concentrations exceeded ATSDR comparison values for air exposure.   
While the environmental information reviewed indicates a south/southwestern groundwater flow 
direction at the site, there was little information available on the concentrations of TCE in 
groundwater north of the building. In the public comment release of the public health 
assessment titled “Evaluation of Environmental Concerns and Cancer Incidence in Belmont and 
Surrounding Communities, Middlesex County, Massachusetts, 1982–1999,” the MDPH 
recommended additional characterization of VOCs in groundwater north of the building.  
Additional groundwater characterization, conducted by OHI Engineering, Inc. on behalf of 
Cambridge Plating Company, was submitted to the MDEP in November 2005.  Using the new 
information about groundwater conditions, MDEP determined that shallow groundwater flow is 
generally in a south-southwest direction across the site (J. Miano, MDEP, personal 
communication, 2006). According to the MDEP, it is unlikely that VOCs found at high 
concentrations near the loading dock would flow upgradient (i.e., against the flow of 
groundwater) toward homes north of the site.  Thus, because groundwater does not appear to 
flow toward these residences, it is not expected that residents north of the site have opportunity 
for exposure to contaminants in groundwater via vapor intrusion. 
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Additionally, in an Interim Deadline letter dated May 20, 2005, MDEP required that Cambridge 
Plating Company obtain a groundwater sample from beneath the floor in the TCE degreasing 
area or boiler room in order to investigate the source of elevated levels of VOCs at the loading 
dock on the southern side of the building. The groundwater sample was taken 10 feet below the 
floor of the degreasing area by OHI Engineering, Inc.  The groundwater sample had detections of 
TCE (15 µg/L), cis-1,2 DCE (20 µg/L), and vinyl chloride (5 µg/L) (OHI 2005).  These levels 
were much lower than concentrations of VOCs in other areas of the Cambridge Plating property: 
49,800 µg/L TCE, 8,150 µg/L cis-1,2 DCE, and 1,200 µg/L vinyl chloride.  Therefore, OHI 
Engineering, Inc. concluded and MDEP concurred that there did not appear to be an ongoing 
source of VOC contamination beneath the Cambridge Plating building that could contribute to 
vapor intrusion in homes north of the facility.   
On the basis of the Johnson-Ettinger modeling results provided by ATSDR and soil gas and 
groundwater investigations at Cambridge Plating required by MDEP, high levels of VOCs 
detected in groundwater near the building (monitoring wells MW-03 and CC-105) do not appear 
to have migrated south toward the site boundary at sufficient concentrations to raise health 
concerns related to VOCs in indoor air in nearby homes along Hittinger Street.  Also, because 
groundwater from beneath the Cambridge Plating facility does not appear to flow toward the 
northern site boundary, it is not expected that residents north of the site would have opportunities 
for exposure to elevated levels of VOCs in indoor air.     
D. Exposure to Ambient Air 
On the basis of the air permit information and TRI data reviewed, opportunities for exposure to 
ambient air emissions from Cambridge Plating are a possibility for nearby residents.  While TCE 
is no longer being used at the facility, it is possible that fugitive emissions of TCE in the past 
may have resulted in potential exposure.  Stack emissions of chromium associated with 
electroplating operations at the facility may also have resulted in exposure opportunities to 
chromium in ambient air in the past.  As stated previously, chromium-electroplating operations 
that resulted in stack emissions of chromium were eliminated in December 2002. 
There are no historical ambient air data available for Cambridge Plating or the surrounding 
neighborhood, making it difficult to evaluate whether facility emissions may have resulted in 
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chemical concentrations in ambient air greater than health-based screening values.  However, 
because the majority of air emissions at Cambridge Plating are fugitive (that is, not from stacks 
or vents) and because stack heights are relatively low, the greatest potential for exposure to 
facility emissions in ambient air would likely be in the nearby residential neighborhoods of 
Belmont.  The emissions would be less likely to impact neighborhoods farther away (e.g., in the 
towns of Arlington, Cambridge, and Watertown).  Therefore, the pattern of those cancer types 
suggested in scientific studies of workers and/or animals to be associated with inhalation 
exposure to TCE and chromium (i.e., kidney, liver, lung, non-Hodgkin’s lymphoma, and 
leukemia) were evaluated in relation to the Cambridge Plating facility as part of the cancer 
incidence analysis. 
VI. ANALYSIS OF CANCER INCIDENCE 
A. Methods for Analyzing Cancer Incidence 
1. Case Identification/Definition 
Cancer incidence data (i.e., reports of new cancer diagnoses) for the years 1982–1999 were 
obtained for the town of Belmont and the surrounding communities of Arlington, Cambridge, 
and Watertown from the Massachusetts Cancer Registry (MCR), a division of the Bureau of 
Health Information, Statistics, Research and Evaluation within the MDPH.  Six cancer types 
were evaluated in this investigation: cancers of the kidney, liver, lung and bronchus, and 
pancreas as well as leukemia and non-Hodgkin’s lymphoma (NHL).  Coding for cancer types in 
this report follows the International Classification of Diseases for Oncology (ICD-O) system.  
(The incidence coding definitions used in this report for these cancer types are shown in 
Appendix B.) These cancer types were selected for evaluation on the basis of elevations 
observed at the town level in a preliminary review of cancer rates in Belmont, potential 
associations with contaminants of concern at the Cambridge Plating site (primarily TCE and 
chromium), and/or residents’ concerns over suspected elevations in some cancer types.  Only 
cases reported to the MCR as a primary site cancer for one of the six cancer types and diagnosed 
among residents of Belmont, Arlington, Cambridge, and Watertown were included in the 
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analysis.  Cases were selected for inclusion based on the address reported to the hospital or 
reporting medical facility at the time of diagnosis. 
The MCR is a population-based surveillance system that began in 1982 to collect information on 
Massachusetts residents diagnosed with cancer in the state.  All newly diagnosed cancer cases 
among Massachusetts residents are required by law to be reported to the MCR within 6 months 
of the date of diagnosis (M.G.L. c.111s.111B). This information is kept in a confidential 
database.  Data are collected on a daily basis and are reviewed for accuracy and completeness on 
an annual basis. This process corrects misclassification of data (i.e., city/town misassignment).  
Once these steps are finished, the data for that year are considered “complete.”  Due to the 
volume of information received by the MCR, the large number of reporting facilities, and the 
6-month period between diagnosis and required reporting, the most current registry data that are 
complete will inherently be a minimum of 2 years prior to the current date.  The 18-year period, 
1982–1999, constitutes the period for which the most recent and complete cancer incidence data 
were available from the MCR at the time of this analysis.2 
The term “cancer” is used to describe a variety of diseases associated with abnormal cell and 
tissue growth. Epidemiologic studies have revealed that different types of cancer are individual 
diseases with separate causes, risk factors, characteristics and patterns of survival (Berg 1996).  
Cancer types are classified by the location in the body where the disease originated (the primary 
site) and the tissue or cell type of the cancer (histology).  Therefore, each cancer type reviewed 
in this report was evaluated separately.  Cancers that occur as the result of the metastasis or the 
spread of a primary site cancer to another location in the body are not considered as separate 
cancers and, therefore, were not included in this analysis. 
It should be noted that the MCR research file might contain duplicate reports of individuals 
diagnosed with cancer.  The data in this report have been controlled for duplicate cases by 
excluding them from the analyses.  Duplicate cases are additional reports of the same primary 
site cancer case. The decision that a case was a duplicate and should be excluded from the 
analyses was made by the MCR after consulting with the reporting hospital/diagnostic facility 
2 The data summarized in this report are drawn from data entered on MCR computer files before April 28, 2003. 
The numbers presented in this report may change slightly in future reports, reflecting late reported cases, address 
corrections, or other changes based on subsequent details from reporting facilities.  
20 

and obtaining additional information regarding the histology and/or pathology of the case.  
However, reports of individuals with multiple primary site cancers were included as separate 
cases in the analyses in this report.  A multiple primary cancer case is defined by the MCR as a 
new cancer in a different location in the body, or a new cancer of the same histology (cell type) 
as an earlier cancer, if diagnosed in the same primary site (original location in the body) more 
than 2 months after the initial diagnosis (MCR 1996).  Therefore, duplicate reports of an 
individual diagnosed with cancer were removed from the analyses whereas individuals who were 
diagnosed with more than one primary site cancer were included as separate cases.  In the town 
of Belmont, four duplicate reports were identified during the years 1982–1999 and excluded 
from the analyses.  In addition, seven duplicate reports in Arlington, 16 duplicate reports in 
Cambridge, and 12 duplicate reports in Watertown were identified during the years 1982–1999 
and excluded from the analyses. 
2. Calculation of Standardized Incidence Ratios 
To determine whether elevated numbers of cancer cases occurred in Belmont and the 
surrounding communities of Arlington, Cambridge, and Watertown, cancer incidence data were 
tabulated by gender according to six age groups to compare the observed number of cancer cases 
to the number that would be expected based on the statewide cancer rate.  Standardized incidence 
ratios (SIRs) were then calculated for the period 1982–1999 for each of the six primary cancer 
types for Belmont as a whole as well as for each census tract (CT) within Belmont.  In addition, 
SIRs were calculated for the city of Cambridge as a whole and the three Cambridge CTs located 
on the border of Belmont.  Townwide SIRs were also calculated for Arlington and Watertown.  
SIRs were also calculated for three smaller time periods, 1982–1987, 1988–1993, 1994–1999, to 
evaluate patterns or trends in cancer incidence over time. 
To calculate SIRs, it is necessary to obtain accurate population information.  The population 
figures used in this analysis were interpolated on the basis of 1980, 1990, and 2000 U.S. Census 
data for each CT in Belmont and Cambridge and for the town of Belmont as a whole, the city of 
Cambridge as a whole, and the towns of Arlington and Watertown (U.S. Census Bureau 1980, 
1990, and 2000). Midpoint population estimates were calculated for each time period evaluated 
(i.e., 1984, 1990, and 1996). To estimate the population between census years, an assumption 
21 

was made that the change in population occurred at a constant rate throughout the 10-year 
interval between each census.3 
Because accurate age group and gender-specific population data are required to calculate SIRs, 
the CT is the smallest geographic area for which cancer rates can be accurately calculated.  
Specifically, a CT is a smaller statistical subdivision of a county as defined by the U.S. Census 
Bureau. Census tracts usually contain between 2,500 and 8,000 persons and are designed to be 
homogenous with respect to population characteristics (U.S. Census Bureau 1990). 
According to the U.S. Census, the town of Belmont is subdivided into eight census tracts (i.e., 
CTs 3571 through 3578). Three of the 30 census tracts in Cambridge are located on the border 
of Belmont (i.e., CTs 3543, 3546, and 3549) (U.S. Census Bureau 2000).  The town boundaries 
and census tract locations for Belmont and surrounding communities are shown in Figure 1.  
Cases for which census tract designation was not possible were included in the city/town totals 
for Belmont and Cambridge. 
3. Interpretation of a Standardized Incidence Ratio 
A standardized incidence ratio (SIR) is an estimate of the occurrence of cancer in a population 
relative to what might be expected if the population had the same cancer experience as a larger 
comparison population designated as “normal” or average.  Usually, the state as a whole is 
selected to be the comparison population.  Using the state of Massachusetts as a comparison 
population provides a stable population base for the calculation of incidence rates. 
Specifically, an SIR is the ratio of the observed number of cancer cases in an area to the expected 
number of cases multiplied by 100.  The population structure of each town is adjusted to the 
statewide incidence rate to calculate the number of expected cancer cases.  The SIR is a 
comparison of the number of cases in the specific area (i.e., city/town or census tract) to the 
statewide rate. Comparisons of SIRs between towns or census tracts are not possible because 
each community has different population characteristics. 
 Using slightly different population estimates or statistical methodologies, such as grouping ages differently or 
rounding off numbers at different points during calculations, may produce results slightly different from those 
published in this report. 
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3
An SIR of 100 indicates that the number of cancer cases observed in the population being 
evaluated is equal to the number of cancer cases expected in the comparison or “normal” 
population. An SIR greater than 100 indicates that more cancer cases occurred than were 
expected, and an SIR less than 100 indicates that fewer cancer cases occurred than were 
expected. Accordingly, an SIR of 150 is interpreted as 50% more cancer cases than the expected 
number; an SIR of 90 indicates 10% fewer cancer cases than expected. 
Caution should be exercised, however, when interpreting an SIR.  The interpretation of an SIR 
depends on both the size and the stability of the SIR.  Two SIRs can have the same size but not 
the same stability.  For example, an SIR of 150 based on four expected cases and six observed 
cases indicates a 50% excess in cancer, but the excess is actually only two cases.  Conversely, an 
SIR of 150 based on 400 expected cases and 600 observed cases represents the same 50% excess 
in cancer, but because the SIR is based upon a greater number of cases, the estimate is more 
stable. It is very unlikely that 200 excess cases of cancer would occur by chance alone.  As a 
result of the instability of incidence rates based on small numbers of cases, SIRs were not 
calculated when fewer than five cases were observed for a particular cancer type. 
4. Calculation of the 95% Confidence Interval 
To help interpret or measure the stability of an SIR, the statistical significance of each SIR was 
assessed by calculating a 95% confidence interval (95% CI) to determine if the observed number 
of cases is “significantly different” from the expected number or if the difference may be due 
solely to chance (Rothman and Boice 1982). Specifically, a 95% CI is the range of estimated 
SIR values that have a 95% probability of including the true SIR for the population.  If the 95% 
CI range does not include the value 100, then the study population is significantly different from 
the comparison or “normal” population.  “Significantly different” means there is less than a 5% 
chance that the observed difference (either increase or decrease) is the result of random 
fluctuation in the number of observed cancer cases. 
For example, if a confidence interval does not include 100 and the interval is above 100 (e.g., 
105–130), there is a statistically significant excess in the number of cancer cases.  Similarly, if 
the confidence interval does not include 100 and the interval is below 100 (e.g., 45–96), the 
number of cancer cases is statistically significantly lower than expected.  If the confidence 
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interval range includes 100, the true SIR may be 100.  In this case, it cannot be determined with 
certainty that the difference between the observed and expected number of cases reflects a real 
cancer increase or decrease or is the result of chance.  It is important to note that statistical 
significance does not necessarily imply public health significance.  Determination of statistical 
significance is just one tool used to interpret SIRs. 
In addition to the range of the estimates contained in the confidence interval, the width of the 
confidence interval also reflects the stability of the SIR estimate.  For example, a narrow 
confidence interval, such as 103–115, allows a fair level of certainty that the calculated SIR is 
close to the true SIR for the population. A wide interval, for instance 85–450, leaves 
considerable doubt about the true SIR, which could be much lower than or much higher than the 
calculated SIR.  This would indicate an unstable statistic.  Again, due to the instability of 
incidence rates based on small numbers of cases, statistical significance was not assessed when 
fewer than five cases were observed. 
5. Evaluation of Cancer Risk Factor Information 
Available information reported to the MCR related to risk factors for cancer development was 
reviewed and compared to known or established incidence patterns for the cancer types 
evaluated in this report.  This information is collected for each individual at the time of cancer 
diagnosis and includes age at diagnosis, stage of disease, smoking history, and occupation.  One 
or even several factors acting over time can be related to the development of cancer.  For 
example, tobacco use has been linked to lung and bronchus, kidney, and pancreatic cancers.  
Other cancer risk factors may include lack of crude fiber in the diet, high fat consumption, 
alcohol abuse, and reproductive history.  Heredity, or family history, is an important factor for 
several types of cancer. To a lesser extent, some occupational exposures, such as jobs involving 
contact with asbestos, have been shown to be carcinogenic (cancer causing).  Environmental 
contaminants have also been associated with certain types of cancer.  The available risk factor 
information from the MCR was evaluated for residents of the four communities who were 
diagnosed with any of the six cancer types included in this report.  However, information about 
personal risk factors such as family history, hormonal events, diet, and other factors that may 
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also influence the development of cancer is not collected by the MCR; therefore, it was not 
possible to evaluate these factors in this investigation. 
6. Determination of Geographic Distribution of Cancer Cases 
In addition to calculation of SIRs, address at the time of diagnosis for each individual diagnosed 
with cancer was mapped using a computerized geographic information system (GIS) (ESRI 
2002). This allowed assignment of census tract location as well as an evaluation of the spatial 
distribution of individual cases at a smaller geographic level (i.e., neighborhoods).  The 
geographic pattern was determined using a qualitative evaluation of the point pattern of cancer 
cases in each of the four communities.  In instances where the address information from the 
MCR was incomplete (i.e., did not include specific streets or street numbers), efforts were made 
to research those cases using telephone books issued within 2 years of an individual’s diagnosis.  
For confidentiality reasons, it is not possible to include maps showing the locations of 
individuals diagnosed with cancer in this report.  (Note: MDPH is bound by Massachusetts 
General Laws and the federal Health Insurance Portability and Accountability Act (HIPAA) not 
to reveal the name or identifying information of an individual diagnosed with cancer whose case 
is reported to the MCR.) 
B. Cancer Incidence in Belmont 
Cambridge Plating is located in CT 3572 close to the border of CT 3571 (see Figure 1).  This 
section presents cancer incidence rates for the town of Belmont as a whole as well as Belmont 
CTs 3571 and 3572, during the 18-year time period, 1982–1999.  A summary of the cancer 
experience in the communities of Cambridge, Arlington, and Watertown is provided in Section 
C. To evaluate possible trends over time, cancer incidence data were also analyzed by three 
smaller time periods, 1982–1987, 1988–1993, and 1994–1999. In addition to the results 
presented in this section, Appendix A provides comprehensive analyses for the town of Belmont 
as a whole and all eight census tracts that comprise the town.  Cancer incidence results for 
Belmont and the census tracts that comprise the town are presented in Tables 1a – 6d of 
Appendix A. SIRs were not calculated for some cancer types in smaller time periods due to the 
small number of observed cases (less than five).  However, the expected number of cases was 
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calculated during each time period, and the observed and expected numbers of cases were 
compared to determine whether more cancer cases were occurring than expected. 
1. Results 
a. Town of Belmont 
With one exception, which is discussed later in this section, the cancer types evaluated in this 
report generally occurred approximately near or below expected rates in the town of Belmont as 
a whole during the 18-year time period, 1982–1999, as well as smaller time periods (i.e., 1982– 
1987, 1988–1993, and 1994–1999). 
Overall, kidney cancer, lung and bronchus cancer, and NHL occurred less often than expected 
during 1982–1999. The incidence of kidney cancer appears to have decreased over time among 
both male and female residents of Belmont.  For example, during 1982–1987, kidney cancer was 
elevated among males (15 diagnoses observed vs. 9.0 expected) and occurred slightly less than 
expected among females (6 diagnoses observed vs. 7.0 expected).  The elevation among males 
was not statistically significant. During the most recent time period evaluated, 1994–1999, 13 
individuals were diagnosed with kidney cancer compared to about 21 diagnoses expected.  Both 
males and females experienced lower than expected incidence of kidney cancer during this time 
period. 
Lung and bronchus cancer occurred statistically significantly less often than expected in the town 
as a whole (270 diagnoses observed vs. 375.3 expected, SIR = 72, 95% CI = 64–81) during the 
18-year time period, 1982–1999.  The incidence of this cancer type was also lower than expected 
during each of the smaller time periods evaluated and statistically significantly lower than 
expected during 1982–1987 and 1994–1999. 
NHL occurred less often than expected in Belmont during 1982–1999, primarily due to a lower-
than-expected rate among males in the town (32 diagnoses observed vs. 44.6 expected, 
SIR = 72), a rate that was borderline statistically significant (95% CI = 49-101).  Males in 
Belmont experienced fewer diagnoses of NHL than expected during each of the smaller time 
periods evaluated. Among females, more cases occurred during 1982–1999 than expected 
(52 diagnoses observed vs. 46.5 expected), but this elevation was not statistically significant.  
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Females were diagnosed about as expected during 1982–1987 and slightly more often than 
expected during the most recent time periods (1988–1993 and 1994–1999).  During each of these 
time periods, approximately three excess cases were diagnosed among females; however, neither 
elevation was statistically significant (19 diagnoses observed vs. 15.3 expected during 1988– 
1993; 20 diagnoses observed vs. 17.0 expected during 1994–1999). 
Pancreatic cancer occurred about as expected during 1982–1999 based on the statewide cancer 
experience. Although the overall rate remained consistent over time, different trends were 
observed among males and females when evaluated separately by gender.  Specifically, the 
incidence of pancreatic cancer in Belmont appears to have increased over time among males 
while decreasing over time among females.  However, no difference in either gender was 
statistically significant. 
Sixteen diagnoses of liver cancer were observed in Belmont during 1982–1999 versus about 14 
expected. The increase was based on approximately one additional diagnosis each over the 
expected number among males and females and was not statistically significant.  When 
examined by smaller time period, liver cancer occurred about as expected in all three time 
periods. 
The incidence of leukemia among females was elevated in Belmont during 1982–1999 (32 
diagnoses observed vs. 23.2 expected, SIR = 138).  This elevation was not statistically 
significant. Among males, leukemia occurred slightly less often than expected during the 
1982–1999 period (26 diagnoses observed vs. 27.1 expected).  Although leukemia was 
diagnosed less often than expected during the earliest time period, 1982–1987, both males and 
females experienced elevations of this cancer type during 1988–1993 and 1994–1999.  None of 
the observed elevations were statistically significant.  Elevations among males were based on 
one to three excess cases, while the elevations in females were due to about four excess cases in 
each time period (11 diagnoses observed vs. 6.9 expected during 1988–1993; 13 diagnoses 
observed vs. 8.7 expected during 1994–1999). 
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b. Belmont CTs 3571 and 3572 
Rates of kidney cancer, lung and bronchus cancer, and NHL were near or below the expected 
rates among males and females combined in Belmont CT 3571 during the 18-year time period, 
1982–1999. Slightly more leukemia, liver cancer, and pancreatic cancer diagnoses were 
observed during the overall time period; however, none of the elevations was statistically 
significant. Lung and bronchus cancer occurred statistically significantly less often than 
expected among males during this time (29 diagnoses observed vs. 46.4 expected, SIR = 63, 95% 
CI = 42-90). 
In general, when cancer rates in CT 3571 were evaluated for smaller time periods, no consistent 
trends over time were observed.  While leukemia occurred at about the rate expected during the 
first time period, 1982–1987, this cancer type occurred slightly more often than expected during 
the two later time periods, 1988–1993 and 1994–1999.  These increases were based on one to 
two additional diagnoses during each time period and were not statistically significant.  Lung and 
bronchus cancer occurred statistically significantly less often than expected among males during 
the first time period, 1982–1987 (7 diagnoses observed vs. 16.1 expected, SIR = 43, 95% CI = 
17–90). The incidence of this cancer type among males was also lower than expected during 
1988–1993 and 1994–1999. The overall elevation of pancreatic cancer in CT 3571 was 
primarily due to an elevation during the earliest time period (1982–1987).  In general, kidney 
cancer, liver cancer, and NHL occurred about as expected in CT 3571 during each of the smaller 
time periods evaluated. 
Of the six cancer types evaluated in this report, five (leukemia, liver cancer, lung and bronchus 
cancer, NHL, and pancreatic cancer) occurred about as or less often than expected in Belmont 
CT 3572, where Cambridge Plating is located, during the 18-year time period (1982–1999) 
among males and females combined.  Lung and bronchus cancer occurred statistically 
significantly less often than expected during this time period (31 diagnoses observed vs. 46.2 
expected, SIR = 67, 95% CI = 46–95). 
Eight individuals were diagnosed with kidney cancer among males and females combined while 
7.2 would have been expected. About three excess cases occurred among males (7 diagnoses 
observed vs. 4.4 expected), while kidney cancer among females occurred less often than 
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expected (1 diagnosis observed vs. 2.8 expected).  The elevation in kidney cancer among males 
was primarily attributable to an excess of approximately two cases during 1982–1987.  During 
1994–1999, kidney cancer occurred less often than expected among males in census tract 3572. 
When examined by smaller time periods, all four diagnoses of NHL in CT 3572 during 1982– 
1999 occurred during the earliest time period, 1982–1987 (versus 3.0 expected), with no 
diagnoses during 1988–1999 compared to almost eight expected.  For leukemia, liver cancer, 
lung and bronchus cancer, and pancreatic cancer, most occurred less frequently or about as 
expected during each time period for each gender.  Any elevations observed were based on about 
one or two additional cases above the expected. Refer to Tables 1a – 6d in Appendix A for 
details. 
2. Review of Cancer Risk Factor Information in Belmont 
As previously mentioned, cancer is not just one disease, but is a term used to describe a variety 
of different diseases. As such, studies have generally shown that different cancer types have 
different causes, patterns of incidence, risk factors, latency periods (the time between exposure 
and development of disease), characteristics, and trends in survival.  Available information from 
the MCR related to age and gender, as well as other factors related to the development of cancer 
such as smoking and occupation, was reviewed for individuals diagnosed with cancer in 
Belmont.  Information for each of the six cancer types evaluated in this report was compared to 
known or established incidence trends to assess whether any unexpected patterns exist among 
these cases.  It is important to note, however, that personal risk factors such as family history, 
pre-existing medical conditions, hormonal events, diet, and other factors also influence the 
development of these cancer types.  This information is not collected by the MCR or any other 
readily accessible source. Therefore, it was not possible to evaluate the role these types of risk 
factors may have played in the incidence of cancer in Belmont and surrounding communities in 
this investigation. For detailed information regarding risk factors associated with the cancer 
types evaluated in this report, please refer to Appendix C. 
Age and gender are risk factors in many types of cancers, including kidney cancer, liver cancer, 
lung and bronchus cancer, leukemia, NHL, and pancreatic cancer.  Therefore, a review of age­
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group specific SIRs was conducted.  Where numbers of cases in each age group were too small 
to calculate SIRs, the distribution of cases by age was reviewed. 
Tobacco use is also a known or suggested causal risk factor in several types of cancer, including 
kidney cancer, lung and bronchus cancer, and pancreatic cancer.  The smoking history of 
individuals diagnosed with these cancer types was reviewed to assess the role tobacco smoking 
may have played in the development of these cancers among residents of Belmont.  However, 
results of smoking history analysis should be interpreted with caution because of the number of 
individuals for which smoking status was unknown. 
In some studies, an association has been found between specific occupational exposures and an 
increase in the incidence of kidney cancer, leukemia, liver cancer, lung and bronchus cancer, 
NHL, and pancreatic cancer. Therefore, occupational information as reported by the MCR at the 
time of diagnosis was reviewed for individuals diagnosed with these cancer types to determine 
the role that occupational factors may have played in the development of these cancers in 
Belmont.  It should be noted, however, that occupational data reported to the MCR are generally 
limited to job title and often do not include specific job duty information that could further define 
exposure potential for individual cases.  In addition, these data are often incomplete as 
occupational information can be reported as unknown, at home, or retired. 
Finally, histologic (cell type) distribution was reviewed for diagnoses of lung and bronchus 
cancer and leukemia.  Patterns of disease were compared to known or established incidence 
trends to assess whether any unexpected patterns exist in these areas. 
Available information on risk factors was compared to known or established trends to evaluate 
whether any unexpected patterns exist in Belmont.  In general, the trends observed in Belmont 
are similar to those seen in the general population.  Review of these data suggests that smoking 
likely played some role in the diagnosis of some cancer types (e.g., cancers of the kidney, lung 
and bronchus, and pancreas) among some individuals.  Review of available data indicated that 
occupational exposures may have been important in the development of cancer among some 
individuals as well. However, it is difficult to fully assess the extent to which these factors 
influenced the overall patterns of cancer in Belmont because of the large number of individuals 
for whom smoking history and/or occupation was unknown.  Refer to Appendix A for more 
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detailed information regarding the prevalence of these risk factors among individuals diagnosed 
with cancer in Belmont. 
3. Analysis of Geographic Distribution of Cancer Incidence in Belmont 
In addition to determining incidence rates for each cancer type, a qualitative evaluation of the 
geographic pattern of cancer diagnoses was conducted for the town of Belmont.  Place of 
residence at the time of diagnosis was mapped for each individual diagnosed with the cancer 
types evaluated in this report to assess any possible geographic concentrations of cases in 
relation to each other or in the vicinity of Cambridge Plating.  As previously mentioned, cancer 
is one word that describes many different diseases.  Therefore, for the purposes of this 
evaluation, the geographic distribution of each cancer type was evaluated separately to determine 
whether an atypical pattern of any one type was occurring.  The geographic distributions of some 
specific types of cancer were also evaluated together because they may have similar etiologies 
(e.g., leukemia and NHL in children). 
Based on a review of address at the time of diagnosis for each individual diagnosed with a cancer 
type considered in this report, no apparent concentrations of cancer diagnoses (of any type) were 
observed in the vicinity of the Cambridge Plating site.  A small concentration of leukemia 
diagnoses was noted in the southeastern corner of Belmont.  However, leukemia is a general 
term that describes a group of four different major subtypes [i.e., acute lymphoid leukemia 
(ALL), acute myeloid leukemia (AML), chronic lymphoid leukemia (CLL), and chronic myeloid 
leukemia (CML)], and a few rare types, such as hairy cell leukemia.  Further review of specific 
case information for these individuals revealed a variety of subtypes of leukemia diagnosed 
among individuals in this area, indicating the occurrence of different diseases with different risk 
factors. 
No other unusual spatial patterns or concentrations of cases at the neighborhood level that would 
suggest a common factor (environmental or nonenvironmental) related to cancer diagnoses 
among residents were apparent for any cancer type.  Any patterns that were observed were 
consistent with what would be expected based on the population distribution and areas of higher 
population density. For example, in Belmont, the majority of individuals with each type of 
cancer tended to be located in areas of the town where population and housing density is greater.  
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Although elevations in the incidence of some cancer types were noted in Belmont during one or 
more time periods evaluated, in general, the geographic distribution of diagnoses for these cancer 
types seemed to coincide closely with the pattern of population and cases did not appear to be 
concentrated in any one area of the town. Thus it does not appear that exposures to 
environmental contamination associated with Cambridge Plating are likely to have played a role 
in the development of cancer among residents of Belmont.   
C. Cancer Incidence in Surrounding Communities 
With some exceptions, cancer incidence in the surrounding towns of Cambridge, Arlington and 
Watertown during the 18-year time period, 1982–1999, and smaller time periods evaluated was 
approximately at or near expected rates for the majority of the six cancer types evaluated.  The 
following sections provide a summary of cancer incidence results for the three surrounding 
communities.  Appendix A of this report provides comprehensive analyses of cancer incidence in 
the communities of Cambridge, Arlington, and Watertown. 
1. Results 
a. City of Cambridge 
Cancer incidence rates were evaluated for the city of Cambridge, with a particular focus on 
census tracts adjacent to Belmont (i.e., CTs 3543, 3546, and 3549).  The results of these analyses 
are summarized for each of the six cancer types in Tables 7a – 12d of Appendix A.  During the 
1982–1999 time period, citywide incidence rates were lower than expected for kidney cancer, 
leukemia, lung and bronchus cancer, and NHL.  Rates were about as expected for pancreatic 
cancer and slightly higher than expected for liver cancer.  Overall, 40 individuals were diagnosed 
with liver cancer compared to 34.2 expected (SIR = 117).  The elevation in liver cancer was not 
statistically significant. 
When evaluated by smaller time periods, kidney cancer, leukemia, lung and bronchus cancer, 
and NHL occurred consistently less than expected over time.  Citywide rates of liver cancer were 
higher than expected during 1982–1987, about as expected during 1988–1993, and slightly 
higher than expected during 1994–1999.  Neither of the elevations was statistically significant.  
Analysis of trends over time suggests that the incidence of pancreatic cancer is decreasing in the 
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city as a whole over time.  During the most recent time period evaluated, 1994–1999, 43 
individuals were diagnosed with pancreatic cancer in Cambridge compared to 48.0 expected 
(SIR = 89). 
Census tract-specific SIRs could not be calculated for the majority of cancer types because of the 
small number of observed cases; however, the number of cases observed was compared with the 
number expected to determine if an atypical pattern of cancer was occurring.  Kidney cancer, 
leukemia, lung and bronchus cancer, and NHL generally occurred equal to or less often than 
expected in Cambridge CTs 3543, 3546, and 3549 during 1982–1999.  Slight elevations in liver 
cancer were observed in some census tracts, however elevations were based on one to two 
additional diagnoses over that expected. While pancreatic cancer occurred about as expected in 
CTs 3543 and 3546 during 1982–1999, an elevation in pancreatic cancer was observed in CT 
3549 during this time (13 diagnoses observed vs. 7.0 expected, SIR=187).  This elevation was 
borderline statistically significant (95% CI = 99–320) and was due to a statistically significant 
elevation among males in this area of Cambridge (9 males diagnosed vs. 3.3 expected, SIR = 
273). This rate appears to be the result of slight elevations in the incidence of this cancer type 
among males during each of the smaller time periods in CT 3549. 
b. Town of Arlington 
In general, residents of Arlington experienced cancer approximately at or below the rates 
expected during 1982–1999 and in the three smaller time periods evaluated.  Cancer incidence 
rates for Arlington are presented in Tables 13a – 13d of Appendix A.  Kidney cancer, leukemia, 
and lung and bronchus cancer all occurred less often than expected during 1982–1999.  Overall, 
the incidence of lung and bronchus cancer in Arlington was statistically significantly decreased 
with respect to the state rate between 1982–1999 (544 diagnoses observed vs. 643.8 expected, 
SIR = 84, 95% CI = 78–92) and statistically significantly decreased during each of the three 
smaller time periods evaluated.  Both NHL and pancreatic cancer were diagnosed at about the 
rates expected during 1982–1999 and the incidence of liver cancer was higher than expected 
during this time (28 diagnoses observed vs. 23.4 expected).  Townwide incidence ratios for liver 
cancer among males and females combined and for pancreatic cancer among males were 
statistically significantly elevated during the earliest time period evaluated (1982–1987).  An 
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elevation in the incidence of leukemia was also observed among females aged 0–19 years in 
Arlington. 
c. Town of Watertown 
With some exceptions, Watertown residents experienced cancer approximately at or near the 
rates expected during 1982–1999 and during the three smaller time periods evaluated.  Cancer 
incidence rates for the town of Watertown are provided in Appendix A, Tables 14a through 14d.  
Specifically, the incidence of both lung and bronchus cancer and pancreatic cancer were lower 
than expected during the time period 1982–1999, and the overall incidence of lung and bronchus 
cancer may be decreasing over time in Watertown.  Slight elevations in kidney cancer and 
leukemia were observed during the overall time period, however neither elevation was 
statistically significant. The incidence of liver cancer among males and females combined was 
higher than expected based on the state rate, and the rate of liver cancer among males alone 
during 1982–1999 was statistically significantly elevated (21 diagnoses observed vs. 11.2 
expected, SIR = 188).  Liver cancer was diagnosed more often than expected among males in 
Watertown during each of the smaller time periods evaluated (1982–1987, 1988–1993, and 
1994–1999), however none of these elevations was statistically significant.  Finally, NHL 
occurred more often than expected in the town of Watertown during 1982–1999 (137 diagnoses 
observed vs. 113.2 expected, SIR = 121), an elevation that was statistically significant (95% CI  
= 102–143). 
2. Review of Risk Factor Information in Surrounding Communities 
Available risk factor information for individuals diagnosed with cancer in Cambridge, Arlington, 
and Watertown was also compared to known or established trends to assess whether any 
unexpected patterns exist in the town.  As with the town of Belmont, the trends observed in the 
surrounding communities are similar to those seen in the general population.  Review of these 
data, which is provided in Appendix A, suggests that smoking likely played a role in the 
development of some types of cancer such as cancers of the kidney, lung and bronchus, and 
pancreas among some individuals in these towns.  However, because of the large number of 
individuals for whom smoking history and/or occupation was unknown, it is difficult to fully 
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assess the extent to which these factors influenced overall cancer patterns in the surrounding 
towns. 
3.	 Analysis of Geographic Distribution of Cancer Incidence in Surrounding 
Communities 
The place of residence for individuals diagnosed with cancer in Cambridge, Arlington, and 
Watertown was evaluated to identify any geographic concentrations of cases that might be 
present within the three communities.  No atypical spatial patterns that would suggest a common 
factor (environmental or nonenvironmental) related to the incidence of cancer in the surrounding 
communities were noted.  In general, any patterns observed were consistent with what would be 
expected based on the population distribution and areas of higher population density.  Further, no 
apparent concentrations of cancer diagnoses (of any type) were observed in the three surrounding 
towns that would suggest a potential relationship to Cambridge Plating.  While portions of 
Cambridge CTs 3546 and 3549 are located in the vicinity of Cambridge Plating, land use in the 
western portion of CT 3549 is primarily non-residential.  Census tract 3546, however, is a 
residential neighborhood and is adjacent to the Belmont border.  There were no unusual 
concentrations of cancer diagnoses in either of these census tracts.   
A small concentration of leukemia diagnoses was observed near the center of Arlington.  
Specifically, six individuals (ages 15–77) in a high-density residential neighborhood were 
diagnosed with leukemia between 1994 and 1998.  However, a variety of histology types were 
represented among these individuals—indicating the occurrence of different diseases.  While an 
elevation in the incidence of leukemia was observed among females aged 0–19 years in 
Arlington (9 diagnoses observed vs. 2.6 expected), in general, the nine diagnoses did not appear 
to be unusually concentrated in time or space.  A small concentration of individuals diagnosed 
with NHL was also noted in Watertown.  On the basis of the available risk factor information for 
these individuals, including a review of residential histories, it does not appear that any single 
factor (environmental or nonenvironmental) would explain the observed distribution.  A 
complete discussion of geographic distribution of cancer incidence in the surrounding 
communities is provided in Appendix A, Section VII. 
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VII. DISCUSSION 
As part of this public health assessment, MDPH evaluated cancer incidence data for Belmont and 
the surrounding communities of Cambridge, Arlington, and Watertown, with a particular focus 
on Belmont CTs 3571 and 3572, and reviewed available environmental information for 
Cambridge Plating to determine possible pathways of exposure for nearby residents.  Although 
some of the soil and groundwater at the site has been contaminated in the past, and is still 
contaminated in recent samples, the information reviewed does not suggest that under present 
conditions the contaminants detected in subsurface media at the Cambridge Plating facility are 
likely to result in health concerns to individuals visiting or residing in neighborhoods adjacent to 
the facility. 
Most of the Cambridge Plating property is covered by asphalt or concrete and it is unlikely that 
residents who live nearby would come into contact with contaminated soil from the site.  Past 
intermittent exposure to chromium-contaminated soil could have been possible for individuals 
who might have trespassed near a 450-square foot area located north of the facility adjacent to 
the MBTA railroad tracks. However, it is unlikely that anyone would have had contact with soil 
from this area for sufficient frequency and duration of time to result in health effects.  It is also 
important to note that while subsurface soil concentrations of total chromium were quite high in 
this location, levels of hexavalent chromium (a carcinogen) were approximately at or below 
health-based comparison values.  In addition, new information indicates that surface soil 
concentrations of chromium are approximately at or below health-based comparison values and, 
therefore, unlikely to result in adverse health effects for residents who may be exposed to on-site 
surface soil. 
In the Cambridge Plating Public Health Assessment report that was released for public comment 
in 2005, the MDPH recommended additional sampling to determine chromium levels in soil 
surrounding Cambridge Plating.  Air emissions modeling conducted by MDEP determined that 
areas with the highest chromium concentrations would likely be located on-site.  To confirm the 
results of the air emissions modeling and to address the recommendation for additional sampling, 
MDEP sampled surface soil at off-site locations near the facility in 2007 (MDEP 2007).  This 
sampling event confirmed the air emissions modeling and indicated that surface soil 
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concentrations of chromium are well below health-based comparison values and, therefore, 
unlikely to result in adverse health effects for residents living near Cambridge Plating.   
TCE and its chlorinated breakdown products (i.e., cis-1,1-DCE and vinyl chloride, which are 
also VOC compounds) were detected in groundwater samples collected at the Cambridge Plating 
site. Sampling of groundwater monitoring wells west of the Cambridge Plating buildings 
showed the highest concentrations of TCE and cis-1,1-DCE.  Although these chlorinated VOCs 
were detected at levels exceeding health-based comparison values for drinking water (see Table 
2), exposure to contaminated groundwater is unlikely for individuals residing in neighborhoods 
abutting the Cambridge Plating site because groundwater in this area is not being used for 
drinking water purposes. In addition, the application of the Johnson-Ettinger model by ATSDR 
indicates that concentrations of VOCs detected in a groundwater well located closer to the site 
boundary near Hittinger Street are not at levels that would be expected to result in indoor air 
concentrations in nearby homes that would be of health concern.  This finding is further 
supported by results of a soil gas and groundwater investigation conducted by Coler and 
Colantonio, which indicated that the high concentrations of VOCs detected in groundwater west 
of the Cambridge Plating building are not likely to result in elevated levels in indoor air of 
homes along Hittinger Street (2004).  Also, because groundwater from beneath the Cambridge 
Plating building does not appear to flow toward the northern site boundary, it is not expected that 
residents north of the site would have opportunities for exposure to levels of VOCs in indoor air 
that could present a health risk. 
A limitation on future uses of the Cambridge Plating property will reduce the possibility of any 
future exposures to subsurface contamination present at the site.  As a result of site investigations 
conducted in 2000, Cambridge Plating filed a Notice of Activity and Use Limitation for the 
property stating it cannot be developed for residential use without subsurface investigation and, 
if necessary, remediation (Coler and Colantonio 2002a). 
Review of air permit information and TRI data for Cambridge Plating indicate that TCE and 
chromium emissions to air are primary contaminants of concern in the past at Cambridge Plating.  
Fugitive (non-stack) air emissions of TCE have been reported in TRI data since 1988 (Table 3); 
however, TCE is no longer being used at the facility and air emissions of TCE have been 
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eliminated.  Stack emissions of chromium were also emitted to the air during the operational 
history of Cambridge Plating, until chrome-plating operations ceased at the end of 2002 (EPA 
Region 1 2003b). There are no ambient air sampling data available to determine whether past air 
emissions of TCE and chromium from the facility resulted in air concentrations in the adjacent 
neighborhoods at levels sufficient to result in exposure and/or health effects to residents.  In 
addition, because limited surface soil sampling data were available, it was not possible to 
evaluate potential exposures associated with deposition of chromium air emissions in the past.   
Occupational studies of workers exposed to unmeasured levels of TCE in air have been unable to 
provide definitive evidence for an increased cancer risk and are often limited by multiple 
chemical exposures and small numbers of study participants.  While some studies have shown no 
association between inhalation exposure to TCE and cancer, others have found slight increases in 
a number of cancer types.  However, problems with study design were often reported, such as the 
inability to distinguish between the effects of TCE and other chemicals used in the same area as 
TCE, and associations were often based on small numbers of individuals and complicated by 
confounding factors (ATSDR 1997). 
As observed in several toxicological investigations in experimental mice and rats, TCE has been 
shown to cause liver, lung, and kidney cancer and, to a lesser extent, lymphomas and leukemia.  
In terms of non-cancer health outcomes associated with TCE, studies of workers chronically 
exposed to TCE in air have reported sleepiness, dizziness, headaches, and nausea, and there is 
some suggestion that people who breathe high levels of TCE may develop damage to the nerves 
in the face (ATSDR 1997). 
The toxicological and epidemiological literature on chromium shows that inhalation exposure to 
chromium may have health effects, depending on the specific form of chromium compound 
involved and the nature of exposure (length of time, concentration).  Both human 
epidemiological and animal studies show that chromium, in particular hexavalent chromium, is a 
carcinogen. In particular, many studies show that occupational exposure to chromium VI can be 
associated with an increased risk of respiratory cancer (ATSDR 2000a).  A range of respiratory 
symptoms, gastrointestinal effects and irritations were seen in workers exposed to chromium 
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(VI) compounds, although in many of the studies there were confounding factors (ATSDR 
2000a). 
Most of the types of cancer evaluated in this report were selected based on their potential 
association with contaminants of concern identified or historically emitted at Cambridge Plating 
(i.e., TCE and chromium).  However, in large part, the rates of those cancer types evaluated in 
the community surrounding the facility (i.e., Belmont CTs 3571 and 3572) were approximately 
near or below the rates expected based on cancer incidence in the state of Massachusetts as a 
whole for the 18-year time period, 1982–1999.  Similar trends were observed in the town of 
Belmont as a whole and in Cambridge, Arlington, and Watertown.  Specifically, with a few 
exceptions, cancer incidence in the four towns during the 18-year time period, 1982–1999, and 
the three smaller time periods evaluated was approximately at or near expected rates for the six 
cancer types evaluated in this report.  Further, available risk factor information for those 
diagnosed with cancer was compared to known or established trends to assess whether any 
unexpected patterns exist in Belmont, Cambridge, Arlington, or Watertown.  In general, cancer 
trends observed in these communities are similar to those seen in the general population.  Review 
of the data suggests that smoking likely played some role in the development of certain types of 
cancer (e.g., kidney cancer, lung and bronchus cancer, and pancreatic cancer) among some 
individuals. Also, occupational exposures may have been important in the development of 
certain cancers, such as leukemia, lung and bronchus cancer, and NHL, among some individuals.  
However, because of the large number of individuals for whom smoking history and/or 
occupation was unknown, it is difficult to fully assess the extent to which these factors 
influenced overall cancer patterns in Belmont or the surrounding communities.   
In addition, analysis of the geographic distribution of place of residence for individuals 
diagnosed with cancer did not reveal any atypical spatial patterns that would suggest a common 
factor (environmental or nonenvironmental) in Belmont as a whole, CTs 3571 and 3572, or the 
surrounding communities of Cambridge, Arlington, and Watertown is related to the incidence of 
cancer. That is, no apparent concentrations of individuals diagnosed with cancer (including 
cancer types with a potential association with exposure to TCE and chromium) were observed in 
the vicinity of the Cambridge Plating site or in any other area of Belmont, Cambridge, Arlington, 
or Watertown that might suggest an association with a common environmental factor. 
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Residents of Belmont living near the Cambridge Plating facility have also conveyed concerns 
about several non-cancer health outcomes including upper respiratory irritation, nausea, and 
headaches (Belmont Department of Health 2003a; 2003c).  In addition, complaints about odors 
have been reported by individuals residing near the facility.  More recently, the Belmont 
Department of Health indicated that odors have subsided and that complaints have decreased 
(Belmont Department of Health 2007).  Of the types of chemicals reported in the TRI data as air 
emissions from the Cambridge Plating site, hydrofluoric and nitric acids have strong acidic, 
irritating odors, while TCE has sweet, chloroform-like odors (HSDB 2002a-c).  It is possible that 
some residents living in close proximity to the facility could have experienced some irritant 
effects associated with TCE (in the past) or acids in ambient air.  It is also important to note that 
some individuals, particularly those with pre-existing conditions such as asthma and allergies, 
may experience irritant reactions that would not necessarily impact the general population 
similarly. 
On the basis of the information reviewed in this evaluation, it does not appear that a common 
factor (environmental or nonenvironmental) played a major role in the incidence of cancer in the 
census tract that contains Cambridge Plating or the adjacent census tracts, in the town of 
Belmont as a whole, or in the surrounding communities of Cambridge, Arlington, and 
Watertown during the 18-year time period, 1982–1999. 
VIII. CHILD HEALTH CONSIDERATIONS 
ATSDR and MDPH recognize that the unique vulnerabilities of infants and children demand 
special emphasis in communities faced with contamination of their environment.  Children are at 
a greater risk than adults from certain kinds of exposure to hazardous substances emitted from 
waste sites or other environmental sources.  They are more likely to be exposed because they 
play outdoors and because they often bring food into contaminated areas.  Because of their 
smaller stature, they might breathe dust, soil, and heavy vapors close to the ground.  Children are 
also smaller, resulting in higher doses of contaminant exposure per body weight.  The developing 
body systems of children can sustain permanent damage if certain toxic exposures occur during 
critical growth stages.  Most importantly, children depend completely on adults for risk 
identification and management decisions, housing decisions, and access to medical care. 
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The incidence and patterns of cancer among children in Belmont, Cambridge, Arlington, and 
Watertown are discussed in detail in Appendix A (“Assessment of Cancer Incidence in Belmont, 
Massachusetts and Surrounding Communities: 1982-1999”) and summarized in Section VI of 
this report. As previously mentioned, an elevation in the incidence of leukemia was observed 
among females aged 0–19 years in Arlington.  However, a review of the geographic distribution 
of diagnoses and available environmental information indicate that it is unlikely that a common 
factor played a role in the occurrence of leukemia among these individuals.  There were reports 
in the Belmont Department of Health files indicating that older children may have trespassed on 
the Cambridge Plating site in the past—specifically one incidence of youth climbing onto the 
roof of a building. However, since the contamination identified in soil and groundwater is 
generally located below the ground surface, children or young adults trespassing at the site 
would be extremely unlikely to come into contact with these contaminated media.  While 
trespassers might have come in contact with chromium contaminated soil identified in an area 
adjacent to the MBTA railroad tracks in the past, it is unlikely that exposure would have 
occurred for sufficient frequency and duration of time to result in health effects.  Based on the 
information reviewed in this evaluation, no evidence was found that would indicate children are 
more likely than adults to come in contact with contamination identified at Cambridge Plating. 
IX. LIMITATIONS 
Several important limitations exist in relation to the environmental data available for this report.  
These limitations make it impossible to determine the role potential exposures to specific 
contaminants or to environmental media harboring those contaminants may have played in the 
development of an individual’s cancer or other health impact.   
The environmental data available from the Cambridge Plating site had several limitations.  The 
total number of samples collected over the entire history of the site was limited, and the sampling 
was conducted for a variety of specific purposes unrelated to the current evaluation.  Some 
samples were collected as part of the response to a spill or release whereas other samples were 
collected as part of state and federal site investigations.  For some of the environmental data 
reviewed, there was no information regarding specific depths or sampling locations.  Finally, 
with the exception of samples collected for chromium analysis in soil, no surface soil samples 
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were collected from the top 0-3 inches of soil where possible exposure would be considered 

more likely. 

This assessment includes an investigation that considers descriptive health outcome data for 
cancer to determine whether the pattern or occurrence of selected cancers is unusual.  The 
purpose of this investigation was to evaluate the patterns of cancer in a geographical context in 
relation to available information about factors, including environmental factors, related to cancer 
to see whether further investigation seems warranted.  Information from descriptive analyses, 
which may suggest that a common etiology (or cause) is possible, can serve to identify areas 
where further public health actions may be warranted.  Inherent limitations in this type of 
analysis and the available data make it impossible to determine the precise causal relationships or 
synergistic roles that may have played a part in the development of individual cancers in these 
communities.  Also, this type of analysis cannot determine what may have caused cancer in any 
one individual. Cancers in general have a variety of risk factors known or suggested to be 
related to the etiology (cause) of the disease that could not be evaluated in this report.  It is 
believed that many types of cancers are related largely to behavioral factors such as cigarette 
smoking, diet, and alcohol consumption.  Other factors associated with cancer are socioeconomic 
status, heredity/genetics, race, and geography.  It is beyond the scope of this report to determine 
the causal relationship of these factors and the development of cancer or other health outcomes 
in Belmont and the surrounding communities.   
X. CONCLUSIONS 
•	 Although some of the groundwater and soil at the Cambridge Plating site has been 
contaminated in the past and some has been found to be contaminated in more recent 
samples, based on the data reviewed, there is no information to suggest that the 
contaminants detected in subsurface media at the Cambridge Plating facility are resulting 
in health impacts for individuals visiting or residing in neighborhoods adjacent to the 
facility (i.e., the majority of the property is paved and contaminated groundwater is not a 
source of drinking water or expected to be at a level of concern for indoor air close to the 
site boundary near Hittinger Street or Channing Road).   
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•	 It has been reported that air emissions of TCE and chromium from Cambridge Plating 
have occurred in the past. However, there are no ambient air sampling data available to 
determine whether historical air emissions resulted in air concentrations of these 
chemicals in the vicinity of the facility at levels sufficient to result in exposure and/or 
health impacts to residents. 
•	 Air modeling conducted by MDEP predicted that the areas with the highest 
concentrations of chromium in soil would likely be located on-site.  Additional analysis 
of surface soils, conducted by Cambridge Plating at the request of MDEP, indicated that 
exposure to surface soil concentrations of chromium located on-site would not be 
expected to result in adverse health effects for nearby residents.  Sampling for chromium 
at locations around the Cambridge Plating facility also indicated that chromium in off-site 
surface soil is unlikely to result in adverse health effects in nearby residents. 
•	 In general, the six cancer types evaluated in relation to Cambridge Plating occurred near 
or below the expected rates for Belmont CTs 3571 and 3572 and the town of Belmont as 
a whole during the 18-year time period, 1982–1999.  Similar trends were observed in the 
surrounding communities of Cambridge, Arlington, and Watertown.  No unusual 
concentrations of individuals diagnosed with cancer (including those cancer types with a 
potential association with exposure to TCE and chromium) were observed in the vicinity 
of the Cambridge Plating site or in any other area of Belmont, Cambridge, Arlington, or 
Watertown. 
•	 It is possible that residents living in proximity to Cambridge Plating may have 
experienced some irritant effects associated with air emissions from the facility.  It is 
important to note that some individuals, particularly those with pre-existing conditions 
such as asthma and allergies, may experience irritant reactions that would not necessarily 
impact the general population similarly. 
•	 On the basis of the information reviewed in this evaluation, including available 
environmental data for Cambridge Plating and risk factor information for individuals 
diagnosed with cancer, it does not appear that a common factor (environmental or 
nonenvironmental) played a major role in the incidence of cancer in the census tract that 
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contains the Cambridge Plating site or the adjacent census tract, in the town of Belmont 
as a whole, or in Cambridge, Arlington, or Watertown during the 18-year time period, 
1982–1999. 
ATSDR requires that one of five conclusion categories be used to summarize findings of a public 
health assessment.  These categories are as follows: (1) Urgent Public Health Hazard; (2) Public 
Health Hazard; (3) Indeterminate Public Health Hazard; (4) No Apparent Public Health Hazard; 
(5) No Public Health Hazard. A category is selected from site-specific conditions such as the 
degree of public health hazard based on the presence and duration of human exposure, 
contaminant concentration, the nature of toxic effects associated with site-related contaminants, 
presence of physical hazards, and community health concerns. 
Although no indication was found that people are being exposed to chemicals from Cambridge 
Plating, past anecdotal reports about odors and nuisance conditions as well as documented 
evidence of fugitive TCE air emissions and stack chromium emissions suggest that past 
exposures may have been possible in areas surrounding the facility.  However, information 
regarding historical ambient air concentrations of emissions is unavailable making it difficult to 
evaluate whether the local population has been exposed to contaminants from the site.  
Therefore, using ATSDR’s criteria, under past conditions Cambridge Plating would be classified 
as posing an Indeterminate Public Health Hazard.  Available information does not indicate that 
possible past exposures have resulted in elevated cancer rates in Belmont CTs 3571 or 3572 or in 
the neighborhoods surrounding the facility.   
In the Cambridge Plating Public Health Assessment released for public comment in 2005, 
current and future opportunities for exposures were classified as an Indeterminate Public Health 
Hazard due to data gaps related to groundwater and surface soil.  Since then, additional surface 
soil sampling was conducted to evaluate whether air emissions in the past resulted in deposition 
of chromium in surface soil at a level of health concern.  The results indicated that surface soil 
concentrations of chromium located both on-site and off-site are unlikely to result in adverse 
health effects for residents who may be exposed.  New groundwater monitoring data and 
additional groundwater characterization indicated that groundwater from beneath the Cambridge 
Plating facility does not appear to flow toward the northern site boundary; therefore, it is not 
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expected that residents north of the site would have opportunities for exposure to levels of VOCs 
in indoor air that could present a health risk.  Based on the previously available data and the 
additional data gathered since the public comment release in 2005, ATSDR would classify 
current and future opportunities for exposures as presenting No Apparent Public Health Hazard.  
MDPH continues to support the efforts of Belmont town officials, state and federal 
environmental agencies, and Cambridge Plating to reduce any potential nuisance impacts to the 
surrounding neighborhoods. 
XI. RECOMMENDATIONS 
•	 Future characterization of groundwater conditions (e.g., chemical concentrations) and 
flow patterns should be conducted in accordance with MDEP regulations, the MCP 310 
CMR 40.000, in the event of any planned construction/demolition or alternative 
development of the Cambridge Plating property to ensure adequate protection of public 
health. On the basis of the subsurface contamination identified at Cambridge Plating 
(e.g., elevated levels of TCE detected in monitoring wells located close to the Cambridge 
Plating building) and potential exposures related to alternative future land uses on the 
property, the MDPH supports the Notice of Activity and Use Limitation registered with 
the Middlesex County Land Court by the company in April 2003.  
•	 If additional environmental data on historical air emissions or ambient air quality related 
to Cambridge Plating become available, MDPH should further characterize the potential 
for past exposure upon request of the Belmont Health Department. 
•	 Due to the unpleasant odors and nuisance conditions reported in the past by residents 
living near the facility, MDPH supports continued collaboration between state and federal 
regulatory agencies, the Belmont Department of Health, and representatives of 
Cambridge Plating to determine any additional actions that would help ensure that odor 
and nuisance conditions do not return in the future. 
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XII. PUBLIC HEALTH ACTION PLAN 
The public health action plan contains recommendations for actions to be taken at and in the 
vicinity of Cambridge Plating.  The purpose of the public health action plan is to ensure that this 
health assessment not only identifies potential public health hazards, but also provides a plan of 
action designed to mitigate and prevent adverse human health effects resulting from exposure to 
hazardous substances in the environment.  Included is a commitment on the part of ATSDR and 
MDPH to follow up on this plan to ensure that it is implemented.  The public health actions to be 
implemented are as follows: 
•	 Should new environmental data be generated for the Cambridge Plating site, particularly 
if site use will change, or if additional data on VOCs in groundwater or historical ambient 
air quality data become available, the MDPH will further characterize opportunities for 
exposure upon request of the Belmont Department of Health.   
•	 The MDPH will continue to monitor the incidence of all cancer types in the towns of 
Belmont, Cambridge, Arlington, and Watertown through city/town cancer incidence 
reports published by the Massachusetts Cancer Registry. 
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PREPARER 
This document was prepared by the Bureau of Environmental Health of the Massachusetts 
Department of Public Health (MDPH).  If you have any questions about this document, please 
contact Suzanne K. Condon, Director of the MDPH Bureau of Environmental Health, at 250 
Washington Street, 7th Floor, Boston, Massachusetts 02108. 
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Table 1

Maximum concentrations of contaminants that exceeded comparison values in soil

samples from the Cambridge Plating Site (samples taken from 1994–2003) 

Contaminant Sample depth (feet) 
Date of 
sample Descriptive location of sample* 
Maximum 
concentration 
(ppm) 
Comparison value (ppm) Background soil levels (ppm) 
Arsenic not specified 6/1/1994 
Soil pile resulting from excavation 
activities associated with contruction 
of loading dock 
44‡ 
CREG 
Chronic EMEG (child), RMEG (child) 
Chronic EMEG (adult), RMEG (adult) 
= 
= 
= 
0.5 
20 
200 
7.4† (range: <0.1 - 73) 
Benzo(a)anthracene 5-7 12/15/1997 CC-1 - west of the Cambridge Plating building 10 EPA RBC = 0.87 
0.005 - 0.02 (rural soil) 
0.169 - 59 (urban soil) 
Benzo(a)pyrene 5-7 12/15/1997 CC-1 11 CREG = 0.1 
0.002 - 1.3 (rural soil) 
0.165 - 0.22 (urban soil) 
Benzo(b)fluoranthene 5-7 12/15/1997 CC-1 11 EPA RBC = 0.87 
0.02 - 0.03 (rural soil) 
15 - 62 (urban soil) 
c11-c22 aromatics 1-3 7/7/1998 B-4 - east of the Cambridge Plating building 340 S-1 & GW-1 MDEP standard = 200 -
Chromium (total) 3-5 5/13/2003 SS-3 (composite) - north of Cambridge Plating building 32,000 
RMEG (child) for Cr VI 
RMEG (adult) for Cr VI 
= 
= 
200 
2,000 
52† 
Chromium (VI) 3-5 5/13/2003 SS-1 (composite) - north of Cambridge Plating building 210 
RMEG (child) 
RMEG (adult) 
= 
= 
200 
2,000 
-
Chrysene 5-7 12/15/1997 CC-1 10 EPA RBC = 87 
0.0383 (rural soil) 
0.251 - 0.64 (urban soil) 
Dibenzo(a,h)anthracene 5-7 12/15/1997 CC-1 1 EPA RBC = 0.087 -
Indeno(1,2,3-cd)Pyrene 5-7 12/15/1997 CC-1 5.8 EPA RBC = 0.87 
0.01 - 0.015 (rural soil) 
8.0 - 61 (urban soil) 
Trichloroethylene 4-8 10/6/2000 CC-106 -west of the Cambridge Plating building 8.5 EPA RBC = 58 -
61 

Table 1 (continued) 
*For sample locations, see Figure 3 
‡ This value was from soil taken from the excavation of a loading dock. The next highest value for arsenic, 7.6 ppm, still exceeds the CREG 
†Estimated arithmetic mean for the Eastern United States (east of 96th meridian). Cited in ATSDR 1993. ATSDR Public Health Assessment Guidance Manual. Atlanta: U.S. Department of Health and Human 
Services. 
Data sources 
Coler and Colantonio, Inc. 2003a.  Immediate Response Action Plan.  RTN 3-22940. August 19, 2003.

Coler and Colantonio, Inc. 2002a.  Phase II  - Comprehensive Site Assessment and Class A-3 Response Action Outcome Statement Pursuant to the Massachusetts Contingency Plan 310 CMR 40.0830 and 

40.0850 for 39 Hittinger Street, Belmont, Massachusetts.

Coler and Colantonio, Inc. 1999. Class B-1 RAO statement RTN 3-18457. August 31, 1999.

Coler and Colantonio, Inc. 1998. RAO documents for RTN #3-16600. April, June, July, 1998.

Unless otherwise noted, soil background concentrations are from ATSDR Toxicological Profiles 2000 (on CD-ROM), ATSDR 2000.  

Comparison values (source organization, reference) 
CREG = Cancer risk evaluation guide for 1 x 10-6 excess cancer risk (ATSDR, ATSDR 2003b)

Chronic EMEG (adult/child) = Environmental media evaluation guide (i.e., for adult or childhood exposures mirroring greater than 1 year) (ATSDR, ATSDR 2003b)

RMEG (adult/child) = Reference dose media evaluation guide (an estimate of a daily exposure to the general public, including sensitive subgroups, that is likely to be without appreciable risk of deleterious 

effects during a specified duration of exposure). (ATSDR, ATSDR 2003b)

EPA RBC = EPA Region 3 risk-based concentration for soil (September 2001)

Intermediate EMEG (pica child) = Environmental media evaluation guide for children who consume very high quantities of soil (i.e., for exposures between 14 days and 1 year, and considers vulnerabilities of 

children who consume high quantities of soil when it comes to environmental exposures) (ATSDR, ATSDR 2003b)

Intermediate EMEG (child) = Environmental media evaluation guide for children (i.e., for exposures between 14 days and 1 year and considers vulnerabilities of children when it comes to environmental exposures). 

(ATSDR, ATSDR 2003b)

Intermediate EMEG (adult) = Environmental media evaluation guide for adults (i.e., for exposures between 14 days and 1 year) (ATSDR, ATSDR 2003b).

S-1 & GW-1 = MCP Method 1 soil category S-1 standards [310 CMR 40.0975(6)(a)] (MDEP, MDEP 2003b)
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Table 2

Maximum concentrations of contaminants that exceeded comparison values in samples of groundwater from the Cambridge Plating site

  (samples taken from 1996–2005) 

Contaminant Date of maximum sample Descriptive location of sample* Maximum concentration (ppb) Drinking water comparison value (ppb) 
Arsenic 7/12/1996 MW-3 - west of the Cambridge Plating building (Fig. 3) 37 
CREG = 0.02
 Chronic EMEG (child) 
RMEG (child) = 3
 Chronic EMEG (adult), 
RMEG (adult), EPA MCL = 10  
Benzo(a)anthracene 1/8/1998 CC-1 - west of the Cambridge Plating building 1 EPA RBC = 0.092 
Benzo(a)pyrene 1/8/1998 CC-1 1.3 
CREG = 0.005 
EPA RBC = 0.0092 
MCLG = 0 
MDEP MMCL, MCL = 0.2 
Benzo(b)fluoranthene 1/8/1998 CC-1 1.5 EPA RBC = 0.092 
c11-c22 aromatics 7/14/1998 CC-3 - west of Cambridge Plating Building near to property line 1,800 MDEP GW-1 = 200 
1,2-Dichloroethene (total) 7/12/1996 MW-3 5,100 
EPA RBC = 55 
MCL; MCLG; LTHA for cis 
isomer = 70  
MCL; MCLG; LTHA for 
trans isomer = 100  
1,2-Dichloroethene, cis­ 1/27/2004 MW-3 8,150 
Intermediate EMEG (child) = 3,000 
Intermediate EMEG (adult) = 10,000 
EPA RBC = 61
 MCL; MCLG; LTHA = 70 
Indeno(1,2,3-cd)Pyrene 1/8/1998 CC-1 1 EPA RBC = 0.092 
Trichloroethylene 1/27/2004 MW-3 49,800 
EPA RBC = 1.6 
MCLG = 0 
MDEP MMCL, MCL = 5 
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Table 2 (continued) 
Vinyl Chloride 9/8/2005 MW-3 1,200 
CREG 
Chronic EMEG (child) 
Chronic EMEG (adult) 
RMEG (child) 
RMEG (adult) 
MCLG 
MDEP MMCL, MCL 
= 
= 
= 
= 
= 
= 
= 
0.03 
0.2 
0.7 
30 
100 
0 
2 
*For sample locations see Figure 3 
Data sources 
Coler and Colantonio, Inc. 2004.  Letter from Coler and Colantonio responding to November 12, 2003, MADEP Interim Deadline. RTN 3-2151. February 23, 2004.  
Coler and Colantonio, Inc. 2003a. Letter from Coler and Colantonio to MDEP NERO - attaching results of groundwater sampling for November and December 2002 and Feb 2003. February 20, 
2003. 
Coler and Colantonio, Inc. 2002a.  Phase II  - Comprehensive Site Assessment and Class A-3 Response Action Outcome Statement Pursuant to the Massachusetts Contingency Plan 310 CMR 

40.0830 and 40.0850 for 39 Hittinger Street, Belmont, Massachusetts.

Coler and Colantonio, Inc. 1998. RAO documents for RTN #3-16600. April, June, July, 1998.

Comparison values (source organization, reference) 
CREG = Cancer risk evaluation guide for 1 x 10-6 excess cancer risk (ATSDR, ATSDR 2003a)

Chronic EMEG (adult/child) = Environmental media evaluation guide (i.e., for adult or childhood exposures of more than 1 year) (ATSDR 2003a)

RMEGs (adult/child) = Reference dose media evaluation guides (an estimate of a daily exposure to the general public, including sensitive subgroups, that is likely to be without appreciable risk of 

deleterious effects during a specified duration of exposure) (ATSDR 2003a)

EPA RBC = EPA Region 3 risk-based concentration for tap water (September 2001)

MMCL = Massachusetts maxiumum contaminant level (MDEP, MDEP 2001 )

MCL = Maximum contaminant level for drinking water (EPA, ATSDR 2003a)

MDEP GW-1 = MCP Method 1 groundwater standards applicable in areas where the groundwater is considered to be category GW-2 per 310 CMR 40.0932 [310 CMR 40.0974 (2)] (MDEP, 

MDEP 2003) 

LTHA = Lifetime health advisory for drinking water (EPA, ATSDR 2003a)

Intermediate EMEG (adult) = Environmental media evaluation guide for adults (i.e., for exposures between 14 days and 1 year) (ATSDR, ATSDR 2003a)

Intermediate EMEG (child) = Environmental media evaluation guide for children (i.e., for exposures between 14 days and 1 year; considers vulnerabilities of children to environmental exposures) 

(ATSDR, ATSDR 2003a)
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Table 3

Toxics Release Inventory data for Cambridge Plating (1987–2005)

Chemical name Media Unit Of Measurement 
Year 
2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1989 1988 1987 
Cyanide compounds  AIR FUG* Pound NR† NR NR NR NR NR NR NR NR NR NR NR NR NR NR NR NR NR 250 
Cyanide compounds SURF IMP‡ Pound  NR  NR  NR  NR  NR  NR  NR  NR  NR  NR  NR  NR  NR  NR  NR  NR  NR  NR  72  
Hydrochloric acid§ AIR FUG Pound NR NR NR NR NR NR NR NR NR NR 250 458 NR 750 7,100 7,300 6,000 6,400 6,400 
Nickel compounds AIR FUG Pound NR NR NR NR NR NR NR NR 5 NR NR 316 NR 255 NR 5 NR NR NR 
Nitric acid AIR FUG Pound 250 250 250 250 250 250 250 250 250 45 250 694 NR 982 NR 650 1,000 1,000 1,000 
Sodium hydroxide 
(solution) AIR FUG Pound NR NR NR NR NR NR NR NR NR NR NR NR NR NR NR NR NR 3,500 3,500 
Sulfuric acid§ AIR FUG  Pound  NR  NR  NR  NR  NR  NR  NR  NR  NR  NR  NR  754  NR  779  NR  NR  NR  NR  NR  
Trichloroethylene  AIR FUG Pound NR NR 11,638 13,585 9,536 15,260 15,207 15,285 23,900 58,500 14,854 18,580 NR 18,640 18,480 52,200 66,960 47,360 NR 
Trichloroethylene  DISP NON METALS Pound NR NR NR NR NR NR NR NR NR NR NR NR NR NR NR 45,400 66,960 NR NR 
*AIR FUG = fugitive or nonpoint air emissions 
†NR = not reported 
‡SURF IMP  = on-site surface impoundment disposal 
§1995 and after "acid aerosols" only 
Data source: Toxics Release Inventory (TRI) US EPA, 2005. 
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Table 4 

Summary of Possible Exposure Pathways for 

Cambridge Plating 

Belmont, Massachusetts

Environmental 
Medium 
Exposure 
Pathway Contaminant(s) 
Point of 
Exposure 
Route of 
Exposure 
Receptor 
Populations 
Time 
Frame 
Type of 
Pathway Notes 
Soil 
Soil/dust 
(near MBTA 
Tracks) 
Chromium On-site 
Incidental 
Ingestion/ 
Dermal contact/ 
Inhalation 
Trespassers Past Potential 
Contaminated area currently 
enclosed by fence.   Estimated 
past exposures to surface soil 
unlikely to result in health 
effects. 
Subsurface 
contamination  
Metals, VOCs, 
PAHs On-site Dermal contact 
Trespassers/ 
Workers 
Past, 
Present, 
Future 
Eliminated 
Contamination identified below 
ground surface and majority of 
site is paved. 
Groundwater 
Groundwater 
contamination 
Metals, VOCs, 
PAHs Off-site Ingestion Residents 
Past, 
Present, 
Future 
Eliminated Groundwater is not a source of drinking water. 
Volatilization of 
shallow 
groundwater  to 
indoor Air 
VOCs 
(e.g. TCE) 
Nearby 
residences Inhalation Residents 
Past, 
Present, 
Future 
Potential 
Concentrations detected in 
down-gradient groundwater 
samples close to property 
boundary are below levels of 
health concern for indoor air. 
Ambient Air 
Stack and non-
stack facility 
emissions 
TCE, Chromium Nearby residences Inhalation Residents Past Potential 
Historical ambient air 
concentrations are unknown. 
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Assessment of Cancer Incidence in Belmont, Massachusetts, 
and Surrounding Communities: 1982–1999 
I. BACKGROUND AND STATEMENT OF ISSUES 
In response to a legislative directive and to requests from community residents and the Belmont 
Department of Health, the Community Assessment Program (CAP) in the Bureau of 
Environmental Health (BEH) of the Massachusetts Department of Public Health (MDPH), 
conducted an evaluation of cancer incidence in Belmont, Massachusetts, and the surrounding 
communities of Arlington, Watertown, and parts of Cambridge, Massachusetts.  This evaluation 
was initiated because of community concerns about cancer and possible environmental 
exposures in relation to an electroplating facility in Belmont, the Cambridge Plating Company. 
II. OBJECTIVES 
This investigation reviews the pattern of the incidence of six cancer types in Belmont and 
adjacent communities and compares that incidence with the incidence of these types of cancer in 
the state of Massachusetts as a whole. In addition, available information about risk factors, 
including environmental factors, related to the development of cancer was evaluated. 
This report provides a descriptive evaluation of the occurrence of cancer for the years 1982–1999 
in the town of Belmont as a whole and its individual census tracts, in the city of Cambridge as a 
whole and selected census tracts in Cambridge, and in the towns of Arlington and Watertown. 
This time period was chosen because it is the time period for which the most recent and complete 
cancer incidence data were available from the Massachusetts Cancer Registry (MCR) when this 
analysis was initiated.  The locations of these towns are shown in Figure 1. 
The results of this descriptive analysis can be useful in identifying cancer patterns or trends in a 
geographic context, may help determine whether a common cause or etiology is possible, and 
can serve to identify areas where further public health investigations or actions may be 
warranted. Descriptive analyses may also indicate that an excess of known risk factors 
associated with a disease, such as environmental exposures, exists in a certain geographic area. 
This descriptive analysis of cancer incidence data cannot be used to establish a causal link 
between a particular risk factor (either environmental or nonenvironmental) and the development 
of cancer. In addition, this analysis cannot determine the cause of cancer for any one individual. 
72 

The purpose of this evaluation is to report the findings of the patterns of cancer in Belmont and 
surrounding communities and discuss them in the context of the available environmental 
information to determine whether recommendations for further public health action are needed. 
The specific objectives of this investigation were as follows: 
•	 To evaluate the incidence of six cancer types in Belmont at the census tract level and the 
whole town level, in adjacent census tracts in Cambridge, and in the towns of Watertown and 
Arlington. The census tract-specific analyses help in understanding whether the incidence of 
cancer observed townwide might be explained by an increase or decrease in the number of 
diagnoses of cancer in a particular geographic area of town. 
•	 To evaluate the geographic distribution of individual cancer cases in Belmont and 
surrounding communities and see if there are any patterns in particular areas of the towns or 
in relation to known sources of environmental contamination. 
•	 To review descriptive information available from the Massachusetts Cancer Registry (MCR) 
for individuals diagnosed with cancer in Belmont, Cambridge, Arlington, and Watertown, to 
see if there are any particular characteristics related to risk factors for developing these 
diseases. 
•	 To review available information regarding oil and hazardous material releases in Belmont, 
Arlington, Cambridge, and Watertown as reported to the Massachusetts Department of 
Environmental Protection (MDEP). 
•	 To consider the results of this evaluation in the context of the available scientific and medical 
literature on cancer to determine whether further investigation or public health action is 
warranted. 
III. METHODS 
A. Case Identification/Definition 
Cancer incidence data (i.e., reports of new cancer diagnoses) for the years 1982–1999 were 
obtained for the town of Belmont and the surrounding communities of Arlington, Cambridge, 
73 

and Watertown from the Massachusetts Cancer Registry (MCR), a division of the Bureau of 
Health Information, Statistics, Research and Evaluation within the MDPH.  Six cancer types 
were evaluated in this investigation, including cancers of the kidney, liver, lung and bronchus, 
and pancreas as well as leukemia and non-Hodgkin’s lymphoma (NHL).  Coding for cancer 
types in this report follows the International Classification of Diseases for Oncology (ICD-O) 
system.  (See Appendix B for the incidence coding definitions used in this report for these cancer 
types.) These cancer types were selected for evaluation on the basis of elevations observed at the 
town level in a preliminary review of cancer rates in Belmont, potential associations with 
contaminants of concern at the Cambridge Plating site (primarily TCE and chromium), and/or 
residents’ concerns about suspected elevations in some cancer types.  Only cases reported to the 
MCR as a primary cancer for one of the six cancer types and diagnosed among residents of 
Belmont, Arlington, Cambridge, and Watertown were included in the analysis.  Cases were 
selected for inclusion based on the address reported to the hospital or reporting medical facility 
at the time of diagnosis. 
The MCR is a population-based surveillance system that began collecting information on 
Massachusetts residents diagnosed with cancer in the state in 1982.  All newly diagnosed cancer 
cases among Massachusetts residents are required by law to be reported to the MCR within six 
months of the date of diagnosis (M.G.L. c.111s.111B).  This information is kept in a confidential 
database.  Data are collected on a daily basis and are reviewed for accuracy and completeness on 
an annual basis. This process corrects misclassification of data (i.e., city/town misassignment). 
Once these steps are finished, the data for that year are considered “complete.”  Due to the 
volume of information received by the MCR, the large number of reporting facilities, and the 
six-month period between diagnosis and required reporting, the most current registry data that 
are complete will inherently be a minimum of two years prior to the current date.  The 18-year 
period 1982–1999 constitutes the period for which the most recent and complete cancer 
incidence data were available from the MCR at the time of this analysis.1 
The term “cancer” is used to describe a variety of diseases associated with abnormal cell and 
tissue growth. Epidemiologic studies have revealed that different types of cancer are individual 
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diseases with separate causes, risk factors, characteristics, and patterns of survival (Berg 1996). 
Cancer types are classified by the location in the body where the disease originated (the primary 
site) and the tissue or cell type of the cancer (histology).  Each cancer type reviewed in this 
report was evaluated separately. Cancers that occur as the result of the metastasis or the spread 
of a primary site cancer to another location in the body are not considered as separate cancers 
and therefore were not included in this analysis. 
It should be noted that the MCR research file might contain duplicate reports of individuals 
diagnosed with cancer. The data in this report have been controlled for duplicate cases by 
excluding them from the analyses.  Duplicate cases are additional reports of the same primary 
site cancer case. The decision that a case was a duplicate and should be excluded from the 
analyses was made by the MCR after consulting with the reporting hospital or diagnostic facility 
and obtaining additional information regarding the histology and/or pathology of the case. 
However, reports of individuals with multiple primary site cancers were included as separate 
cases in the analyses in this report.  A multiple primary cancer case is defined by the MCR as a 
new cancer in a different location in the body, or a new cancer of the same histology (cell type) 
as an earlier cancer, if diagnosed in the same primary site (original location in the body) more 
than two months after the initial diagnosis (MCR 1996).  Therefore, duplicate reports of an 
individual diagnosed with cancer were removed from the analyses whereas individuals who were 
diagnosed with more than one primary site cancer were included as separate cases.  In the town 
of Belmont, four duplicate reports were identified during the years 1982–1999 and excluded 
from the analyses.  In addition, seven duplicate reports in Arlington, 16 duplicate reports in 
Cambridge, and 12 duplicate reports in Watertown were identified during the years 1982–1999 
and excluded from the analyses. 
B. Calculation of Standardized Incidence Ratios 
To determine whether elevated numbers of cancer cases occurred in Belmont and the 
surrounding communities of Arlington, Cambridge, and Watertown, cancer incidence data were 
tabulated by gender according to six age groups to compare the observed number of cancer cases 
1 The data summarized in this report are drawn from data entered on MCR computer files before April 28, 2003. 
The numbers presented in this report may change slightly in future reports, reflecting late reported cases, address 
corrections, or other changes based on subsequent details from reporting facilities. 
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to the number that would be expected based on the statewide cancer rate.  Standardized incidence 
ratios (SIRs) were then calculated for the period 1982–1999 for each of the six primary cancer 
types for Belmont as a whole as well as for each census tract (CT) within Belmont.  In addition, 
SIRs were calculated for the city of Cambridge as a whole and the three Cambridge CTs located 
on the border of Belmont.  Townwide SIRs were also calculated for Arlington and Watertown. 
SIRs were also calculated for three smaller time periods, 1982–1987, 1988–1993, 1994–1999, in 
order to evaluate patterns or trends in cancer incidence over time. 
To calculate SIRs, it is necessary to obtain accurate population information.  The population 
figures used in this analysis were interpolated on the basis of 1980, 1990, and 2000 U.S. Census 
data for each CT in Belmont and Cambridge and for the town of Belmont as a whole, the city of 
Cambridge as a whole, and the towns of Arlington and Watertown (U.S. Census Bureau 1980, 
1990, and 2000). Midpoint population estimates were calculated for each time period evaluated 
(i.e., 1984, 1990 and 1996). To estimate the population between census years, an assumption 
was made that the change in population occurred at a constant rate throughout the 10-year 
interval between each census.2 
Because accurate age group and gender specific population data are required to calculate SIRs, 
the CT is the smallest geographic area for which cancer rates can be accurately calculated. 
Specifically, a CT is a smaller statistical subdivision of a county as defined by the U.S. Census 
Bureau. CTs usually contain between 2,500 and 8,000 persons and are designed to be 
homogenous with respect to population characteristics (U.S. Census Bureau 1990). 
According to the U.S. Census, the town of Belmont is subdivided into eight census tracts (i.e., 
CTs 3571–3578). Of the 30 census tracts in Cambridge, three are located on the border of 
Belmont (i.e., CTs 3543, 3546, and 3549) (U.S. Census Bureau 2000).  The town boundaries and 
census tract locations for Belmont and surrounding communities are illustrated in Figure 1. 
Cases for which census tract designation was not possible were included in the city/town totals 
for Belmont and Cambridge. 
 Using slightly different population estimates or statistical methodologies, such as grouping ages differently or 
rounding off numbers at different points during calculations, may produce results slightly different from those 
published in this report. 
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2
C. Interpretation of a Standardized Incidence Ratio 
A standardized incidence ratio (SIR) is an estimate of the occurrence of cancer in a population 
relative to what might be expected if the population had the same cancer experience as a larger 
comparison population designated as “normal” or average.  Usually, the state as a whole is 
selected to be the comparison population.  Using the state of Massachusetts as a comparison 
population provides a stable population base for the calculation of incidence rates. 
Specifically, an SIR is the ratio of the observed number of cancer cases in an area to the expected 
number of cases multiplied by 100.  The population structure of each town is adjusted to the 
statewide incidence rate to calculate the number of expected cancer cases.  The SIR is a 
comparison of the number of cases in the specific area (i.e., city/town or census tract) to the 
statewide rate. Comparisons of SIRs between towns or census tracts are not possible because 
each community has different population characteristics. 
An SIR of 100 indicates that the number of cancer cases observed in the population being 
evaluated is equal to the number of cancer cases expected in the comparison or “normal” 
population. An SIR greater than 100 indicates that more cancer cases occurred than were 
expected, and an SIR less than 100 indicates that fewer cancer cases occurred than were 
expected. Accordingly, an SIR of 150 is interpreted as 50% more cancer cases than the expected 
number; an SIR of 90 indicates 10% fewer cancer cases than expected. 
Caution should be exercised, however, when interpreting an SIR.  The interpretation of an SIR 
depends on both the size and the stability of the SIR.  Two SIRs can have the same size but not 
the same stability.  For example, an SIR of 150 based on four expected cases and six observed 
cases indicates a 50% excess in cancer, but the excess is actually only two cases.  Conversely, an 
SIR of 150 based on 400 expected cases and 600 observed cases represents the same 50% excess 
in cancer, but because the SIR is based upon a greater number of cases, the estimate is more 
stable. It is very unlikely that 200 excess cases of cancer would occur by chance alone.  As a 
result of the instability of incidence rates based on small numbers of cases, SIRs were not 
calculated when fewer than five cases were observed for a particular cancer type. 
D. Calculation of the 95% Confidence Interval 
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To help interpret or measure the stability of an SIR, the statistical significance of each SIR was 
assessed by calculating a 95% confidence interval (95% CI) to determine if the observed number 
of cases is “significantly different” from the expected number or if the difference may be due 
solely to chance (Rothman and Boice 1982).  Specifically, a 95% CI is the range of estimated 
SIR values that have a 95% probability of including the true SIR for the population.  If the 95% 
CI range does not include the value 100, then the study population is significantly different from 
the comparison or “normal” population.  “Significantly different” means there is less than a 5% 
chance that the observed difference (either increase or decrease) is the result of random 
fluctuation in the number of observed cancer cases. 
For example, if a confidence interval does not include 100 and the interval is above 100 (e.g., 
105–130), there is a statistically significant excess in the number of cancer cases.  Similarly, if 
the confidence interval does not include 100 and the interval is below 100 (e.g., 45–96), the 
number of cancer cases is statistically significantly lower than expected.  If the confidence 
interval range includes 100, the true SIR may be 100.  In this case, it cannot be determined with 
certainty that the difference between the observed and expected number of cases reflects a real 
cancer increase or decrease or is the result of chance.  It is important to note that statistical 
significance does not necessarily imply public health significance.  Determination of statistical 
significance is just one tool used to interpret SIRs. 
In addition to the range of the estimates contained in the confidence interval, the width of the 
confidence interval also reflects the stability of the SIR estimate.  For example, a narrow 
confidence interval, such as 103–115, allows a fair level of certainty that the calculated SIR is 
close to the true SIR for the population.  A wide interval, for instance 85–450, leaves 
considerable doubt about the true SIR, which could be much lower than or much higher than the 
calculated SIR.  This would indicate an unstable statistic.  Again, due to the instability of 
incidence rates based on small numbers of cases, statistical significance was not assessed when 
fewer than five cases were observed. 
E. Evaluation of Cancer Risk Factor Information 
Available information reported to the MCR related to risk factors for cancer development was 
reviewed and compared to known or established incidence patterns for the cancer types 
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evaluated in this report.  This information is collected for each individual at the time of cancer 
diagnosis and includes the individual’s age at time of diagnosis, the stage of disease, and the 
individual’s smoking history and occupation.  One or even several factors acting over time can 
be related to the development of cancer.  For example, tobacco use has been linked to lung and 
bronchus, kidney, and pancreatic cancers. Other cancer risk factors may include lack of crude 
fiber in the diet, high fat consumption, alcohol abuse, and reproductive history.  Heredity, or 
family history, is an important factor for several cancers.  To a lesser extent, some occupational 
exposures, such as jobs involving contact with asbestos, have been shown to be carcinogenic 
(cancer causing).  Environmental contaminants have also been associated with certain types of 
cancer. The available risk factor information from the MCR was evaluated for residents of the 
four communities who were diagnosed with any of the six cancer types included in this report. 
However, information about personal risk factors such as family history, hormonal events, diet, 
and other factors that may also influence the development of cancer is not collected by the MCR, 
and therefore, it was not possible to evaluate these factors in this investigation. 
F. Determination of Geographic Distribution of Cancer Cases 
In addition to calculation of SIRs, address at the time of diagnosis for each individual diagnosed 
with cancer was mapped using a computerized geographic information system (GIS) (ESRI 
2002). This allowed assignment of census tract location as well as an evaluation of the spatial 
distribution of individual cases at a smaller geographic level (i.e., neighborhoods).  The 
geographic pattern was determined using a qualitative evaluation of the point pattern of cancer 
cases in each of the four communities. In instances where the address information from the 
MCR was incomplete (i.e., did not include specific streets or street numbers), efforts were made 
to research those cases using telephone books issued within two years of an individual's 
diagnosis. For confidentiality reasons, it is not possible to include maps showing the locations of 
individuals diagnosed with cancer in this report.  (Note: MDPH is bound by Massachusetts 
General Laws and the new federal Health Insurance Portability and Accountability Act (HIPAA) 
not to reveal the name or identifying information of an individual diagnosed with cancer whose 
case is reported to the MCR.) 
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IV. RESULTS OF CANCER INCIDENCE ANALYSIS 
The following sections present cancer incidence rates for Belmont and its individual census 
tracts, Cambridge and selected census tracts, Arlington, and Watertown during the 18-year time 
period 1982–1999. To evaluate possible trends over time, these data were also analyzed by three 
smaller time periods, 1982–1987, 1988–1993, and 1994–1999.  SIRs were not calculated for 
some cancer types in smaller time periods due to the small number of observed cases (less than 
five). However, the expected number of cases was calculated during each time period, and the 
observed and expected numbers of cases were compared to determine whether excess numbers 
of cancer cases were occurring. 
A. Cancer Incidence in Belmont 
With a few exceptions, the six cancer types evaluated in this report generally occurred 
approximately near or below expected rates in the town of Belmont as a whole during the 
18-year time period 1982–1999 as well as smaller time periods (i.e., 1982–1987, 1988–1993, and 
1994–1999) (see Tables 1a through 6d). The increases observed were mostly based on 
approximately three or fewer additional cases above the expected number and incidence rates 
were not statistically significant.  Overall, kidney cancer, lung and bronchus cancer, and NHL 
occurred less often than expected during 1982–1999.  In general, with some exceptions which 
are noted in the following paragraphs, residents of most Belmont census tracts experienced 
cancer approximately at or near the rates expected during 1982–1999 and during the smaller time 
periods evaluated in this report. 
1. Kidney Cancer 
As detailed in Tables 1a – 1d, the incidence of kidney cancer appears to have decreased over 
time among both male and female residents of Belmont.  During the most recent time period 
evaluated, 1994–1999, 13 individuals were diagnosed with kidney cancer compared to 
approximately 21 diagnoses expected. 
During the 18-year time period 1982–1999, kidney cancer occurred slightly below expected rates 
in the majority of census tracts in Belmont.  Residents of CT 3576 experienced a slight increase 
in the incidence of this cancer type (7 diagnoses observed vs. 5.4 expected, SIR = 129).  In CT 
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3572, eight individuals were diagnosed with kidney cancer compared to 7.2 expected.  However, 
these elevations were not statistically significant.  No specific trends were observed when cancer 
incidence data were evaluated by smaller time periods.  That is, kidney cancer generally occurred 
about as expected (i.e., within one or two cases of the expected number) in individual census 
tracts during 1982–1987, 1988–1993, and 1994–1999 (see Tables 1a – 1d). 
2. Leukemia 
The incidence of leukemia was slightly elevated in the town of Belmont as a whole during 
1982–1999 (58 diagnoses observed vs. 50.3 expected, SIR = 115).  Although leukemia was 
diagnosed less often than expected during the earliest time period, 1982–1987, both males and 
females experienced slight increases in the rate of this cancer type during 1988–1993 and during 
1994–1999. None of the observed elevations were statistically significant (see Tables 2a – 2d). 
The incidence of leukemia was slightly elevated with respect to the state rate in several Belmont 
census tracts during the overall time period 1982–1999.  Specifically, residents of CTs 3571, 
3573, 3574, 3577, and 3578 were diagnosed with leukemia slightly more often than expected 
during this time period.  These increases were not statistically significant.  When these data were 
analyzed for smaller time periods, no consistent trends in the incidence of leukemia were noted. 
In CT 3751 during 1982–1987, leukemia occurred at about the rate expected, but occurred 
slightly more often than expected in 1988–1993 and 1994–1999.  Although one individual in CT 
3573 was diagnosed with leukemia during 1982–1993 compared to 3.2 expected, residents of 
this census tract experienced a statistically significant elevation in the incidence of leukemia 
during the most recent time period 1994–1999 (7 diagnoses observed vs. 1.8 expected, 
SIR = 383, 95% CI = 153–789).  However, the wide confidence interval indicates that the 
increased SIR is somewhat unstable.  Therefore, it is uncertain based on this data whether the 
incidence of leukemia is increasing in this area of Belmont.  Additional information for the 
individuals diagnosed with leukemia in Belmont will be evaluated later in this report. 
In CT 3574, leukemia was diagnosed slightly more often than expected during 1982–1987 and 
about as often as expected during 1988–1993 and 1994–1999.  In CT 3577, leukemia occurred 
about as often as expected during 1982–1987, more often than expected during 1988–1993, and 
less often than expected during 1994–1999.  Finally, residents of CT 3578 experienced lower-
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than-expected rates of leukemia during 1982–1987, but a statistically significant elevation in the 
incidence of this cancer type during 1988–1993 (7 diagnoses observed vs. 2.4 expected, 
SIR = 290, 95% CI = 116-598).  Again, this SIR should be interpreted with caution because of 
the wide confidence interval.  The incidence of leukemia was lower than expected in more recent 
years (i.e., 1994–1999) in this census tract. Refer to Tables 2a – 2d for a summary of these data. 
3. Liver Cancer 
A slight elevation in the incidence of liver cancer was observed in the town of Belmont as a 
whole during 1982–1999. However, the increase was primarily based on approximately one 
additional diagnosis over the expected number each among males and females during the 1988– 
1993 time period and was not statistically significant. 
No individuals were diagnosed with liver cancer during 1982–1999 in CT 3574 where about one 
case was expected. There was one diagnosis each in CTs 3572, 3575, 3576, and 3578. 
Residents of CTs 3571, 3573, and 3577 experienced slight elevations in the incidence of liver 
cancer during 1982 – 1999. However, these increases were generally based on fewer than three 
cases above the expected numbers (in most instances, the numbers of observed cases was less 
than five and therefore statistical significance was not evaluated).  Analysis over time revealed 
no specific trends in the incidence of liver cancer in Belmont census tracts (see Tables 3a – 3d). 
4. Lung and Bronchus Cancer 
The incidence rate of lung and bronchus cancer was statistically significantly lower than 
expected in the town as a whole (270 diagnoses observed vs. 375.3 expected, SIR = 72, 95% CI 
= 64–81) during the 18-year time period 1982–1999.  Analysis of trends over time revealed that 
incidence rates for this cancer type were lower than expected during each of the smaller time 
periods evaluated and statistically significantly lower than expected during 1982–1987 and 
1994–1999 (see Tables 4a – 74d). 
The incidence of lung and bronchus cancer was lower than expected in all Belmont census tracts 
during the 18-year time period 1982–1999.  Moreover, the rates were statistically significantly 
lower than expected among males and females combined in CTs 3572, 3573, 3574, 3576, and 
3578 and among males when evaluated separately by gender in CTs 3571, 3573, and 3578. 
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Similar trends were observed when these data were evaluated for smaller time periods (i.e., 
1982–1987, 1988–1993, and 1994–1999) (see Tables 4a – 4d). 
5. Non-Hodgkin’s Lymphoma 
NHL occurred less often than expected in the town of Belmont as a whole during 1982–1999, 
primarily due to a lower-than-expected rate among males in the town (32 diagnoses observed vs. 
44.6 expected, SIR = 72), a rate that was borderline statistically significant (95% CI = 49–101). 
Males in Belmont experienced fewer diagnoses of NHL than expected during each of the smaller 
time periods evaluated while females were diagnosed about as expected during 1982–1987 and 
slightly more often than expected during the most recent time periods (i.e., 1988–1993 and 
1994–1999) (see Tables 5a – 5d). Each of the elevations in the recent time periods represented 
an excess of about three cases and neither was statistically significant. 
While NHL occurred less often than expected in some census tracts in Belmont during 
1982–1999 (i.e., CTs 3572, 3573, 3574, and 3576), this cancer type was diagnosed more often 
than expected among males and females combined in CTs 3575, 3577, and 3578.  Although 
these elevations were not statistically significant, females in CT 3577 experienced a statistically 
significant elevation in the incidence of NHL during the 18-year time period evaluated 
(14 diagnoses observed vs. 7.4 expected, SIR = 189, 95% CI = 103–316).  This elevation was 
primarily due to increases in NHL diagnoses observed among females during 1988–1993 and 
1994–1999. Moreover, the elevation observed during the most recent time period (i.e., 1994– 
1999) was also statistically significant.  Slight elevations were also noted in other Belmont 
census tracts during one or more of the smaller time periods evaluated; the observed elevations 
were generally based on one to two additional diagnoses over the expected number (see Tables 
5a – 5d). 
6. Pancreatic Cancer 
Pancreatic cancer in the town of Belmont during 1982–1999 occurred about as expected when 
compared with the statewide cancer experience.  Although the overall rate remained consistent 
over time, different trends were observed among males and females when evaluated separately 
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by gender. Specifically, the incidence of pancreatic cancer in Belmont appears to have increased 
over time among males while decreasing over time among females (see Tables 6a – 6d). 
Pancreatic cancer occurred less often than expected in Belmont CTs 3572, 3573, 3574, 3575, and 
3576 and more often than expected in CTs 3571, 3577, and 3578 during the 18-year time period 
1982–1999. However, none of the observed elevations were statistically significant.  The overall 
rate of pancreatic cancer in CT 3571 was due to slight elevations during the earliest time period 
(i.e., 1982–1987) and the most recent time period (i.e., 1994–1999). In CT 3577, slight 
elevations in the incidence of pancreatic cancer were observed during 1988–1993 and 1994– 
1999. Finally, in CT 3578, pancreatic cancer was diagnosed more often than expected during 
1982–1987 and 1988–1993. The CT 3578 elevations were the result of increased diagnoses 
among females, who experienced a statistically significant elevation during 1982–1987 
(5 diagnoses observed vs. 1.5 expected, SIR = 343, 95% CI = 110–800).  The increased SIR 
should be interpreted with caution due to the wide confidence interval.  Pancreatic cancer among 
females in CT 3878 was also elevated during 1988–1993 (4 diagnoses observed vs. 1.4 
expected).  During the more recent time period (i.e., 1994–1999), no females were diagnosed 
with pancreatic cancer in CT 3578 (see Tables 6a – 6d). 
B. Cancer Incidence in Cambridge 
As described previously, cancer incidence rates were also evaluated for the city of Cambridge, 
with a particular focus on census tracts adjacent to Belmont (i.e., CTs 3543, 3546, and 3549). 
During the 1982–1999 time period, citywide incidence rates were lower than expected for kidney 
cancer, leukemia, lung and bronchus cancer, and NHL; about as expected for pancreatic cancer; 
and slightly higher than expected for liver cancer.  The elevation in liver cancer incidence was 
not statistically significant. Census tract-specific SIRs could not be calculated for the majority of 
cancer types because of the small numbers of observed cases; however, the number of cases 
observed was compared to the number of cases expected to determine if an atypical pattern of 
cancer was occurring. The results of these analyses are summarized in the following paragraphs 
and presented in Tables 7a – 12d. 
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1. Kidney Cancer 
A statistically significant decrease in the incidence of kidney cancer was observed in the city of 
Cambridge as a whole during 1982–1999 (109 diagnoses observed vs. 146.3 expected, SIR = 75, 
95% CI = 61–90). Both males and females experienced lower-than-expected rates of this cancer 
type with the rate among males statistically significantly less than expected.  Residents of CT 
3543 experienced kidney cancer at about the rate expected among males and females combined 
while residents of CTs 3546 and 3549 were diagnosed with kidney cancer less often than 
expected (see Table 7a). 
Both males and females in Cambridge as a whole experienced lower-than-expected rates of 
kidney cancer during each of the smaller time periods evaluated (i.e., 1982–1987, 1988–1993, 
and 1994–1999). Moreover, the rates were statistically significantly decreased among males and 
females combined and among males separately during 1988–1993 (see Tables 7b – 7d). 
2. Leukemia 
Statistically significant decreases in leukemia incidence were observed among males and among 
males and females combined in Cambridge as a whole during 1982–1999.  In addition, females 
experienced lower-than-expected incidence that was borderline statistically significant. 
Specifically, 102 individuals were diagnosed with leukemia compared to 134.1 expected 
(SIR = 76, 95% CI = 62–92).  Overall rates were also lower than expected in each of the three 
Cambridge census tracts evaluated (i.e., CTs 3543, 3546, and 3549) (see Table 8a).  Similar 
trends were noted when these data were reviewed by smaller time periods.  Specifically, citywide 
rates were lower than expected during 1982–1987, 1988–1993, and 1994–1999 and statistically 
significantly lower than expected during 1988–1993 and during 1994–1999.  In CTs 3543, 3546, 
and 3549, leukemia generally occurred at or near expected rates (i.e., within one or two cases of 
the expected number) during each smaller time period (see Tables 8b – 8d). 
3. Liver Cancer 
Both males and females in Cambridge experienced a slight elevation in the incidence of liver 
cancer during 1982–1999. Overall, 40 individuals were diagnosed with this disease compared to 
34.2 expected (SIR = 117). This elevation was not statistically significant.  In CT 3543, three 
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diagnoses were observed vs. 1.8 expected; in CT 3546, two diagnoses were observed vs. 1.7 
expected; and in CT 3549, four diagnoses were observed vs. 1.8 expected (see Table 12a). 
Citywide rates of liver cancer were higher than expected during 1982–1987, about as expected 
during 1988–1993, and slightly higher than expected during 1994–1999.  Neither of the 
elevations was statistically significant.  Liver cancer generally occurred about as expected during 
each of the smaller time periods in CTs 3543, 3546, and 3549 (see Tables 9b – 9d). 
4. Lung and Bronchus Cancer 
Lung and bronchus cancer occurred statistically significantly less often than expected in the city 
of Cambridge during the 18-year time period 1982–1999 (799 diagnoses observed vs. 897.4 
expected, SIR = 89, 95% CI = 83-95). Similar trends were observed when these data were 
evaluated separately by gender, with both males and females experiencing statistically significant 
decreases in the rate of this cancer.  Residents of CTs 3543 and 3546 also experienced decreased 
rates of lung and bronchus cancer during this time period.  In CT 3549, the incidence of lung and 
bronchus was about as expected (see Table 10a).  Review of these data by smaller time period 
revealed that the rate of lung and bronchus cancer was about as expected in Cambridge during 
1982–1987, statistically significantly lower than expected during 1988–1993, and statistically 
significantly decreased during 1994–1999.  In CT 3543, the incidence of lung and bronchus 
cancer appears to have decreased over time.  Specifically, the incidence of lung and bronchus 
cancer was elevated during 1982–1987 (primarily due to an elevation among males), lower than 
expected during 1988–1993, and statistically significantly lower than expected during 1994– 
1999. In CT 3546, rates were about as expected during 1982–1987 and lower than expected 
during 1988–1993 and 1994–1999. Finally, in CT 3549, rates of lung and bronchus cancer were 
about as expected during 1982–1987 and 1988–1993 and slightly elevated during 1994–1999. 
However, the elevation observed during the latest time period was not statistically significant (20 
diagnoses observed vs. about 17 expected) (see Tables 10b – 10d). 
5. Non-Hodgkin’s Lymphoma 
The incidence of NHL was statistically significantly lower than expected in the city of 
Cambridge during 1982–1999 (186 diagnoses observed vs. 242.5 expected, SIR = 77, 
95% CI = 66–89). Rates were also statistically significantly below those expected among males 
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and borderline statistically significantly lower among females when evaluated separately by 
gender. NHL was also diagnosed less often than expected in CTs 3543, 3546, and 3549 during 
this time period (see Table 11a).  The incidence of NHL in Cambridge has been consistently 
below the state rate over time, with statistically significant decreases during 1982–1987 and 
1994–1999. Separate analyses of these data by gender revealed lower-than-expected incidence 
among both males and females, however, rates among males were borderline statistically 
significantly lower than expected during 1982–1987 and statistically significantly lower than 
expected during 1994–1999. NHL also occurred approximately at expected rates in Cambridge 
CTs 3543, 3546, and 3549 during each of the smaller time periods evaluated, with the observed 
numbers of cases generally within one to two cases of the expected numbers (see Tables 11b – 
11d). 
6. Pancreatic Cancer 
Overall, pancreatic cancer was diagnosed slightly more often than expected in the city of 
Cambridge during 1982–1999 (139 diagnoses observed vs. 136.4 expected, SIR = 102), 
primarily due to an increase in diagnoses among males in the city.  The elevation among males 
was not statistically significant (67 diagnoses observed vs. approximately 61 expected). 
Residents of CTs 3543 and 3546 were diagnosed with pancreatic cancer at about the rates 
expected.  However, an elevation in the incidence of this cancer type was observed in CT 3549 
during this time period (13 diagnoses observed vs. 7.0 expected, SIR = 187).  This elevation was 
borderline statistically significant (95% CI = 99–320) and was due to a statistically significant 
elevation among males in this area of Cambridge (9 males diagnosed vs. 3.3 expected, SIR = 
273, 95% CI = 125–519) (see Table 12a). 
Analysis of trends over time suggests that the incidence of pancreatic cancer in the city as a 
whole is decreasing over time.  During the most recent time period evaluated, 1994–1999, 43 
individuals were diagnosed with pancreatic cancer in Cambridge compared to 48.0 expected 
(SIR = 89). Although SIRs could not be calculated due to the small number of observed cases 
(i.e., less than five), the incidence of pancreatic cancer also appears to be declining in CTs 3543 
and 3546. The overall rate of pancreatic cancer observed in CT 3549 for the 18-year time period 
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1982–1999 appears to be the result of slight elevations in the incidence of this cancer type among 
males during each of the smaller time periods evaluated (see Tables 12b – 12d). 
C. Cancer Incidence in Arlington 
In general, with the exceptions noted in the following paragraphs, residents of Arlington 
experienced cancer approximately at or below the rates expected during 1982–1999 and the 
smaller time periods evaluated in this report.  The results of the cancer incidence analyses for 
Arlington are summarized in the following paragraphs and shown in Tables 13a – 13d. 
1. Kidney Cancer 
During the 18-year time period 1982–1999, the overall incidence of kidney cancer was lower 
than expected in Arlington. While males were diagnosed with kidney cancer at about the rate 
expected, females in the town were diagnosed less often than expected.  No consistent trends 
were noted when these data were evaluated by smaller time period.  During 1982–1987, males 
were diagnosed with kidney cancer slightly more often than expected while females were 
diagnosed less often than expected. During 1988–1993, both males and females experienced a 
decreased incidence of kidney cancer with respect to the state rate.  During the most recent time 
period evaluated, 1994–1999, females were diagnosed with kidney cancer at about the rate 
expected while males in Arlington experienced a slight elevation in the incidence of this cancer 
type. However, none of the elevations observed during smaller time periods were statistically 
significant. 
2. Leukemia 
Leukemia was diagnosed about as expected in Arlington during 1982–1999 (85 diagnoses 
observed vs. 86.3 expected, SIR = 98). Similar trends were observed among males and females 
when evaluated separately by gender. During 1982–1987, the overall rate of leukemia was 
slightly higher than expected in Arlington (30 diagnoses observed vs. 27.5 expected, SIR = 109). 
During 1988–1993, both males and females were diagnosed with leukemia less often than 
expected. Finally, during 1994–1999, males were diagnosed with leukemia slightly less often 
than expected while females experienced an elevation in the incidence of this cancer type.  This 
elevation was not statistically significant (20 diagnoses observed vs. about 15 expected). 
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3. Liver Cancer 
Overall, the incidence of liver cancer was higher than expected in Arlington during 1982–1999 
(28 diagnoses observed vs. 23.4 expected, SIR = 120).  This elevation, which was not 
statistically significant, was primarily due to an increase in the number of diagnoses among 
females in the town (11 diagnoses observed vs. 7.5 expected, SIR = 147).  Liver cancer occurred 
about twice as often as expected during the earliest time period evaluated 1982–1987 (12 
diagnoses observed vs. 6.0 expected, SIR = 201).  This elevation was statistically significant 
(95% CI = 104–351). Similar trends were observed among males and females when evaluated 
separately by gender; however, the elevation among males was not statistically significant (8 
diagnoses observed vs. about 4 expected), while an excess of about two cases was observed 
among females (4 diagnoses observed vs. about 2 expected).  During 1988–1993, females were 
diagnosed with liver cancer about as expected, while males were diagnosed less often than 
expected.  Finally, during the most recent time period, 1994–1999, males were diagnosed with 
liver cancer at about the rate expected while females were diagnosed slightly more often than 
expected (5 diagnoses observed vs. 3.0 expected). 
4. Lung and Bronchus Cancer 
Overall, during 1982–1999, the incidence of lung and bronchus cancer in Arlington was 
statistically significantly decreased with respect to the state rate (544 diagnoses observed vs. 
643.8 expected, SIR = 84, 95% CI = 78–92).  Both males and females were diagnosed with lung 
and bronchus cancer less often than expected during this time period.  The rate among females 
was statistically significant.  The overall incidence of lung and bronchus cancer was also 
statistically significantly lower than expected during each of the three smaller time periods 
evaluated (i.e., 1982–1987, 1988–1993, and 1994–1999). Statistically significantly lower-than-
expected rates were also noted among females when evaluated separately by gender during 
1982–1987 and 1994–1999). 
5. Non-Hodgkin’s Lymphoma 
NHL was diagnosed at about the rate expected in Arlington during 1982–1999 (161 diagnoses 
observed vs. 158.7 expected, SIR = 101). Analysis of these data by smaller time period revealed 
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that among males, NHL was diagnosed less often than expected during 1982–1987, about as 
often as expected during 1988–1993, and slightly more often than expected during 1994–1999. 
Among females, NHL occurred more often than expected during 1982–1987, less often than 
expected during 1988–1993, and near the expected rate (i.e., within approximately one case of 
the expected number) during 1994–1999. 
6. Pancreatic Cancer 
The overall incidence of pancreatic cancer in Arlington was about as expected during 1982–1999 
(102 diagnoses observed vs. 100.0 expected, SIR = 102).  Males were diagnosed slightly more 
often than expected during this time period while females were diagnosed slightly less often than 
expected and neither difference was statistically significant.  Among males and females 
combined, rates of pancreatic cancer have decreased over time in Arlington and were lower than 
expected during the most recent time period 1994–1999 (25 diagnoses observed vs. 34.0 
expected, SIR = 74).  Although males experienced a statistically significant elevation in the 
incidence of pancreatic cancer during 1982–1987 (25 diagnoses observed vs. 14.3 expected, 
SIR = 174, 95% CI = 113–257), rates among males were lower than expected during 1988–1993 
and 1994–1999. Females were diagnosed with pancreatic cancer about as expected during 
1982–1987, more often than expected during 1988–1993, and less often than expected during 
1994–1999. 
D. Cancer Incidence in Watertown 
In general, with some exceptions noted below, residents of Watertown experienced cancer 
approximately at or near the rates expected during 1982–1999 and smaller time periods 
evaluated in this report.  The results of the cancer incidence analyses for Watertown are 
summarized below and in Tables 14a – 14d. 
1. Kidney Cancer 
During the 18-year time period 1982–1999, kidney cancer occurred slightly more often than 
expected in Watertown as a whole (76 diagnoses observed vs. 70.4 expected, SIR = 108).  This 
elevation was not statistically significant and was due primarily to an increased rate of this 
cancer type among males that was not statistically significant (48 diagnoses observed vs. about 
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40 expected).  When these data were analyzed by smaller time periods, females were diagnosed 
with kidney cancer less often than expected during the two earlier time periods while males were 
diagnosed with this cancer type more often than expected.  The elevation observed among males 
during 1988–1993 was statistically significant (24 diagnoses observed vs. 14.3 expected, 
SIR = 168, 95% CI = 108–251).  However, during more recent years (i.e., 1994–1999), the 
incidence among males was lower than expected (11 diagnoses observed vs. 15 expected), while 
the incidence among females was about as expected. 
2. Leukemia 
A slight elevation in the incidence of leukemia in Watertown was noted during 1982–1999 (68 
diagnoses observed vs. 61.1 expected, SIR = 111).  However, this elevation was based on an 
elevation in males (38 diagnoses observed vs. 31.5 expected), and neither elevation was 
statistically significant.  Review of smaller time periods revealed that during the earliest time 
period evaluated (1982–1987), 18 individuals were diagnosed with leukemia compared to 19.1 
expected (SIR = 94). During 1988–1993, 21 diagnoses were reported vs. 18.5 expected 
(SIR = 113).  Finally, during 1994–1999, 29 individuals were diagnosed where 23.5 diagnoses 
were expected (SIR = 124), an elevation that was not statistically significant.  The elevation 
during 1994–1999 was due to an excess of about three cases each among males and females. 
3. Liver Cancer 
In Watertown during 1982–1999, the incidence of liver cancer was higher than expected based 
on the state rate (21 diagnoses observed vs. 16.5 expected, SIR = 127).  No females were 
diagnosed with liver cancer during the 18 years evaluated where approximately five diagnoses 
were expected. The rate of liver cancer among males in Watertown was statistically significantly 
elevated during this time period (21 diagnoses observed vs. 11.2 expected, SIR = 188, 
95% CI = 116–287).  Liver cancer was diagnosed more often than expected among males in 
Watertown during each of the smaller time periods evaluated (i.e., 1982–1987, 1988–1993, and 
1994–1999). None of the elevations in smaller time periods was statistically significant, 
although the incidence in the most recent time period nearly achieved statistical significance (10 
diagnoses observed vs. 4.9 expected, SIR = 204, 95% CI = 98–376). 
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4. Lung and Bronchus Cancer 
Overall, during 1982–1999, lung and bronchus cancer occurred less often than expected in 
Watertown (423 diagnoses observed vs. 452.4 expected, SIR = 93).  Similar trends were 
observed among males and females when evaluated separately by gender.  Results of analyses by 
smaller time period suggest that the overall incidence of lung and bronchus cancer may be 
decreasing over time in Watertown.  During the most recent time period, 1994–1999, the 
decrease in lung and bronchus cancer diagnoses was statistically significant among males (60 
diagnoses observed vs. 82.5 expected, SIR = 73, 95% CI = 56–94) and among males and females 
combined (134 diagnoses observed vs. 160.5, SIR = 83, 95% CI = 70–99). 
5. Non-Hodgkin’s Lymphoma 
NHL occurred more often than expected in the town of Watertown as a whole during 1982–1999 
(137 diagnoses observed vs. 113.2 expected, SIR = 121).  The observed elevation was 
statistically significant (95% CI = 102–143).  Both males and females experienced increases in 
the incidence of NHL during this time period; however, neither elevation was statistically 
significant. NHL occurred more often than expected based on the state rate among both males 
and females during 1982–1987 and 1988–1993, although females experienced a relatively higher 
incidence of this cancer type during these years.  During the most recent time period evaluated, 
1994–1999, the incidence of NHL among females occurred about as expected, while an excess of 
about five cases occurred among males (26 diagnoses observed vs. approximately 21 expected). 
6. Pancreatic Cancer 
The overall incidence of pancreatic cancer was lower than expected in Watertown during 
1982–1999 (66 diagnoses observed vs. 70.3 expected, SIR = 94).  This rate reflected a slightly 
higher-than-expected rate among males and a lower-than-expected rate among females when 
evaluated separately by gender, but no difference was statistically significant.  Analysis of these 
data by smaller time periods revealed that among males, the incidence of pancreatic cancer 
occurred less often than expected during 1982–1987 and more often than expected during the 
latter two time periods.  Among females, the incidence of pancreatic cancer was about as 
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expected during 1982–1987 and lower than expected during 1988–1993 and 1994–1999.  No 
difference was statistically significant. 
V. REVIEW OF CANCER RISK FACTOR INFORMATION 
As previously mentioned, cancer is not just one disease, but is a term used to describe a variety 
of different diseases. As such, studies have generally shown that different cancer types have 
different causes, patterns of incidence, risk factors, latency periods (the time between exposure 
and development of disease), characteristics, and trends in survival.  Available information from 
the MCR related to age and gender, as well as other factors related to the development of cancer 
such as smoking and occupation, was reviewed for individuals diagnosed with cancer in 
Belmont, Cambridge, Arlington, and Watertown.  Information for each of the six cancer types 
evaluated in this report was compared to known or established incidence trends to assess whether 
any unexpected patterns exist among these cases.  It is important to note, however, that personal 
risk factors such as family history, pre-existing medical conditions, hormonal events, diet, and 
other factors also influence the development of these cancer types.  This information is not 
collected by the MCR or any other readily accessible source.  In this investigation, therefore, it 
was not possible to evaluate the role these types of risk factors may have played in the incidence 
of cancer in Belmont and surrounding communities.  For detailed information regarding risk 
factors associated with the cancer types evaluated in this report, please refer to Appendix C. 
Age and gender are risk factors in many types of cancers, including kidney cancer, liver cancer, 
lung and bronchus cancer, leukemia, NHL, and pancreatic cancer.  Therefore, a review of age-
group specific SIRs was conducted.  Where numbers of cases in each age group were too small 
to calculate SIRs, the distribution of cases by age was reviewed. 
Tobacco use is also a known or suggested causal risk factor in several types of cancer, including 
kidney cancer, lung and bronchus cancer, and pancreatic cancer.  The smoking history of 
individuals diagnosed with these cancer types in Belmont and surrounding towns was reviewed 
to assess the role tobacco smoking may have played in the development of these types of cancer 
among residents of Belmont.  However, results of smoking history analysis should be interpreted 
with caution because of the number of individuals for which smoking status was unknown. 
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In some studies, an association has been found with specific occupational exposure and an 
increase in the incidence of kidney cancer, leukemia, liver cancer, lung and bronchus cancer, 
NHL, and pancreatic cancer. Therefore, occupational information as reported by the MCR at the 
time of diagnosis was reviewed for individuals diagnosed with these cancer types to determine 
the role that occupational factors may have played in the development of these types of cancer in 
Belmont and surrounding towns.  It should be noted, however, that occupational data reported to 
the MCR are generally limited to job title and often do not include specific job duty information 
that could further define exposure potential for individuals.  In addition, these data are often 
incomplete as occupational information can be reported as unknown, at home, or retired. 
Finally, histologic (cell type) distribution was reviewed for diagnoses of lung and bronchus 
cancer and leukemia.  Patterns of disease were compared to known or established incidence 
trends to assess whether any unexpected patterns exist in these areas. 
A. Kidney Cancer 
Kidney cancer is twice as common in males as it is in females, and the incidence most often 
occurs in the fifth and sixth decades of life (50–70 year age group) (ACS 2001a).  The etiology 
of kidney cancer is not fully understood. However, a number of environmental, hormonal, 
cellular, and genetic factors have been studied as possible causal factors in the development of 
renal cell carcinoma.  Cigarette smoking is the most important known risk factor for renal cell 
cancer. Smoking increases the risk of developing renal cell cancer by 30% to 100% (ACS 
2001a). In both males and females, a statistically significant dose-response relationship between 
smoking and this cancer has been observed.  Approximately one-third of renal cell cancers in 
men and one-quarter of the renal cell cancers in women may be caused by cigarette smoking 
(ACS 2001a). 
Although kidney cancer is not generally considered an occupationally associated cancer, some 
studies have suggested that environmental and occupational factors may be associated with its 
development.  Some studies have shown an increased incidence of this cancer type among 
leather tanners, shoe workers, and workers exposed to asbestos.  In addition, exposure to 
cadmium is associated with an increased incidence of kidney cancer, particularly among men 
who smoke.  In addition, workplace exposure to organic solvents, such as trichloroethylene 
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(TCE), may increase the risk of this cancer (ACS 2001a).  More recently, renal cell carcinoma 
(RCC), the most common type of kidney cancer, has been suggested to be associated with 
occupational exposure to petroleum, tar, and pitch products.  However, studies of oil refinery 
workers and petroleum products distribution workers have not identified a definitive relationship 
between exposure to gasoline or other petroleum products and kidney cancer (Linehan et al. 
1997; McLaughlin et al. 1996). 
1. Age and Gender 
The average age of individuals diagnosed with kidney cancer in Belmont during 1982–1999 was 
63 years. Eighty-three percent (n = 43) were age 50 or older at the time of diagnosis.  This 
pattern is consistent with what would be expected in the general population.  Overall, males 
experienced kidney cancer at about the rate expected, while females were diagnosed less often 
than expected based on the state rate. Review of age-group-specific SIRs revealed a slightly 
increased rate of kidney cancer among males aged 20–44 years while males in older age groups 
(e.g., 75–84 years and 85+ years) were diagnosed less often than expected.  Females in all age 
groups were diagnosed with kidney cancer approximately at or below rates expected. 
In Cambridge, the average age of individuals diagnosed with kidney cancer during 1982–1999 
was 61 years. This is comparable to that observed in the general population.  The majority of 
those diagnosed (82%, n = 89) were age 50 or older at the time of diagnosis.  Incidence rates 
were lower than expected among males in all age groups, resulting in an overall rate that was 
statistically significantly lower than expected.  Similar trends were observed when age-group-
specific rates were reviewed for females in Cambridge.  Females in most age groups were 
diagnosed with kidney cancer about as or less often than expected. 
In Arlington, the average age of individuals diagnosed with kidney cancer during 1982–1999 
was 65 years. Eighty-four percent (n = 79) were age 50 or older at the time of diagnosis.  Males 
in most age groups experienced kidney cancer approximately at or below expected rates. 
However, males between the ages of 65 and 74 were diagnosed with kidney cancer slightly more 
often than expected. Females in all age groups were diagnosed with kidney cancer either 
approximately at or below expected rates. 
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The average age of individuals diagnosed with kidney cancer in Watertown during 1982–1999 
was 68 years. Ninety-seven percent (n = 74) were over the age of 50 at the time of diagnosis. 
The slight overall elevation in kidney cancer incidence among males in Watertown was the result 
of increased diagnoses among males aged 45–84 years.  Females in most age groups experienced 
rates of kidney cancer that were lower than expected.  However, a slight elevation in incidence 
was noted among females aged 65–74 years. 
2. Smoking History 
Of the 52 individuals diagnosed with kidney cancer in Belmont during 1982–1999, 31% (n = 16) 
reported being current or former smokers at the time of diagnosis.  Fifty percent (n = 26) were 
nonsmokers and smoking history was unknown for the remaining 19% (n = 10).  This 
distribution is different than that observed for the state as a whole during this time period.  In 
Massachusetts, 45% of individuals diagnosed with kidney cancer were current or former smokers 
at the time of diagnosis, 33% were nonsmokers, and smoking history was unknown for 
approximately 22%. 
In Cambridge, 39% (n = 42) of those diagnosed with kidney cancer in Cambridge during 
1982–1999 reported being current or former smokers at the time of diagnosis.  Forty-six percent 
(n = 50) were nonsmokers and smoking history was unknown for 16% (n = 17). 
Of the 94 individuals diagnosed with kidney cancer in Arlington during 1982–1999, 41% 
(n = 39) reported being current or former smokers at the time of diagnosis.  Forty-nine percent 
(n = 46) were nonsmokers and smoking history was unknown for the remaining 10% (n = 9). 
In Watertown, 50% of those diagnosed with kidney cancer during 1982–1999 (n = 38) reported 
being current or former smokers at the time of diagnosis.  Thirty-seven percent (n = 28) were 
nonsmokers and smoking history was unknown for the remaining 13% (n = 10).  Of the four 
communities evaluated, Watertown was the only community with an overall elevation (not 
statistically significant) in kidney cancer during 1982–1999.  The smoking information suggests 
that smoking may have played a role in the overall elevation of kidney cancer among residents of 
Watertown. 
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3. Occupation 
Review of occupational information as reported to the MCR for individuals diagnosed with 
kidney cancer in Belmont did not reveal any jobs likely to be related to an increased risk of 
developing kidney cancer. However, occupation was reported as retired, unknown, or “at home” 
for almost half of these individuals (44%, n = 23). 
In Cambridge, one individual reported an occupation that may be associated with exposures 
related to kidney cancer. No other jobs likely associated with an increased risk of kidney cancer 
were indicated. However, occupation was unknown or reported as retired or at home for 39% of 
individuals (n = 42). 
In Arlington, five individuals reported jobs in which occupational exposures possibly associated 
with kidney cancer could have been possible.  However, specific job duty information that could 
further define exposure potential for these individuals was unavailable.  Occupation was 
unknown or reported as retired or at home for 38 individuals (39%). 
Most individuals diagnosed with kidney cancer in Watertown during 1982–1999 did not indicate 
working in jobs in which occupational exposures possibly associated with kidney cancer would 
have been likely. However, one individual reported an occupation in which an increased risk is 
possible. Occupation was unknown or reported as retired or at home for the majority of those 
diagnosed (53%, n = 40). 
B. Leukemia 
In 2003, leukemia is expected to affect approximately 30,600 individuals (17,900 males and 
12,700 females) in the United States, resulting in 21,900 deaths.  In Massachusetts, 
approximately 700 individuals will be diagnosed with the disease in 2003, representing more 
than 2% of all cancer diagnoses. There are four major types of leukemia: acute lymphoid 
leukemia (ALL), acute myeloid leukemia (AML), chronic lymphoid leukemia (CLL), and 
chronic myeloid leukemia (CML).  There are also several rare types of leukemia (e.g., hairy cell 
leukemia, myelomonocytic leukemia).  In adults, the most common types are AML and CLL. 
Leukemia is the most common type of childhood cancer, accounting for more than 30% of all 
cancers diagnosed in children. The majority of these cases are of the ALL type (ACS 2003). 
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The various subtypes of leukemia occur with different frequencies in the population.  For the 
purpose of classification in this evaluation, if the histology (i.e., cell type) of the leukemia 
diagnosis was not otherwise specified or not classified as one of the four main subtypes, then the 
individual case was categorized as “other.”  Available information regarding the expected 
distribution of leukemia by histology types can vary considerably depending on coding methods, 
making comparisons of type-specific incidence rates from different cancer registries difficult 
(Linet and Cartwright 1996). In the state of Massachusetts during the time period 1982–1999, 
33.7% of all leukemia cases were AML, 26.3% were CLL, 13.1% were ALL, 10.9% were CML, 
and 16.0% were other histology types. 
Several occupational exposures have been identified as playing a role in the development of 
leukemia.  For example, exposures to particular chemicals are thought to increase the risk of 
developing certain kinds of leukemia.  Exposure to ionizing radiation and chronic, high-dose 
exposure to pesticides and other chemicals such as benzene, have also been suggested as possible 
risk factors for leukemia (Linet and Cartwright 1996).  Chronic occupational exposure to 
benzene has been established as a cause of AML.  High doses of radiation among survivors of 
atomic bomb blasts or nuclear reactor accidents are associated with an increased incidence of 
AML, CML, and ALL, but no association has been established for lower doses such as those 
used in medical diagnostics. 
1. Age and Gender 
The average age of individuals diagnosed with leukemia in Belmont was 67 years.  Eighty-four 
percent (n = 49) were age 50 or older at the time of diagnosis.  Three diagnoses occurred among 
children (all under the age of 10 at diagnosis), which is about the number expected.  The 
townwide elevation in the incidence of leukemia was due primarily to increased incidence 
among females in Belmont during 1982–1999.  Review of age-group-specific SIRs suggests that 
this elevation was not the result of increased diagnoses among females in any one age group. 
Males generally experienced leukemia approximately at or below the expected rates, with the 
exception of males aged 65–74 years who were diagnosed with leukemia slightly more often 
than expected. 
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In Cambridge, the average age at diagnosis for individuals diagnosed with leukemia during 
1982–1999 was 56 years. Fourteen individuals (14%) were between the ages of 0 and 19 years 
at diagnosis. This was about the number expected in this age group (8 diagnoses observed 
among males vs. 7.7 expected; 6 diagnoses observed among females vs. 5.9 expected).  As noted 
previously, overall rates of leukemia were statistically significantly lower than expected among 
both males and females.  Review of age-group-specific incidence rates revealed that both males 
and females experienced leukemia approximately at or below the rates expected for each age 
group. 
Among the 85 individuals diagnosed with leukemia in Arlington during 1982–1999, the average 
age of diagnosis was 57 years. Sixty-eight percent of the diagnoses (n = 58) occurred among 
adults over the age of 50 years. Twelve of the diagnoses (14%) occurred among children under 
the age of 19 years. Among males aged 0–19 years, three individuals were diagnosed, about the 
number expected.  However, nine females aged 0–19 years were diagnosed with leukemia in 
Arlington compared to 2.6 diagnoses expected.  For other age groups among males and females, 
no unusual patterns were observed. 
In Watertown, the average age of individuals diagnosed with leukemia was 64 years.  Eighty-one 
percent (n = 55) were over the age of 50 at the time of diagnosis.  Four diagnoses occurred 
among children (i.e., individuals aged 0–19 years), about the number expected.  Overall, there 
was a slight elevation in the incidence of this cancer type among males in the town while females 
experienced leukemia at about the rate expected.  Among males, increased rates were noted 
among individuals aged 65–84 years.  Females in most age groups were diagnosed with 
leukemia less often than expected.  However, slight elevations were noted among females aged 
45–64 and 75–84. 
2. Histology 
Of the 58 individuals diagnosed with leukemia in Belmont during 1982–1999, 41.4% were 
diagnosed with the AML subtype, 27.6% were diagnosed with CLL, 8.6% were diagnosed with 
ALL, 6.9% were diagnosed with CML, and 15.5% were diagnosed with other types of leukemia. 
This distribution is similar to that seen statewide, with the exception that the AML subtype 
comprised a relatively larger proportion of leukemia diagnoses while the ALL and CML 
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subtypes comprised a relatively smaller proportion of diagnoses.  However, considering the 
relatively small number of total diagnoses in the town of Belmont compared to the state as a 
whole during the 1982–1999 time period, the overall pattern does not appear to be atypical.  All 
three children diagnosed with leukemia in Belmont were diagnosed with the ALL subtype, the 
most common subtype among children. 
Among the 102 leukemia diagnoses in Cambridge during 1982–1999, 38.2% of the diagnoses 
were of the AML subtype, 20.6% were CLL, 8.8% were ALL, 8.8% were CML, and 19.6% were 
other types. This pattern is generally consistent with the statewide pattern.  Among the 14 
individuals between the ages of 0 and 19 years at diagnosis, four were diagnosed with ALL, 
eight were diagnosed with AML, and two were diagnosed with other subtypes. 
In Arlington, the distribution of leukemia diagnoses by histology type was generally consistent 
with that seen in the state as a whole. Specifically, 34.1% of the individuals were diagnosed with 
AML, 20.0% were diagnosed with CLL, 21.2% were diagnosed with ALL, 10.6% were 
diagnosed with CML, and 14.1% were diagnosed with other types of leukemia.  The fact that 
ALL diagnoses represented a relatively larger proportion of total diagnoses in Arlington 
compared to the state can likely be attributed to the increased incidence of leukemia among 
children aged 0–19 years in Arlington, among whom 11 out of 12 were diagnosed with the ALL 
subtype, the most commonly diagnosed leukemia in children. 
Of the 69 individuals diagnosed with leukemia in Watertown during 1982–1999, 29.4% were 
diagnosed with the AML subtype, 22.1% were diagnosed with CLL, 10.3% were diagnosed with 
ALL, 11.8% were diagnosed with CML, and 25.0% were diagnosed with other types of 
leukemia.  This is similar to the distribution seen in Massachusetts as a whole.  All four 
individuals under the age of 19 were diagnosed with the ALL subtype. 
3. Occupation 
Review of occupations for individuals diagnosed with leukemia in Belmont revealed that two 
individuals may have worked in jobs in which occupational exposures potentially related to the 
development of leukemia may have been possible.  However, information regarding specific job 
duties that could help to further define exposure potential for these individuals was not available. 
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Occupations reported for the remaining individuals are not likely to be related to an increased 
risk of this cancer type. However, for more than half of the individuals diagnosed with leukemia 
in Belmont (53%, n = 31), occupation was reported as retired, unknown, or “at home.” 
Occupational exposures possibly related to an increased risk of leukemia may have been possible 
for three individuals diagnosed in Cambridge during 1982–1999.  Occupation was unknown or 
reported as retired or at home for almost half of those diagnosed (45%, n = 46). 
None of the 85 individuals diagnosed with leukemia in Arlington indicated working in 
occupations in which occupational exposures associated with leukemia are likely.  Occupation 
was unknown or reported as retired or at home for 25% of those diagnosed (n = 21). 
In Watertown, one individual reported working in a job in which occupational exposures 
associated with an increased risk of leukemia may have been possible.  Occupation was 
unknown or reported as retired or at home for half of those diagnosed (n = 34). 
C. Liver Cancer 
An estimated 17,300 people in the United States (11,700 men and 5,600 women) will be 
diagnosed with liver cancer in 2003, accounting for approximately 1% of all new diagnoses of 
cancer (ACS 2003).  Hepatocellular carcinoma (HCC) is the most common primary cancer of the 
liver, accounting for about 75% of all cases.  Men are at least two to three times more likely to 
develop liver cancer than women (Yu et al. 2000).  Although the risk of developing HCC 
increases with increasing age, the disease can occur in persons of any age (London and McGlynn 
1996). Although chronic infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are 
the most significant risk factors for developing liver cancer (ACS 2001b), epidemiologic and 
environmental evidence indicates that exposure to certain chemicals and toxins can also 
contribute significantly to the development of liver cancer.  For example, vinyl chloride (a 
known human carcinogen used in the manufacturing of some plastics) and thorium dioxide (used 
in the past for certain x-ray tests) are risk factors for a rare type of liver cancer called 
angiosarcoma (ACS 2001b; London and McGlynn 1996).  These chemicals may also increase 
the risk of HCC, but to a lesser degree.  In addition, arsenic has been associated with an 
increased risk of liver cancer (ATSDR 2000b). 
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1. Age and Gender 
For the 16 individuals diagnosed with liver cancer in Belmont during 1982–1999, the average 
age at diagnosis was 66 years, which is consistent with trends for this cancer type in the general 
population. The majority of individuals (88%, n = 14) were age 50 or older at the time of 
diagnosis. As discussed previously, both males and females experienced slightly increased rates 
of liver cancer during 1982–1999 (i.e., approximately one additional diagnosis each).  While 
males aged 75–84 were diagnosed with liver cancer more often than expected, males in each of 
the other age groups evaluated were diagnosed approximately at or below the rates expected. 
Females in each age group were generally diagnosed at approximately the rates expected. 
The average age at diagnosis for individuals diagnosed with liver cancer in Cambridge during 
1982–1999 was 64 years. Eight-three percent (n = 33) of those diagnosed were age 50 or older 
at the time of diagnosis.  The slight elevation in incidence observed among males in Cambridge 
was primarily the result of an elevation among males aged 65–74 years.  Among females, 
incidence was about as expected for most age groups. 
In Arlington, the average age of individuals diagnosed with liver cancer during 1982–1999 was 
72 years. Among the 28 individuals diagnosed, only one was under the age of 50 years at the 
time of diagnosis.  The slight elevation in incidence observed among males during this time 
period was primarily due to an increased number of diagnoses among males aged 75–84 while 
males in other age groups were diagnosed approximately at or below expected rates.  Among 
females, the observed elevation was due to increases in diagnoses among individuals aged 65–84 
years. 
The average age of individuals diagnosed with liver cancer in Watertown was 65 years.  Ninety 
percent (n = 19) of those diagnosed were over the age of 50 at the time of diagnosis.  The 
statistically significant elevation observed in the rate of liver cancer among males in Watertown 
during 1982–1999 was primarily the result of increased diagnoses among individuals aged 45–84 
years. There were no liver cancer diagnoses among females in Watertown compared to about 5 
expected. 
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2. Occupation 
None of the 16 individuals diagnosed with liver cancer in Belmont reported working in an 
occupation likely to be associated with an increased risk of developing liver cancer.  However, 
occupation was unknown or reported as “at home” for three individuals. 
Review of occupational information for the 40 individuals diagnosed with liver cancer in 
Cambridge did not indicate any jobs likely to be associated with an increased risk of this cancer 
type. However, occupation was unknown or reported as retired or at home for 40% (n = 16) of 
those diagnosed. 
None of the jobs reported by the 28 individuals diagnosed with liver cancer in Arlington were 
likely associated with an increased risk of this cancer type.  However, occupation was unknown 
or reported as retired or at home for half of the individuals (n = 14). 
None of the 21 individuals diagnosed with liver cancer in Watertown indicated possible 
occupational exposures that could be associated with liver cancer.  However, occupation was 
unknown or reported as retired for almost a third of the individuals (29%, n = 6). 
D. Lung and Bronchus Cancer 
According to epidemiologic literature, the incidence of lung cancer increases sharply with age 
peaking at about age 60 to 70. Only 2% of lung cancers occur before the age of 40.  In addition, 
lung cancer is generally observed more often among men than women (Blot and Fraumeni 1996, 
MCR 2002). 
Lung cancer is divided into two main types: small cell lung cancer and nonsmall cell lung 
cancer. Nonsmall cell lung cancer is further subdivided into three types: adenocarcinoma, 
squamous cell carcinoma, and large cell undifferentiated carcinoma. The different types of lung 
cancer occur with different frequencies in the population.  The American Cancer Society 
estimates that approximately 40% of all lung cancers are adenocarcinomas, 25%–30% are 
squamous cell carcinomas, 20% are small cell cancers, and 10%–15% of cases are large cell 
carcinomas (ACS 2002).  Rates in Massachusetts are very similar to those seen nationally. 
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About 87% of all lung cancers are thought to be caused directly by smoking cigarettes or by 
exposure to secondhand smoke, or environmental tobacco smoke (ACS 2002).  An increase in 
cigarette smoking among women has produced lung cancer incidence rates that more closely 
resemble those experienced by males.  The risk of developing lung cancer depends on the 
intensity of an individual’s smoking habits (e.g., duration of habit, amount smoked, tar yield of 
cigarette, and filter type).  Smoking cessation decreases the elevated risk by about 50%; 
however, former smokers still carry a greater risk of developing lung cancer than those who have 
never smoked. 
Several occupational exposures have been identified as playing a role in the development of lung 
cancer. For example, workplace exposure to asbestos is an established risk factor for this disease 
(ACS 2002). Underground miners exposed to radon and uranium are also at an increased risk for 
developing lung cancer (ACS 2002; Samet and Eradze 2000).  Other occupations potentially 
associated with this cancer include chemical workers, talc miners and millers, paper and pulp 
workers, metal workers, butchers and meat packers, vineyard workers, carpenters and painters, 
and shipyard and railroad manufacture workers.  In addition to asbestos and radon, chemical 
compounds such as arsenic, chloromethyl ethers, chromium, vinyl chloride, nickel chromates, 
coal products, mustard gas, ionizing radiation, and fuels such as gasoline are also occupational 
risk factors for lung cancer. Occupational exposure to these compounds in conjunction with 
cigarette smoking can dramatically increase the risk of developing lung cancer (Blot and 
Fraumeni 1996). 
1. Age and Gender 
Of the 270 individuals diagnosed with lung and bronchus cancer in Belmont during 1982–1999, 
the average age at diagnosis was 70 years.  Less than one percent of these individuals (n = 2) 
were under the age of 40 at the time of diagnosis.  Overall, during the 18-year time period 1982– 
1999, both males and females experienced decreased rates of lung and bronchus cancer 
compared to the state rates, with the rate among males statistically significant.  Males in all age 
groups were diagnosed with lung and bronchus cancer less often than expected in Belmont 
during 1982–1999. Similar trends were observed among females in most age groups. 
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In Cambridge, the average age at diagnosis for the 799 individuals diagnosed with lung and 
bronchus cancer during 1982–1999 was 67 years.  Less than one percent of these individuals 
(n = 6) were under the age of 40 at the time of diagnosis.  As described previously, both males 
and females experienced statistically significantly lower-than-expected rates of lung and 
bronchus cancer in Cambridge during this time period.  Incidence rates of lung and bronchus 
cancer were about as expected or lower than expected for males and females in all age groups 
evaluated. 
The average age at diagnosis for individuals with lung and bronchus cancer in Arlington was 69 
years. Less than one percent of these individuals (n = 5) were under the age of 40 at the time of 
diagnosis. Review of age-group-specific SIRs revealed that males and females in all age groups 
were diagnosed with lung and bronchus cancer either about at or below expected rates. 
In Watertown, the average age of individuals diagnosed with lung and bronchus cancer during 
1982–1999 was 70 years. Less than one percent of those diagnosed were under the age of 40 at 
the time of diagnosis.  Males in most age groups were diagnosed with lung and bronchus cancer 
about as often as expected or less often than expected; however, individuals aged 75–84 
experienced a slight elevation in the incidence of this cancer type.  The overall incidence rate 
among males was lower than expected.  Among females, individuals in all age groups were 
diagnosed approximately at or below the rates expected. 
2. Histology 
Of the 228 lung and bronchus cancer diagnoses in Belmont with a specific histology 
classification, 48% were diagnosed as adenocarcinomas, 27% were squamous cell carcinomas, 
20% were small cell cancers, and 5% were large cell carcinomas.  This pattern is generally 
consistent with the distribution of histology types seen in the general population with the 
exception that adenocarcinomas comprised a somewhat larger proportion of all diagnoses while 
large cell carcinomas comprised a somewhat smaller proportion of all diagnoses. 
In Cambridge, 667 lung and bronchus cancer individuals were diagnosed with one of the four 
major subtypes of this disease.  Of these, about 43% were adenocarcinomas, 30% were 
squamous cell carcinomas, 19% were small cell carcinomas, and 8% were large cell carcinomas. 
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The observed distribution is consistent with established prevalence patterns of disease for lung 
and bronchus cancer in the general population. 
Among the 445 lung and bronchus cancer diagnoses in Arlington that could be classified as one 
of the four major subtypes, 36% were adenocarcinomas, 29% were squamous cell carcinomas, 
21% were small cell carcinomas, and 14% were large cell carcinomas.  This pattern is 
comparable to that seen in the general population. 
Of the 354 lung and bronchus cancer diagnoses in Watertown with a specific histology 
classification, 40% were diagnosed as adenocarcinomas, 32% were squamous cell carcinomas, 
18% were small cell carcinomas, and 9% were large cell carcinomas.  This distribution is 
consistent with that observed in the general population. 
3. Smoking History 
Of the 270 individuals diagnosed with lung and bronchus cancer in Belmont during 1982–1999, 
85% (n = 230) reported being current or formers smokers at the time of diagnosis.  Eight percent 
(n = 22) were nonsmokers and smoking history was unknown for the remaining 7% (n = 18).  In 
comparison, 79% of individuals diagnosed with lung and bronchus cancer in Massachusetts as a 
whole during this time period reported being current or former smokers, 7% were nonsmokers, 
and smoking history was unknown for 14%.  Review of this information suggests that smoking 
likely played a role in the incidence of lung and bronchus cancer in Belmont. 
The majority of individuals diagnosed with lung and bronchus cancer in Cambridge reported 
being current or former smokers at the time of diagnosis (83%, n = 663).  Five percent (n = 42) 
were nonsmokers, and smoking history was unknown for 12% of the diagnoses (n = 94).  Again, 
it is likely that smoking played a role in the pattern of lung and bronchus cancer in Cambridge. 
Of the 544 individuals diagnosed with lung and bronchus cancer in Arlington during 1982–1999, 
the majority (84%, n = 459) were current or former smokers at the time of diagnosis.  Seven 
percent (n = 39) were nonsmokers and smoking history was unknown for the remaining 8% 
(n = 46). 
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Of the 423 individuals diagnosed with lung and bronchus cancer in Watertown during 1982– 
1999, 79% (n = 335) reported being current or former smokers at the time of diagnosis.  Ten 
percent (n = 44) were nonsmokers, and smoking history was unknown for the remainder 
(n = 44). 
4. Occupation 
The majority of individuals diagnosed with lung and bronchus cancer in Belmont did not indicate 
working in jobs likely to have been a factor in their development of cancer.  However, 14 
individuals (5%) reported either a history of asbestos exposure or occupations where exposures 
to asbestos or other chemical compounds possibly associated with lung and bronchus cancer may 
have been possible. Occupation was reported as retired, unknown, or at home for almost half 
(46%, n = 125) of the individuals. 
Seven percent (n = 56) of the individuals diagnosed with lung and bronchus cancer in Cambridge 
reported a history of asbestos exposure or working in jobs where occupational exposures 
possibly related to an increased risk of this disease could have been possible.  Occupation was 
unknown or reported as retired or at home for 43% (n = 342) of those diagnosed. 
Review of job information for individuals diagnosed with lung and bronchus cancer in Arlington 
during 1982–1999 revealed that occupational or other exposures possibly associated with lung 
and bronchus cancer could have been possible for at least 35 individuals (7%).  However, 
occupation was unknown or reported as retired or at home for 37% of the individuals (n = 199). 
In Watertown, 21 individuals diagnosed with lung and bronchus cancer during 1982–1999 (5%) 
reported working in jobs possibly associated with an increased risk of this cancer type or a 
history of exposure to asbestos, radiation, or other substances that may have possibly played a 
role in their developing cancer.  However, occupation was unknown or reported as retired or at 
home for almost half (48%, n = 204) of those diagnosed.  Therefore, it is difficult to determine 
the role that occupation may have played in the incidence of lung and bronchus cancer in 
Watertown. 
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E. Non-Hodgkin’s Lymphoma 
Non-Hodgkin’s lymphoma (NHL) can occur at all ages; however, the average age at diagnosis is 
the early 60s, and the incidence of this disease generally increases with age.  This disease is more 
common in men than in women and affects whites more often than African Americans or Asian 
Americans (ACS 2000a).  The American Cancer Society estimates that approximately 53,400 
Americans will be diagnosed with NHL in 2003, making it the sixth most common cancer in the 
United States among both men and women, excluding nonmelanoma skin cancers (ACS 2003). 
Although the primary factors related to the development of NHL include viral infections and 
conditions that suppress the immune system, certain exposures related to occupations involving 
chemicals or agriculture have been associated with an increased risk of developing NHL. 
Farmers, herbicide and pesticide applicators, and grain workers appear to have the most 
increased risk (Zahm et al. 1990 and 1993; Tatham et al. 1997).  An elevated risk for NHL 
development has also been noted among fence workers, orchard workers, and meat workers. 
High-dose exposure to benzene has been associated with NHL (ACS 2000a); however, a recent 
international cohort study indicated that petroleum workers exposed to benzene were not at an 
increased risk of NHL (Wong and Raabe 2000). 
1. Age and Gender 
The average age at diagnosis for individuals diagnosed with NHL in Belmont during 1982–1999 
was 66 years, which is generally consistent with that seen in the general population.  Review of 
age-group-specific SIRs revealed slightly different trends among males and females.  While 
males in all age groups were diagnosed with NHL at or below expected rates, resulting in an 
overall incidence rate that was borderline statistically significantly lower than expected, a slight 
elevation in the incidence of NHL was noted among females aged 20–44.  Females in other age 
groups experienced NHL about as often as expected or less often than expected. 
In Cambridge, the average age at diagnosis for individuals diagnosed with NHL during 1982– 
1999 was 59 years. As described previously, incidence rates for NHL were statistically 
significantly lower than expected for males and females combined and for males when evaluated 
separately by gender. In addition, incidence rates were borderline statistically significantly lower 
than expected for females.  Review of age-group-specific SIRs revealed that both males and 
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females in all age groups evaluated experienced NHL about as often as expected or less often 
than expected. 
Among the 161 individuals diagnosed with NHL in Arlington during 1982–1999, the average 
age at the time of diagnosis was 67 years.  The incidence of NHL among males in Arlington was 
approximately at or below expected rates for most age groups.  The slight elevation in NHL 
incidence observed among females in Arlington was primarily the result of additional diagnoses 
among females aged 45–64 years.  Females in other age groups were diagnosed with NHL about 
as often as expected or less often than expected in Arlington during 1982–1999. 
In Watertown, a statistically significant elevation in the incidence of NHL was noted for the 
18-year time period 1982–1999. Among the 137 individuals diagnosed, the average age at 
diagnosis was 64 years.  Among males, the elevated rate was primarily due to an increase in the 
number of NHL diagnoses among individuals aged 20–44 and 45–64.  Among females, the 
elevated rate was primarily the result of additional diagnoses among individuals aged 65–74 and 
75–84. 
2. Occupation 
Review of occupational information for individuals diagnosed with NHL in Belmont revealed 
that three individuals may have worked jobs in which occupational exposures potentially related 
to the development of NHL may have been possible.  However, information regarding specific 
job duties that could help to further define exposure potential for these individuals was not 
available. Occupation was reported as retired, unknown, or at home for almost 75% of 
individuals (n = 62). Therefore, it is difficult to assess the role that occupation may have played 
in the incidence of NHL among residents of Belmont. 
On the basis of a review of job title information as reported to the MCR for individuals in 
Cambridge diagnosed with NHL during 1982–1999, occupational exposure do not appear likely 
for the majority of those diagnosed.  However, one individual reported working in an occupation 
in which exposure to pesticides may have been possible.  Occupation was unknown or reported 
as retired or at home for 37% (n = 68) of the individuals. 
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Review of occupational information for individuals diagnosed with NHL in Arlington revealed 
that occupational exposures possibly associated with an increased risk of NHL may have been 
possible for five individuals (3%).  Occupation was unknown or reported as retired or at home 
for 43% of those diagnosed (n = 70). 
In Watertown, three individuals reported occupations in which exposures possibly related to the 
development of NHL may have been possible.  Again, specific job duty information was not 
available for these individuals. Occupation was reported as retired, unknown, or at home for half 
of all individuals (n = 69). 
F. Pancreatic Cancer 
The risk of developing pancreatic cancer increases with age, and the majority of cases occur 
between ages 60 and 80. Men are approximately 30% more likely to develop pancreatic cancer 
than are women (ACS 2000b).  Besides age, the most consistent and only established risk factor 
for pancreatic cancer is cigarette smoking.  According to the American Cancer Society, 
approximately 30% of all pancreatic cancer cases are thought to result directly from cigarette 
smoking (ACS 2000b).  Studies have estimated that the risk of pancreatic cancer is two to six 
times greater in heavy smokers than in nonsmokers (Anderson et al. 1996). 
Numerous occupations have been investigated for their potential role in the development of 
pancreatic cancer, but studies have not produced consistent results.  Heavy exposure to certain 
pesticides (including DDT and its derivatives) may increase the risk of pancreatic cancer (ACS 
2000b; Ji et al. 2001; Porta et al. 1999).  Exposure to certain dyes and to certain chemicals 
related to gasoline, in addition to exposure to asbestos and ionizing radiation, have also been 
associated with the development of pancreatic cancer in some studies.  Other studies, however, 
have found no link between these agents and pancreatic cancer (ACS 2000b; Anderson et al. 
1996). A recent evaluation of data from several studies has implicated organic solvents (e.g., 
chlorinated hydrocarbons and polycyclic aromatic hydrocarbons), nickel compounds, and 
chromium compounds in the development of pancreatic cancer, but further studies are needed to 
corroborate this finding (Ojajarvi et al. 2000). 
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1. Age and Gender 
The average age at diagnosis for individuals with pancreatic cancer in Belmont during 1982– 
1999 was 72 years, consistent with established prevalence patterns of this disease.  Eighty-two 
percent of those diagnosed were age 60 years or older at the time of diagnosis.  Overall, females 
were diagnosed slightly more often than expected while males were diagnosed less often than 
expected. Further review of this data by age indicated that females and males in each age group 
experienced pancreatic cancer approximately at or below the expected rates. 
In Cambridge, the average age of diagnosis for individuals diagnosed with pancreatic cancer 
during 1982–1999 was 62 years. Eighty-one percent (n = 113) were age 60 years or older at the 
time of diagnosis.  The overall elevation in pancreatic cancer incidence observed among males in 
Cambridge was primarily the result of an increased number of diagnoses among males aged 
45–64 years. Females in each age group were diagnosed with pancreatic cancer about as often as 
expected or less often than expected. 
Among the 102 individuals diagnosed with pancreatic cancer in Arlington during 1982–1999, the 
average age of diagnosis was 73 years. The majority of those diagnosed were age 60 years or 
older at the time of diagnosis (91%, n = 93).  Review of age group-specific SIRs revealed that 
males aged 45–64 years were diagnosed with this cancer type about half as often as expected 
while males aged 65–74 years were diagnosed more often than expected.  Females in most age 
groups were diagnosed with pancreatic cancer at lower-than-expected rates, with the exception 
of females aged 75–84 years, who experienced an elevation in the incidence of this cancer type. 
In Watertown, the average age of diagnosis for individuals diagnosed with pancreatic cancer 
during 1982–1999 was 71 years. Eighty-five percent of these individuals were age 60 years or 
older at the time of diagnosis.  Overall, males were diagnosed slightly more often than expected. 
Males in most age groups were diagnosed about as often as expected or less often than expected; 
however, males aged 85 years and older were diagnosed more often than expected.  Incidence 
rates were elevated among females aged 45–64 years.  However, females aged 45–64 and 65–74 
were diagnosed with pancreatic cancer less often than expected resulting in an overall incidence 
rate that was lower than expected among females. 
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2. Smoking History 
Of the 57 individuals diagnosed with pancreatic cancer in Belmont during 1982–1999, 28% 
(n = 16) reported being current or former smokers at the time of diagnosis.  Another 28% (n = 
19) were nonsmokers, and smoking history was unknown for 44% (n =25).  In the state as a 
whole, 32% of those diagnosed with pancreatic cancer during 1982–1999 were current or former 
smokers at the time of diagnosis, 43% were nonsmokers, and smoking history was unknown for 
26%. 
In Cambridge, 46% (n = 64) of those diagnosed with pancreatic cancer during 1982–1999 
reported being current or former smokers at the time of diagnosis.  Thirty-one percent (n = 43) 
were nonsmokers, and smoking history was unknown for 23% (n = 32). 
Forty-six percent of the individuals (n = 44) diagnosed with pancreatic cancer in Arlington 
during 1982–1999 reported being current or former smokers at the time of diagnosis.  Forty-three 
percent (n = 47) were nonsmokers, and smoking history was unknown for the remaining 11% 
(n = 11).  Review of this information suggests that smoking likely played a role in the overall 
incidence of pancreatic cancer in Arlington. 
In Watertown, 45% of those diagnosed with pancreatic cancer during 1982–1999 (n = 30) 
reported being current or former smokers at the time of diagnosis.  Fifteen percent (n = 23) were 
nonsmokers, and smoking history was unknown for the remaining 20% (n = 13). 
3. Occupation 
None of the individuals diagnosed with pancreatic cancer in Belmont during 1982–1999 
indicated working in a job likely to be associated with occupational exposures related to an 
increased risk of pancreatic cancer. However, occupation was reported as unknown, retired, or at 
home for almost half (47%, n = 27) of these individuals.  Therefore, it is difficult to assess the 
role that occupation may have played in the pattern of pancreatic cancer in Belmont. 
Two individuals diagnosed with pancreatic cancer in Cambridge during 1982–1999 may have 
had occupational exposures possibly associated with pancreatic cancer.  No other jobs likely to 
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be associated with this cancer type were reported.  However, occupation was unknown or 
reported as retired or at home for almost half (49%, n = 68) of these individuals. 
On the basis of a review of occupational information as reported to the MCR, none of the 
individuals diagnosed with pancreatic cancer in Arlington during 1982–1999 worked jobs likely 
to be associated with an increased risk of this cancer type.  However, occupation was unknown 
or reported as retired or at home for more than half of those diagnosed (54%, n = 55). 
No jobs likely to be associated with occupational exposures related to the development of 
pancreatic cancer were reported among those diagnosed with this cancer type in Watertown. 
Occupation was reported as unknown, retired, or at home for almost half of those diagnosed 
(48%, n = 32). 
VI. MDEP OIL AND HAZARDOUS MATERIAL RELEASES 
In 1983, the Massachusetts legislature established a statewide hazardous waste site cleanup 
program (the state Superfund program) under Chapter 21E of Massachusetts General Laws 
(M.G.L c21E, 310 CRM 40.0000). Under this legislation, the Massachusetts Department of 
Environmental Protection (MDEP) administers investigation and cleanup of hazardous material 
and oil release sites, known as “21E sites,” in the Commonwealth.  MDPH reviewed available 
information regarding these releases to determine the possibility that known sources of potential 
environmental exposures could have played a role in the overall incidence of cancer in Belmont, 
Cambridge, Arlington, and Watertown. 
The 21E sites are characterized by one or more releases of oil or other hazardous material. 
Releases can result from a variety of sources, including oil trucks, underground storage tanks, 
and aboveground storage drums.  Releases vary widely with respect to materials involved, the 
relative amount of materials released, and the geographic extent of contamination.  Depending 
on the relative severity of the release, the deadline for reporting a release to MDEP is either two 
hours, 72 hours, or 120 days. 
The MDEP Bureau of Waste Site Cleanup has information on hazardous material and oil 
releases, including assessment and remedial response measures, for 1977 to the present (MDEP 
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2003). MDPH obtained the most recent information regarding all hazardous material and/or oil 
releases (approximately 1,800 records) located in Belmont, Arlington, Cambridge, and 
Watertown. The high number of releases in the study area precluded individual examination of 
each release in relation to patterns of cancer incidence.  Therefore, MDPH focused the analysis 
on only those releases categorized by 2-hour or 72-hour reporting categories and excluded 
releases categorized by 120-day reporting notification and releases where reporting category 
information was unavailable. 
Conditions requiring notification to MDEP within two hours of obtaining knowledge of the spill 
may include, but are not limited to the following: the release results in oil or hazardous materials 
found in a private drinking water well in concentrations greater than a reportable quantity for 
groundwater used as drinking water; the release poses an imminent hazard, including explosion, 
fire, public safety and serious and immediate public health and environmental hazards; and/or the 
release is indirectly discharged to the sanitary sewage system (310 CMR, 40.0311). 
Conditions requiring notification to MDEP within 72 hours of obtaining knowledge of the spill 
may include, but are not limited to the following: the release is within a 400-foot radius of a 
public supply well; the release is within 500-feet of a private water supply well; and/or the 
release results in contaminated groundwater with the level of total volatile organic compounds 
(VOC) exceeding 5 milligrams per liter (mg/L) and the contamination exists within 30 feet of a 
school or residential structure at a depth less than 15 feet below the surface of the ground 
(310 CMR, 40.0313). 
MDEP reporting categories are based upon broad categories of negative environmental impact. 
In general, acute risks to human health are considered in assigning categories to MDEP 21E 
releases, but the categories are nonspecific with respect to particular health outcomes, especially 
chronic health outcomes such as cancer.  For example, a release may be categorized as a 2-hour 
release because of its potential severe impact on the local environment, but the release may pose 
little or no threat of human exposure to contaminants.  Conversely, a relatively small amount of a 
contaminant might have potential impacts to human health if the opportunity exists for long-term 
chronic exposure, but in the short term may be considered environmentally benign. 
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Hazardous material and oil releases represent potential sources of exposure to contamination.  It 
is not possible to determine whether individuals residing in the study area were actually exposed 
to contaminants without detailed information about contaminant movement through the 
environment, the population at risk of exposure, a location of actual human contact with the 
contaminant, and evidence that the contaminant actually entered the body of persons at risk of 
exposure through ingestion, dermal absorption, or inhalation. 
Using a geographic information system, MDPH mapped the approximate location of 2-hour and 
72-hour releases for which sufficient address information was available (ESRI 2002).  According 
to the most current information, from 1991 to 2003, 28 releases were reported in the town of 
Belmont; 179 releases were reported in Cambridge; 60 releases were reported in Arlington; and 
74 releases were reported in Watertown.  The majority of these releases could be mapped to an 
address in one of the four towns (see Figure 2); however, approximately 3% of the releases (n = 
12) could not be mapped because sufficient address information was not available. 
The majority of the 341 releases reported (72%) involved petroleum-based oil (e.g., gasoline, 
fuel oil, waste oil). In addition, 13% involved a combination of oil and some other material 
(either known or unknown). Type of material was unknown for 22 (6%) of the releases. 
Information specific to each release is provided in Table 15. 
As discussed in the next section, the pattern of cancer in Belmont, Cambridge, Arlington, and 
Watertown was reviewed in relation to these potential sources of environmental exposures. 
VII. ANALYSIS OF GEOGRAPHIC DISTRIBUTION OF CANCER 
INCIDENCE 
In addition to determining incidence rates for each cancer type, a qualitative evaluation of the 
point pattern of cancer diagnoses was conducted.  Place of residence at the time of diagnosis was 
mapped for each individual diagnosed with the types of cancer evaluated in this report to assess 
any possible geographic concentrations of cases in relation to each other or in relation to a 
potential source of environmental contamination.  As previously mentioned, cancer is one word 
that describes many different diseases.  Therefore, for the purposes of this evaluation, the 
geographic distribution of each cancer type was evaluated separately to determine whether an 
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atypical pattern of any one type was occurring. The geographic distributions of some specific 
types of cancer were also evaluated together because they may have similar etiologies (e.g., 
leukemia and NHL in children).  In addition, cancers that may be associated with specific 
environmental exposures of concern were also evaluated geographically to determine whether 
any atypical patterns of cases exist that might suggest an association with an environmental 
factor. 
Review of the geographic distribution of cancer for the years 1982–1999 in Belmont revealed a 
small concentration of leukemia diagnoses in the southeastern corner of the town (i.e., CT 3573). 
This was the census tract with a statistically significant elevation in the incidence of leukemia 
during 1994–1999, and most of the diagnoses observed in this concentration occurred during this 
time period.  However, further review of specific case information for these individuals revealed 
a variety of subtypes of leukemia diagnosed among individuals in this area, indicating the 
occurrence of different diseases.  In addition, the available information indicated that the 
diagnosis of leukemia was not the first cancer diagnosis for some of these individuals.  If these 
individuals received ionizing radiation therapy to treat another cancer, then that could have 
played a role in their subsequent development of leukemia because ionizing radiation is a known 
risk factor for leukemia.  There were no reported hazardous material or oil releases in the 
immediate vicinity.  On the basis of this information, it appears unlikely that a common 
environmental factor contributed to the concentration of leukemia diagnoses observed in 
Belmont CT 3573. 
No other unusual spatial patterns or concentrations of diagnoses at the neighborhood level that 
would suggest a common factor (environmental or nonenvironmental) related to cancer 
diagnoses among residents were observed. Any patterns that were observed were consistent with 
what would be expected based on the population distribution and areas of higher population 
density. For example, in Belmont, the majority of individuals with each type of cancer tended to 
be located in areas of the town where population and housing density are greater.  Moreover, 
although slight elevations in the incidence of some cancer types were noted in Belmont during 
one or more time periods evaluated, in general, the geographic distribution of diagnoses for these 
cancer types seemed to coincide closely with the pattern of population and cases did not appear 
to be concentrated in any one area of the town. In addition, no apparent concentrations of cancer 
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diagnoses (of any type) were observed in the vicinity of the Cambridge Plating site or in relation 
to any other potential sources of environmental contamination (i.e., 21E sites). 
Although there was a statistically significant elevation in the incidence of leukemia in Belmont 
CT 3578 during 1988–1993, the cases were fairly evenly distributed throughout the census tract 
and were not located in any one neighborhood.  A similar pattern was observed for females 
diagnosed with pancreatic cancer, which was statistically significantly elevated in this census 
tract during 1982–1987. Females in Belmont CT 3577 experienced a statistically significant 
elevation in the incidence of NHL during 1982–1999 and 1994–1999.  Most of these individuals 
resided in the southern part of this census tract consistent with residential patterns in this area of 
Belmont. 
In general, review of the geographic distribution of cancer in Cambridge, Arlington, and 
Watertown revealed no apparent spatial patterns at the neighborhood level that could not be 
attributed to such factors as areas of higher population density (e.g., the presence of multiunit 
housing complexes). However, a small concentration of leukemia diagnoses was observed near 
the center of Arlington. Specifically, six individuals (ages 15–77) in a high-density residential 
neighborhood were diagnosed with leukemia between 1994 and 1998.  Although a fuel 
oil/gasoline spill resulting from an underground storage tank in the vicinity of these residences 
was reported to MDEP in 1994, this release is unlikely to be related to these diagnoses because 
of the low likelihood of exposure to residents in this area.  Moreover, a variety of histology types 
were represented among these individuals, indicating the occurrence of different diseases. 
A small concentration of individuals diagnosed with NHL was also noted in Watertown.  On the 
basis of a review of the available risk factor information for these individuals, including 
residential histories, MDPH previously concluded that the occurrence of NHL among these 
individuals did not suggest any single factor (environmental or nonenvironmental) that might 
explain the observed distribution (ATSDR 1996, 2000a, 2002). 
A statistically significant elevation in the incidence of pancreatic cancer among males was noted 
in Cambridge CT 3549, located in the western part of Cambridge adjacent to Belmont, during 
1982–1999. Review of the geographic distribution of cases revealed that these individuals 
resided in the eastern part of the census tract, where population density is greatest.  In Arlington, 
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statistically significant elevations were observed for liver cancer among males and females 
combined and for pancreatic cancer among males during 1982–1987.  The majority of those 
diagnosed with liver cancer resided in the eastern part of Arlington, but they were not 
concentrated in any one census tract or in any one neighborhood.  A small concentration of 
males with pancreatic cancer was noted in the western part of Arlington near the Lexington 
border. However, these individuals lived in a high-density residential neighborhood and review 
of case-specific information did not suggest a common factor (environmental or 
nonenvironmental) related to these diagnoses.  A statistically significant elevation in the 
incidence of NHL was observed in Watertown during 1982–1999.  In addition, males in 
Watertown experienced statistically significant elevations in the incidence of liver cancer during 
1982–1999 and in the incidence of kidney cancer during 1988–1993.  With the exception of a 
small concentration of individuals diagnosed with NHL, discussed previously, review of the 
geographic distribution of these cases revealed no apparent spatial concentrations of diagnoses; 
in general, the geographic distribution was consistent with the population density of Watertown. 
As noted previously, an elevation in the incidence of leukemia was observed among females 
aged 0–19 years in Arlington (9 diagnoses observed vs. 2.6 expected).  With one exception, the 
nine diagnoses did not appear to be unusually concentrated in time or space.  However, two 
females (ages 3 and 4) who were diagnosed with leukemia in 1998 and 1999 resided in relatively 
close proximity to each other.  The neighborhood is a high-density residential area with no 
known sources of environmental contamination.  Therefore, the possible role of an 
environmental factor is unlikely.  Review of more recent data available from the MCR indicates 
three additional childhood leukemia diagnoses in Arlington since 1999.3  However, these 
individuals did not reside near each other or near the two children discussed above. 
VIII. DISCUSSION 
The rates of cancer types evaluated in the community surrounding Cambridge Plating (i.e., CTs 
3571 and 3572) were approximately near or below the rates expected based on cancer incidence 
 Although all newly diagnosed cases of cancer are required to be reported to the MCR within six months of 
diagnosis (M.G.L. C.111s.111B), due to intensive efforts to ensure data quality, there is a significant lag time 
between diagnosis and reporting.  Therefore, data for more recent years (i.e., 2000-present) cannot be considered 
complete. 
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3
in the state of Massachusetts as a whole for the 18-year time period 1982–1999.  Similar trends 
were observed in the town of Belmont as a whole and in the surrounding communities of 
Cambridge, Arlington, and Watertown.  That is, with some exceptions, cancer incidence in these 
towns during the 18-year time period 1982–1999 and smaller time periods evaluated was 
approximately at or near expected rates for the six cancer types evaluated in this report. 
Some statistically significant elevations were observed.  In Belmont, the incidence of leukemia 
was statistically significantly elevated in CT 3573 during 1994–1999 and CT 3578 during 1988– 
1993. Also, females in Belmont CT 3577 experienced a statistically significant elevation in the 
incidence of NHL during 1994–1999 and the overall time period 1982–1999.  Pancreatic cancer 
was also statistically significantly elevated among females in Belmont CT 3578 during 1982– 
1987. In Cambridge CT 3549, males were diagnosed with pancreatic cancer statistically 
significantly more often than expected.  Townwide incidence ratios for liver cancer among males 
and females combined and for pancreatic cancer among males were statistically significantly 
elevated in Arlington during 1982–1987. Finally, there was a statistically significant elevation in 
the incidence of NHL in Watertown during 1982–1999.  Males in Watertown also experienced 
statistically significant elevations in the incidence of liver cancer during 1982–1999 and kidney 
cancer during 1988–1993. An elevation in the incidence of leukemia was also observed among 
females aged 0–19 years in Arlington.  Based on a review of the geographic distribution of 
diagnoses and available environmental information, it is unlikely that environmental factors 
played a role in the occurrence of leukemia among these individuals. 
Available risk factor information for individuals diagnosed with cancer in Belmont, Cambridge, 
Arlington, and Watertown was compared to known or established trends to assess whether any 
unexpected patterns exist in the towns.  In general, trends observed in Belmont and surrounding 
communities are similar to those seen in the general population.  Review of this data suggests 
that smoking likely played some role in the diagnosis of some cancer types (e.g., cancers of the 
kidney, lung and bronchus, and pancreas) among some individuals in Belmont, Cambridge, 
Arlington, and Watertown.  Also, occupational exposures may have been important in the 
development of cancer among some individuals.  However, because of the large number of 
individuals for whom smoking history and/or occupation was unknown, it is difficult to fully 
assess the extent to which these factors influenced overall cancer patterns in these towns. 
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Finally, analysis of the geographic distribution of place of residence for individuals diagnosed 
with cancer did not reveal any atypical spatial patterns that would suggest a common factor 
(environmental or nonenvironmental) related to the incidence of cancer in Belmont or 
surrounding communities. 
Based on the information reviewed in this evaluation, including available environmental data 
regarding hazardous material and oil releases reported to MDEP, it does not appear that 
environmental exposures played a major role in the incidence of most cancer types in the town of 
Belmont or in adjacent communities (i.e., Cambridge, Arlington, and Watertown) during the 
18-year time period 1982–1999. 
IX. LIMITATIONS 
This assessment is an investigation that analyzes descriptive health outcome data for cancer to 
determine whether the pattern or occurrence of selected types of cancer is unusual.  The purpose 
of this investigation is to evaluate the patterns of cancer in a geographical context in relation to 
available information about factors (including environmental factors) related to cancer to see 
whether further investigation seems warranted.  Information from descriptive analyses, which 
may suggest that a common etiology (or cause) is possible, can serve to identify areas where 
further public health actions may be warranted.  Inherent limitations in this type of analysis and 
the available data make it impossible to determine the precise causal relationships or the 
synergistic roles that may have played a part in the development of individual cancers in these 
communities. Also, this type of analysis cannot determine what may have caused cancer in any 
one individual. Cancers in general have a variety of risk factors known or suggested to be 
related to the etiology (cause) of the disease that could not be evaluated in this report.  It is 
believed that many types of cancer are related largely to behavioral factors such as cigarette 
smoking, alcohol consumption, and diet.  Other factors associated with cancer are socioeconomic 
status, heredity/genetics, race, and geography.  It is beyond the scope of this report to determine 
the causal relationship of these factors and the development of cancer in Belmont and 
surrounding communities. 
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X. CONCLUSIONS 
•	 In general, the six cancer types evaluated in this report occurred approximately at, near, or 
below the expected rates for Belmont and its individual census tracts, and for the surrounding 
communities of Cambridge, Arlington, and Watertown during the 18-year time period 
1982–1999. 
•	 Review of the geographic distribution of individuals diagnosed with cancer in Belmont, 
Cambridge, Arlington, and Watertown revealed no apparent spatial patterns at the 
neighborhood level that would suggest a common factor (environmental or 
nonenvironmental) related to cancer diagnoses among residents. 
•	 Review of available risk factor information for individuals diagnosed with cancer (e.g., age, 
gender, smoking history, and occupation) suggest that the trends observed in Belmont and 
surrounding communities are similar to those seen in the general population.  Moreover, this 
information suggests that smoking and, to a lesser extent, occupation, likely played some role 
in the incidence of some cancer types in Belmont, Cambridge, Arlington, and Watertown. 
•	 Based on the information reviewed in this evaluation, including available environmental data 
regarding hazardous material and oil releases reported to MDEP, it does not appear that 
environmental exposures played a major role in the incidence of most cancers in the town of 
Belmont or in adjacent communities (i.e., Cambridge, Arlington, and Watertown) during the 
18-year time period 1982–1999. 
XI. RECOMMENDATIONS 
•	 If requested, BEH’s Environmental Health Education Program should work with the Belmont 
Health Department and the community to provide educational information and conduct 
outreach activities to Belmont residents about ways to reduce their risk of cancer. 
•	 The MDPH/BEH will continue to monitor the incidence of cancer in Belmont, Cambridge, 
Arlington, and Watertown through city/town cancer incidence reports published by the 
Massachusetts Cancer Registry. 
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TABLE 1a

Kidney Cancer Incidence

Belmont, Massachusetts

1982–1999

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3571 11 12.6 88 44 157 -- 6 7.1 85 31 184 -- 5 5.5 91 29 213 --
3572 8 7.2 111 48 218 -- 7 4.4 158 63 325 -- 1 2.8 NC NC NC --
3573 5 5.7 88 28 204 -- 5 3.2 155 50 361 -- 0 2.5 NC NC NC --
3574 3 5.0 NC NC NC -- 3 3.0 NC NC NC -- 0 2.0 NC NC NC --
3575 2 4.3 NC NC NC -- 1 2.6 NC NC NC -- 1 1.8 NC NC NC --
3576 7 5.4 129 52 266 -- 3 3.2 NC NC NC -- 4 2.2 NC NC NC --
3577 6 8.2 73 27 159 -- 3 4.6 NC NC NC -- 3 3.6 NC NC NC --
3578 9 9.7 93 42 177 -- 5 6.1 82 26 191 -- 4 3.6 NC NC NC --
City Total† 52 58.1 89 67 117 -- 34 34.2 99 69 139 -- 18 23.9 75 45 119 --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
129 
TABLE 1b

Kidney Cancer Incidence

Belmont, Massachusetts

1982–1987

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3571 3 3.4 NC NC NC -- 2 1.9 NC NC NC -- 1 1.5 NC NC NC --
3572 4 1.9 NC NC NC -- 3 1.1 NC NC NC -- 1 0.8 NC NC NC --
3573 1 1.7 NC NC NC -- 1 0.9 NC NC NC -- 0 0.8 NC NC NC --
3574 3 1.4 NC NC NC -- 3 0.8 NC NC NC -- 0 0.6 NC NC NC --
3575 0 1.3 NC NC NC -- 0 0.7 NC NC NC -- 0 0.6 NC NC NC --
3576 3 1.5 NC NC NC -- 0 0.8 NC NC NC -- 3 0.6 NC NC NC --
3577 1 2.3 NC NC NC -- 1 1.2 NC NC NC -- 0 1.1 NC NC NC --
3578 5 2.6 NC NC NC -- 4 1.6 NC NC NC -- 1 1.0 NC NC NC --
City Total† 21 16.0 131 81 201 -- 15 9.0 167 93 275 -- 6 7.0 85 31 186 --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 1c

Kidney Cancer Incidence

Belmont, Massachusetts

1988–1993

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3571 3 4.4 NC NC NC -- 1 2.5 NC NC NC -- 2 1.9 NC NC NC --
3572 3 2.5 NC NC NC -- 3 1.6 NC NC NC -- 0 1.0 NC NC NC --
3573 3 2.0 NC NC NC -- 3 1.2 NC NC NC -- 0 0.8 NC NC NC --
3574 0 1.8 NC NC NC -- 0 1.1 NC NC NC -- 0 0.7 NC NC NC --
3575 2 1.5 NC NC NC -- 1 0.9 NC NC NC -- 1 0.6 NC NC NC --
3576 2 1.9 NC NC NC -- 1 1.1 NC NC NC -- 1 0.8 NC NC NC --
3577 1 2.8 NC NC NC -- 0 1.6 NC NC NC -- 1 1.2 NC NC NC --
3578 4 3.4 NC NC NC -- 1 2.2 NC NC NC -- 3 1.2 NC NC NC --
City Total† 18 20.3 89 52 140 -- 10 12.2 82 39 151 -- 8 8.1 98 42 194 --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 1d

Kidney Cancer Incidence

Belmont, Massachusetts

1994–1999

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3571 5 4.5 112 36 261 -- 3 2.6 NC NC NC -- 2 1.9 NC NC NC --
3572 1 2.6 NC NC NC -- 1 1.6 NC NC NC -- 0 1.0 NC NC NC --
3573 1 2.0 NC NC NC -- 1 1.2 NC NC NC -- 0 0.9 NC NC NC --
3574 0 1.9 NC NC NC -- 0 1.2 NC NC NC -- 0 0.7 NC NC NC --
3575 0 1.6 NC NC NC -- 0 1.0 NC NC NC -- 0 0.6 NC NC NC --
3576 2 2.0 NC NC NC -- 2 1.2 NC NC NC -- 0 0.8 NC NC NC --
3577 4 2.9 NC NC NC -- 2 1.6 NC NC NC -- 2 1.3 NC NC NC --
3578 0 3.6 NC NC NC -- 0 2.2 NC NC NC -- 0 1.3 NC NC NC --
City Total† 13 21.1 62 33 105 -- 9 12.5 72 33 137 -- 4 8.6 NC NC NC --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 2a

Leukemia Incidence

Belmont, Massachusetts

1982–1999

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3571 13 10.7 121 64 207 -- 6 5.6 108 39 234 -- 7 5.2 136 54 279 --
3572 6 6.1 98 36 213 -- 4 3.5 NC NC NC -- 2 2.7 NC NC NC --
3573 8 5.1 158 68 311 -- 4 2.6 NC NC NC -- 4 2.4 NC NC NC --
3574 6 4.3 139 51 303 -- 2 2.4 NC NC NC -- 4 1.9 NC NC NC --
3575 3 3.8 NC NC NC -- 2 2.1 NC NC NC -- 1 1.8 NC NC NC --
3576 2 4.7 NC NC NC -- 1 2.6 NC NC NC -- 1 2.2 NC NC NC --
3577 9 7.5 120 55 228 -- 2 3.7 NC NC NC -- 7 3.8 177 71 365 --
3578 10 8.0 125 60 231 -- 5 4.7 107 34 249 -- 5 3.3 152 49 354 --
City Total† 58 50.3 115 88 149 -- 26 27.1 96 63 141 -- 32 23.2 138 94 195 --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 2b

Leukemia Incidence

Belmont, Massachusetts

1982–1987

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3571 3 3.3 NC NC NC -- 2 1.7 NC NC NC -- 1 1.6 NC NC NC --
3572 1 1.9 NC NC NC -- 0 1.1 NC NC NC -- 1 0.8 NC NC NC --
3573 0 1.7 NC NC NC -- 0 0.9 NC NC NC -- 0 0.8 NC NC NC --
3574 3 1.5 NC NC NC -- 1 0.8 NC NC NC -- 2 0.7 NC NC NC --
3575 0 1.3 NC NC NC -- 0 0.7 NC NC NC -- 0 0.6 NC NC NC --
3576 1 1.5 NC NC NC -- 0 0.8 NC NC NC -- 1 0.7 NC NC NC --
3577 3 2.4 NC NC NC -- 0 1.2 NC NC NC -- 3 1.2 NC NC NC --
3578 1 2.4 NC NC NC -- 1 1.4 NC NC NC -- 0 1.0 NC NC NC --
City Total† 12 16.0 75 39 131 -- 4 8.5 NC NC NC -- 8 7.5 107 46 210 --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 2c

Leukemia Incidence

Belmont, Massachusetts

1988–1993

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3571 5 3.2 156 50 363 -- 2 1.7 NC NC NC -- 3 1.5 NC NC NC --
3572 1 1.9 NC NC NC -- 1 1.1 NC NC NC -- 0 0.8 NC NC NC --
3573 1 1.5 NC NC NC -- 1 0.8 NC NC NC -- 0 0.7 NC NC NC --
3574 1 1.3 NC NC NC -- 0 0.7 NC NC NC -- 1 0.6 NC NC NC --
3575 2 1.2 NC NC NC -- 1 0.6 NC NC NC -- 1 0.5 NC NC NC --
3576 1 1.4 NC NC NC -- 1 0.8 NC NC NC -- 0 0.6 NC NC NC --
3577 4 2.3 NC NC NC -- 1 1.1 NC NC NC -- 3 1.1 NC NC NC --
3578 7 2.4 290 * 116 598 -- 4 1.4 NC NC NC -- 3 1.0 NC NC NC --
City Total† 22 15.2 145 91 220 -- 11 8.3 133 66 237 -- 11 6.9 160 80 287 --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 2d

Leukemia Incidence

Belmont, Massachusetts

1994–1999

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3571 5 3.9 127 41 297 -- 2 2.1 NC NC NC -- 3 1.9 NC NC NC --
3572 4 2.3 NC NC NC -- 3 1.3 NC NC NC -- 1 1.0 NC NC NC --
3573 7 1.8 383 * 153 789 -- 3 0.9 NC NC NC -- 4 0.9 NC NC NC --
3574 2 1.6 NC NC NC -- 1 0.9 NC NC NC -- 1 0.7 NC NC NC --
3575 1 1.4 NC NC NC -- 1 0.8 NC NC NC -- 0 0.7 NC NC NC --
3576 0 1.8 NC NC NC -- 0 0.9 NC NC NC -- 0 0.8 NC NC NC --
3577 2 2.7 NC NC NC -- 1 1.3 NC NC NC -- 1 1.4 NC NC NC --
3578 2 3.0 NC NC NC -- 0 1.7 NC NC NC -- 2 1.3 NC NC NC --
City Total† 24 18.6 129 83 192 -- 11 10.0 110 55 197 -- 13 8.7 150 80 257 --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 3a

Liver Cancer Incidence

Belmont, Massachusetts

1982–1999

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3571 5 3.0 168 54 393 -- 3 2.0 NC NC NC -- 2 1.0 NC NC NC --
3572 1 1.7 NC NC NC -- 0 1.2 NC NC NC -- 1 0.5 NC NC NC --
3573 4 1.3 NC NC NC -- 3 0.9 NC NC NC -- 1 0.4 NC NC NC --
3574 0 1.2 NC NC NC -- 0 0.8 NC NC NC -- 0 0.3 NC NC NC --
3575 1 1.0 NC NC NC -- 1 0.7 NC NC NC -- 0 0.3 NC NC NC --
3576 1 1.3 NC NC NC -- 1 0.9 NC NC NC -- 0 0.4 NC NC NC --
3577 3 2.0 NC NC NC -- 2 1.3 NC NC NC -- 1 0.7 NC NC NC --
3578 1 2.3 NC NC NC -- 1 1.7 NC NC NC -- 0 0.6 NC NC NC --
City Total† 16 13.8 116 66 189 -- 11 9.6 115 57 205 -- 5 4.2 120 39 280 --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 3b

Liver Cancer Incidence

Belmont, Massachusetts

1982–1987

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3571 1 0.7 NC NC NC -- 1 0.5 NC NC NC -- 0 0.3 NC NC NC --
3572 0 0.4 NC NC NC -- 0 0.3 NC NC NC -- 0 0.1 NC NC NC --
3573 1 0.4 NC NC NC -- 0 0.2 NC NC NC -- 1 0.1 NC NC NC --
3574 0 0.3 NC NC NC -- 0 0.2 NC NC NC -- 0 0.1 NC NC NC --
3575 1 0.3 NC NC NC -- 1 0.2 NC NC NC -- 0 0.1 NC NC NC --
3576 0 0.3 NC NC NC -- 0 0.2 NC NC NC -- 0 0.1 NC NC NC --
3577 1 0.5 NC NC NC -- 1 0.3 NC NC NC -- 0 0.2 NC NC NC --
3578 0 0.6 NC NC NC -- 0 0.4 NC NC NC -- 0 0.2 NC NC NC --
City Total† 4 3.5 NC NC NC -- 3 2.3 NC NC NC -- 1 1.2 NC NC NC --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 3c

Liver Cancer Incidence

Belmont, Massachusetts

1988–1993

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3571 1 0.9 NC NC NC -- 0 0.6 NC NC NC -- 1 0.3 NC NC NC --
3572 0 0.5 NC NC NC -- 0 0.4 NC NC NC -- 0 0.1 NC NC NC --
3573 2 0.4 NC NC NC -- 2 0.3 NC NC NC -- 0 0.1 NC NC NC --
3574 0 0.4 NC NC NC -- 0 0.3 NC NC NC -- 0 0.1 NC NC NC --
3575 0 0.3 NC NC NC -- 0 0.2 NC NC NC -- 0 0.1 NC NC NC --
3576 0 0.4 NC NC NC -- 0 0.3 NC NC NC -- 0 0.1 NC NC NC --
3577 2 0.6 NC NC NC -- 1 0.4 NC NC NC -- 1 0.2 NC NC NC --
3578 1 0.7 NC NC NC -- 1 0.5 NC NC NC -- 0 0.2 NC NC NC --
City Total† 6 4.3 141 51 306 -- 4 3.0 NC NC NC -- 2 1.2 NC NC NC --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 3d

Liver Cancer Incidence

Belmont, Massachusetts

1994–1999

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3571 3 1.2 NC NC NC -- 2 0.8 NC NC NC -- 1 0.4 NC NC NC --
3572 1 0.7 NC NC NC -- 0 0.5 NC NC NC -- 1 0.2 NC NC NC --
3573 1 0.5 NC NC NC -- 1 0.4 NC NC NC -- 0 0.2 NC NC NC --
3574 0 0.5 NC NC NC -- 0 0.4 NC NC NC -- 0 0.1 NC NC NC --
3575 0 0.4 NC NC NC -- 0 0.3 NC NC NC -- 0 0.1 NC NC NC --
3576 1 0.5 NC NC NC -- 1 0.4 NC NC NC -- 0 0.2 NC NC NC --
3577 0 0.8 NC NC NC -- 0 0.5 NC NC NC -- 0 0.3 NC NC NC --
3578 0 1.0 NC NC NC -- 0 0.7 NC NC NC -- 0 0.2 NC NC NC --
City Total† 6 5.7 105 38 228 -- 4 4.1 NC NC NC -- 2 1.7 NC NC NC --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
140 
TABLE 4a

Lung and Bronchus Cancer Incidence

Belmont, Massachusetts

1982–1999

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3571 70 82.9 84 66 107 -- 29 46.4 63 * 42 90 -- 41 36.6 112 80 152 --
3572 31 46.2 67 * 46 95 -- 18 27.8 65 38 103 -- 13 18.5 70 37 120 --
3573 22 36.3 61 * 38 92 -- 11 20.2 55 * 27 98 -- 11 16.2 68 34 122 --
3574 20 31.7 63 * 38 97 -- 13 18.7 70 37 119 -- 7 13.1 54 21 110 --
3575 27 27.4 98 65 143 -- 15 15.9 94 53 155 -- 12 11.5 104 54 183 --
3576 23 35.0 66 * 42 99 -- 14 20.3 69 38 116 -- 9 14.7 61 28 117 --
3577 43 52.7 82 59 110 -- 19 29.3 65 39 101 -- 24 23.3 103 66 153 --
3578 33 63.0 52 * 36 74 -- 13 39.0 33 * 18 57 -- 20 24.0 83 51 129 --
City Total† 270 375.3 72 * 64 81 -- 133 217.6 61 * 51 72 -- 137 157.7 87 73 103 --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 4b

Lung and Bronchus Cancer Incidence

Belmont, Massachusetts

1982–1987

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3571 19 26.0 73 44 114 -- 7 16.1 43 * 17 90 -- 12 9.9 122 63 212 --
3572 10 14.3 70 33 128 -- 7 9.2 76 31 157 -- 3 5.1 NC NC NC --
3573 4  12.5  NC  NC  NC  -- 3  7.5  NC  NC  NC  -- 1  5.0  NC  NC  NC  --
3574 4  10.7  NC  NC  NC  -- 1  6.7  NC  NC  NC  -- 3  3.9  NC  NC  NC  --
3575 8 9.3 86 37 169 -- 4 5.8 NC NC NC -- 4 3.5 NC NC NC --
3576 10 10.9 92 44 169 -- 8 6.8 117 50 230 -- 2 4.1 NC NC NC --
3577 8 16.7 48 * 21 94 -- 5 10.0 50 16 116 -- 3 6.7 NC NC NC --
3578 13 19.6 66 35 113 -- 5 12.9 39 * 12 90 -- 8 6.7 119 51 235 --
City Total† 76 119.9 63 * 50 79 -- 40 75.0 53 * 38 73 -- 36 45.0 80 56 111 --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 4c

Lung and Bronchus Cancer Incidence

Belmont, Massachusetts

1988–1993

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3571 30 27.5 109 74 156 -- 13 15.4 84 45 144 -- 17 12.1 141 82 226 --
3572 12 15.4 78 40 136 -- 6 9.3 64 23 140 -- 6 6.1 98 36 213 --
3573 10 12.1 83 40 152 -- 4 6.8 NC NC NC -- 6 5.4 112 41 244 --
3574 9 10.6 85 39 161 -- 6 6.3 96 35 208 -- 3 4.3 NC NC NC --
3575 12 9.1 131 68 229 -- 8 5.3 150 64 295 -- 4 3.8 NC NC NC --
3576 8 11.6 69 30 135 -- 6 6.8 88 32 192 -- 2 4.9 NC NC NC --
3577 22 17.4 126 79 191 -- 9 9.8 92 42 175 -- 13 7.6 170 91 291 --
3578 7 21.1 33 * 13 68 -- 4 13.1 NC NC NC -- 3 8.0 NC NC NC --
City Total† 110 124.9 88 72 106 -- 56 72.8 77 58 100 -- 54 52.1 104 78 135 --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 4d

Lung and Bronchus Cancer Incidence

Belmont, Massachusetts

1994–1999

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3571 21 28.2 75 46 114 -- 9 14.8 61 28 116 -- 12 13.4 90 46 157 --
3572 9 15.8 57 26 108 -- 5 8.9 56 18 132 -- 4 6.9 NC NC NC --
3573 8 12.0 66 29 131 -- 4 6.2 NC NC NC -- 4 5.8 NC NC NC --
3574 7 11.1 63 25 130 -- 6 6.2 96 35 209 -- 1 4.9 NC NC NC --
3575 7 9.5 74 30 152 -- 3 5.1 NC NC NC -- 4 4.3 NC NC NC --
3576 5 11.9 42 * 14 98 -- 0 6.4 NC NC NC -- 5 5.5 91 29 213 --
3577 13 18.1 72 38 123 -- 5 9.1 55 18 129 -- 8 9.0 89 38 175 --
3578 13 21.7 60 32 102 -- 4 12.5 NC NC NC -- 9 9.2 98 45 186 --
City Total† 84 128.3 65 * 52 81 -- 37 69.2 53 * 38 74 -- 47 59.1 80 58 106 --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 5a

Non-Hodgkin's Lymphoma Incidence

Belmont, Massachusetts

1982–1999

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3571 20 19.7 102 62 157 -- 7 9.0 77 31 160 -- 13 10.6 122 65 209 --
3572 4  11.0  NC  NC  NC  -- 3  5.7  NC  NC  NC  -- 1  5.3  NC  NC  NC  --
3573 5 9.3 54 17 125 -- 1 4.4 NC NC NC -- 4 4.9 NC NC NC --
3574 6 7.7 78 28 169 -- 1 3.9 NC NC NC -- 5 3.8 132 42 308 --
3575 8 6.9 116 50 229 -- 5 3.4 146 47 340 -- 3 3.4 NC NC NC --
3576 3 8.6 NC NC NC -- 1 4.2 NC NC NC -- 2 4.4 NC NC NC --
3577 21 13.6 155 96 236 -- 7 6.2 114 46 234 -- 14 7.4 189 * 103 316 --
3578 17 14.3 118 69 190 -- 7 7.7 91 36 187 -- 10 6.6 151 72 277 --
City Total† 84 91.1 92 74 114 -- 32 44.6 72 49 101 -- 52 46.5 112 84 147 --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 5b

Non-Hodgkin's Lymphoma Incidence

Belmont, Massachusetts

1982–1987

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3571 6 5.4 110 40 241 -- 2 2.5 NC NC NC -- 4 2.9 NC NC NC --
3572 4 3.0 NC NC NC -- 3 1.5 NC NC NC -- 1 1.5 NC NC NC --
3573 1 2.8 NC NC NC -- 0 1.3 NC NC NC -- 1 1.5 NC NC NC --
3574 2 2.3 NC NC NC -- 0 1.1 NC NC NC -- 2 1.2 NC NC NC --
3575 3 2.1 NC NC NC -- 2 1.0 NC NC NC -- 1 1.1 NC NC NC --
3576 1 2.4 NC NC NC -- 0 1.1 NC NC NC -- 1 1.2 NC NC NC --
3577 4 3.9 NC NC NC -- 2 1.7 NC NC NC -- 2 2.2 NC NC NC --
3578 3 3.9 NC NC NC -- 2 2.1 NC NC NC -- 1 1.9 NC NC NC --
City Total† 24 25.8 93 60 139 -- 11 12.2 90 45 161 -- 13 13.6 96 51 164 --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 5c

Non-Hodgkin's Lymphoma Incidence

Belmont, Massachusetts

1988–1993

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3571 5 6.4 78 25 181 -- 0 2.9 NC NC NC -- 5 3.5 143 46 333 --
3572 0 3.6 NC NC NC -- 0 1.9 NC NC NC -- 0 1.7 NC NC NC --
3573 3 3.1 NC NC NC -- 0 1.5 NC NC NC -- 3 1.6 NC NC NC --
3574 1 2.6 NC NC NC -- 0 1.3 NC NC NC -- 1 1.3 NC NC NC --
3575 4 2.3 NC NC NC -- 3 1.1 NC NC NC -- 1 1.1 NC NC NC --
3576 0 2.8 NC NC NC -- 0 1.4 NC NC NC -- 0 1.4 NC NC NC --
3577 7 4.5 156 62 321 -- 2 2.0 NC NC NC -- 5 2.5 203 65 475 --
3578 7 4.7 148 59 306 -- 3 2.5 NC NC NC -- 4 2.2 NC NC NC --
City Total† 27 30.0 90 59 131 -- 8 14.7 54 23 107 -- 19 15.3 124 75 193 --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 5d

Non-Hodgkin's Lymphoma Incidence

Belmont, Massachusetts

1994–1999

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3571 9 7.2 125 57 236 -- 5 3.5 145 47 338 -- 4 3.8 NC NC NC --
3572 0 4.1 NC NC NC -- 0 2.2 NC NC NC -- 0 1.9 NC NC NC --
3573 1 3.4 NC NC NC -- 1 1.7 NC NC NC -- 0 1.7 NC NC NC --
3574 3 2.9 NC NC NC -- 1 1.5 NC NC NC -- 2 1.4 NC NC NC --
3575 1 2.6 NC NC NC -- 0 1.3 NC NC NC -- 1 1.3 NC NC NC --
3576 2 3.2 NC NC NC -- 1 1.6 NC NC NC -- 1 1.6 NC NC NC --
3577 10 5.0 199 95 366 -- 3 2.3 NC NC NC -- 7 2.8 254 * 102 524 --
3578 7 5.5 128 51 264 -- 2 2.9 NC NC NC -- 5 2.5 197 63 459 --
City Total† 33 34.0 97 67 136 -- 13 17.0 76 41 131 -- 20 17.0 117 72 181 --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 6a

Pancreatic Cancer Incidence

Belmont, Massachusetts

1982–1999

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3571 16 13.2 121 69 196 -- 8 5.6 143 62 282 -- 8 7.6 105 45 206 --
3572 5 6.8 73 24 171 -- 3 3.3 NC NC NC -- 2 3.5 NC NC NC --
3573 4 5.7 NC NC NC -- 3 2.4 NC NC NC -- 1 3.2 NC NC NC --
3574 3 4.7 NC NC NC -- 0 2.2 NC NC NC -- 3 2.5 NC NC NC --
3575 1 4.2 NC NC NC -- 0 1.9 NC NC NC -- 1 2.3 NC NC NC --
3576 5 5.4 93 30 217 -- 1 2.4 NC NC NC -- 4 2.9 NC NC NC --
3577 10 8.8 113 54 208 -- 4 3.6 NC NC NC -- 6 5.2 NC NC NC --
3578 13 9.1 143 76 245 -- 4 4.6 NC NC NC -- 9 4.4 203 93 385 --
City Total† 57 57.9 98 75 127 -- 23 26.1 88 56 132 -- 34 31.8 107 74 149 --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 6b

Pancreatic Cancer Incidence

Belmont, Massachusetts

1982–1987

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3571 7 4.3 164 66 337 -- 2 1.9 NC NC NC -- 5 2.4 206 66 481 --
3572 1 2.2 NC NC NC -- 0 1.1 NC NC NC -- 1 1.2 NC NC NC --
3573 2 2.1 NC NC NC -- 1 0.9 NC NC NC -- 1 1.2 NC NC NC --
3574 1 1.7 NC NC NC -- 0 0.8 NC NC NC -- 1 1.0 NC NC NC --
3575 0 1.6 NC NC NC -- 0 0.7 NC NC NC -- 0 0.9 NC NC NC --
3576 2 1.7 NC NC NC -- 0 0.8 NC NC NC -- 2 1.0 NC NC NC --
3577 2 3.0 NC NC NC -- 0 1.2 NC NC NC -- 2 1.8 NC NC NC --
3578 5 2.9 171 55 399 -- 0 1.5 NC NC NC -- 5 1.5 343 * 110 800 --
City Total† 20 19.5 102 63 158 -- 3 8.6 NC NC NC -- 17 10.9 156 91 250 --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
150 
TABLE 6c

Pancreatic Cancer Incidence

Belmont, Massachusetts

1988–1993

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3571 3 4.2 NC NC NC -- 2 1.7 NC NC NC -- 1 2.4 NC NC NC --
3572 1 2.2 NC NC NC -- 0 1.0 NC NC NC -- 1 1.1 NC NC NC --
3573 2 1.8 NC NC NC -- 2 0.8 NC NC NC -- 0 1.0 NC NC NC --
3574 1 1.5 NC NC NC -- 0 0.7 NC NC NC -- 1 0.8 NC NC NC --
3575 1 1.3 NC NC NC -- 0 0.6 NC NC NC -- 1 0.7 NC NC NC --
3576 1 1.7 NC NC NC -- 0 0.8 NC NC NC -- 1 0.9 NC NC NC --
3577 4 2.8 NC NC NC -- 2 1.1 NC NC NC -- 2 1.6 NC NC NC --
3578 5 2.9 174 56 406 -- 1 1.5 NC NC NC -- 4 1.4 NC NC NC --
City Total† 18 18.2 99 58 156 -- 7 8.2 85 34 176 -- 11 10.0 109 55 196 --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 6d

Pancreatic Cancer Incidence

Belmont, Massachusetts

1994–1999

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3571 6 4.5 134 49 292 -- 4 2.0 NC NC NC -- 2 2.5 NC NC NC --
3572 3 2.3 NC NC NC -- 3 1.1 NC NC NC -- 0 1.2 NC NC NC --
3573 0 1.8 NC NC NC -- 0 0.8 NC NC NC -- 0 1.0 NC NC NC --
3574 1 1.6 NC NC NC -- 0 0.8 NC NC NC -- 1 0.8 NC NC NC --
3575 0 1.4 NC NC NC -- 0 0.7 NC NC NC -- 0 0.8 NC NC NC --
3576 2 1.8 NC NC NC -- 1 0.8 NC NC NC -- 1 1.0 NC NC NC --
3577 4 3.0 NC NC NC -- 2 1.2 NC NC NC -- 2 1.8 NC NC NC --
3578 3 3.2 NC NC NC -- 3 1.6 NC NC NC -- 0 1.6 NC NC NC --
City Total† 19 19.7 96 58 150 -- 13 9.0 144 77 246 -- 6 10.7 56 20 122 --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 7a

Kidney Cancer Incidence

Cambridge, Massachusetts

1982–1999

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3543 8 7.8 103 44 203 -- 2 4.2 NC NC NC -- 6 3.6 167 61 363 --
3546 4 7.5 NC NC NC -- 1 4.2 NC NC NC -- 3 3.4 NC NC NC --
3549 3 7.8 NC NC NC -- 0 4.6 NC NC NC -- 3 3.2 NC NC NC --
City Total† 109 146.3 75 * 61 90 -- 57 85.9 66 * 50 86 -- 52 60.4 86 64 113 --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 7b

Kidney Cancer Incidence

Cambridge, Massachusetts

1982–1987

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3543 1 2.1 NC NC NC -- 0 1.1 NC NC NC -- 1 1.0 NC NC NC --
3546 0 2.0 NC NC NC -- 0 1.1 NC NC NC -- 0 0.9 NC NC NC --
3549 0 2.0 NC NC NC -- 0 1.1 NC NC NC -- 0 0.9 NC NC NC --
City Total† 30 39.0 77 52 110 -- 18 21.8 83 49 131 -- 12 17.3 70 36 121 --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 7c

Kidney Cancer Incidence

Cambridge, Massachusetts

1988–1993

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3543 3 2.7 NC NC NC -- 0 1.5 NC NC NC -- 3 1.2 NC NC NC --
3546 3 2.6 NC NC NC -- 1 1.5 NC NC NC -- 2 1.2 NC NC NC --
3549 1 2.7 NC NC NC -- 0 1.6 NC NC NC -- 1 1.1 NC NC NC --
City Total† 32 51.4 62 * 43 88 -- 14 30.7 46 * 25 76 -- 18 20.7 87 52 138 --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 7d

Kidney Cancer Incidence

Cambridge, Massachusetts

1994–1999

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3543 4 2.7 NC NC NC -- 2 1.4 NC NC NC -- 2 1.3 NC NC NC --
3546 1 2.9 NC NC NC -- 0 1.6 NC NC NC -- 1 1.3 NC NC NC --
3549 2 2.9 NC NC NC -- 0 1.7 NC NC NC -- 2 1.2 NC NC NC --
City Total† 47 56.4 83 61 111 -- 25 33.5 75 48 110 -- 22 22.9 96 60 145 --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 8a

Leukemia Incidence

Cambridge, Massachusetts

1982–1999

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3543 7 7.1 98 39 202 -- 2 3.5 NC NC NC -- 5 3.7 137 44 320 --
3546 6 6.7 90 33 195 -- 4 3.4 NC NC NC -- 2 3.3 NC NC NC --
3549 5 7.1 71 23 165 -- 5 3.9 129 41 300 -- 0 3.2 NC NC NC --
City Total† 102 134.1 76 * 62 92 -- 55 72.0 76 * 58 99 -- 47 62.1 76 56 101 --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 8b

Leukemia Incidence

Cambridge, Massachusetts

1982–1987

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3543 2 2.3 NC NC NC -- 0 1.1 NC NC NC -- 2 1.1 NC NC NC --
3546 3 2.0 NC NC NC -- 2 1.1 NC NC NC -- 1 1.0 NC NC NC --
3549 3 2.1 NC NC NC -- 3 1.1 NC NC NC -- 0 1.0 NC NC NC --
City Total† 38 41.7 91 64 125 -- 24 22.1 109 70 162 -- 14 19.6 71 39 120 --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 8c

Leukemia Incidence

Cambridge, Massachusetts

1988–1993

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3543 4 2.1 NC NC NC -- 2 1.1 NC NC NC -- 2 1.1 NC NC NC --
3546 1 2.0 NC NC NC -- 0 1.0 NC NC NC -- 1 1.0 NC NC NC --
3549 1 2.2 NC NC NC -- 1 1.2 NC NC NC -- 0 1.0 NC NC NC --
City Total† 27 41.1 66 * 43 96 -- 13 22.3 58 31 100 -- 14 18.8 75 41 125 --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 8d

Leukemia Incidence

Cambridge, Massachusetts

1994–1999

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3543 1 2.5 NC NC NC -- 0 1.2 NC NC NC -- 1 1.3 NC NC NC --
3546 2 2.6 NC NC NC -- 2 1.3 NC NC NC -- 0 1.3 NC NC NC --
3549 1 2.7 NC NC NC -- 1 1.5 NC NC NC -- 0 1.2 NC NC NC --
City Total† 37 52.2 71 * 50 98 -- 18 28.0 64 38 102 -- 19 24.1 79 47 123 --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 9a

Liver Cancer Incidence

Cambridge, Massachusetts

1982–1999

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3543 3 1.8 NC NC NC -- 3 1.2 NC NC NC -- 0 0.7 NC NC NC --
3546 2 1.7 NC NC NC -- 0 1.2 NC NC NC -- 2 0.6 NC NC NC --
3549 4 1.8 NC NC NC -- 2 1.3 NC NC NC -- 2 0.5 NC NC NC --
City Total† 40 34.2 117 84 159 -- 26 23.9 109 71 160 -- 14 10.3 136 74 227 --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 9b

Liver Cancer Incidence

Cambridge, Massachusetts

1982–-1987

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3543 1 0.5 NC NC NC -- 1 0.3 NC NC NC -- 0 0.2 NC NC NC --
3546 0 0.4 NC NC NC -- 0 0.3 NC NC NC -- 0 0.1 NC NC NC --
3549 2 0.4 NC NC NC -- 1 0.3 NC NC NC -- 1 0.1 NC NC NC --
City Total† 13 8.5 153 82 262 -- 7 5.5 127 51 261 -- 6 3.0 203 74 442 --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 9c

Liver Cancer Incidence

Cambridge, Massachusetts

1988–1993

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3543 1 0.6 NC NC NC -- 1 0.4 NC NC NC -- 0 0.2 NC NC NC --
3546 0 0.5 NC NC NC -- 0 0.4 NC NC NC -- 0 0.2 NC NC NC --
3549 1 0.6 NC NC NC -- 1 0.4 NC NC NC -- 0 0.2 NC NC NC --
City Total† 10 10.7 94 45 173 -- 7 7.5 93 37 192 -- 3 3.1 NC NC NC --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 9d

Liver Cancer Incidence

Cambridge, Massachusetts

1994–1999

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3543 1 0.7 NC NC NC -- 1 0.5 NC NC NC -- 0 0.2 NC NC NC --
3546 2 0.8 NC NC NC -- 0 0.5 NC NC NC -- 2 0.2 NC NC NC --
3549 1 0.8 NC NC NC -- 0 0.6 NC NC NC -- 1 0.2 NC NC NC --
City Total† 17 15.1 113 66 181 -- 12 10.9 110 57 193 -- 5 4.2 119 38 278 --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 10a

Lung and Bronchus Cancer Incidence

Cambridge, Massachusetts

1982–1999

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3543 41 50.0 82 59 111 -- 24 26.9 89 57 133 -- 17 23.2 73 43 117 --
3546 39 47.6 82 58 112 -- 19 25.6 74 45 116 -- 20 22.0 91 55 140 --
3549 51 48.4 105 78 139 -- 31 27.8 111 76 158 -- 20 20.6 97 59 150 --
City Total† 799 897.4 89 * 83 95 -- 460 509.6 90 * 82 99 -- 339 387.8 87 * 78 97 --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 10b

Lung and Bronchus Cancer Incidence

Cambridge, Massachusetts

1982–1987

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3543 21 15.6 135 83 206 -- 15 9.4 159 89 262 -- 6 6.2 97 36 212 --
3546 14 14.4 97 53 163 -- 7 8.8 80 32 164 -- 7 5.6 124 50 256 --
3549 14 14.5 97 53 162 -- 9 8.7 104 47 197 -- 5 5.8 86 28 201 --
City Total† 276 278.0 99 88 112 -- 179 169.1 106 91 123 -- 97 109.0 89 72 109 --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 10c

Lung and Bronchus Cancer Incidence

Cambridge, Massachusetts

1988–1993

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3543 12 16.6 72 37 127 -- 5 9.0 56 18 130 -- 7 7.6 92 37 190 --
3546 11 15.9 69 35 124 -- 4 8.6 NC NC NC -- 7 7.3 96 38 198 --
3549 17 16.2 105 61 168 -- 9 9.4 96 44 182 -- 8 6.9 117 50 230 --
City Total† 251 300.1 84 * 74 95 -- 134 171.8 78 * 65 92 -- 117 128.4 91 75 109 --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 10d

Lung and Bronchus Cancer Incidence

Cambridge, Massachusetts

1994–1999

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3543 8 16.6 48 * 21 95 -- 4 8.0 NC NC NC -- 4 8.6 NC NC NC --
3546 14 16.8 83 46 140 -- 8 8.3 96 41 190 -- 6 8.5 71 26 154 --
3549 20 16.9 118 72 183 -- 13 9.0 144 77 247 -- 7 7.9 89 35 182 --
City Total† 272 320.2 85 * 75 96 -- 147 169.0 87 73 102 -- 125 151.2 83 * 69 99 --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 11a

Non-Hodgkin's Lymphoma Incidence

Cambridge, Massachusetts

1982–1999

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3543 11 12.9 85 43 153 -- 4 5.7 NC NC NC -- 7 7.2 97 39 199 --
3546 10 12.2 82 39 151 -- 2 5.7 NC NC NC -- 8 6.5 122 53 241 --
3549 6 12.3 49 18 106 -- 2 6.3 NC NC NC -- 4 5.9 NC NC NC --
City Total† 186 242.5 77 * 66 89 -- 88 123.1 72 * 57 88 -- 98 119.4 82 66 100 --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 11b

Non-Hodgkin's Lymphoma Incidence

Cambridge, Massachusetts

1982–1987

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3543 1 3.6 NC NC NC -- 0 1.6 NC NC NC -- 1 2.0 NC NC NC --
3546 3 3.2 NC NC NC -- 1 1.5 NC NC NC -- 2 1.7 NC NC NC --
3549 2 3.2 NC NC NC -- 0 1.5 NC NC NC -- 2 1.7 NC NC NC --
City Total† 48 66.3 72 * 53 96 -- 21 32.0 66 41 100 -- 27 34.4 79 52 114 --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 11c

Non-Hodgkin's Lymphoma Incidence

Cambridge, Massachusetts

1988–1993

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3543 6 4.3 141 51 307 -- 2 1.9 NC NC NC -- 4 2.4 NC NC NC --
3546 4 4.0 NC NC NC -- 1 1.9 NC NC NC -- 3 2.2 NC NC NC --
3549 1 4.1 NC NC NC -- 1 2.1 NC NC NC -- 0 2.0 NC NC NC --
City Total† 68 81.2 84 65 106 -- 35 41.7 84 59 117 -- 33 39.5 83 57 117 --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 11d

Non-Hodgkin's Lymphoma Incidence

Cambridge, Massachusetts

1994–1999

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3543 4 4.6 NC NC NC -- 2 2.1 NC NC NC -- 2 2.6 NC NC NC --
3546 3 4.8 NC NC NC -- 0 2.3 NC NC NC -- 3 2.5 NC NC NC --
3549 3 4.8 NC NC NC -- 1 2.5 NC NC NC -- 2 2.3 NC NC NC --
City Total† 70 96.8 72 * 56 91 -- 32 50.4 64 * 43 90 -- 38 46.4 82 58 112 --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 12a

Pancreatic Cancer Incidence

Cambridge, Massachusetts

1982–1999

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3543 9 8.4 107 49 203 -- 3 3.3 NC NC NC -- 6 5.1 117 43 255 --
3546 8 7.4 109 47 214 -- 3 3.1 NC NC NC -- 5 4.3 117 38 272 --
3549 13 7.0 187 99 320 -- 9 3.3 273 * 125 519 -- 4 3.7 NC NC NC --
City Total† 139 136.4 102 86 120 -- 67 61.2 110 85 139 -- 72 75.2 96 75 121 --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
173 

TABLE 12b

Pancreatic Cancer Incidence

Cambridge, Massachusetts

1982–1987

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3543 4 2.8 NC NC NC -- 2 1.1 NC NC NC -- 2 1.7 NC NC NC --
3546 4 2.3 NC NC NC -- 2 1.0 NC NC NC -- 2 1.3 NC NC NC --
3549 5 2.2 224 72 523 -- 4 1.0 NC NC NC -- 1 1.3 NC NC NC --
City Total† 51 45.5 112 83 147 -- 24 19.5 123 79 183 -- 27 26.0 104 68 151 --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 12c

Pancreatic Cancer Incidence

Cambridge, Massachusetts

1988–1993

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3543 3 2.6 NC NC NC -- 1 1.0 NC NC NC -- 2 1.6 NC NC NC --
3546 3 2.3 NC NC NC -- 1 1.0 NC NC NC -- 2 1.4 NC NC NC --
3549 4 2.2 NC NC NC -- 3 1.1 NC NC NC -- 1 1.2 NC NC NC --
City Total† 45 43.3 104 76 139 -- 24 19.5 123 79 183 -- 21 23.8 88 55 135 --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 12d

Pancreatic Cancer Incidence

Cambridge, Massachusetts

1994–1999

Census Tract Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
3543 2 2.7 NC NC NC -- 0 1.1 NC NC NC -- 2 1.6 NC NC NC --
3546 1 2.6 NC NC NC -- 0 1.1 NC NC NC -- 1 1.5 NC NC NC --
3549 4 2.4 NC NC NC -- 2 1.2 NC NC NC -- 2 1.3 NC NC NC --
City Total† 43 48.0 89 65 121 -- 19 22.1 86 52 134 -- 24 26.0 92 59 137 --
† Cases for which census tract designation was not possible are included in the city total. 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 13a

Cancer Incidence

Arlington, Massachusetts

1982–1999

Cancer Type Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
Kidney 94 99.9 94 76 115 -- 58 56.8 102 78 132 -- 36 43.1 83 58 116 --
Leukemia 85 86.3 98 79 122 -- 45 44.8 100 73 134 -- 40 41.5 96 69 131 --
Liver 28 23.4 120 79 173 -- 17 16.0 107 62 171 -- 11 7.5 147 73 264 --
Lung & Bronchus 544 643.8 84 * 78 92 -- 328 359.1 91 82 102 -- 216 284.7 76 * 66 87 --
NHL 161 158.7 101 86 118 -- 73 75.0 97 76 122 -- 88 83.7 105 84 130 --
Pancreatic 102 100.0 102 83 124 -- 46 42.7 108 79 144 -- 56 57.2 98 74 127 --
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
NHL = Non-Hodgkin's Lymphoma 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 13b

Cancer Incidence

Arlington, Massachusetts

1982–1987

Cancer Type Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
Kidney 28 27.6 102 67 147 -- 18 15.2 118 70 187 -- 10 12.3 81 39 149 --
Leukemia 30 27.5 109 74 156 -- 18 14.3 125 74 198 -- 12 13.2 91 47 159 --
Liver 12 6.0 201 * 104 351 -- 8 3.9 205 88 404 -- 4 2.1 NC NC NC --
Lung & Bronchus 174 204.9 85 * 73 99 -- 113 125.6 90 74 108 -- 61 79.3 77 * 59 99 --
NHL 43 44.7 96 70 130 -- 13 20.8 62 33 107 -- 30 23.9 126 85 179 --
Pancreatic 44 33.4 132 96 177 -- 25 14.3 174 * 113 257 -- 19 19.0 100 60 156 --
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
NHL = Non-Hodgkin's Lymphoma 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 13c

Cancer Incidence

Arlington, Massachusetts

1988–1993

Cancer Type Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
Kidney 26 35.0 74 49 109 -- 16 20.3 79 45 128 -- 10 14.7 68 33 125 --
Leukemia 20 26.1 77 47 118 -- 12 13.8 87 45 152 -- 8 12.3 65 28 128 --
Liver 4 7.3 NC NC NC -- 2 5.0 NC NC NC -- 2 2.2 NC NC NC --
Lung & Bronchus 183 214.7 85 * 73 99 -- 106 120.5 88 72 106 -- 77 94.2 82 64 102 --
NHL 53 52.6 101 76 132 -- 27 24.9 108 71 158 -- 26 27.7 94 61 138 --
Pancreatic 33 31.6 105 72 147 -- 11 13.5 81 41 146 -- 22 18.1 122 76 184 --
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
NHL = Non-Hodgkin's Lymphoma 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 13d

Cancer Incidence

Arlington, Massachusetts

1994–1999

Cancer Type Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
Kidney 40 36.3 110 79 150 -- 24 20.9 115 74 171 -- 16 15.5 104 59 168 --
Leukemia 35 31.9 110 76 153 -- 15 16.5 91 51 150 -- 20 15.3 131 80 201 --
Liver 12 9.8 123 63 214 -- 7 6.8 103 41 212 -- 5 3.0 168 54 393 --
Lung & Bronchus 187 221.2 85 * 73 98 -- 109 114.7 95 78 115 -- 78 106.5 73 * 58 91 --
NHL 65 59.3 110 85 140 -- 33 28.7 115 79 162 -- 32 30.6 104 71 147 --
Pancreatic 25 34.0 74 48 109 -- 10 14.8 68 33 124 -- 15 19.2 78 44 129 --
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
NHL = Non-Hodgkin's Lymphoma 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
180 

TABLE 14a

Cancer Incidence

Watertown, Massachusetts

1982–1999

Cancer Type Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
Kidney 76 70.4 108 85 135 -- 48 39.7 121 89 160 -- 28 30.7 91 61 132 --
Leukemia 68 61.1 111 86 141 -- 38 31.5 121 85 165 -- 30 29.6 101 68 145 --
Liver 21 16.5 127 79 195 -- 21 11.2 188 * 116 287 -- 0 5.3 NC NC NC --
Lung & Bronchus 423 452.4 93 85 103 -- 233 250.7 93 81 106 -- 190 201.8 94 81 109 --
NHL 137 113.2 121 * 102 143 -- 63 53.4 118 91 151 -- 74 59.9 124 97 155 --
Pancreatic 66 70.3 94 73 119 -- 32 29.9 107 73 151 -- 34 40.4 84 58 118 --
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
NHL = Non-Hodgkin's Lymphoma 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 14b

Cancer Incidence

Watertown, Massachusetts

1982–1987

Cancer Type Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
Kidney 21 19.0 111 68 169 -- 13 10.5 124 66 212 -- 8 8.5 94 40 185 --
Leukemia 18 19.1 94 56 149 -- 12 9.9 121 62 211 -- 6 9.1 66 24 143 --
Liver 5 4.1 121 39 283 -- 5 2.7 186 60 435 -- 0 1.4 NC NC NC --
Lung & Bronchus 147 140.6 105 88 123 -- 90 85.7 105 84 129 -- 57 54.9 104 79 135 --
NHL 40 31.0 129 92 175 -- 17 14.5 118 68 188 -- 23 16.6 139 88 208 --
Pancreatic 19 23.0 83 50 129 -- 6 9.8 61 22 133 -- 13 13.1 99 53 170 --
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
NHL = Non-Hodgkin's Lymphoma 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 14c

Cancer Incidence

Watertown, Massachusetts

1988–1993

Cancer Type Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
Kidney 33 24.7 134 92 188 -- 24 14.3 168 * 108 251 -- 9 10.5 86 39 163 --
Leukemia 21 18.5 113 70 173 -- 11 9.7 113 56 203 -- 10 8.8 113 54 208 --
Liver 6 5.1 117 43 254 -- 6 3.5 169 62 368 -- 0 1.6 NC NC NC --
Lung & Bronchus 142 151.0 94 79 111 -- 83 84.2 99 79 122 -- 59 66.8 88 67 114 --
NHL 48 37.6 128 94 169 -- 20 17.8 112 69 174 -- 28 19.8 141 94 204 --
Pancreatic 22 22.2 99 62 150 -- 12 9.5 127 65 221 -- 10 12.8 78 38 144 --
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
NHL = Non-Hodgkin's Lymphoma 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 14d

Cancer Incidence

Watertown, Massachusetts

1994–1999

Cancer Type Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
Kidney 22 26.4 83 52 126 -- 11 15.0 73 37 131 -- 11 11.4 97 48 173 --
Leukemia 29 23.5 124 83 177 -- 15 12.1 124 69 205 -- 14 11.4 123 67 206 --
Liver 10 7.1 141 68 259 -- 10 4.9 204 98 376 -- 0 2.2 NC NC NC --
Lung & Bronchus 134 160.5 83 * 70 99 -- 60 82.5 73 * 56 94 -- 74 78.0 95 74 119 --
NHL 49 44.0 111 82 147 -- 26 21.2 123 80 180 -- 23 22.9 101 64 151 --
Pancreatic 25 24.9 100 65 148 -- 14 10.7 131 72 220 -- 11 14.2 77 38 138 --
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
NHL = Non-Hodgkin's Lymphoma 
Data Source: Massachusetts Cancer Registry, Center for Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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Table 15

MDEP 21E Hazardous Material and Oil Releases

 Arlington, Belmont, Cambridge, and Watertown, Massachusetts  

MAPPED/ 
NOT 
MAPPED RTN LOCATION AID ADDRESS TOWN  DATE CATEGORY MATERIALS SOURCES STATUS 
MAPPED 3-0010373 NO LOCATION AID (RESIDNTIAL) 72 HATHAWAY CIR ARLINGTON 12/29/1993 TWO HR FUEL OIL #2 (100 GAL) AST; PIPE RAO 
MAPPED 3-0010409 NO LOCATION AID (RESIDNTIAL) 76 BRANTWOOD RD ARLINGTON 1/9/1994 TWO HR FUEL OIL #2 (25 GAL); FUEL OIL #2 (15 
GAL) 
AST; PIPE RAO 
MAPPED 3-0010500 NO LOCATION AID (RESIDNTIAL) 95 PAUL REVERE RD ARLINGTON 2/1/1994 TWO HR FUEL OIL #2 (100 GAL); FUEL OIL #2 (200 
GAL) 
AST RAO 
MAPPED 3-0010645 NEAR SUMMER ST COMMUNITY 112 MYSTIC ST ARLINGTON 3/7/1994 72 HR GASOLINE (600 PPMV) UST RAO 
SAFETY BUILDING (COMMERCIAL; 
MUNICIPAL) 
MAPPED 3-0010856 RTE 2 MWRA PUMP STA (STATE) JASON ST/SPRING ST ARLINGTON 4/12/1994 TWO HR FUEL OIL #2 (600 GAL); FUEL OIL #2 (150 
GAL) 
AST RAO 
MAPPED 3-0010969 SYMMES HOSPITAL 
(COMMERCIAL) 
HOSPITAL RD ARLINGTON 5/8/1994 TWO HR OIL; PETROLEUM BASED OIL UST TIER 2 
MAPPED 3-0011199 NO LOCATION AID (RESIDNTIAL) 7 MOHAWK RD ARLINGTON 4/23/1994 72 HR FUEL OIL #2 (60 PPMV); FUEL OIL #2 UST RAO 
MAPPED 3-0011481 MIRAK CHEVROLET 
(COMMERCIAL) 
26 HOBBS CT ARLINGTON 8/17/1994 72 HR GASOLINE (174 PPMV); GASOLINE (50 
PPMV) 
UST RAO 
MAPPED 3-0011482 BACK OF GARAGE 
(COMMERCIAL) 
26 HOBBES CT ARLINGTON 8/17/1994 72 HR FUEL OIL #2 (53 PPMV); FUEL OIL #2 (50 
PPMV) 
UST RAO 
NOT 3-0011738 NO LOCATION AID (RESIDNTIAL; PAUL REVERE RD ARLINGTON 10/17/1994 TWO HR OIL (2 GAL); 1,1'-BIPHENYL, CHLORO- TRANSFORM RAO 
MAPPED ROADWAY) DERIVS. (500 MG/L); 1,1'-BIPHENYL, 
CHLORO-DERIVS. (5 PPM); MINERAL OIL 
(4 GAL) 
MAPPED 3-0011771 FRONT OF BUILDING 
(COMMERCIAL) 
50 GROVE ST ARLINGTON 10/25/1994 72 HR FUEL OIL #2 (105 PPMV) UST RAO 
NOT 
MAPPED 
3-0011921 POLE 83/1 (RESIDNTIAL) WASHINGTON 
ST/ARLINGTON ST 
ARLINGTON 12/2/1994 TWO HR UNKNOWN CHEMICAL OF TYPE - OIL (12 
GAL); MINERAL OIL (12 GAL) 
TRANSFORM RAO 
MAPPED 3-0012002 POLE #18 (COMMERCIAL; 
ROADWAY) 
SUMMER ST/MYSTIC ST ARLINGTON 12/24/1994 TWO HR UNKNOWN CHEMICAL OF TYPE - OIL (50 
GAL); PETROLEUM BASED OIL (30 GAL) 
TRANSFORM RAO 
MAPPED 3-0012118 ANDERSON & SONS INC 
(COMMERCIAL) 
895-901 
MASSACHUSETTS AVE 
ARLINGTON 1/30/1995 72 HR FUEL OIL #2 (220 PPMV); UNKNOWN 
CHEMICAL OF TYPE - OIL (226 PPMV) 
UST RAO 
MAPPED 3-0012170 NO LOCATION AID (COMMERCIAL) 305 BROADWAY ARLINGTON 2/13/1995 TWO HR DIESEL FUEL (25 GAL) VEHICLE DEF TIER 1B 
NOT 
MAPPED 
3-0012342 NEAR WILDWOOD APTS 
(ROADWAY) 
PLEASANT ST ARLINGTON 4/4/1995 TWO HR UNKNOWN CHEMICAL OF UNKNOWN 
TYPE (40 GAL) 
PIPE RAO 
MAPPED 3-0013059 NO LOCATION AID (COMMERCIAL) 1425 MASSACHUSETTS 
AVE 
ARLINGTON 10/19/1995 72 HR FUEL OIL #2 (100 PPM) UST RAO 
MAPPED 3-0013084 ARLINGTON GARDENS APTS 
(RESIDNTIAL) 
130 EVERETT ST ARLINGTON 10/25/1995 72 HR FUEL OIL #2 (0.5 INCH) UST RAO 
MAPPED 3-0013738 NO LOCATION AID (RESIDNTIAL) 24 CENTRAL ST ARLINGTON 5/8/1996 TWO HR FUEL OIL #2 (15 GAL) AST; PIPE RAO 
MAPPED 3-0013858 NO LOCATION AID (RESIDNTIAL) 38 TOWERS RD ARLINGTON 6/6/1996 72 HR FUEL OIL #2 (100 PPMV) UST RAO 
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MAPPED 3-0014110 NO LOCATION AID (COMMERCIAL; 
RESIDNTIAL) 
8 WELLINGTON ST ARLINGTON 12/23/1996 72 HR FUEL OIL #2 (107 PPMV) UST RAO 
MAPPED 3-0014443 MBTA PARKING LOT (STATE) 1395-1425 MASS AVE ARLINGTON 10/29/1996 72 HR KEROSENE (11 MG/L); GASOLINE; UST RTN CLOSED 
PROPANE, 2-METHOXY-2-METHYL- (130 
UG/L); NAPHTHALENE (67 UG/L) 
MAPPED 3-0014668 ALPHA AUTO BODY 
(COMMERCIAL) 
30 PARK AVE ARLINGTON 12/25/1996 TWO HR UNKNOWN CHEMICAL OF TYPE -
HAZARDOUS MATERIAL (25 GAL); 
UNKNOWN CHEMICAL OF TYPE -
HAZARDOUS MATERIAL (10 GAL) 
DRUMS RAO 
MAPPED 3-0014989 NO LOCATION AID (COMMERCIAL) 30 MILL ST ARLINGTON 4/10/1997 72 HR FUEL OIL #2 (102 PPMV); UNKNOWN 
CHEMICAL OF UNKNOWN TYPE (0.5 
INCH) 
UST RAO 
MAPPED 3-0015709 SUNOCO (COMMERCIAL) 46 BROADWAY ARLINGTON 11/11/1997 TWO HR WASTE OIL; OIL (1 GAL) 4; DRUMS RTN CLOSED 
MAPPED 3-0015826 MA HWY DEPT (STATE) 519 APPLETON ST ARLINGTON 12/15/1997 72 HR PETROLEUM BASED OIL (0.6 INCH) UST RTN CLOSED 
MAPPED 3-0015938 RIDGE ST (RESIDNTIAL) 32 TERESA CIR ARLINGTON 11/12/1997 TWO HR FUEL OIL #2 (50 GAL); FUEL OIL #2 (50 
GAL) 
AST; PIPE RAO 
MAPPED 3-0016615 NO LOCATION AID (RESIDNTIAL) 93 WAVERLY AND 160 
RENFREW STS 
ARLINGTON 3/19/1998 TWO HR FUEL OIL #2; FUEL OIL #2 (11000 MG/KG); 
FUEL OIL #2 (48 MG/L) 
LINE; PIPE RAO 
MAPPED 3-0017104 BRACKETT SCHOOL (MUNICIPAL; 
SCHOOL) 
EASTERN AVE ARLINGTON 7/30/1998 72 HR FUEL OIL #4; FUEL OIL #4 (1000 GAL); 
FUEL OIL #2; FUEL OIL #2 (1000 GAL) 
PIPE; UST RAO 
MAPPED 3-0017441 NO LOCATION AID (COMMERCIAL) 81 MYSTIC ST ARLINGTON 10/16/1998 72 HR UNKNOWN CHEMICAL OF TYPE -
HAZARDOUS MATERIAL (1043 PPMV); 
UNKNOWN CHEMICAL OF TYPE -
UST TIER 2 
HAZARDOUS MATERIAL (100 PPMV) 
MAPPED 3-0017442 NO LOCATION AID (COMMERCIAL) 81 MYSTIC ST ARLINGTON 10/16/1998 72 HR UNKNOWN CHEMICAL OF UNKNOWN UST RTN CLOSED 
TYPE (125 PPMV); FUEL OIL #2 (100 
PPMV) 
MAPPED 3-0017565 DUDLEY FUEL (COMMERCIAL) 9 DUDLEY ST PL ARLINGTON 11/12/1998 72 HR GASOLINE; UNKNOWN CHEMICAL OF 
UNKNOWN TYPE; KEROSENE (2000 
PPMV); KEROSENE; FUEL OIL #2 
UST RAO 
MAPPED 3-0017599 DUDLEY FUEL (COMMERCIAL) 9 DUDLEY ST PL ARLINGTON 11/19/1998 72 HR WASTE OIL (122 PPMV); WASTE OIL UST RTN CLOSED 
MAPPED 3-0017697 BRIGHAMS  EAST EDGE OF 
PARKING LOT (COMMERCIAL) 
30 MILL ST ARLINGTON 12/7/1998 72 HR FUEL OIL #6; FUEL OIL #6 UST RTN CLOSED 
MAPPED 3-0017698 NO LOCATION AID 140 MYSTIC ST ARLINGTON 12/8/1998 72 HR GASOLINE; GASOLINE (100 PPMV); UST RAO 
UNKNOWN CHEMICAL OF UNKNOWN 
TYPE 
MAPPED 3-0018021 NO LOCATION AID (COMMERCIAL) 440 MASSACHUSETTS 
AVE REAR 
ARLINGTON 2/22/1999 72 HR GASOLINE (104 PPMV); GASOLINE (101 
PPM) 
UST RAO 
MAPPED 3-0018209 TELEPHONE POLE AND CATCH 
BASIN 
MASS AVE AND 
PLEASANT ST 
ARLINGTON 4/20/1999 TWO HR OIL (3 GAL); UNKNOWN CHEMICAL OF 
TYPE - OIL (2 GAL) 
SWITCH RAO 
MAPPED 3-0018766 BOSTON EDISON STATION 59 
(COMMERCIAL) 
88 MYSTIC ST ARLINGTON 9/18/1999 TWO HR UNKNOWN CHEMICAL OF UNKNOWN 
TYPE (25 GAL); UNKNOWN CHEMICAL OF 
TYPE - OIL (25 GAL) 
TRANSFORM RAO 
MAPPED 3-0018828 EVERETT ST (COMMERCIAL) 125 BROADWAY ARLINGTON 10/6/1999 72 HR GASOLINE; GASOLINE (0.05 GAL/HR) UST TIER 2 
MAPPED 3-0019131 NO LOCATION AID (COMMERCIAL) 180 MOUNTAIN AVE ARLINGTON 1/3/2000 TWO HR OIL; FUEL OIL #4 (11 GAL) UNKNOWN TIER 2 
MAPPED 3-0019235 NO LOCATION AID (RESIDNTIAL) 25 MILL ST ARLINGTON 2/2/2000 TWO HR FUEL OIL #2 (40 GAL) VEHICLE RAO 
MAPPED 3-0019499 BRIGHAMS  REAR LOADING DOCK 
(COMMERCIAL) 
42 MILL ST ARLINGTON 5/3/2000 TWO HR PETROLEUM BASED OIL (50 GAL); 
PETROLEUM BASED OIL 
PIPE RAO 
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MAPPED 3-0019754 DPW YARD (MUNICIPAL) 51 GROVE ST ARLINGTON 7/21/2000 72 HR UNKNOWN CHEMICAL OF UNKNOWN 
TYPE (1.2 INCH) 
UNKNOWN TIER 2 
MAPPED 3-0019829 RAAB RESIDENCE (RESIDNTIAL) 117 GRAY ST ARLINGTON 8/10/2000 72 HR FUEL OIL #2 (252 PPMV); FUEL OIL #2 (101 
PPM) 
UST RAO 
MAPPED 3-0019873 NO LOCATION AID (RESIDNTIAL) 10 UNIVERSITY RD ARLINGTON 8/25/2000 72 HR FUEL OIL #2 (2200 PPMV); FUEL OIL #2 
(100 PPMV) 
UST RAO 
MAPPED 3-0020164 NO LOCATION AID (COMMERCIAL) 1395 MASSACHUSETTS 
AVE 
ARLINGTON 11/29/2000 72 HR GASOLINE (160 PPMV); GASOLINE UST RTN CLOSED 
MAPPED 3-0020262 NO LOCATION AID (OPENSPACE) 1395 MASSACHUSETTS 
AVE 
ARLINGTON 12/28/2000 72 HR OIL (222 PPMV); FUEL OIL #2 UST RTN CLOSED 
MAPPED 3-0020732 SUNRISE (COMMERCIAL) 1395 MASSACHUSETTS 
AVE 
ARLINGTON 5/24/2001 72 HR DIESEL FUEL (4 INCH) UST RTN CLOSED 
MAPPED 3-0021070 MAGNOLIA ST (RESIDNTIAL) 104 MASS AVE ARLINGTON 9/11/2001 TWO HR FUEL OIL #2 (40 GAL); FUEL OIL #2 (39.6 
GAL) 
AST; PIPE TIER 2 
MAPPED 3-0021092 REAR LOADING DOCK 
(COMMERCIAL) 
42 MILL ST ARLINGTON 9/18/2001 TWO HR PETROLEUM BASED OIL (15 GAL); 
PETROLEUM BASED OIL (11 GAL) 
VEHICLE RAO 
NOT 
MAPPED 
3-0021196 NO LOCATION AID (COMMERCIAL) HOSPITAL RD ARLINGTON 10/19/2001 72 HR UNKNOWN CHEMICAL OF UNKNOWN 
TYPE (0.5 INCH); UNKNOWN CHEMICAL 
UST RTN CLOSED 
OF UNKNOWN TYPE (2.64 INCH); 
PETROLEUM BASED OIL (2.64 INCH) 
MAPPED 3-0021235 DR AND MRS CHARLES H BURKE 
RESIDENCE (RESIDNTIAL) 
7 ARROWHEAD LANE ARLINGTON 11/4/2001 TWO HR FUEL OIL #2 (60 GAL); FUEL OIL #2 PIPE UNCLASSIFIED 
MAPPED 3-0021327 NO LOCATION AID (COMMERCIAL) 125 BROADWAY ARLINGTON 12/13/2001 72 HR UNKNOWN CHEMICAL OF UNKNOWN 
TYPE (0.5 INCH) 
UST UNCLASSIFIED 
MAPPED 3-0021646 INTERSECTION WITH SUMMER ST MYSTIC ST ARLINGTON 4/5/2002 TWO HR UNKNOWN CHEMICAL OF TYPE - OIL (500 PIPE RAO 
(COMMERCIAL) GAL); UNKNOWN CHEMICAL OF 
UNKNOWN TYPE (500 GAL) 
MAPPED 3-0021658 LOCKLAND AVE (COMMERCIAL) 880 MASSACHUSETTS 
AVE 
ARLINGTON 4/9/2002 72 HR GASOLINE (180 PPMV) UST UNCLASSIFIED 
MAPPED 3-0021734 SKATING RINK (MUNICIPAL) 422 SUMMER ST ARLINGTON 5/5/2002 TWO HR AMMONIA (50 LBS); AMMONIA (50 LBS) PIPE; UNCLASSIFIED 
REFRIGERAT; 
UNIT 
MAPPED 3-0022274 NO LOCATION AID (RESIDNTIAL) 93 SUNNYSIDE AVE ARLINGTON 11/4/2002 TWO HR FUEL OIL #2 (42 GAL); FUEL OIL #2 (40 
GAL) 
PIPE UNCLASSIFIED 
MAPPED 3-0022328 NO LOCATION AID (RESIDNTIAL) 5 REED ST ARLINGTON 11/20/2002 TWO HR FUEL OIL #2 (100 GAL) AST UNCLASSIFIED 
MAPPED 3-0022352 NO LOCATION AID (SCHOOL) 869 MASS AVE ARLINGTON 11/27/2002 TWO HR FUEL OIL #2 (25 GAL); FUEL OIL #4 (25 
GAL) 
PIPE UNCLASSIFIED 
MAPPED 3-0022371 ARLINGTON HIGH SCHOOL 
(MUNICIPAL; SCHOOL) 
869 MASSACHUSETTS 
AVE 
ARLINGTON 12/9/2002 TWO HR FUEL OIL #4 (6000 GAL); FUEL OIL #4 
(3000 GAL) 
PIPE RAO 
MAPPED 3-0011536 FMR MDC RINK (MUNICIPAL; 
STATE) 
LAKE ST/RTE 2 BELMONT 8/26/1994 72 HR FUEL OIL #2 (108 PPMV); UNKNOWN 
CHEMICAL OF TYPE - OIL (50 PPM) 
UST RAO 
MAPPED 3-0011922 NO LOCATION AID (RESIDNTIAL) 77 SNAKE HILL RD BELMONT 12/5/1994 72 HR FUEL OIL #2 (127 PPMV); FUEL OIL #2 (50 UST RAO 
PPMV) 
NOT 3-0011938 RTE 60/RTE 2 (ROADWAY) RTE 60 BELMONT 12/7/1994 TWO HR LEAD (1200 LBS); SULFURIC ACID DRUMS; DEF TIER 1B 
MAPPED VEHICLE 
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MAPPED 3-0012253 GETTY GASOLINE STATION 350 PLEASANT ST BELMONT 3/9/1995 72 HR WASTE OIL (180 PPMV); UNKNOWN 
CHEMICAL OF TYPE - OIL (180 PPM); 
ETHENE, TETRACHLORO- (7810 PPB); 
ETHENE, TRICHLORO- (988 PPB) 
UST RAO 
MAPPED 3-0013348 BASEMENT (RESIDNTIAL) 11 ORCHARD ST BELMONT 1/19/1996 TWO HR FUEL OIL #2 PIPE RAO 
MAPPED 3-0013550 FMR BEST PETROLEUM 
(COMMERCIAL) 
80 CONCORD ST BELMONT 3/13/1996 72 HR FUEL OIL #2 (120 PPMV) UST RAO 
NOT 3-0013935 POLE#3 @ #23 (ROADWAY) BENTON RD BELMONT 6/25/1996 TWO HR UNKNOWN CHEMICAL OF TYPE - OIL (20 TRANSFORM RAO 
MAPPED GAL) 
MAPPED 3-0013975 NO LOCATION AID (COMMERCIAL) 337 MILL ST BELMONT 7/9/1996 72 HR PETROLEUM BASED OIL (100 PPM) UST RAO 
MAPPED 3-0014072 CHENEY MIDDLE SCHOOL 
(MUNICIPAL; SCHOOL) 
95 WASHINGTON ST BELMONT 7/31/1996 72 HR FUEL OIL #2 (7.5 INCH) UNKNOWN RAO 
MAPPED 3-0014636 NO LOCATION AID (RESIDNTIAL) 86 MONROE ST BELMONT 12/17/1996 72 HR FUEL OIL #2 (143 PPMV); UNKNOWN UST RAO 
CHEMICAL OF TYPE - OIL (100 PPMV) 
MAPPED 3-0015254 RESIDENCE (RESIDNTIAL) 11 WOODFALL RD BELMONT 6/27/1997 TWO HR FUEL OIL #2 (100 GAL) PIPE RAO 
MAPPED 3-0015893 WINBROOK SCHOOL (SCHOOL) 97 WATERHOUSE RD BELMONT 1/5/1998 TWO HR FUEL OIL #4; FUEL OIL #4; UNKNOWN UST RAO 
CHEMICAL OF TYPE - HAZARDOUS 
MATERIAL 
MAPPED 3-0016600 CAMBRIDGE PLATING 
(COMMERCIAL; INDUSTRIAL) 
39 HITTINGER ST BELMONT 3/15/1998 TWO HR FUEL OIL #2 (100 GAL); FUEL OIL #2 (20 
GAL) 
HEATER; SPACE RAO 
MAPPED 3-0016874 MUNICIPAL LIGHT DEPT  POLE 13 9 BRETTWOOD RD BELMONT 6/3/1998 TWO HR UNKNOWN CHEMICAL OF TYPE - OIL (30 TRANSFORM RAO 
(RESIDNTIAL) GAL); UNKNOWN CHEMICAL OF TYPE -
OIL (12 GAL) 
MAPPED 3-0017080 NO LOCATION AID (RESIDNTIAL) 40 HOWELLS RD BELMONT 7/23/1998 72 HR FUEL OIL #2 (103.7 PPMV); FUEL OIL #2 
(104 PPM) 
UST RAO 
MAPPED 3-0017677 NO LOCATION AID (COMMERCIAL) 297 TRAPELO RD BELMONT 12/3/1998 72 HR GASOLINE (553 PPMV); UNKNOWN 
CHEMICAL OF UNKNOWN TYPE; 
UST RAO 
PETROLEUM BASED OIL (100 PPMV) 
MAPPED 3-0018823 NO LOCATION AID (ROADWAY) BEACH & MAPLE BELMONT 10/4/1999 TWO HR FUEL OIL #2 (60 GAL); FUEL OIL #2 (100 
GAL) 
VEHICLE RAO 
MAPPED 3-0019570 BELMONT SPRINGS WATER CO 
(COMMERCIAL) 
1010 PLEASANT ST BELMONT 5/24/2000 72 HR OIL; DIESEL FUEL PIPE; UST RAO 
MAPPED 3-0020322 NO LOCATION AID (MUNICIPAL; 112 STONEY BROOK RD BELMONT 1/18/2001 TWO HR FUEL OIL #2 (49 GAL); FUEL OIL #2 (40 PIPE; VEHICLE RAO 
ROADWAY) GAL) 
MAPPED 3-0020406 NO LOCATION AID (COMMERCIAL; 
HOSPITAL) 
115 MILL ST BELMONT 2/19/2001 TWO HR PETROLEUM BASED OIL; FUEL OIL #2 (11 
GAL) 
UNKNOWN TIER 2 
MAPPED 3-0020576 INTERSECTION OF BRIGHT RD 82 CONCORD AVE BELMONT 4/6/2001 72 HR UNKNOWN CHEMICAL OF UNKNOWN UST RTN CLOSED 
(COMMERCIAL) TYPE (0.5 INCH); UNKNOWN CHEMICAL 
OF UNKNOWN TYPE 
MAPPED 3-0020587 NO LOCATION AID (RESIDNTIAL) 36 HILLCREST RD BELMONT 4/10/2001 72 HR FUEL OIL #2 (140 PPMV); UNKNOWN 
CHEMICAL OF TYPE - OIL (158 PPM) 
UST RAO 
MAPPED 3-0021025 NO LOCATION AID (COMMERCIAL) 270 TRAPELO RD BELMONT 8/24/2001 72 HR UNKNOWN CHEMICAL OF UNKNOWN 
TYPE (17 INCH) 
UNKNOWN RTN CLOSED 
MAPPED 3-0021120 FORMER MOBIL S/S 1-193 337 PLEASANT ST BELMONT 10/1/2001 72 HR UNKNOWN CHEMICAL OF UNKNOWN UNKNOWN RTN CLOSED 
(COMMERCIAL) TYPE (12 INCH); UNKNOWN CHEMICAL 
OF UNKNOWN TYPE (1 INCH) 
MAPPED 3-0021369 NO LOCATION AID (RESIDNTIAL) 26 CEDAR ST BELMONT 1/3/2002 72 HR GASOLINE (362 PPMV) UST RAO 
MAPPED 3-0022041 NO LOCATION AID (COMMERCIAL) 2 LEONARD ST BELMONT 8/19/2002 72 HR FUEL OIL #2 (280 PPMV); FUEL OIL #2 (500 
PPMV) 
UST UNCLASSIFIED 
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MAPPED 3-0022406 NO LOCATION AID (RESIDNTIAL) 3 CLARKE LANE BELMONT 12/18/2002 TWO HR FUEL OIL #2 (10 GAL) AST UNCLASSIFIED 
MAPPED 3-0022478 NO LOCATION AID (COMMERCIAL) 563 TRAPELO RD BELMONT 1/9/2003 TWO HR GASOLINE (18 GAL); UNKNOWN 
CHEMICAL OF UNKNOWN TYPE (18 GAL) 
VEHICLE UNCLASSIFIED 
MAPPED 3-0001442 RIVERSIDE CAMBRIDGE 
GALLERIA 
88 FIRST ST CAMBRIDGE 7/15/1989 TWO HR UNKNOWN CHEMICAL OF UNKNOWN 
TYPE; CADMIUM (38 MG/KG) 
RAO 
MAPPED 3-0010005 CORNER OF HAMPSHIRE ST 
(COMMERCIAL) 
284 NORFOLK ST CAMBRIDGE 10/1/1993 72 HR FUEL OIL #6; FUEL OIL #6 (5600 MG/KG) UST RAO 
MAPPED 3-0010053 HERMAN BLDG #E53 
(COMMERCIAL) 
30 WADSWORTH ST CAMBRIDGE 10/6/1993 TWO HR PETROLEUM BASED OIL (65 GAL); 
PETROLEUM BASED OIL (85 GAL) 
PISTON RAO 
MAPPED 3-0010119 ACROSS FROM MUSEUM OF 
SCIENCE (STATE) 
OBRIEN HWY CAMBRIDGE 10/29/1993 TWO HR DIESEL FUEL (5000 GAL); FUEL OIL #2 
(200 GAL) 
PIPE; UST RAO 
MAPPED 3-0010139 CAMBRIDGE WATER DEPT 
(MUNICIPAL) 
250 FRESH POND PKWY CAMBRIDGE 11/3/1993 72 HR FUEL OIL #2; WASTE OIL (150 GAL) UNKNOWN RAO 
MAPPED 3-0010151 NO LOCATION AID (INDUSTRIAL; 
ROADWAY) 
324 RINDGE RD CAMBRIDGE 11/4/1993 TWO HR METHANE, DICHLORO- (55 GAL); 
METHANE, DICHLORO- (55 GAL) 
DRUMS; 
VEHICLE 
RAO 
MAPPED 3-0010162 DPW YARD (COMMERCIAL) 147 HAMPSHIRE ST CAMBRIDGE 11/8/1993 72 HR DIESEL FUEL (300 PPMV); GASOLINE (300 UST RAO 
PPM); DIESEL FUEL (100 PPM) 
MAPPED 3-0010176 BRISTON ARMS APTS 
(COMMERCIAL) 
247 GARDEN ST CAMBRIDGE 10/5/1993 TWO HR METHANE; UNKNOWN CHEMICAL OF 
TYPE - HAZARDOUS MATERIAL 
LANDFILL ADEQUATE REG 
MAPPED 3-0010267 NO LOCATION AID (COMMERCIAL) 320 BROADWAY CAMBRIDGE 10/1/1993 72 HR WASTE OIL (118 PPMV); FUEL OIL #2 (3.6 
PPMV) 
PIPE; UST TIER 2 
MAPPED 3-0010304 NO LOCATION AID (COMMERCIAL) 10-12 WENDALL ST CAMBRIDGE 12/14/1993 72 HR FUEL OIL #2 (50 PPMV); FUEL OIL #2 UST RAO 
MAPPED 3-0010338 SHELL SERVICE STATION 
(COMMERCIAL) 
820 MEMORIAL DR CAMBRIDGE 12/22/1993 72 HR WASTE OIL UST RAO 
MAPPED 3-0010374 GULF STATION #118517 
(COMMERCIAL) 
1725 MASSACHUSETTS 
AVE 
CAMBRIDGE 12/30/1993 72 HR FUEL OIL #2 PIPE TIER 2 
MAPPED 3-0010446 NEAR BENT ST (COMMERCIAL) 160 SECOND ST CAMBRIDGE 1/18/1994 72 HR FUEL OIL #2 (5 INCH); FUEL OIL #2 UST RAO 
MAPPED 3-0010490 REAR OF BLDG (COMMERCIAL; 
RESIDNTIAL; ROADWAY) 
2000 MASSACHUSETTS 
AVE 
CAMBRIDGE 1/29/1994 TWO HR FUEL OIL #2 (50 GAL); FUEL OIL #2 (300 
GAL) 
PIPE; UST RAO 
MAPPED 3-0010513 NO LOCATION AID (MUNICIPAL) 250 FRESH POND PKWY CAMBRIDGE 2/3/1994 TWO HR SILICATE(2-), HEXAFLUORO-, TANK RAO 
DIHYDROGEN (5 GAL); SILICATE(2-), 
HEXAFLUORO-, DIHYDROGEN (5 GAL) 
MAPPED 3-0010535 NO LOCATION AID (RESIDNTIAL) 343 CONCORD AVE CAMBRIDGE 9/20/1994 72 HR GASOLINE; ETHANE, 1,2-DICHLORO- UST RAO 
MAPPED 3-0010558 MT AUBURN HOSPITAL 330 MT AUBURN 
HOSPITAL 
CAMBRIDGE 10/1/1993 72 HR FUEL OIL #2 UST TIER 2 
MAPPED 3-0010567 ST PETERS CHURCH 100 CONCORD AVE CAMBRIDGE 10/1/1993 72 HR FUEL OIL #2 (21100 MG/KG) UST RAO 
MAPPED 3-0010568 NO LOCATION AID 64 MOULTON ST CAMBRIDGE 10/1/1993 72 HR FUEL OIL #2 (66000 MG/KG) UST RAO 
MAPPED 3-0010625 CAMBRIDGE WATER DEPT 
(MUNICIPAL) 
250 FRESH POND PKWY CAMBRIDGE 10/1/1993 TWO HR FUEL OIL #2 UST RTN CLOSED 
MAPPED 3-0010664 NO LOCATION AID (COMMERCIAL) 357-359 HURON AVE CAMBRIDGE 3/11/1994 TWO HR UNKNOWN CHEMICAL OF UNKNOWN UNKNOWN RAO 
TYPE; FUEL OIL #2 (28 MG/L); DIESEL 
FUEL; BTEX (0.06 MG/L) 
MAPPED 3-0010711 NO LOCATION AID (COMMERCIAL) 2055 MASS AVE CAMBRIDGE 3/21/1994 72 HR GASOLINE (205 PPMV); GASOLINE PIPE; UST TIER 2 
MAPPED 3-0010760 16 CHAUNCY ST CONDO ASSOC 
(RESIDNTIAL) 
16 CHAUNCY ST CAMBRIDGE 3/29/1994 TWO HR FUEL OIL #2 (1 INCH); PETROLEUM 
BASED OIL 
UST TIER 1C 
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MAPPED 3-0010805 NEVILLE NURSING HOME 650 CONCORD AVE CAMBRIDGE 4/6/1994 72 HR GASOLINE (158 PPMV); GASOLINE UST RAO 
MAPPED 3-0010823 HARVARD UNIVERSITY 
(COMMERCIAL) 
3 SACRAMENTO ST CAMBRIDGE 4/11/1994 TWO HR FUEL OIL #2 (60 GAL) PIPE; TANKER RAO 
MAPPED 3-0010876 NEAR INTERSECTION WITH 
CONCORD AVE (RESIDNTIAL) 
6 FALLON ST CAMBRIDGE 4/12/1994 TWO HR FUEL OIL #2 (300 GAL) AST RAO 
MAPPED 3-0010916 NO LOCATION AID (COMMERCIAL) 173 HARVEY ST CAMBRIDGE 4/26/1994 72 HR GASOLINE; FUEL OIL #2 (4460 PPM) UST RAO 
MAPPED 3-0010928 PAYNE ELEVATOR (INDUSTRIAL) 75 RICHDALE AVE CAMBRIDGE 4/28/1994 72 HR FUEL OIL #2 (50 PPMV); FUEL OIL #4 (91 
PPM) 
UST RAO 
MAPPED 3-0010952 NO LOCATION AID (COMMERCIAL; 
INDUSTRIAL) 
60 MOULTON ST CAMBRIDGE 5/4/1994 72 HR FUEL OIL #2 (200 PPMV); BENZENE, 1,3-
DIMETHYL- (6.4 PPB); BENZENE, 1,4-
DIMETHYL- (6.4 PPB); BENZENE, 1,2-
DIMETHYL (9.5 PPB); ETHENE, 
TRICHLORO- (5.5 PPB); TOTAL 
PETROLEUM HYDROCARBONS (TPH) 
(2000 PPM) 
UST RAO 
MAPPED 3-0011030 NO LOCATION AID (COMMERCIAL) 10 WARE ST CAMBRIDGE 5/8/1994 72 HR FUEL OIL #2 (750 PPM); FUEL OIL #2 (50 
PPMV) 
UST RAO 
MAPPED 3-0011077 GULF STA (COMMERCIAL) 1725 MASSACHUSETTS 
AVE 
CAMBRIDGE 6/2/1994 72 HR GASOLINE (1248 PPMV); GASOLINE (1248 
PPM) 
UST RTN CLOSED 
MAPPED 3-0011110 NO LOCATION AID (RESIDNTIAL) 20 GREY GARDENS 
WEST 
CAMBRIDGE 6/9/1994 72 HR FUEL OIL #2 (148 PPMV); FUEL OIL #2 UST RAO 
MAPPED 3-0011113 NO LOCATION AID 210 BENT ST CAMBRIDGE 6/10/1994 72 HR KEROSENE (160 PPMV); KEROSENE (160 
PPMV) 
UST RAO 
MAPPED 3-0011196 NO LOCATION AID (COMMERCIAL) 50 MOULTON ST CAMBRIDGE 6/23/1994 72 HR FUEL OIL #2 (102 PPMV); TOTAL UST RAO 
PETROLEUM HYDROCARBONS (TPH) (50 
PPM) 
MAPPED 3-0011198 NO LOCATION AID (COMMERCIAL) 60 LANDSDOWNE ST CAMBRIDGE 6/23/1994 72 HR FUEL OIL #2 UST RAO 
MAPPED 3-0011247 NO LOCATION AID (COMMERCIAL) 222 THIRD ST CAMBRIDGE 7/9/1994 72 HR FUEL OIL #2 (50 PPMV); DIESEL FUEL 
(22000 MG/KG) 
UST RAO 
MAPPED 3-0011319 FRESH POND MALL 185 ALEWIFE BROK 
PKWY 
CAMBRIDGE 7/16/1994 TWO HR UNKNOWN CHEMICAL OF UNKNOWN 
TYPE (10 GAL); UNKNOWN CHEMICAL OF 
UNKNOWN TYPE (30 GAL) 
ELEVATOR RAO 
MAPPED 3-0011325 @INTERSECTION OF HIGHLAND 
(RESIDNTIAL) 
395 BROADWAY CAMBRIDGE 7/19/1994 72 HR FUEL OIL #2 (150 PPMV); FUEL OIL #2 (30 
GAL) 
UST RAO 
MAPPED 3-0011334 CAMBRIDGE ELECTRIC CO 
(INDUSTRIAL; SEWER) 
46 BLACKSTONE ST CAMBRIDGE 7/20/1994 TWO HR FUEL OIL #6 (100 GAL); FUEL OIL #6 (150 
GAL) 
FUEL OIL; 
HEATER 
RAO 
MAPPED 3-0011341 NO LOCATION AID (COMMERCIAL) 1120 MASSACHUSETTS 
AVE 
CAMBRIDGE 7/22/1994 TWO HR AMMONIA GAS CYLIND RAO 
MAPPED 3-0011358 MIT POWER PLANT (INDUSTRIAL; 
SCHOOL) 
59 VASSAR ST CAMBRIDGE 7/26/1994 72 HR FUEL OIL #2 (0.5 INCH); FUEL OIL #6 (0.5 
INCH); FUEL OIL #6 
UST RAO 
MAPPED 3-0011533 B & M RAILROAD YARD 
(INDUSTRIAL) 
INDUSTRIAL PARK DR CAMBRIDGE 8/26/1994 72 HR UNKNOWN CHEMICAL OF UNKNOWN 
TYPE (1 INCH); FUEL OIL #2 (330000 
MG/KG) 
UNKNOWN TIER 2 
MAPPED 3-0011646 NO LOCATION AID (RESIDNTIAL) 21 LAKEVIEW AVE CAMBRIDGE 9/26/1994 72 HR FUEL OIL #2 (100 PPMV); FUEL OIL #2 UST RAO 
MAPPED 3-0011657 NO LOCATION AID (COMMERCIAL) 46 BLACKSTONE ST CAMBRIDGE 9/9/1994 72 HR DIESEL FUEL (50 PPMV); GASOLINE (50 UST RAO 
PPMV); GASOLINE; FUEL OIL #6 (50 
PPMV); FUEL OIL #6; FUEL OIL #2 
MAPPED 3-0011759 NO LOCATION AID 25-27 RESERVOIR ST CAMBRIDGE 10/21/1994 72 HR FUEL OIL #2 UST RAO 
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MAPPED/ 
NOT 
MAPPED RTN LOCATION AID ADDRESS TOWN  DATE CATEGORY MATERIALS SOURCES STATUS 
MAPPED 3-0011772 NO LOCATION AID (COMMERCIAL) 239 PROSPECT ST CAMBRIDGE 10/25/1994 72 HR GASOLINE (83 PPMV); UNKNOWN 
CHEMICAL OF TYPE - OIL (83.4 PPM) 
UST RAO 
MAPPED 3-0011809 NO LOCATION AID 28 DANA ST CAMBRIDGE 11/2/1994 72 HR FUEL OIL #2 (100 PPMV); FUEL OIL #2 UST RAO 
MAPPED 3-0012068 BRISTON ARMS APTS 
(RESIDNTIAL) 
247 GARDEN ST CAMBRIDGE 1/13/1995 TWO HR METHANE BURIED SW ADEQUATE REG 
MAPPED 3-0012193 @ HARVARD BOATHOUSE 245 MEMORIAL DR CAMBRIDGE 2/22/1995 TWO HR JET FUEL (100 GAL) CRASH; RAO 
(BOATHOUSE; WATERBODY) FUELTANK; 
HELICOPTER 
MAPPED 3-0012210 OFF CONNECTOR RD CORNER 
OF AMES COURT (COMMERCIAL) 
100 BROADWAY CAMBRIDGE 3/2/1995 72 HR GASOLINE (200 PPMV); UNKNOWN 
CHEMICAL OF TYPE - OIL (1820 PPM) 
UST RAO 
MAPPED 3-0012276 WISE POTATO CHIPS 
(COMMERCIAL) 
141 RINDGE AVE CAMBRIDGE 3/16/1995 72 HR GASOLINE (200 PPMV); GASOLINE UST RAO 
MAPPED 3-0012325 NO LOCATION AID (COMMERCIAL) 432 COLUMBIA ST CAMBRIDGE 3/30/1995 TWO HR UNKNOWN CHEMICAL OF TYPE - OIL (10 
GAL); FUEL OIL #6 (640 MG/KG) 
TRANSFORM RAO 
MAPPED 3-0012329 HARVARD UNIVERSITY MORSE 
HALL (SCHOOL) 
124 WALKER ST CAMBRIDGE 3/31/1995 TWO HR FUEL OIL #4 (30 GAL); FUEL OIL #4 (15 
GAL) 
FUELTANK RAO 
MAPPED 3-0012440 PORTION OF HARVARD 
UNIVERSITY (COMMERCIAL) 
870 MEMORIAL DR CAMBRIDGE 5/3/1995 72 HR FUEL OIL #2 (443 PPMV) UST RAO 
MAPPED 3-0012519 APARTMENT BUILDING 
(RESIDNTIAL) 
16-19A FOREST ST CAMBRIDGE 5/26/1995 72 HR FUEL OIL #2; TOTAL PETROLEUM 
HYDROCARBONS (TPH) 
UST RAO 
MAPPED 3-0012531 NO LOCATION AID (COMMERCIAL) 18-20 MOULTON ST CAMBRIDGE 5/31/1995 72 HR FUEL OIL #2 (300 PPMV) UST RAO 
MAPPED 3-0012611 NO LOCATION AID (COMMERCIAL) 615 CONCORD AVE CAMBRIDGE 6/23/1995 72 HR FUEL OIL #2 (130 PPMV); FUEL OIL #2 (180 
PPMV) 
UST RAO 
MAPPED 3-0012699 NO LOCATION AID (COMMERCIAL) 87 FAWCETT ST CAMBRIDGE 7/19/1995 72 HR FUEL OIL #2 (290 PPMV) UST RAO 
MAPPED 3-0012743 WOK EAST RESTAURANT 
(COMMERCIAL) 
645 CAMBRIDGE ST CAMBRIDGE 7/27/1995 TWO HR VEGETABLE OIL (110 GAL) RAO 
MAPPED 3-0012856 CAMBRIDGE BRANDS 
(COMMERCIAL) 
810 MAIN ST CAMBRIDGE 8/25/1995 TWO HR AMMONIA (40 GAL) AST; PIPE RAO 
MAPPED 3-0012881 FMR MIDLAND ROSS SITE 445 CONCORD AVE CAMBRIDGE 9/1/1995 72 HR ETHENE, TRICHLORO- (2500 ); UNKNOWN RTN CLOSED 
(COMMERCIAL) CHRYSENE (55000 ); TOTAL PETROLEUM 
HYDROCARBONS (TPH) (94000 MG/KG) 
MAPPED 3-0012885 NO LOCATION AID (COMMERCIAL; 
INDUSTRIAL) 
810 MAIN ST CAMBRIDGE 9/4/1995 TWO HR AMMONIA (50 LBS) PIPE RAO 
MAPPED 3-0012892 NO LOCATION AID (COMMERCIAL) 25 ACORN PARK CAMBRIDGE 9/6/1995 72 HR FUEL OIL #4 (142 PPMV) UST RAO 
MAPPED 3-0012966 HAVILAND CANDY INC 
(COMMERCIAL; INDUSTRIAL) 
134 CAMBRIDGE & FIRST 
STS 
CAMBRIDGE 9/23/1995 TWO HR AMMONIA (1991 LBS); AMMONIA (350 GAL) PIPE; UNKNOWN RAO 
MAPPED 3-0012975 NO LOCATION AID (COMMERCIAL) 281 BROADWAY CAMBRIDGE 9/27/1995 72 HR UNKNOWN CHEMICAL OF TYPE - OIL UST RAO 
MAPPED 3-0013105 U HAUL (COMMERCIAL) 849 MAIN ST CAMBRIDGE 11/1/1995 TWO HR FUEL OIL #2 (0.5 INCH) AST STMRET 
MAPPED 3-0013203 NO LOCATION AID (RESIDNTIAL) 351 VASSAR ST CAMBRIDGE 12/1/1995 72 HR FUEL OIL #2 (100 PPMV) UST RAO 
MAPPED 3-0013330 CAMBRIDGE HOUSING 
AUTHORITY (RESIDNTIAL) 
900 CAMBRIDGE ST CAMBRIDGE 1/13/1996 TWO HR FUEL OIL #4 (6 INCH) UST RAO 
MAPPED 3-0013335 JIMMYS FOREIGN AUTO 
(COMMERCIAL) 
2055 MASSACHUSETTS 
AVE 
CAMBRIDGE 1/17/1996 TWO HR FUEL OIL #2 (50 GAL) AST RAO 
MAPPED 3-0013599 YARD 7 RAIL FACILITY (RAIL 
SIDNG) 
EAST ST CAMBRIDGE 3/24/1996 TWO HR DIESEL FUEL (200 GAL) VEHICLE RAO 
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MAPPED/ 
NOT 
MAPPED RTN LOCATION AID ADDRESS TOWN  DATE CATEGORY MATERIALS SOURCES STATUS 
MAPPED 3-0013797 NO LOCATION AID (COMMERCIAL) 605 MT AUBURN ST CAMBRIDGE 5/21/1996 72 HR GASOLINE (287 PPM) UST TIER 2 
MAPPED 3-0013866 STAR MARKET PARKING LOT 
REAR (COMMERCIAL) 
699 MT AUBURN ST CAMBRIDGE 6/6/1996 TWO HR DIESEL FUEL (20 GAL) PIPE; VEHICLE RAO 
MAPPED 3-0013933 NO LOCATION AID (COMMERCIAL) 812 MEMORIAL DR CAMBRIDGE 6/25/1996 72 HR FUEL OIL #2 (0.5 INCH) UNKNOWN RAO 
MAPPED 3-0013987 HARRISON & LOYD 
(COMMERCIAL) 
80-88 TROWBRIDGE ST CAMBRIDGE 7/12/1996 72 HR FUEL OIL #2 (105 PPMV); FUEL OIL #2 (100 
PPMV) 
UST RAO 
MAPPED 3-0014055 NO LOCATION AID (COMMERCIAL) RIVER ST AND PUTNAM 
AVE 
CAMBRIDGE 7/29/1996 TWO HR FUEL OIL #2 (11 GAL); TOTAL 
PETROLEUM HYDROCARBONS (TPH) 
(1900 GAL) 
UST RAO 
MAPPED 3-0014168 NEAR MASS AVE (COMMERCIAL) 844 MAIN ST CAMBRIDGE 8/28/1996 72 HR GASOLINE (436 PPMV) UST STMRET 
MAPPED 3-0014217 GUEST QUARTERS HOTEL 
(WATERBODY) 
WESTERN AVE BRIDGE CAMBRIDGE 9/10/1996 TWO HR UNKNOWN CHEMICAL OF TYPE - OIL UNKNOWN DEF TIER 1B 
MAPPED 3-0014310 LOT (COMMERCIAL) RIVER & PUTNAM ST CAMBRIDGE 10/8/1996 72 HR FUEL OIL #2 (100 PPMV) UST RAO 
MAPPED 3-0014329 CAMBRIDGE AUTO CLINIC 
(COMMERCIAL; ROADWAY) 
297 CONCORD AVE CAMBRIDGE 10/14/1996 TWO HR GASOLINE (100 GAL) TANKER RAO 
MAPPED 3-0014637 NO LOCATION AID (COMMERCIAL) 1 KENDALL SQ CAMBRIDGE 12/17/1996 72 HR UNKNOWN CHEMICAL OF UNKNOWN UNKNOWN RAO 
TYPE (5.5 INCH); UNKNOWN CHEMICAL 
OF UNKNOWN TYPE 
MAPPED 3-0014643 RIVER STREET (COMMERCIAL) 44 BLACKSTONE ST CAMBRIDGE 12/19/1996 TWO HR FUEL OIL #6 (100 GAL) AST; PIPE; 
PUMP SEAL 
RAO 
MAPPED 3-0014698 POLE 18 (ROADWAY) 58-64 HIGHLAND ST CAMBRIDGE 1/7/1997 TWO HR UNKNOWN CHEMICAL OF TYPE - OIL (8 
GAL) 
TRANSFORM RAO 
MAPPED 3-0014706 NO LOCATION AID (COMMERCIAL) 287 PROSPECT ST CAMBRIDGE 1/8/1997 72 HR GASOLINE (7.5 INCH); PETROLEUM 
BASED OIL (0.5 INCH) 
UNKNOWN RTN CLOSED 
MAPPED 3-0014930 GREENLEAF BLDG (SCHOOL) 76 BRATTLE ST CAMBRIDGE 3/19/1997 TWO HR DIESEL FUEL (60 GAL); DIESEL FUEL (25 
GAL) 
VEHICLE RAO 
MAPPED 3-0014935 ATLANTIC PAPER BOX 
(COMMERCIAL) 
270 ALBANY ST CAMBRIDGE 3/21/1997 72 HR FUEL OIL #2 (120 PPMV); FUEL OIL #2 
(2500 MG/KG); FUEL OIL #4 (2500 MG/KG) 
UST RAO 
MAPPED 3-0015001 NO LOCATION AID (RESIDNTIAL) 169 CHILTON ST CAMBRIDGE 4/14/1997 TWO HR FUEL OIL #2 (70 GAL); FUEL OIL #2 (10 
GAL) 
AST RAO 
MAPPED 3-0015062 KENDALL TANK & BOILER 
(COMMERCIAL) 
275 THIRD ST CAMBRIDGE 5/1/1997 72 HR FUEL OIL #2 (14 INCH); FUEL OIL #2 (300 
MG/L) 
UNKNOWN RAO 
MAPPED 3-0015190 SCHOOL (SCHOOL) 74R FAYERWEATHER ST CAMBRIDGE 6/11/1997 72 HR UNKNOWN CHEMICAL OF TYPE - OIL (10 
PPM); BENZENE (2.5 PPM); TOTAL 
PETROLEUM HYDROCARBONS (TPH) 
UST RAO 
MAPPED 3-0015211 NO LOCATION AID (RESIDNTIAL) 8 FOLLEN ST CAMBRIDGE 6/16/1997 72 HR FUEL OIL #2 (114 PPMV); FUEL OIL #2 UST RAO 
MAPPED 3-0015243 KENDALL STATION (INDUSTRIAL) 265 FIRST ST CAMBRIDGE 6/25/1997 TWO HR FUEL OIL #6 (3000 GAL); FUEL OIL #6 
(5000 GAL) 
AST; PIPE RAO 
MAPPED 3-0015303 NO LOCATION AID (COMMERCIAL) 603 CONCORD AVE CAMBRIDGE 7/16/1997 72 HR WASTE OIL (438 PPMV); UNKNOWN 
CHEMICAL OF TYPE - OIL (438 PPM) 
UST TIER 2 
MAPPED 3-0015332 NO LOCATION AID (COMMERCIAL) 30 CAMBRIDGE PARK DR CAMBRIDGE 7/25/1997 72 HR FUEL OIL #2 (6 INCH); FUEL OIL #2 (8 
INCH) 
UNKNOWN RAO 
MAPPED 3-0015351 NO LOCATION AID (COMMERCIAL) 287 PROSPECT ST CAMBRIDGE 7/29/1997 72 HR GASOLINE UST RTN CLOSED 
MAPPED 3-0015367 CAMBRIDGE CHEVROLET 
(COMMERCIAL) 
275 FRESH POND PKWY CAMBRIDGE 7/31/1997 72 HR FUEL OIL #2 (140 PPMV) UST RAO 
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NOT 
MAPPED RTN LOCATION AID ADDRESS TOWN  DATE CATEGORY MATERIALS SOURCES STATUS 
MAPPED 3-0015448 MWRA PRISON PT INDUSTRIAL 
PARK RD (INDUSTRIAL) 
1 MONSIGNOR OBRIEN 
HWY 
CAMBRIDGE 8/20/1997 72 HR FUEL OIL #2; FUEL OIL #2 UST RTN CLOSED 
NOT 
MAPPED 
3-0015700 NO LOCATION AID (WATERBODY) MEMORIAL DR CAMBRIDGE 11/6/1997 TWO HR GASOLINE BOAT RAO 
MAPPED 3-0015765 MWRA  INDUSTRIAL PARK RD 
(STATE) 
1 MONSIGNER OBRIEN 
HWY 
CAMBRIDGE 11/26/1997 72 HR UNKNOWN CHEMICAL OF UNKNOWN 
TYPE (3.6 INCH); OIL (3.6 INCH) 
UST RTN CLOSED 
MAPPED 3-0015776 MDC (COMMERCIAL; RESIDNTIAL; 
STATE) 
751 MEMORIAL DR CAMBRIDGE 12/2/1997 72 HR FUEL OIL #2 (113 PPMV) UST RAO 
MAPPED 3-0015786 NO LOCATION AID (RESIDNTIAL) 48 KIRKLAND ST CAMBRIDGE 12/4/1997 72 HR FUEL OIL #2 (500 PPMV); FUEL OIL #2 (500 UST RAO 
PPMV) 
MAPPED 3-0016014 NO LOCATION AID (INDUSTRIAL) MILLERS RIVER CAMBRIDGE 11/16/1999 TWO HR OIL SETTLING; TANK DEF TIER 1B 
MAPPED 3-0016604 MT AUBURN SER STAT 
(COMMERCIAL) 
605 MT AUBURN ST CAMBRIDGE 3/17/1998 72 HR GASOLINE (30 INCH); OIL UST TIER 2 
MAPPED 3-0016710 NO LOCATION AID (COMMERCIAL) 200 CAMBRIDGE PARK 
DR 
CAMBRIDGE 4/17/1998 TWO HR ASBESTOS; ASBESTOS (1 LBS) UNKNOWN RAO 
MAPPED 3-0016735 REAR BIOCHEM BLDG 
(OPENSPACE; SCHOOL) 
7 DIVINITY AVE CAMBRIDGE 4/28/1998 TWO HR UNKNOWN CHEMICAL OF TYPE -
HAZARDOUS MATERIAL (3000 GAL); 
UNKNOWN CHEMICAL OF TYPE -
AST RAO 
HAZARDOUS MATERIAL 
MAPPED 3-0016739 CITY OF CAMBRIDGE (MUNICIPAL) 113 GARDEN ST CAMBRIDGE 4/30/1998 72 HR GASOLINE (186 PPMV); GASOLINE (112 
PPMV) 
UST RAO 
MAPPED 3-0016747 NO LOCATION AID (INDUSTRIAL) 315 VASSER ST CAMBRIDGE 5/1/1998 TWO HR UNKNOWN CHEMICAL OF TYPE - OIL (10 
GAL); UNKNOWN CHEMICAL OF TYPE -
OIL (20 GAL) 
TRANSFORM RAO 
MAPPED 3-0016793 FRESH POND ROTARY CONVERGENCE OF CAMBRIDGE 5/13/1998 TWO HR UNKNOWN CHEMICAL OF TYPE - OIL PIPE RAO 
(INDUSTRIAL) RTES 2 16 AND 3 (2100 GAL); UNKNOWN CHEMICAL OF 
TYPE - OIL (3000 GAL) 
MAPPED 3-0016878 CAMBRIDGE SAVINGS BANK 1960 MASSACHUSETTS CAMBRIDGE 6/4/1998 72 HR UNKNOWN CHEMICAL OF UNKNOWN UNKNOWN RTN CLOSED 
469500000N325400E AVE TYPE (15 INCH); FUEL OIL #2 (0.5 INCH) 
MAPPED 3-0016883 KENNEDY SQUARE (RESIDNTIAL; 
ROADWAY) 
CRAIGIE ST CAMBRIDGE 6/5/1998 TWO HR GASOLINE (10 GAL); DIESEL FUEL (80 
GAL) 
TANKER RAO 
MAPPED 3-0016997 ACCESS RD (RR TRACKS; 222 AND 224 ALBANY ST CAMBRIDGE 7/2/1998 TWO HR UNKNOWN CHEMICAL OF TYPE - OIL (40 UNKNOWN RAO 
SCHOOL) GAL) 
MAPPED 3-0017013 ADJACENT TO 12 GERRYS FRESH POND PKWY @ CAMBRIDGE 7/8/1998 TWO HR UNKNOWN CHEMICAL OF TYPE - OIL PIPE RAO 
LANDING (UTILITY) MT AUBURN ST (1400 GAL); UNKNOWN CHEMICAL OF 
TYPE - OIL (8316 GAL) 
MAPPED 3-0017107 B&M RAILROAD (INDUSTRIAL) WATER ST @ B&M RR 
YARD 
CAMBRIDGE 7/31/1998 TWO HR HYDROCHLORIC ACID (500 GAL) CAR; RR TANK RAO 
MAPPED 3-0017136 REAR SCISSOR LIFT 
(COMMERCIAL) 
87 CAMBRIDGEPARK DR CAMBRIDGE 8/10/1998 TWO HR UNKNOWN CHEMICAL OF UNKNOWN 
TYPE (10 GAL); DIESEL FUEL (10 GAL) 
AST; PIPE RAO 
MAPPED 3-0017214 BLACKSTONE STATION OUTFALL MEMORIAL DR @ RIVER CAMBRIDGE 8/25/1998 TWO HR OIL; LUBRICATING OIL (1 GAL) PIPE RAO 
(WATERBODY) ST 
MAPPED 3-0017229 NO LOCATION AID (COMMERCIAL) 30 CAMBRIDGEPARK DR CAMBRIDGE 8/28/1998 72 HR FUEL OIL #2 (330 PPMV) UST RAO 
MAPPED 3-0017273 CORNER OF MUNROE 303 THIRD ST CAMBRIDGE 9/10/1998 72 HR PETROLEUM BASED OIL (120 PPMV); UST RAO 
(COMMERCIAL) GASOLINE (100 PPMV); DIESEL FUEL (100 
PPMV) 
MAPPED 3-0017298 MAGAZINE BEACH VETERANS 
MEMORIAL POOL (STATE) 
MEMORIAL DR CAMBRIDGE 9/15/1998 TWO HR OIL (10 GAL); FUEL OIL #2 (10 GAL) UNKNOWN RAO 
193 

MAPPED/ 
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MAPPED 3-0017299 NO LOCATION AID (RESIDNTIAL) 38 MIDDLESEX ST CAMBRIDGE 9/20/1998 72 HR FUEL OIL #2; FUEL OIL #2 (11000 MG/KG); 
FUEL OIL #2 (24 MG/L) 
PIPE RAO 
MAPPED 3-0017455 NO LOCATION AID (COMMERCIAL) 10 NORTH POINT BLVD CAMBRIDGE 10/21/1998 72 HR UNKNOWN CHEMICAL OF UNKNOWN 
TYPE; GASOLINE (110 PPMV); DIESEL 
FUEL 
UST TIER 2 
MAPPED 3-0017637 NO LOCATION AID (COMMERCIAL) 60 ABERDEEN AVE CAMBRIDGE 11/25/1998 72 HR UNKNOWN CHEMICAL OF UNKNOWN FMR; UST RAO 
TYPE (24 INCH); FUEL OIL #6 (0.5 INCH); 
FUEL OIL #4 (0.5 INCH) 
MAPPED 3-0017750 BU BOATHOUSE CONSTRUCTION 619 MEMORIAL DR CAMBRIDGE 12/16/1998 TWO HR UNKNOWN CHEMICAL OF TYPE - OIL; OIL UNKNOWN RAO 
MAPPED 3-0017753 NO LOCATION AID (COMMERCIAL) 254 MASSACHUSETTS 
AVE 
CAMBRIDGE 12/18/1998 72 HR FUEL OIL #6 (6 INCH); FUEL OIL #6 (1.5 
INCH) 
UST TIER 2 
MAPPED 3-0017819 NO LOCATION AID (MUNICIPAL) 48 SIXTH ST CAMBRIDGE 1/5/1999 72 HR FUEL OIL #2 (118 PPMV); FUEL OIL #2 (121 UST RAO 
PPMV) 
MAPPED 3-0017884 NO LOCATION AID (SCHOOL) 38 OXFORD ST CAMBRIDGE 1/22/1999 TWO HR HYDROGEN PEROXIDE (H2O2) (5 GAL) 5 GAL PAIL RAO 
MAPPED 3-0018096 NO LOCATION AID (COMMERCIAL) 75 SIDNEY ST CAMBRIDGE 3/22/1999 TWO HR PETROLEUM BASED OIL (10 GAL); 
PETROLEUM BASED OIL (13 GAL) 
PIPE RAO 
MAPPED 3-0018133 RADCLIFFE QUAD ATLETIC 
BUILDING (SCHOOL) 
60 GARDEN ST CAMBRIDGE 3/29/1999 72 HR UNKNOWN CHEMICAL OF UNKNOWN 
TYPE (1 INCH) 
ELEVATOR; 
SYSTEM 
RAO 
MAPPED 3-0018161 NO LOCATION AID (ROADWAY) BINNEY & THIRD STS CAMBRIDGE 4/5/1999 TWO HR DIESEL FUEL (75 GAL); DIESEL FUEL (60 VEHICLE RAO 
GAL) 
MAPPED 3-0018261 NO LOCATION AID (COMMERCIAL) 975 MASSACHUSETTS 
AVE 
CAMBRIDGE 5/4/1999 72 HR GASOLINE (1000 PPMV); GASOLINE (100 
PPMV) 
UST RAO 
MAPPED 3-0018477 NO LOCATION AID (COMMERCIAL) 985 MEMORIAL DR CAMBRIDGE 7/2/1999 72 HR FUEL OIL #2 (138 PPMV); FUEL OIL #2 UST RAO 
MAPPED 3-0018479 NO LOCATION AID (RESIDNTIAL; 192 ELM ST CAMBRIDGE 7/6/1999 TWO HR UNKNOWN CHEMICAL OF TYPE - OIL (15 TRANSFORM RAO 
ROADWAY) GAL); UNKNOWN CHEMICAL OF TYPE -
OIL (13 GAL); 1,1'-BIPHENYL, CHLORO-
DERIVS. (130 MG/L); 1,1'-BIPHENYL, 
CHLORO-DERIVS. (131 PPM) 
MAPPED 3-0018656 NO LOCATION AID (COMMERCIAL) 1012 CAMBRIDGE PL CAMBRIDGE 8/18/1999 TWO HR PETROLEUM BASED OIL (30 GAL); 
PETROLEUM BASED OIL (10 GAL) 
PIPE; VEHICLE RAO 
MAPPED 3-0018804 NO LOCATION AID (COMMERCIAL) 15 CAMBRIDGE CTR CAMBRIDGE 9/28/1999 72 HR PETROLEUM BASED OIL (165 PPMV) UST RTN CLOSED 
MAPPED 3-0018884 BROADWAY (COMMERCIAL) 90 ELLERY ST CAMBRIDGE 10/26/1999 72 HR FUEL OIL #2 (116 PPMV); FUEL OIL #2 (100 
PPMV) 
UST RAO 
MAPPED 3-0019147 MIT (SCHOOL; UNIVERSITY) 304 VASSAR ST CAMBRIDGE 1/10/2000 TWO HR UNKNOWN CHEMICAL OF UNKNOWN 
TYPE (10 GAL); PETROLEUM BASED OIL 
(0.5 INCH) 
ELEVATOR RAO 
MAPPED 3-0019168 NO LOCATION AID (SCHOOL) 60 ALBANY ST CAMBRIDGE 1/16/2000 TWO HR FUEL OIL #6 (200 GAL); FUEL OIL #6 (100 
GAL) 
PIPE; UST RAO 
NOT 
MAPPED 
3-0019315 MYSTIC RIVER (WATERBODY) ALEWIFE BROOK CAMBRIDGE 2/24/2000 TWO HR OIL UNKNOWN RAO 
NOT 3-0019649 NO LOCATION AID (ROADWAY) CAMBRIDGE ST CAMBRIDGE 6/19/2000 TWO HR PETROLEUM BASED OIL (20 GAL); PIPE; VEHICLE RAO 
MAPPED UNKNOWN CHEMICAL OF UNKNOWN 
TYPE (20 GAL) 
MAPPED 3-0019837 HAVILAND CANDY INC 
(INDUSTRIAL) 
134 CAMBRIDGE ST CAMBRIDGE 8/15/2000 TWO HR AMMONIA; AMMONIA (10 LBS) PIPE; UNKNOWN RAO 
MAPPED 3-0019919 NO LOCATION AID (COMMERCIAL) 111 CHARLES ST CAMBRIDGE 9/8/2000 72 HR GASOLINE (800 PPMV); PETROLEUM 
BASED OIL (200 PPM) 
UST RAO 
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MAPPED 3-0020011 MIT  CORNER OF VASSAR AND 10 TO 40 VASSAR ST CAMBRIDGE 10/4/2000 TWO HR UNKNOWN CHEMICAL OF TYPE - UST RTN CLOSED 
MAIN STS (COMMERCIAL; HAZARDOUS MATERIAL (100 GAL); 
SCHOOL) KEROSENE (100 GAL) 
MAPPED 3-0020020 THIRD ST AND LINSKEY WAY 364 THIRD ST CAMBRIDGE 10/6/2000 TWO HR UNKNOWN CHEMICAL OF UNKNOWN FAILED; RTN CLOSED 
(COMMERCIAL; INDUSTRIAL; TYPE (5 GAL); OIL SYSTEM; 
WATERBODY) TREATMENT 
MAPPED 3-0020057 NEAR INTERSECTION OF 
HANCOCK AND HARVARD 
(COMMERCIAL) 
149 HANCOCK ST CAMBRIDGE 10/25/2000 TWO HR FUEL OIL #2 (10 GAL); FUEL OIL #2 (22 
GAL) 
PIPE RAO 
MAPPED 3-0020174 MASSACHUSETTS AVE 
(APARTMENTS; RESIDNTIAL) 
9 ELLERY ST CAMBRIDGE 12/3/2000 TWO HR FUEL OIL #2 (10 GAL); FUEL OIL #2 (20 
GAL) 
AST; UST RAO 
MAPPED 3-0020202 NO LOCATION AID (RESIDNTIAL) 20 HIGHLAND AVE CAMBRIDGE 12/8/2000 72 HR FUEL OIL #2 (230 PPMV); FUEL OIL #2 (230 UST RAO 
PPM) 
MAPPED 3-0020305 NSTAR ELECTRIC POWER EDMUNDS ST & MASS CAMBRIDGE 1/12/2001 TWO HR UNKNOWN CHEMICAL OF UNKNOWN TRANSFORM RAO 
SUBSTATION (RESIDNTIAL) AVE CORNER TYPE (40 GAL); UNKNOWN CHEMICAL OF 
UNKNOWN TYPE (20 GAL) 
MAPPED 3-0020315 NSTAR ELECTRIC POWER EDMUNDS ST & MASS CAMBRIDGE 1/13/2001 TWO HR UNKNOWN CHEMICAL OF UNKNOWN TRANSFORM RAO 
SUBSTATION (COMMERCIAL) AVE CORNER TYPE (35 GAL); UNKNOWN CHEMICAL OF 
UNKNOWN TYPE (70 GAL) 
MAPPED 3-0020317 SOUTH SIDE OF GILMORE 
BRIDGE (ROADWAY) 
CHARLESTOWN AVE CAMBRIDGE 1/16/2001 TWO HR FUEL OIL #6 (15 GAL); FUEL OIL #6 (15 
GAL) 
TANKER RAO 
MAPPED 3-0020321 DEPT OF PUBLIC WORKS 
(COMMERCIAL) 
147 HAMPSHIRE ST CAMBRIDGE 1/18/2001 TWO HR UNKNOWN CHEMICAL OF UNKNOWN 
TYPE (15 GAL); DIESEL FUEL (15 GAL) 
PIPE; 
SCHOOLBUS 
RAO 
MAPPED 3-0020346 CORNER CAMERON AND MASS 
AVE (COMMERCIAL) 
5 CAMERON AVE CAMBRIDGE 1/24/2001 TWO HR ETHENE, TETRACHLORO-; ETHENE, 
TETRACHLORO- (87.5 GAL) 
UNKNOWN RTN CLOSED 
MAPPED 3-0020386 NO LOCATION AID (COMMERCIAL) 265 FIRST ST CAMBRIDGE 2/12/2001 TWO HR SULFURIC ACID (5 GAL); SULFURIC ACID 
(20 GAL) 
AST; PIPE RAO 
MAPPED 3-0020420 CORNER OF DUDLEY ST 2366 MASSACHUSETTS CAMBRIDGE 2/22/2001 TWO HR UNKNOWN CHEMICAL OF UNKNOWN VEHICLE RAO 
(ROADWAY) AVE TYPE (12 GAL); DIESEL FUEL (15 GAL) 
MAPPED 3-0020577 SUNOCO (COMMERCIAL) 515 CONCORD AVE CAMBRIDGE 4/6/2001 TWO HR PETROLEUM BASED OIL (40 GAL); PIPE RTN CLOSED 
UNKNOWN CHEMICAL OF UNKNOWN 
TYPE 
MAPPED 3-0020609 AT CORNER OF HARVARD ST 
(COMMERCIAL) 
191 TO 193 WINDSOR ST CAMBRIDGE 4/20/2001 TWO HR FUEL OIL #2; WASTE OIL (477 PPM) UST RAO 
MAPPED 3-0020736 US PETROLEUM GAS STATION 
(COMMERCIAL) 
297 CONCORD AVE CAMBRIDGE 5/25/2001 72 HR GASOLINE (340 PPMV) UST TIER 2 
MAPPED 3-0020744 NO LOCATION AID (COMMERCIAL) 820 MEMORIAL DR CAMBRIDGE 5/29/2001 TWO HR UNKNOWN CHEMICAL OF UNKNOWN TIER 2 
TYPE (10 GAL); UNKNOWN CHEMICAL OF 
UNKNOWN TYPE 
MAPPED 3-0020881 SIDNEY ST 70 PACIFIC ST CAMBRIDGE 7/6/2001 TWO HR DIESEL FUEL (50 GAL); DIESEL FUEL (30 
GAL) 
VEHICLE RAO 
MAPPED 3-0020988 NSTAR STA (INDUSTRIAL) TERMINAL RD CAMBRIDGE 8/9/2001 TWO HR UNKNOWN CHEMICAL OF TYPE - OIL PIPE RAO 
(1000 GAL); UNKNOWN CHEMICAL OF 
UNKNOWN TYPE (1700 GAL) 
MAPPED 3-0021004 LOADING DOCK ON BLANCHE ST 
(COMMERCIAL; INDUSTRIAL) 
38 SIDNEY ST CAMBRIDGE 8/16/2001 TWO HR SODIUM HYDROXIDE (55 LBS) DRUMS RAO 
MAPPED 3-0021097 NO LOCATION AID (RESIDNTIAL) 325-345 FRANKLIN ST CAMBRIDGE 9/20/2001 72 HR UNKNOWN CHEMICAL OF UNKNOWN UST RAO 
TYPE (282 PPMV); UNKNOWN CHEMICAL 
OF UNKNOWN TYPE (282 MG/KG) 
MAPPED 3-0021252 NO LOCATION AID (INDUSTRIAL) 125 BROOKLINE ST CAMBRIDGE 11/15/2001 72 HR PETROLEUM BASED OIL (8.5 INCH) UNKNOWN UNCLASSIFIED 
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MAPPED 3-0021256 NO LOCATION AID (ROADWAY; 
STATE) 
MEMORIAL DR AT MASS 
AVE 
CAMBRIDGE 11/15/2001 TWO HR PETROLEUM BASED OIL (20 GAL) VEHICLE RAO 
MAPPED 3-0021265 MIT (COMMERCIAL; SCHOOL) 60 ALBANY ST CAMBRIDGE 11/25/2001 TWO HR FUEL OIL #6 (60 GAL); FUEL OIL #6 (60 PIPE; PUMP RAO 
GAL) 
MAPPED 3-0021556 N42 DEGREES E71 DEGREES 
(INDUSTRIAL) 
87 CAMBRIDGE PARK DR CAMBRIDGE 3/8/2002 TWO HR UNKNOWN CHEMICAL OF UNKNOWN 
TYPE (75 GAL); DIESEL FUEL (30 GAL) 
AST RAO 
MAPPED 3-0021574 HARVARD U  OXFORD ST 
PLAYGROUND (OPENSPACE) 
FRANCES AVE CAMBRIDGE 3/14/2002 TWO HR ARSENIC (46 PPM); ARSENIC (48 MG/KG); 
LEAD (550 MG/KG) 
UNKNOWN RAO 
MAPPED 3-0021751 NECCO (INDUSTRIAL) 254 MASSACHUSETTS 
AVE 
CAMBRIDGE 5/12/2002 TWO HR AMMONIA; AMMONIA (571 LBS); OIL PIPE RAO 
MAPPED 3-0021939 ELECTRICAL SERVICE BAY 320 CHARLES ST CAMBRIDGE 7/15/2002 TWO HR UNKNOWN CHEMICAL OF UNKNOWN TRANSFORM RAO 
FACING BENT ST (COMMERCIAL) TYPE (50 GAL); UNKNOWN CHEMICAL OF 
TYPE - OIL (100 GAL) 
MAPPED 3-0021947 EDMUNDS ST (COMMERCIAL) 2485 MASS AVE CAMBRIDGE 7/18/2002 72 HR PETROLEUM BASED OIL (12 INCH); 
PETROLEUM BASED OIL (13.56 INCH) 
UNKNOWN UNCLASSIFIED 
MAPPED 3-0022002 WEST OF MT. AUBURN HOSPITAL 
(STATE; WATERBODY) 
GERRYS LANDING ROAD CAMBRIDGE 8/6/2002 TWO HR UNKNOWN CHEMICAL OF TYPE - OIL 
(2200 GAL); MINERAL OIL (10000 GAL) 
PIPE UNCLASSIFIED 
MAPPED 3-0022050 NO LOCATION AID (ROADWAY) 2192 MASS AVE CAMBRIDGE 8/25/2002 TWO HR DIESEL FUEL (100 GAL) VEHICLE UNCLASSIFIED 
MAPPED 3-0022080 NO LOCATION AID (COMMERCIAL) 148 SYDNEY ST CAMBRIDGE 9/6/2002 72 HR FUEL OIL #2 (100 PPMV); FUEL OIL #2 (18 
INCH); OIL (18 INCH) 
UST UNCLASSIFIED 
MAPPED 3-0022116 NO LOCATION AID (RESIDNTIAL) 66 HOMER AVE CAMBRIDGE 9/17/2002 72 HR FUEL OIL #2 (286 PPMV); TOTAL UST UNCLASSIFIED 
PETROLEUM HYDROCARBONS (TPH) 
(286 MG/KG) 
MAPPED 3-0022185 NO LOCATION AID (COMMERCIAL) WHEELER ST AND RTE 2 CAMBRIDGE 10/5/2002 TWO HR UNKNOWN CHEMICAL OF UNKNOWN 
TYPE (2000 GAL); MINERAL OIL (1500 
GAL) 
PIPE UNCLASSIFIED 
MAPPED 3-0022270 NO LOCATION AID (COMMERCIAL) 740 TO 770 MAIN ST CAMBRIDGE 11/1/2002 72 HR FUEL OIL #2 (100 PPMV); FUEL OIL #6 (100 
PPMV) 
UST RAO 
MAPPED 3-0022369 NO LOCATION AID (COMMERCIAL) 2505 MASSACHUSETTS CAMBRIDGE 12/6/2002 72 HR PETROLEUM BASED OIL (3 INCH); UST UNCLASSIFIED 
AVE UNKNOWN CHEMICAL OF TYPE -
HAZARDOUS MATERIAL (3 INCH) 
MAPPED 3-0022376 NO LOCATION AID (COMMERCIAL) 127 SMITH PLACE CAMBRIDGE 12/10/2002 TWO HR FUEL OIL #2 (20 GAL); FUEL OIL #2 (13300 AST UNCLASSIFIED 
MG/KG) 
MAPPED 3-0022441 HARVARD UNIV (SCHOOL) 1737 CAMBRIDGE ST CAMBRIDGE 1/2/2003 TWO HR FUEL OIL #2; FUEL OIL #6 (30 GAL) UST UNCLASSIFIED 
MAPPED 3-0022509 WR GRACE (COMMERCIAL; 
INDUSTRIAL) 
62 WHITTEMORE AVE CAMBRIDGE 1/22/2003 TWO HR ASBESTOS BURIED ACM UNCLASSIFIED 
MAPPED 3-0022639 BLDG 15 (COMMERCIAL) 15 ACORN PARK CAMBRIDGE 3/3/2003 TWO HR FUEL OIL #4 (200 GAL) PIPE UNCLASSIFIED 
MAPPED 3-0022673 SUNOCO (COMMERCIAL) 266 MASSACHUSETTS 
AVE 
CAMBRIDGE 3/14/2003 TWO HR GASOLINE (15 GAL) PIPE UNCLASSIFIED 
MAPPED 3-0022752 HARVARD UNIVERSITY (SCHOOL) 29 GARDEN ST CAMBRIDGE 4/7/2003 72 HR OIL UNKNOWN UNCLASSIFIED 
MAPPED 3-0010080 GETTY SERVICE STATION 
(COMMERCIAL) 
110 GALEN ST WATERTOWN 10/21/1993 72 HR WASTE OIL; UNKNOWN CHEMICAL OF 
TYPE - OIL (0.1 GAL) 
UNKNOWN TIER 2 
MAPPED 3-0010154 SUNOCO SERVICE STATION 
(COMMERCIAL) 
170 GALEN ST WATERTOWN 11/5/1993 72 HR FUEL OIL #2 (50 PPMV); GASOLINE (50 
PPMV); WASTE OIL (50 PPMV); 
UNKNOWN CHEMICAL OF TYPE - OIL 
UST TIER 2 
(1133 PPM) 
MAPPED 3-0010381 BOSTON EDISON SERVICE 
CENTER (COMMERCIAL) 
480 ARSENAL ST WATERTOWN 12/30/1993 72 HR OIL (0.48 INCH); UNKNOWN CHEMICAL OF 
TYPE - OIL 
UNKNOWN RAO 
MAPPED 3-0010461 US ARMY RESEARCH LAB 
(INDUSTRIAL) 
WATERTOWN ARSENAL WATERTOWN 1/19/1994 TWO HR FUEL OIL #6 (50 GAL) PIPE RAO 
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MAPPED 3-0010598 MJ ROLLIE (COMMERCIAL) 56 IRVING ST WATERTOWN 2/18/1994 TWO HR UNKNOWN CHEMICAL OF TYPE - OIL (13 
GAL); PETROLEUM BASED OIL (17.9 GAL) 
DRUMS RAO 
MAPPED 3-0011565 INTERSECTION OF N BEACON AND WATERTOWN 9/6/1994 TWO HR PETROLEUM BASED OIL (1200 GAL); PIPE; UST TIER 2 
(COMMERCIAL) ARSENAL ST UNKNOWN CHEMICAL OF TYPE - OIL 
(1226 GAL) 
MAPPED 3-0011799 OFF AUBURN ST ROUTE 16 REAR 30 WASHBURN ST WATERTOWN 10/26/1994 72 HR OIL (1.5 INCH); UNKNOWN CHEMICAL OF AST; DRUMS; TIER 2 
OF BUILDING (COMMERCIAL) UNKNOWN TYPE FUELTANK; 
PIPE; UST 
MAPPED 3-0011882 GAS STATION 22084720303 ON 
ROUTE 20 (COMMERCIAL) 
448 MAIN ST WATERTOWN 11/22/1994 72 HR GASOLINE (280 PPMV); GASOLINE (360 
PPM) 
UST RAO 
MAPPED 3-0012009 NO LOCATION AID (RESIDNTIAL) 31 BACON ST WATERTOWN 12/27/1994 TWO HR FUEL OIL #2 (50 GAL); FUEL OIL #2 (200 
PPM) 
AST RAO 
MAPPED 3-0012132 FMR WATERTOWN ARSENAL ARSENAL ST WATERTOWN 2/3/1995 TWO HR ARSENIC (66 MG/KG); ARSENIC (30 UNKNOWN TIER 1C 
NOW ARSENAL PARK (FEDERAL) MG/KG); ACENAPHTHYLENE, 1,2-
DIHYDRO (3.1 UG/G); 
BENZ[A]ANTHRACENE (1.3 UG/G); 
BENZO(K)FLUORANTHENE (12 UG/G); 
BENZ[E]ACEPHENANTHRYLENE (13 
UG/G); BENZO[A]PYRENE (9.8 UG/G); 
CHRYSENE (11 UG/G); INDENO(1,2,3-
CD)PYRENE (3 3 UG 
MAPPED 3-0012488 UST AREA (COMMERCIAL; 29 BRIDGE ST REAR WATERTOWN 5/18/1995 72 HR FUEL OIL #4 (100 PPMV); FUEL OIL #4 UST RAO 
INDUSTRIAL) 
MAPPED 3-0012808 NO LOCATION AID (INDUSTRIAL) 480 ARSENAL ST WATERTOWN 10/4/1995 TWO HR UNKNOWN CHEMICAL OF UNKNOWN 
TYPE (18 GAL) 
PIPE RAO 
MAPPED 3-0012861 NO LOCATION AID (INDUSTRIAL) 405 ARSENAL ST WATERTOWN 8/29/1995 TWO HR MERCURY (3 LBS) GAUGE RAO 
MAPPED 3-0012996 CROSS ST ROSEDALE RD 
(COMMERCIAL) 
380 PLEASANT ST WATERTOWN 10/2/1995 72 HR CUTTING OIL (1.75 INCH) UNKNOWN TIER 2 
MAPPED 3-0013088 NYNEX CENTRAL OFFICE 143 WALNUT ST WATERTOWN 10/26/1995 72 HR KEROSENE (160 PPMV) UST RAO 
(COMMERCIAL) 
MAPPED 3-0013339 WET OF SCHOOL ST 
(COMMERCIAL) 
314 ARSENAL ST WATERTOWN 1/18/1996 72 HR UNKNOWN CHEMICAL OF TYPE - OIL (120 
PPMV) 
UST RAO 
MAPPED 3-0013746 NO LOCATION AID (COMMERCIAL) 70-80 GROVE ST WATERTOWN 5/10/1996 72 HR PETROLEUM BASED OIL (18 INCH); FUEL 
OIL #6 
UNKNOWN RTN CLOSED 
MAPPED 3-0013776 NO LOCATION AID (COMMERCIAL) 74 ACTON ST WATERTOWN 5/17/1996 72 HR FUEL OIL #2; FUEL OIL #4; FUEL OIL #6; 
PETROLEUM BASED OIL (100 PPM) 
UST RTN CLOSED 
MAPPED 3-0014273 ARSENAL PARK (OPENSPACE) 455-663 ARSENAL ST WATERTOWN 9/25/1996 TWO HR ARSENIC (209 PPMV); ARSENIC (181 UNKNOWN RTN CLOSED 
MG/KG) 
MAPPED 3-0014713 ARSENAL MALL (COMMERCIAL) 485 ARSENAL ST WATERTOWN 1/9/1997 TWO HR 1,1'-BIPHENYL, CHLORO-DERIVS. (15 
PPMV); 1,1'-BIPHENYL, CHLORO-DERIVS. 
(15 PPM) 
UNKNOWN RTN CLOSED 
MAPPED 3-0015315 SCARBOROUGHT REALTY TRUST 
(COMMERCIAL) 
20 BRIDGE ST WATERTOWN 7/18/1997 72 HR OIL (8 INCH); FUEL OIL #4 (0.5 INCH) UST RTN CLOSED 
MAPPED 3-0015418 GETTY SER STA (COMMERCIAL) 110 GALEN ST WATERTOWN 8/14/1997 72 HR GASOLINE (260 PPMV) UST RTN CLOSED 
MAPPED 3-0015541 BLDG 60 (FEDERAL) 395 ARSENAL ST WATERTOWN 9/18/1997 TWO HR DIESEL FUEL (125 GAL); DIESEL FUEL 
(100 GAL) 
DRUMS RAO 
MAPPED 3-0015590 YACHT CLUB (COMMERCIAL) 425 CHARLES RIVER RD WATERTOWN 10/3/1997 72 HR GASOLINE (450 PPMV); GASOLINE (100 
PPMV) 
UST RAO 
MAPPED 3-0015600 NO LOCATION AID (RESIDNTIAL) 27 CAREY AVE WATERTOWN 10/7/1997 72 HR FUEL OIL #2 (245 PPMV); FUEL OIL #2 (245 
PPMV) 
UST RAO 
MAPPED 3-0015763 NO LOCATION AID (COMMERCIAL) 656 MAIN ST WATERTOWN 11/26/1997 72 HR GASOLINE (100 PPMV); GASOLINE (180 
PPMV); NAPHTHALENE (25 PPM) 
UST RAO 
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MAPPED 3-0015785 MAIN ST (RESIDNTIAL) 86-88 EDENFIELD AVE WATERTOWN 12/4/1997 TWO HR FUEL OIL #2 (100 GAL); FUEL OIL #2 (120 
GAL) 
AST RAO 
MAPPED 3-0016549 STOP AND SHOP (COMMERCIAL) 700 PLEASANT ST WATERTOWN 2/27/1998 TWO HR UNKNOWN CHEMICAL OF UNKNOWN PIPE; RAO 
TYPE (10 GAL); UNKNOWN CHEMICAL OF UNKNOWN; 
UNKNOWN TYPE (20 GAL) VEHICLE 
NOT 
MAPPED 
3-0016569 OUTFALL #12 (WATERBODY) CHARLES RIVER RD WATERTOWN 3/7/1998 TWO HR UNKNOWN CHEMICAL OF TYPE - OIL RAO 
MAPPED 3-0016601 COOLIDGE SQ SERVICE  
MELENDY AVE (COMMERCIAL) 
575 TO 577 MT AUBURN 
ST 
WATERTOWN 3/16/1998 72 HR DIESEL FUEL (410 PPMV); GASOLINE (410 
PPMV) 
UST RTN CLOSED 
MAPPED 3-0016607 42 AND 47 MAIN ST 
(COMMERCIAL; RESIDNTIAL) 
MAIN ST AT BECO 
MANHOLE 3706 
WATERTOWN 3/18/1998 TWO HR DIESEL FUEL (30 GAL); DIESEL FUEL (20 
GAL) 
BUS FUEL; TANK RAO 
MAPPED 3-0016821 BETWEEN BRIDGE AND SEYON 555 PLEASANT ST WATERTOWN 5/18/1998 TWO HR AMMONIA (17 LBS); AMMONIA (26 LBS) PIPE RAO 
STS (COMMERCIAL) 
MAPPED 3-0017084 NO LOCATION AID (COMMERCIAL) 64 GROVE ST WATERTOWN 7/24/1998 72 HR FUEL OIL #2 (100 PPMV); FUEL OIL #2 (100 
PPMV) 
UST RAO 
MAPPED 3-0017393 ROUTE 20 (ROADWAY) MAIN & MIDDLE @ WATERTOWN 10/8/1998 TWO HR UNKNOWN CHEMICAL OF UNKNOWN VEHICLE RAO 
WATERTOWN SQ TYPE (10 GAL); UNKNOWN CHEMICAL OF 
UNKNOWN TYPE (70 GAL) 
MAPPED 3-0017443 NO LOCATION AID (RESIDNTIAL) 10-12 HUNT ST WATERTOWN 10/16/1998 TWO HR FUEL OIL #2 (250 GAL); FUEL OIL #2 (250 AST RAO 
GAL) 
MAPPED 3-0017528 NO LOCATION AID (COMMERCIAL) 60 TO 70 NORTH 
BEACON ST 
WATERTOWN 11/5/1998 72 HR GASOLINE (130 PPMV); GASOLINE (135 
PPM) 
UST RTN CLOSED 
MAPPED 3-0017608 BARDON TRIMOUNT 105 COOLIDGE HILL RD WATERTOWN 11/20/1998 72 HR UNKNOWN CHEMICAL OF UNKNOWN UST RAO 
(COMMERCIAL) TYPE (310 PPMV); DIESEL FUEL (315 
PPMV) 
MAPPED 3-0017620 NO LOCATION AID (COMMERCIAL) 626 ARSENAL ST WATERTOWN 11/23/1998 72 HR GASOLINE (1120 PPMV); UNKNOWN 
CHEMICAL OF TYPE - OIL (1170 PPMV) 
UST RAO 
MAPPED 3-0017672 INTERSECTION WITH PATTEN ST 76 ARSENAL ST WATERTOWN 12/3/1998 72 HR FUEL OIL #2 (180 PPMV); OIL (226 PPMV) UST TIER 2 
(COMMERCIAL) 
MAPPED 3-0017719 BOSTON EDISON COMPANY 480 ARSENAL ST WATERTOWN 12/10/1998 72 HR UNKNOWN CHEMICAL OF UNKNOWN UST RAO 
(COMMERCIAL) TYPE (400 PPMV); DIESEL FUEL (373 
PPM) 
MAPPED 3-0017833 A RUSSO & SONS INC 
(COMMERCIAL) 
560 PLEASANT ST WATERTOWN 1/7/1999 TWO HR UNKNOWN CHEMICAL OF UNKNOWN 
TYPE (20 GAL); DIESEL FUEL (20 GAL) 
SADDLETNK; 
VEHICLE 
RAO 
MAPPED 3-0017896 FMR EXXON (COMMERCIAL) 14 ARSENAL 11 TO 13 MT 
AUBURN 
WATERTOWN 1/22/1999 72 HR GASOLINE (513 PPMV); GASOLINE (212 
PPMV) 
UNKNOWN RAO 
MAPPED 3-0017958 NO LOCATION AID (COMMERCIAL) 14 ARSENAL 11 TO 13 MT WATERTOWN 2/8/1999 TWO HR GASOLINE; UNKNOWN CHEMICAL OF UST RAO 
AUBURN UNKNOWN TYPE 
MAPPED 3-0017982 NO LOCATION AID (COMMERCIAL) 480 ARSENAL ST WATERTOWN 2/12/1999 TWO HR UNKNOWN CHEMICAL OF UNKNOWN 
TYPE (10 GAL) 
TRANSFORM RAO 
MAPPED 3-0018144 EVERETT AVE (RESIDNTIAL) 194 PALFREY ST WATERTOWN 6/9/1999 TWO HR FUEL OIL #2 (100 GAL); PETROLEUM 
BASED OIL (150 GAL) 
AST RAO 
MAPPED 3-0018308 AT TAYLOR ST (COMMERCIAL) 49 TO 59 MT AUBURN ST WATERTOWN 5/17/1999 72 HR PETROLEUM BASED OIL (16 INCH); 
PETROLEUM BASED OIL 
UST RTN CLOSED 
MAPPED 3-0018471 BIGELOW AVE (COMMERCIAL) 631 MT AUBURN ST WATERTOWN 7/1/1999 72 HR UNKNOWN CHEMICAL OF UNKNOWN UNKNOWN TIER 2 
TYPE (12 INCH); ACENAPHTHYLENE, 1,2-
DIHYDRO (51 MG/KG); 2-
METHYLNAPHTHALENE (131 MG/KG); 
NAPHTHALENE (8.8 MG/KG) 
MAPPED 3-0018590 14 ARSENAL ST (COMMERCIAL) 11 TO 13 MT AUBURN ST WATERTOWN 8/4/1999 TWO HR GASOLINE UST RTN CLOSED 
MAPPED 3-0018592 CONSTRUCTION SITE 
(COMMERCIAL) 
9 GALEN ST WATERTOWN 8/4/1999 72 HR GASOLINE (1300 PPMV) UST RAO 
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MAPPED 3-0018860 HIGH SCHOOL (SCHOOL) 50 COLUMBIA ST WATERTOWN 10/19/1999 TWO HR FUEL OIL #2 (100 GAL); FUEL OIL #2 (100 
GAL) 
PIPE RAO 
MAPPED 3-0018876 BIGELOW AVE (COMMERCIAL) 631 MT AUBURN ST WATERTOWN 10/25/1999 72 HR FUEL OIL #2 (100 PPMV); FUEL OIL #2 (100 UST RTN CLOSED 
PPMV) 
MAPPED 3-0018880 ORCHARD ST (COMMERCIAL) 917 BELMONT ST WATERTOWN 10/25/1999 TWO HR DIESEL FUEL (150 GAL); DIESEL FUEL 
(100 GAL) 
VEHICLE RAO 
MAPPED 3-0019013 NO LOCATION AID (COMMERCIAL) 75 NORTH BEACON ST WATERTOWN 11/29/1999 72 HR GASOLINE (192 PPMV); GASOLINE (100 
PPMV) 
UST RAO 
MAPPED 3-0019344 ARSENAL PARK (COMMERCIAL) ARSENAL ST WATERTOWN 3/9/2000 TWO HR ASBESTOS ASBESTOS; 
PIPE 
DEF TIER 1B 
MAPPED 3-0019544 NEAR NONANTUM RD 
(COMMERCIAL) 
2 GALEN ST WATERTOWN 5/15/2000 72 HR FUEL OIL #2 (2 INCH); UNKNOWN 
CHEMICAL OF TYPE - OIL (2 INCH) 
UST TIER 2 
MAPPED 3-0019625 INTERSECT WITH WILLIAMS ST 
(COMMERCIAL) 
170 GALEN ST WATERTOWN 6/14/2000 72 HR UNKNOWN CHEMICAL OF TYPE - OIL (29 
PPM); GASOLINE 
UNKNOWN RTN CLOSED 
MAPPED 3-0019683 NO LOCATION AID (OPENSPACE) 158 WALTHAM ST WATERTOWN 4/11/2002 72 HR GASOLINE (2000 PPMV); GASOLINE (100 
PPM) 
UST RAO 
MAPPED 3-0019698 NO LOCATION AID (COMMERCIAL) 76 ARSENAL ST WATERTOWN 7/7/2000 72 HR OIL (6 INCH) UNKNOWN RTN CLOSED 
MAPPED 3-0020350 BIRCH ST PRIVATE 480 ARSENAL ST WATERTOWN 1/25/2001 72 HR NAPHTHALENE, 2-CHLORO- (300 PPMV); UST RAO 
(COMMERCIAL) UNKNOWN CHEMICAL OF TYPE - OIL (300 
PPM) 
MAPPED 3-0020433 BIRCH ST PRIVATE 
(COMMERCIAL) 
480 ARSENAL ST WATERTOWN 3/2/2001 TWO HR FUEL OIL #6 (60 GAL); UNKNOWN 
CHEMICAL OF UNKNOWN TYPE (60 GAL) 
UST RAO 
MAPPED 3-0020501 WATERTOWN MALL REAR OF 550 ARSENAL ST WATERTOWN 3/20/2001 TWO HR UNKNOWN CHEMICAL OF TYPE - OIL (100 TRANSFORM RAO 
BEST BUY (COMMERCIAL) GAL); UNKNOWN CHEMICAL OF 
UNKNOWN TYPE (200 GAL) 
MAPPED 3-0020623 OFF BIRTH ST PRIVATE 
(COMMERCIAL) 
480 ARSENAL ST WATERTOWN 4/24/2001 72 HR GASOLINE (200 PPMV); UNKNOWN 
CHEMICAL OF TYPE - OIL (350 PPM) 
UST RAO 
MAPPED 3-0020765 OFF BIRCH ST PRIVATE 
(COMMERCIAL) 
480 ARSENAL ST WATERTOWN 6/6/2001 72 HR PETROLEUM BASED OIL; UNKNOWN 
CHEMICAL OF TYPE - OIL (350 PPM) 
UST RAO 
MAPPED 3-0020833 HIGH SCHOOL BOILER ROOM 
(WATERBODY) 
50 COLUMBIA ST WATERTOWN 6/23/2001 TWO HR FUEL OIL #2 (1000 GAL); FUEL OIL #2 (600 
GAL) 
PIPE RAO 
MAPPED 3-0021258 NO LOCATION AID (COMMERCIAL) 270 PLEASANT ST WATERTOWN 11/16/2001 72 HR FUEL OIL #6 (36 INCH); FUEL OIL #6 UST UNCLASSIFIED 
MAPPED 3-0021328 NO LOCATION AID (OPENSPACE) 30 CALIFORNIA ST WATERTOWN 12/12/2001 TWO HR PETROLEUM BASED OIL UNKNOWN RAO 
MAPPED 3-0021419 NO LOCATION AID (INDUSTRIAL) 58 IRVING ST WATERTOWN 1/23/2002 TWO HR FUEL OIL #2; FUEL OIL #2 (30 GAL) UST RAO 
MAPPED 3-0021509 NO LOCATION AID (RESIDNTIAL) 110 COOLIDGE HILL RD WATERTOWN 2/22/2002 72 HR PETROLEUM BASED OIL (18 INCH); OIL 
(18.72 INCH) 
UNKNOWN UNCLASSIFIED 
MAPPED 3-0021773 WATERTOWN YACHT CLUB 425 CHARLES RIVER RD WATERTOWN 5/20/2002 TWO HR UNKNOWN CHEMICAL OF TYPE - OIL; UNKNOWN RAO 
(WATERBODY) UNKNOWN CHEMICAL OF TYPE - OIL 
MAPPED 3-0021799 HESS STATION NO 21526 
(COMMERCIAL) 
NORTH BEACON & 
ARSENAL STS 
WATERTOWN 5/31/2002 72 HR GASOLINE (3 INCH) UST UNCLASSIFIED 
MAPPED 3-0021937 NO LOCATION AID (INDUSTRIAL) 58 IRVING ST WATERTOWN 7/15/2002 72 HR FUEL OIL #2 (0.05 GAL/HR); FUEL OIL #2 UST UNCLASSIFIED 
NOT 3-0022045 NO LOCATION AID (MUNICIPAL) ARSENAL ST WATERTOWN 8/22/2002 TWO HR UNKNOWN CHEMICAL OF UNKNOWN SADDLE; TANK UNCLASSIFIED 
MAPPED TYPE (20 GAL); UNKNOWN CHEMICAL OF 
UNKNOWN TYPE (30 GAL) 
MAPPED 3-0022172 NO LOCATION AID (RESIDNTIAL; CUSHMAN AND FAYETTE WATERTOWN 10/3/2002 TWO HR UNKNOWN CHEMICAL OF UNKNOWN TRANSFORM UNCLASSIFIED 
ROADWAY) STS TYPE (40 GAL); UNKNOWN CHEMICAL OF 
UNKNOWN TYPE (38 GAL) 
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NOT 
MAPPED 
3-0022685 NO LOCATION AID (STATE) SCHOOL ST E OF WATERTOWN 3/20/2003 TWO HR ARSENIC (190 PPM) UNKNOWN UNCLASSIFIED 
Source:  MDEP Bureau of Waste Site Cleanup. 2003.  Downloadable Site Lists.  http://www.state.ma.us/dep/bwsc/sites/sdown.htm (information contained in table is presented as downloaded). 
Notes: 
RTN - Release Tracking Number. Unique ID number assigned to releases not remediated by October 1993 and to those occuring October 1993-present 
Location Aid - Place name of release 
Address - Street location of release 
Date - Date of release (releases prior to October 1993), or date release was reported to MDEP (for releases occurring October 1993-present) 
Cateogory - Reporting category of release 
Materials - Chemical(s) in release 
Sources - Origin(s) of release contamination 
Status - Current remediation status of release. Definitions: ADQREG Adequately Regulated; DEFT1B Default Tier 1B; DEPMOU DEP Memorandum of Understanding; DEPNDS Not a Disposal Site 
(DEP); DEPNFA No Further Action (DEP Determined); DPS Downgradient Property Status; DPSTRM Downgradient Property Status Terminated; INVSUB Submittal Invalidated by DEP; LSPNFA LSP 
No Further Action; PENNDS Pending Not a Disposal Site; PENNFA Pending No Further Action; RAO Release Action Outcome; RAONR Response Action Outcome Not Required; REMOPS Remedy 
Operation Status; SPECPR Special Project; STMRET Response Action Outcome Statement Retracted; TCLASS Tier Classification; TIER1A Tier 1A; TIER1B Tier 1B; TIER1C Tier 1C; TIERII Tier II; 
UNCLSS Unclassified; WCSPRM Waiver Completion Statement Permanent. 
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Appendix B

Coding Definitions of Cancer Site/Type* 

Cancer Site / Type 
ICD-O-1 and Other  
Pre-ICD-O-2 Codes ICD-O-2 Codes 
Site code Histology code Site code Histology code 
Kidney and 
Renal Pelvis 
189.0, 189.1 except 9590– 
9980 
C64.9, C65.9 except 9590– 
9989 
Leukemia 140.0–199.9 includes 
O9800–O9943, 
O9951, 
P9803–P9943, 
B9803–B9943 
1. C00.0–C80.9 
and 
2. C42.0, C42.1, 
C42.4 
1. includes 
9800–9822, 
9824–9826, 
9828–9941 
2. includes 
9823, 9827 
Liver 155.0 except 9590– 
9980 
C22.0 except 9590– 
9989 
Lung and Bronchus 162.2–162.9 except 9050– 
9053, 9590–9980 
C34.0–C34.9 except 9590– 
9989 
Non-Hodgkin's 
Lymphoma (NHL) 
140.0–199.9 includes 
O9590–O9642, 
O9670–O9710, 
O9750, 
P9593–P9643, 
P9693–P9713, 
P9753, B9593– 
B9643, B9703 
1. C00.0–C80.9 
and 
2. All sites 
except C42.0, 
C42.1, C42.4 
1. includes 
9590–9595, 
9670–9717 
2. includes 
9823, 9827 
Pancreas 157.0–157.9 except 9590– 
9980 
C25.0–C25.9 except 9590– 
9989 
*Note: Includes invasive tumors only, selected by excluding in situ stages J0, S0, TTISNXM0, 
TTANXMX, TTANXM0, TTAN0MX, TTISN0M0, TTISNXMX, TTISN0MX, TTISN0M0, 
and TTIN0M0 (1982–1994 data) or by specifying behavior code (1995–1999 data). 
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Risk Factor Information for Kidney Cancer 
Kidney cancer involves a number of tumor types located in various areas of the kidney and renal system.  
Renal cell cancer (which affects the main area of the kidney) accounts for over 90% of all malignant 
kidney tumors (ACS 2006).  The American Cancer Society estimates that there will be approximately 
38,890 cases of kidney and upper urinary tract cancer, resulting in more than 12,840 deaths in 2006 (ACS 
2006).  Kidney cancer is twice as common in males as it is in females and the incidence most often occurs 
in individuals between 55 and 84 years of age (ACS 2006).  The gender distribution of this disease may 
be attributed to the fact that men are more likely to smoke and are more likely to be exposed to potentially 
carcinogenic chemicals at work. 
Since 1970, U.S. incidence rates for renal cell cancer have risen between 2% and 4% annually among the 
four major race and gender groups (i.e., white males, white females, black males, and black females) 
(Chow et al. 1999; McLaughlin et al. 1996).  Rapid increases in incidence among blacks as compared to 
among whites have resulted in an excess of the disease among blacks; age-adjusted incidence rates 
between 1975 and 1995 for white men, white women, black men, and black women were 9.6, 4.4, 11.1, 
and 4.9 per 100,000 person-years, respectively (Chow et al. 1999).  Rising incidence rates may be 
partially due to the increased availability of screening for kidney cancer. 
The etiology of kidney cancer is not fully understood.  However, a number of environmental, cellular, and 
genetic factors have been studied as possible causal factors in the development of renal cell carcinoma.  
Cigarette smoking is the most important known risk factor for renal cell cancer.  Smoking increases the 
risk of developing renal cell cancer by about 40% (ACS 2006).  In both males and females, a statistically 
significant dose-response relationship between smoking and this cancer has been observed (Yuan et al. 
1998). 
Virtually every study that has examined body weight and renal cell cancer has observed a positive 
association. Some studies suggest that obesity is a factor in 20% of people who develop kidney cancer 
(ACS 2006).  A diet high in protein (meat, animal fats, milk products, margarine and oils) has been 
implicated in epidemiological studies as a risk factor for renal cell carcinoma (McLaughlin et al. 1996).  
Consumption of adequate amounts of fruits and vegetables lowers the risk of renal cell cancer.  In 
addition, use of diuretics and antihypertensive medications are associated with increased risk of renal cell 
carcinoma.  However, hypertension has also been linked to kidney cancer and it is not clear whether the 
disease or the medications used to treat them is the cause (ACS 2000).  Long-term use of pain relievers 
such as phenacetin (and possibly acetaminophen and aspirin) increases the risk for cancer of the renal 
pelvis and renal cell carcinoma (McLaughlin et al. 1996). 
Certain medical conditions that affect the kidneys have also been shown to increase kidney cancer risk.  
There is an increased incidence of renal carcinoma in patients with end-stage renal disease who develop 
acquired cystic disease of the kidney.  This phenomenon is seen among patients on long-term dialysis for 
renal failure (Linehan et al. 1997). In addition, an association has been established between the incidence 
of von Hippel-Lindau disease and certain other inherited conditions in families and renal cell carcinoma, 
suggesting that genetic and hereditary risk factors may be important in the development of kidney cancer 
(ACS 2006; McLaughlin et al. 1996). 
Environmental and occupational factors have also been associated with the development of kidney cancer.  
Some studies have shown an increased incidence of this cancer type among leather tanners, shoe workers, 
and workers exposed to asbestos. Exposure to cadmium is associated with an increased incidence of 
kidney cancer, particularly in men who smoke (ACS 2006; Linehan et al. 1997).   In addition, workplace 
exposure to organic solvents, particularly trichloroethylene, may increase the risk of this cancer (ACS 
2006).  Although occupational exposure to petroleum, tar, and pitch products has been implicated in the 
development of kidney cancer, most studies of oil refinery workers and petroleum products distribution 
Source: Community Assessment Program, Center for Environmental Health, Massachusetts Department of Public Health. 
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workers have not identified a definitive relationship between gasoline exposure and renal cancer (Linehan 
et al. 1997; McLaughlin et al. 1996). 
Wilms’ tumor is the most common type of kidney cancer affecting children and accounts for 
approximately 5% to 6% of all kidney cancers and about 6% of all childhood cancers.  This cancer is 
more common among African Americans than other races and among females than males.  Wilms’ tumor 
most often occurs in children under the age of 7 years.  The causes of Wilms’ tumor are not known, but 
certain birth defect syndromes and other genetic risk factors (such as family history or genetic mutations) 
are connected with this cancer.  However, most children who develop Wilms’ tumor do not have any 
known birth defects or inherited gene changes.  No environmental risk factors, either before or after a 
child’s birth, have been shown to be associated with the development of Wilms’ tumor (ACS 2006a). 
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Leukemia is the general term that includes a group of different cancers that occur in the blood forming 
organs and result in the formation of abnormal amounts and types of white blood cells in the blood and 
bone marrow.  Individuals with leukemia generally maintain abnormally high amounts of leukocytes or 
white blood cells in their blood.  This condition results in an individual’s inability to maintain certain 
body functions, particularly a person’s ability to combat infection. 
In 2006, leukemia is expected to affect approximately 35,070 individuals in the United States (20,000 
males and 15,070 females) in the United States, resulting in 22,280 deaths. Acute cases of leukemia are 
slightly more common that chronic, 15,860 and 14,520 respectively. In Massachusetts, approximately 770 
individuals will be diagnosed with the disease in 2006, representing more than 2% of all cancer 
diagnoses. There are four major types of leukemia: acute lymphoid leukemia (ALL), acute myeloid 
leukemia (AML), chronic lymphoid leukemia (CLL), and chronic myeloid leukemia (CML). There are 
also a few rare types, such as hairy cell leukemia.  In adults, the most common types are AML 
(approximately 11,700 cases) and CLL (approximately 9,560 cases). Incidences of ALL have increased 
approximately 1.8% per year since 1988 while incidences of CLL have decreased approximately 1.9% 
each year since 1988. Leukemia is the most common type of childhood cancer, accounting for about 30% 
of all cancers diagnosed in children.  The majority (74%) of these cases are of the ALL type (ACS 
2006a). 
While ALL occurs predominantly among children (peaking between ages 2 and 3 years), an elevation in 
incidence is also seen among older individuals, and 1300 (one-third) of total cases of ALL will occur in 
adults. ALL risk is lowest for adults aged 25 through 50 and then begins to pick up (ACS 2006b). The 
increase in incidence among older individuals begins at approximately 40-50 years of age, peaking at 
about age 85 (Linet and Cartwright 1996).  ALL is more common among whites than African Americans 
and among males than females (Weinstein and Tarbell 1997).  Exposure to high-dose radiation (e.g., by 
survivors of atomic bomb blasts or nuclear reactor accidents) is a known environmental risk factor 
associated with the development of ALL (ACS 2006b).  Significant radiation exposure (e.g., diagnostic x-
rays) within the first few months of development may carry up to a 5-fold increased risk of developing 
ALL (ACS 2006b).  However, few studies report an increased risk of leukemia associated with residing in 
proximity to nuclear plants or occupational exposure to low-dose radiation (Linet and Cartwright 1996; 
Scheinberg et al. 1997).  There is conflicting evidence about whether exposure to electromagnetic fields 
(EMF) plays a role in the development of ALL, however, most studies to date have found little or no risk 
(ACS 2006b). 
Few other risk factors for ALL have been identified.  There is evidence that genetics may play an 
important role in the development of this leukemia type.  Studies indicate that siblings of twins who 
develop leukemia are at an increased risk of developing the disease.  Children with Down’s syndrome are 
10 to 20 times more likely to develop acute leukemia (Weinstein and Tarbell 1997).  In addition, other 
genetic diseases, such as Li-Fraumeni syndrome and Klinefelter’s syndrome, are associated with an 
increased risk of developing leukemia.  Patients receiving medication that suppresses the immune system 
(e.g., organ transplant patients) may be more likely to develop ALL (ACS 2006c).  ALL has not been 
definitively linked to chemical exposure, however, childhood ALL may be associated with maternal 
occupational exposure to pesticides during pregnancy (Infante-Rivard et al. 1999).  Certain rare types of 
adult ALL are caused by human T-cell leukemia/lymphoma virus-I (HTLV-I) (ACS 2006c).  Some 
reports have linked other viruses with various types of leukemia, including Epstein-Barr virus and 
hepatitis B virus. Still others propose that leukemia may develop as a response to viral infection.  
However, no specific virus has been identified as related to ALL (Linet and Cartwright 1996).  Reports 
also suggest an infectious etiology for some childhood ALL cases, although a specific viral agent has not 
been identified and findings from studies exploring contact among children in day-care do not support 
this hypothesis (Greaves MF 1997; Kinlen and Balkwill 2001; Rosenbaum et al. 2000). 
Source: Community Assessment Program, Center for Environmental Health, Massachusetts Department of Public Health. 
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Although AML can occur in children (usually during the first two years of life), AML is the most 
common leukemia among adults, with an average age at diagnosis of 65 years (ACS 2006d).  This type of 
leukemia is more common among males than among females but affects African Americans and whites at 
similar rates (Scheinberg et al. 1997).  High-dose radiation exposure (e.g., by survivors of atomic bomb 
blasts or nuclear reactor accidents), long-term occupational exposure to benzene (a chemical in gasoline 
and cigarette smoke), and exposure to certain chemotherapy drugs, especially alkylating agents (e.g., 
mechlorethamine, cyclophosphamide), have been associated with an increased risk of developing AML 
among both children and adults (ACS 2006d).  The development of childhood AML is suspected to be 
related to parental exposure to pesticides and other chemicals, although findings are inconsistent (Linet 
and Cartwright 1996).  Studies have suggested a link between electromagnetic field (EMF) exposure (e.g., 
from power lines) and leukemia (Minder and Pfluger 2001; Schuz et al. 2001). However, there is 
conflicting evidence regarding EMF exposure and leukemia and it is clear that most cases are not related 
to EMF (Kleinerman et al. 2000). 
Other possible risk factors related to the development of AML include cigarette smoking and genetic 
disorders. It is estimated that approximately one-fifth of cases of AML are caused by smoking 
(Scheinberg et al. 1997). Also, a small number of AML cases can be attributed to rare inherited disorders, 
such as Down’s syndrome (ACS 2006d).  Recently, scientists have suggested that a mutation in a gene 
responsible for the deactivation of certain toxic metabolites may have the ability to increase the risk of 
acute myeloid leukemia in adults.  However, further research is necessary in order to confirm the findings 
of this study (Smith et al. 2001).  
CLL is chiefly an adult disease; the average age at diagnosis is about 70 years (ACS 2006e). Twice as 
many men as women are affected by this type of leukemia (Deisseroth et al. 1997).  While genetics and 
diseases of the immune system have been suggested as playing a role in the development of CLL, high-
dose radiation and benzene exposure have not (ACS 1999; Weinstein and Tarbell 1997).  It is thought that 
individuals with a family history of CLL are two to four times as likely to develop the disease.  Some 
studies have identified an increased risk of developing CLL (as well as ALL, AML, and CML) among 
farmers due to long-term exposure to herbicides and/or pesticides (Linet and Cartwright 1996).  Although 
viruses have been implicated in the etiology of other leukemias, there is no evidence that viruses cause 
CLL (Deisseroth et al. 1997). 
Of all the leukemias, CML is among the least understood.  While this disease can occur at any age, CML 
is extremely rare in children (about 2% of leukemias in children) and the average age of diagnosis is 40 to 
50 years (ACS 2006f).  Incidence rates are higher in males than in females, but unlike the other leukemia 
types, rates are higher in blacks than in whites in the U.S. (Linet and Cartwright 1996).  High-dose 
radiation exposure may increase the risk of developing CML (ACS 2006f).  Finally, CML has been 
associated with chromosome abnormalities such as the Philadelphia chromosome (Weinstein and Tarbell 
1997). 
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An estimated 18,510 people in the U.S. (12,600 men and 5,910 women) will be diagnosed with liver and 
intrahepatic bile duct cancer in 2006, accounting for approximately 1% of all new cancers (ACS 2006).  
Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver and accounts for about 
75% of all cases. Rarer forms of malignant liver cancer include the fibrolamellar subtype of HCC, 
cholangiocarcinoma, and angiosarcomain adults and hepatoblastoma in children.  Cholangriocarcinomas 
account for approximately 10% to 20% of all primary liver cancers and people with gallstones, gall 
bladder inflammation, chronic ulcerative colitis (long-standing inflammation of the large bowel) or 
chronic infection with certain types of parasitic worms are at an increased risk for developing this cancer.  
Hepatoblastoma is a rare cancer that forms usually in children under age 4 and has a 90% survival rate 
with early detection (ACS 2006a). 
In some developing countries, HCC is most common type of cancer diagnosed particularly in East Asia 
and Africa. Incidence in the United States had been increasing up to 1999.  Recently, the rate has 
become more stable (ACS 2006a).  Rates of HCC in the U.S. had increased by 70% during the 1980s and 
1990s (Yu et al. 2000).  Similar trends were observed in Canada and Western Europe.  The primary 
reason for the higher rates observed during those years was the increase in hepatitis C virus infection, an 
important factor related to liver cancer (El-Serag 2001; El-Serag and Mason 2000).   
Men are at least three times more likely to develop HCC than women.  Much of this is likely due to 
differences in lifestyle factors which increase a person’s risk for developing liver cancer (ACS 2006a).  
Although 85% of individuals diagnosed with liver cancer are between 45 and 85 years of age, the disease 
can occur in persons of any age (ACS 2006a). 
Several important risk factors for liver cancer have been identified.  Chronic infection with hepatitis B 
virus (HBV) and hepatitis C virus (HCV) are the most significant risk factors for developing liver cancer 
(ACS 2006a). It is estimated that 80% of HCC cases worldwide can be attributed to HBV infection (Yu 
et al. 2000). In the United States, HBV accounts for less than a quarter of the cases and infection with 
HCV plays a much larger role in the incidence of this cancer.  HBV and HCV can be spread through 
intravenous drug use (e.g., the sharing of contaminated needles), unprotected sexual intercourse, and 
transfusion of and contact with unscreened blood and blood products.  In addition, mothers who are 
infected with these viruses can pass them on to their children at birth or in early infancy (ACS 2006a). 
Cirrhosis is also a major risk factor for the development of liver cancer.  Cirrhosis is a progressive disease 
that is the result of scar tissue formation on the liver, which can lead to cancer.  Researchers estimate that 
60% to 80% of HCC cases are associated with cirrhosis.  However, it is unclear if cirrhosis itself causes 
liver cancer or if the underlying causes of cirrhosis contribute to the development of this disease (Garr et 
al. 1997).  Most liver cirrhosis in the U.S. occurs as a result of chronic alcohol abuse, but HBV and HCV 
are also major causes of cirrhosis (ACS 2006a).  In addition, certain inherited metabolic diseases, such as 
hemochromatosis, which causes excess iron accumulation in the body, can lead to cirrhosis (ACS 2006a).  
Some studies have shown that people with hemochromatosis are at an increased risk of developing liver 
cancer (Fracanzani et al. 2001). 
Epidemiological and environmental evidence indicates that exposure to certain chemicals and toxins can 
also contribute significantly to the development of liver cancer.  For example, chronic consumption of 
alcoholic beverages has been associated with liver cancer (Wogan 2000).  As noted above, it is unclear if 
alcohol itself causes HCC or if underlying cirrhosis is the cause (London and McGlynn 1996).  However, 
it is clear that alcohol abuse can accelerate liver disease and may act as a co-carcinogen in the 
development of liver cancer (Ince and Wands 1999).  Long-term exposure to aflatoxin can also cause 
liver cancer. Aflatoxins are carcinogenic agents produced by a fungus found in tropical and subtropical 
regions. Individuals may be exposed to aflatoxins if they consume contaminated peanuts and other foods 
that have been stored under hot, humid conditions (Wogan 2000).  Vinyl chloride, a known human 
Source: Community Assessment Program, Center for Environmental Health, Massachusetts Department of Public Health. 
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carcinogen used in the manufacturing of some plastics, and thorium dioxide, used in the past for certain x-
ray tests, are risk factors for a rare type of liver cancer called angiosarcoma (ACS 2006a; London and 
McGlynn 1996).  These chemicals may also increase the risk of cholangiocarcinoma and HCC, but to a 
lesser degree.  The impact of both thorium dioxide and vinyl chloride on the incidence of liver cancer was 
much greater in the past, since thorium dioxide has not been used for decades and exposure of workers to 
vinyl chloride is now strictly regulated in the U.S. (ACS 2006a).  Drinking water contaminated with 
arsenic may increase the risk of liver cancer in some parts of the world (ACS 2006a; ATSDR 2001). 
The use of oral contraceptives by women may also be a risk factor in the development of liver cancer.  
However, most of the studies linking oral contraceptives and HCC involved types of oral contraceptives 
that are no longer used. There is some indication that the increased risk may be confined to oral 
contraceptives containing mestranol.  It is not known if the newer oral contraceptives, which contain 
different types and doses of estrogen and different combinations of estrogen with other hormones, 
significantly increase the risk of HCC (ACS 2006a; London and McGlynn 1996).  Long-term anabolic 
steroid use may slightly increase the risk of HCC (ACS 2006a).  Although many researchers believe that 
cigarette smoking plays a role in the development of liver cancer, the evidence for this is still inconclusive 
(Mizoue et al. 2000; London and McGlynn 1996). 
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Lung cancer generally arises in the epithelial tissue of the lung.  Several different histologic or cell types 
of lung cancer have been observed.  The various types of lung cancer occur in different regions of the 
lung and each type is associated with slightly different risk factors (Blot and Fraumeni 1996).  The most 
common type of lung cancer in the United States today is adenocarcinoma which accounts for about 40% 
of all lung cancers (ACS 2005).  The greatest established risk factor for all types of lung cancer is 
cigarette smoking, followed by occupational and environmental exposures. 
The incidence of lung cancer increases sharply with age peaking at about age 60 or 70.  Lung cancer is 
very rare in people under the age of 40.  The incidence is greater among men than women (probably 
because men are more likely to be smokers than women) and among blacks than whites (Blot and 
Fraumeni 1996).  The American Cancer Society estimates that lung and bronchus cancer will be 
diagnosed in 174,470 people (92,700 cases in men and 81,770 in women) in the U.S. in 2006, accounting 
for about 12% of all new cancer diagnoses. For purposes of treatment, lung cancer is divided into two 
clinical groups: small cell lung cancer (13%) and non-small cell lung cancer (87%) (ACS 2006).  Lung 
cancer is the leading cause of cancer death among both men and women; more people die of lung cancer 
than of colon, breast, and prostate cancers combined (ACS 2005).  In Massachusetts, an estimated 4,070 
individuals will be diagnosed with lung and bronchus cancer in 2006.  Incidence rates for lung and 
bronchus cancer in Massachusetts from 1998 through 2002 were 86.5 per 100,000 and 60.4 per 100,000 
for males and females, respectively (ACS 2006).  Nationwide, the incidence rate declined significantly in 
men during the 1990s, most likely as a result of decreased smoking rates over the past 30 years.  Rates for 
women are approaching a plateau, after a long period of increase. This is likely because decreasing 
smoking patterns among women have lagged behind those of men (ACS 2006).  Trends in lung cancer 
incidence suggest that the disease has become increasingly associated with populations of lower 
socioeconomic status, since these individuals have higher rates of smoking than individuals of other 
groups (Blot and Fraumeni 1996). 
Approximately 87% of all lung cancers are caused directly by smoking cigarettes and some of the rest are 
due to exposure to second hand smoke, or environmental tobacco smoke.  The longer a person has been 
smoking and the higher the number of cigarettes smoked per day, the greater the risk of lung cancer.  
Smoking cessation decreases the elevated risk and ten years after smoking cessation the risk is reduced by 
one-third of what it would have been had smoking continued. However, former smokers still carry a 
greater risk than those who have never smoked.  There is no evidence that smoking low tar or “light” 
cigarettes reduces the risk of lung cancer and mentholated cigarettes are thought to increase the risk of 
lung cancer. Additionally, breathing secondhand smoke also increases an individual’s risk of developing 
lung cancer. A nonsmoking spouse of a smoker has a 30% greater risk of developing lung cancer than the 
spouse of a nonsmoker (ACS 2005). 
Workplace exposures have also been identified as playing important roles in the development of lung 
cancer. Occupational exposure to asbestos is an established risk factor for this disease; asbestos workers 
are about seven times more likely to die from lung cancer than the general population (ACS 2005).  
Underground miners exposed to radon and uranium are at an increased risk for developing lung cancer 
(Samet and Eradze 2000).  Chemical workers, talc miners and millers, paper and pulp workers, 
carpenters, metal workers, butchers and meat packers, vineyard workers, carpenters and painters, and 
shipyard and railroad manufacture workers are some of the occupations associated with an increased risk 
of lung cancer (Blot and Fraumeni 1996; Pohlabeln et al. 2000).  In addition to asbestos and radon, 
chemical compounds such as arsenic, chloromethyl ethers, chromium, vinyl chloride, nickel chromates, 
coal products, mustard gas, ionizing radiation, and fuels such as gasoline are also occupational risk factors 
for lung cancer (ACS 2005; Blot and Fraumeni 1996).  Industrial sand workers exposed to crystalline 
silica are also at an increased risk for lung cancer (Rice et al. 2001; Steenland and Sanderson 2001).  
Occupational exposure to the compounds noted above in conjunction with cigarette smoking dramatically 
increases the risk of developing lung cancer (Blot and Fraumeni 1996). 
Source: Community Assessment Program, Center for Environmental Health, Massachusetts Department of Public Health. 
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As noted above, exposure to radon (a naturally occurring radioactive gas produced by the breakdown of 
radium and uranium) has been associated with increased risk of developing lung cancer among miners.  
Recently, a number of studies have demonstrated that exposure to elevated levels of residential radon may 
also increase lung cancer risk (Lubin and Boice 1997; Kreienbrock et al. 2001; Tomasek et al. 2001).  
Epidemiological evidence suggests that radon may be the second leading cause of lung cancer after 
smoking (Samet and Eradze 2000).  However, actual lung cancer risk is determined by cumulative 
lifetime exposure to indoor radon.  Therefore, normal patterns of residential mobility suggest that most 
people living in high-radon homes experience lifetime exposures equivalent to residing in homes with 
lower radon levels (Warner et al. 1996). 
Some types of pneumonia may increase the risk of lung cancer due to scarred lung tissue (ACS 2002).  In 
addition, people who have had lung cancer have a higher risk of developing another tumor.  A family 
history of lung cancer also increases an individual’s risk this is due to an abnormality on chromosome 6 
(ACS 2005). 
Air pollution may increase the risk of developing lung cancer in some cities.  However, this risk is much 
lower than that due to cigarette smoking (ACS 2005). 
Diet has also been implicated in the etiology of lung cancer, however, the exact relationship is unclear.  
Diets high in fruits and vegetables decrease lung cancer risk, but the reasons for this are unknown 
(Brownson et al. 1998). A study showed a positive association between total fat, monounsaturated fat, 
and saturated fat and lung cancer among males, however, this effect was not observed among women 
(Bandera et al. 1997). 
References 
American Cancer Society. 2006. Cancer Facts & Figures 2006.  Atlanta: American Cancer Society, Inc. 
American Cancer Society. 2005. Detailed Guide: Lung Cancer - Non-small Cell. Available at: 
http://www.cancer.org. Cited April 18, 2006. 
American Cancer Society.  2002. Workplace Exposure to Secondhand Smoke Ups Women’s Lung 
Cancer Risk.  Available at: http://www.cancer.org.  Cited May 9, 2006. 
Bandera EV, Freudenheim JL, Marshall JR, et al. 1997. Diet and alcohol consumption and lung cancer 
risk in the New York State Cohort (United States). Cancer Causes Control 8:828-40. 
Blot WJ, Fraumeni JF, Jr. 1996. Cancers of the lung and pleura. In: Cancer Epidemiology and Prevention. 
2nd Ed, edited by Schottenfeld D,  Fraumeni. JF. New York:  Oxford University Press. 
Brownson RC, Alavanja MCR, Caporaso N, et al. 1998. Epidemiology and prevention of lung cancer in 
nonsmokers. Epidemiol Rev 20(2):218-36. 
Kreienbrock L, Kreuzer M, Gerken M, et al. 2001. Case-control study on lung cancer and residential 
radon in western Germany. Am J Epidemiol 153(1):42-52. 
Lubin JH, Boice JD. 1997. Lung cancer risk from residential radon: meta-analysis of eight epidemiologic 
studies. J Natl Cancer Inst 87:49-57. 
Source: Community Assessment Program, Center for Environmental Health, Massachusetts Department of Public Health. 
May 2006 
213 
Risk Factor information for Lung Cancer 
Tomasek L, Kunz E, Muller T, et al. 2001. Radon exposure and lung cancer risk – Czech cohort study on 
residential radon. Sci Total Environ 272(1-3):43-51. 
Pohlabeln H, Boffetta P, Ahrens W, et al. 2000. Occupational risks for lung cancer among nonsmokers. 
Epidemiology 11:532-38. 
Rice FL, Park R, Stayner L, et al. 2001. Crystalline silica exposure and lung cancer mortality in 
diatomaceous earth industry workers: a quantitative risk assessment. Occup Environ Med 58(1):38-45. 
Samet JM, Eradze GR. 2000.  Radon and lung cancer risk: taking stock at the millenium. Environ Health 
Perspect 108(Suppl 4):635-41. 
Steenland K, Sanderson W. 2001. Lung cancer among industrial sand workers exposed to crystalline 
silica. Am J Epidemiol 153:695-703. 
Warner KE, Mendez D, Courant PN. 1996. Toward a more realistic appraisal of the lung cancer risk from 
radon: the effects of residential mobility. Am J Public Health 86:1222-7. 
Source: Community Assessment Program, Center for Environmental Health, Massachusetts Department of Public Health. 
May 2006 
214 
Risk Factor Information for non-Hodgkin’s Lymphoma 
Lymphomas are cancers involving the cells of the lymphatic system.  The majority of lymphomas involve 
the lymph nodes and spleen but the disease may also affect other areas within the body.  Non-Hodgkin’s 
lymphoma (NHL) is a classification of all lymphomas except Hodgkin’s disease.  Thus NHL is a mixed 
group of diseases that is characterized by the malignant increase in specific cells of the immune system (B 
or T lymphocytes).  B-cell lymphomas are more common than T-cell lymphomas, accounting for about 
85% of all cases of NHL (ACS 2006a).  The various types of NHL are thought to represent different 
diseases with different causes (Scherr and Mueller 1996).  NHL can occur at any age. However, the 
average age at diagnosis is in the early 60s and the incidence of this disease generally increases with age.  
This disease is more common in men than in women and affects whites more often than African 
Americans or Asian Americans (ACS 2006a).  The American Cancer Society estimates that 
approximately 58,870 Americans will be diagnosed with NHL in 2006 with 30,680 diagnoses occurring 
among males and 28,190 diagnoses occurring among females (ACS 2006b). 
Overall, between 1973 and 1997, the incidence of NHL in the U.S. grew 81% (Garber 2001), although 
over the past 20 years, the incidence rate appears to have stabilized (ACS 2006b).  In Massachusetts, the 
incidence of NHL increased 50% during 1982-1997 from 10.5 cases per 100,000 to 15.7 cases per 
100,000 (MCR 1997, 2000).  The increase in NHL incidence has been attributed to better diagnosis, 
greater exposure to causative agents, and, to a lesser extent, the increasing incidence of AIDS-related 
lymphomas (Devesa and Fears 1992; Scherr and Mueller 1996).  Although the primary factors related to 
the development of NHL include conditions that suppress the immune system, viral infections, and certain 
occupational exposures, these factors are thought to account for only a portion of the increase observed in 
this cancer type (Scherr and Mueller 1996). 
NHL is more common among people who have abnormal or compromised immune systems, such as 
those with inherited diseases that suppress the immune system, individuals with autoimmune disorders, 
and people taking immunosuppressant drugs following organ transplants.  Genetic predisposition (e.g., 
inherited immune deficiencies) only accounts for a small proportion of NHL cases (Scherr and Mueller 
1996).  AIDS patients have a 100- to 300-fold higher risk for NHL than the general population (again, 
these cases account for only a minor part of overall NHL incidence) (Garber 2001).  NHL has also been 
reported to occur more frequently among individuals with conditions that require medical treatment 
resulting in suppression of the immune system, such as cancer chemotherapy. However, current evidence 
suggests that the development of NHL is related to suppression of the individual’s immune system as a 
result of treatment, rather than the treatment itself (Scherr and Mueller 1996). 
Several viruses have been shown to play a role in the development of NHL.  Among organ transplant 
recipients, suppression of the immune system required for acceptance of the transplant leads to a loss of 
control or the reactivation of viruses that have been dormant in the body [e.g., Epstein - Barr virus (EBV) 
and herpes virus infections].  In addition, because cancer-causing viruses are known to cause lymphomas 
in various animals, it has been proposed that these types of viruses may also be associated with the 
development of NHL among humans without compromised immune systems.  Infection with the human 
T-cell leukemia/lymphoma virus (HTLV-I) is known to cause T-cell lymphoma among adults.  However, 
this is a relatively rare infection and most likely contributes only a small amount to the total incidence of 
NHL (Scherr and Mueller 1996).  EBV infection is common among the general population and has been 
shown to play a role in the development of most cases of transplant and AIDS related NHL.  Although 
viruses are causal factors for some subtypes of NHL, to date, studies have shown that the role of EBV in 
the development of NHL in the general population may not be large (Scherr and Mueller 1996).  
Moreover, the high prevalence of EBV in the general population suggests that EBV may be only one of 
several factors in the development of this cancer. 
Source: Community Assessment Program, Center for Environmental Health, Massachusetts Department of Public Health. 
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Recent studies have found that a type of bacteria, Helicobacter pylori, a common cause of stomach ulcers, 
can also cause some lymphomas of the stomach (ACS 2006).  An important implication of this finding is 
that treatment with antibiotics could prevent some NHL of the stomach. 
Some occupations have been associated with an increased risk of developing NHL, such as occupations 
related to chemicals or agriculture.  Farmers, herbicide and pesticide applicators, and grain workers 
appear to have the most increased risk (Zahm 1990, 1993; Tatham et al. 1997).  Studies conducted among 
agricultural workers have demonstrated increases in NHL among those using herbicides for more than 20 
days per year and individuals who mix or apply herbicides.  A greater incidence of NHL appears to be 
related specifically to exposure to the herbicide 2,4-dichlorophenoxyacetic acid (2,4-D) and 
organophosphate insecticides (Wigle et al. 1990; Zahm et al. 1990; Zahm et al. 1993).  Further studies of 
exposure to these chemicals and NHL incidence have shown that the increased risk is attributed to a 
specific impurity, 2,3,7,8-tetrachlorodibenzo-p-dioxin or 2,3,7,8-TCDD, present in these herbicides.  
However, reports of accidental industrial exposures to TCDD alone have not demonstrated an increased 
risk of NHL (Scherr and Mueller 1996).  An elevated risk for NHL development has also been noted 
among fence workers, orchard workers, and meat workers.  High-dose exposure to benzene has been 
associated with NHL (ACS 2006a).  However, a recent international cohort study indicated that petroleum 
workers exposed to benzene were not at an increased risk of NHL (Wong and Raabe 2000). 
In addition, epidemiological studies of long-term users of permanent hair coloring products have 
suggested an increased incidence of NHL (Zahm et al. 1992; Scherr and Mueller 1996).  However, a 
population based study found no association between the use of hair color products and an increased risk 
of developing NHL. The researchers further stated that results from this study and previous studies, 
including experimental animal studies, provide little convincing evidence linking NHL with normal use of 
hair dye (Holly et al. 1998). 
Although radiation (e.g., nuclear explosions or radioactive fallout from reactor accidents) has been 
implicated in the development of some cancers, including NHL (ACS 2006a), there is little evidence for 
an increased risk of lymphoma due to radiation (Scherr and Mueller 1996). 
Studies have suggested that contamination of drinking water with nitrate may be associated with an 
increased risk of NHL (Ward et al. 1996).  Nitrate forms N-nitroso compounds which are known 
carcinogens and can be found in smoked or salt-dried fish, bacon, sausages, other cured meats, beer, 
pickled vegetables, and mushrooms. 
Smoking has also been suggested to increase the risk of NHL.  A study that evaluated the history of 
tobacco use and deaths from NHL determined that people who had ever smoked had a two-fold increase 
of dying from NHL as compared to those who never smoked.  Further, a four-fold increase was found 
among the heaviest smokers (Linet et al. 1992).  In addition, a more recent study that primarily examined 
occupation and NHL risk found a significant association with high levels of cigarette smoking and all 
NHL types (Tatham et al. 1997).  However, a review of five cohort studies and 14 case-control studies 
concludes that results of epidemiological studies have been inconsistent and that smoking has not been 
determined to be a definitive risk factor in the development of NHL (Peach and Barnett 2000). 
A Danish study has linked the use of tricyclic and tetracyclic antidepressants to NHL.  However, more 
research is needed on this possible association (Dalton et al. 2000). 
Although NHL is associated with a number of risk factors, the causes of this disease remain unknown.  
Most patients with NHL do not have any known risk factors (ACS 2006a). 
Source: Community Assessment Program, Center for Environmental Health, Massachusetts Department of Public Health. 
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The American Cancer Society estimates that approximately 33,730 people in the U.S. (17,150 men and 
16,580 women) will develop pancreatic cancer in 2006.  This disease accounts for approximately 2% of 
all new cases of cancer in both men and women, but between 5% and 6% of all cancer deaths (ACS 
2006a). This discrepancy has been attributed to detection of pancreatic cancer at an advanced stage and 
the short median survival time for this cancer of approximately three months.  Between 1920 and 1965, 
mortality from this disease increased nearly 200% from 2.9 to 8.2 per 100,000 people.  These increases 
are believed to be due, in part, to improved diagnosis during this time period (Anderson et al. 1996).  
However, over the past 25 years, incidence rates have declined slowly but consistently in men and a slight 
decline in rates among women has been observed since the mid-1980s.  Further, since the 1970s, men 
have experienced a slight decrease in mortality from pancreatic cancer, although rates among women 
have not dropped (ACS 2006a).  The risk of developing pancreatic cancer increases with age and the 
majority of cases occur between age 60 and 80.  Men are approximately 20% more likely to develop 
pancreatic cancer than are women (ACS 2006b). 
Very little is known about what causes pancreatic cancer and how to prevent it. However, a number of 
risk factors have been identified. Besides age, the most consistent and only established risk factor for 
pancreatic cancer is cigarette smoking.  According to the American Cancer Society, approximately 30% 
of all pancreatic cancer cases are thought to result directly from cigarette smoking (ACS 2006b).  Studies 
have estimated that the risk of pancreatic cancer is two to six times greater in heavy smokers than in non-
smokers (Anderson et al. 1996). 
Certain medical conditions, such as chronic pancreatitis, diabetes mellitus, and cirrhosis, have been 
associated with pancreatic cancer, but the reasons for these associations are largely unknown.  More 
recently, a possible role for the bacteria Helicobacter pylori, which causes ulcers and some gastric 
cancers, has been suggested in the development of pancreatic cancer (ACS 2006b; Stolzenberg-Solomon 
et al. 2001). Some researchers also believe that excess stomach acid may increase the risk of pancreatic 
cancer (ACS 2006b).   
There is also some evidence to suggest that certain dietary factors may be related to the development of 
pancreatic cancer.  Increased risks of pancreatic cancer may be associated with animal protein and fat 
consumption as evidenced by higher rates of this cancer in countries whose populations eat a diet high in 
fat (ACS 2006a). Decreased risks for the disease are usually associated with fruit and vegetable 
consumption (ACS 2006).  Obesity is also a risk factor for pancreatic cancer, and very overweight people 
are 20% more likely to develop pancreatic cancer (ACS 2006b).  Although older studies suggested that 
coffee and alcohol consumption may be risk factors, more recent studies do not support this association 
(Michaud et al. 2001).  
Numerous occupations have been investigated for their potential role in the development of pancreatic 
cancer, but studies have not produced consistent results.  Heavy exposure to certain pesticides (including 
DDT and its derivatives) may increase the risk of pancreatic cancer (ACS 2006b; Ji et al. 2001; Porta et 
al. 1999).  Exposure to certain dyes and chemicals related to gasoline, in addition to asbestos and ionizing 
radiation, has also been associated with the development of pancreatic cancer in some studies.  However, 
other studies have found no link between these agents and pancreatic cancer (ACS 2006b; Anderson et al. 
1996). A recent evaluation of data from several studies has implicated organic solvents (e.g., chlorinated 
hydrocarbons and polycyclic aromatic hydrocarbons), nickel compounds, and chromium compounds in 
the development of pancreatic cancer, but further studies are needed to corroborate this claim (Ojajarvi et 
al. 2000).  Although occupational exposures may have played a role in the incidence of this cancer in the 
past, currently most newly diagnosed patients with pancreatic cancer do not have evidence of a specific 
chemical exposure or relevant occupational history (Evans et al. 1997). 
Source: Community Assessment Program, Center for Environmental Health, Massachusetts Department of Public Health. 
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Finally, pancreatic cancer seems to run in some families.  According to the American Cancer Society, an 
inherited tendency to develop pancreatic cancer may account for as many as 10% of cases. Also, inherited 
DNA mutations that increase risk of developing pancreatic cancer can also increase the risk of developing 
other cancers. For example, some people with inherited BRCA2 mutations (which increases risk of breast 
cancer), an inherited tendency for melanoma (skin cancer), or an inherited tendency for colorectal cancer 
are also at an increased risk of developing pancreatic cancer (ACS 2006b).  Pancreatic cancer has been 
observed in both familial clusterings among siblings as well as in individuals of consecutive generations 
(Anderson et al. 1996). 
References 
American Cancer Society.  2006a. Cancer Facts & Figures 2006.  Atlanta: American Cancer Society, Inc. 
American Cancer Society.  2006b. Detailed Guide: Pancreatic Cancer. Available at: 
http://www.cancer.org/. Cited April 19, 2006. 
Anderson D, Potter J, Mack T. 1996.  Pancreatic Cancer. In: Cancer Epidemiology and Prevention. 2nd 
Ed, edited by Schottenfeld D,  Fraumeni. JF. New York:  Oxford University Press. 
Evans DB, Abbruzzese JL, Rich TA. 1997. Cancer of the Pancreas. In: Cancer: Principles and Practice of 
Oncology, Fifth Edition, edited by Devita V, Hellman S, Rosenberg S.  Lippincott-Raven Publishers, 
Philadelphia P. 1271-1297. 
Ji BT, Silverman DT, Stewart PA, Blair A, Swanson GM, Baris D, Greenberg RS, Hayes RB, Brown LM, 
Lillemoe KD, Schoenberg JB, Pottern LM, Schwartz AG, Hoover RN. 2001. Occupational exposure to 
pesticides and pancreatic cancer. Am J Ind Med 39(1):92-9. 
Michaud DS, Giovannucci E, Willett WC, Colditz GA, Fuchs CS. 2001. Coffee and alcohol consumption 
and the risk of pancreatic cancer in two prospective United States cohorts. Cancer Epidemiol Biomarkers 
Prev 10(5):429-37. 
Ojajarvi IA, Partanen TJ, Ahlbom A, Boffetta P, Hakulinen T, Jourenkova N, Kauppinen TP, Kogevinas 
M, Porta M, Vainio HU, Weiderpass E, Wesseling CH. 2000. Occupational exposures and pancreatic 
cancer: a meta-analysis. Occup Environ Med 57(5):316-24. 
Porta M, Malats N, Jariod M, Grimalt JO, Rifa J, Carrato A, Guarner L, Salas A, Santiago-Silva M, 
Corominas JM, Andreu M, Real FX. 1999. Serum concentrations of organochlorine compounds and K-ras 
mutations in exocrine pancreatic cancer. Lancet 354:2125-29. 
Stolzenberg-Solomon RZ, Blaser MJ, Limburg PJ, Perez-Perez G, Taylor PR, Virtamo J, Albanes D. 
2001. Helicobacter pylori seropositivity as a risk factor for pancreatic cancer. J Natl Cancer Inst 
93(12):937-41. 
Source: Community Assessment Program, Center for Environmental Health, Massachusetts Department of Public Health. 
April 2006 
220 
Appendix D 

ATSDR Glossary of Environmental Health Terms 

221 

ATSDR Glossary of Terms 

The Agency for Toxic Substances and Disease Registry (ATSDR) is a federal public health 
agency with headquarters in Atlanta, Georgia, and 10 regional offices in the United States. 
ATSDR's mission is to serve the public by using the best science, taking responsive public health 
actions, and providing trusted health information to prevent harmful exposures and diseases 
related to toxic substances. ATSDR is not a regulatory agency, unlike the U.S. Environmental 
Protection Agency (EPA), which is the federal agency that develops and enforces environmental 
laws to protect the environment and human health. This glossary defines words used by ATSDR 
in communications with the public. It is not a complete dictionary of environmental health terms. 
If you have questions or comments, call ATSDR's toll-free telephone number, 1-888-42-ATSDR 
(1-888-422-8737). 
General Terms 
Absorption 
The process of taking in. For a person or an animal, absorption is the process of a substance 
getting into the body through the eyes, skin, stomach, intestines, or lungs.  
Acute 
Occurring over a short time [compare with chronic].  
Acute exposure 
Contact with a substance that occurs once or for only a short time (up to 14 days) [compare with 
intermediate duration exposure and chronic exposure].  
Additive effect 
A biologic response to exposure to multiple substances that equals the sum of responses of all the 
individual substances added together [compare with antagonistic effect and synergistic effect].  
Adverse health effect 
A change in body function or cell structure that might lead to disease or health problems 
Aerobic 
Requiring oxygen [compare with anaerobic].  
Ambient 
Surrounding (for example, ambient air).  
Anaerobic 
Requiring the absence of oxygen [compare with aerobic].  
Analyte 
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A substance measured in the laboratory. A chemical for which a sample (such as water, air, or 
blood) is tested in a laboratory. For example, if the analyte is mercury, the laboratory test will 
determine the amount of mercury in the sample.  
Analytic epidemiologic study  
A study that evaluates the association between exposure to hazardous substances and disease by 
testing scientific hypotheses. 
Antagonistic effect 
A biologic response to exposure to multiple substances that is less than would be expected if the 
known effects of the individual substances were added together [compare with additive effect 
and synergistic effect]. 
Background level 
An average or expected amount of a substance or radioactive material in a specific environment, 
or typical amounts of substances that occur naturally in an environment.  
Biodegradation 
Decomposition or breakdown of a substance through the action of microorganisms (such as 
bacteria or fungi) or other natural physical processes (such as sunlight).  
Biologic indicators of exposure study  
A study that uses (a) biomedical testing or (b) the measurement of a substance [an analyte], its 
metabolite, or another marker of exposure in human body fluids or tissues to confirm human 
exposure to a hazardous substance [also see exposure investigation].  
Biologic monitoring 
Measuring hazardous substances in biologic materials (such as blood, hair, urine, or breath) to 
determine whether exposure has occurred. A blood test for lead is an example of biologic 
monitoring. 
Biologic uptake  
The transfer of substances from the environment to plants, animals, and humans.  
Biomedical testing 
Testing of persons to find out whether a change in a body function might have occurred because 
of exposure to a hazardous substance. 
Biota 
Plants and animals in an environment. Some of these plants and animals might be sources of 
food, clothing, or medicines for people.  
Body burden  
The total amount of a substance in the body. Some substances build up in the body because they 
are stored in fat or bone or because they leave the body very slowly.  
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CAP [see Community Assistance Panel.]  
Cancer 
Any one of a group of diseases that occur when cells in the body become abnormal and grow or 
multiply out of control.  
Cancer risk 
A theoretical risk for getting cancer if exposed to a substance every day for 70 years (a lifetime 
exposure). The true risk might be lower.  
Carcinogen 
A substance that causes cancer. 
Case study 
A medical or epidemiologic evaluation of one person or a small group of people to gather 
information about specific health conditions and past exposures.  
Case-control study 
A study that compares exposures of people who have a disease or condition (cases) with people 
who do not have the disease or condition (controls). Exposures that are more common among the 
cases may be considered as possible risk factors for the disease.  
CAS registry number 
A unique number assigned to a substance or mixture by the American Chemical Society 
Abstracts Service. 
Central nervous system 
The part of the nervous system that consists of the brain and the spinal cord.  
CERCLA [see Comprehensive Environmental Response, Compensation, and Liability Act of 
1980] 
Chronic 
Occurring over a long time [compare with acute].  
Chronic exposure 
Contact with a substance that occurs over a long time (more than 1 year) [compare with acute 
exposure and intermediate duration exposure]  
Cluster investigation 
A review of an unusual number, real or perceived, of health events (for example, reports of 
cancer) grouped together in time and location. Cluster investigations are designed to confirm 
case reports; determine whether they represent an unusual disease occurrence; and, if possible, 
explore possible causes and contributing environmental factors.  
Community Assistance Panel (CAP)  
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A group of people from a community and from health and environmental agencies who work 
with ATSDR to resolve issues and problems related to hazardous substances in the community. 
CAP members work with ATSDR to gather and review community health concerns, provide 
information on how people might have been or might now be exposed to hazardous substances, 
and inform ATSDR on ways to involve the community in its activities.  
Comparison value (CV) 
Calculated concentration of a substance in air, water, food, or soil that is unlikely to cause 
harmful (adverse) health effects in exposed people. The CV is used as a screening level during 
the public health assessment process. Substances found in amounts greater than their CVs might 
be selected for further evaluation in the public health assessment process.  
Completed exposure pathway [see exposure pathway]. 
Comprehensive Environmental Response, Compensation, and Liability Act of 1980 
(CERCLA) 
CERCLA, also known as Superfund, is the federal law that concerns the removal or cleanup of 
hazardous substances in the environment and at hazardous waste sites. ATSDR, which was 
created by CERCLA, is responsible for assessing health issues and supporting public health 
activities related to hazardous waste sites or other environmental releases of hazardous 
substances. This law was later amended by the Superfund Amendments and Reauthorization Act 
(SARA). 
Concentration 
The amount of a substance present in a certain amount of soil, water, air, food, blood, hair, urine, 
breath, or any other media.  
Contaminant 
A substance that is either present in an environment where it does not belong or is present at 
levels that might cause harmful (adverse) health effects.  
Delayed health effect 
A disease or an injury that happens as a result of exposures that might have occurred in the past.  
Dermal 
Referring to the skin. For example, dermal absorption means passing through the skin.  
Dermal contact  
Contact with (touching) the skin [see route of exposure]. 
Descriptive epidemiology  
The study of the amount and distribution of a disease in a specified population by person, place, 
and time.  
Detection limit 
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The lowest concentration of a chemical that can reliably be distinguished from a zero 
concentration.  
Disease prevention 
Measures used to prevent a disease or reduce its severity.  
Disease registry  
A system of ongoing registration of all cases of a particular disease or health condition in a 
defined population. 
DOD 
United States Department of Defense.  
DOE 
United States Department of Energy.  

Dose (for chemicals that are not radioactive)  

The amount of a substance to which a person is exposed over some time period. Dose is a 

measurement of exposure. Dose is often expressed as milligram (amount) per kilogram (a 

measure of body weight) per day (a measure of time) when people eat or drink contaminated 

water, food, or soil. In general, the greater the dose, the greater the likelihood of an effect. An 

"exposure dose" is how much of a substance is encountered in the environment. An "absorbed 

dose" is the amount of a substance that actually got into the body through the eyes, skin, 

stomach, intestines, or lungs.  

Dose (for radioactive chemicals)  

The radiation dose is the amount of energy from radiation that is actually absorbed by the body. 

This is not the same as measurements of the amount of radiation in the environment.  

Dose-response relationship  
The relationship between the amount of exposure [dose] to a substance and the resulting changes 
in body function or health (response). 
Environmental media 
Soil, water, air, biota (plants and animals), or any other parts of the environment that can contain 
contaminants.  
Environmental media and transport mechanism  
Environmental media include water, air, soil, and biota (plants and animals). Transport 
mechanisms move contaminants from the source to points where human exposure can occur. The 
environmental media and transport mechanism is the second part of an exposure pathway.  
EPA 
United States Environmental Protection Agency.  
Epidemiologic surveillance [see Public health surveillance]. 
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Epidemiology  
The study of the distribution and determinants of disease or health status in a population; the 
study of the occurrence and causes of health effects in humans.  
Exposure 
Contact with a substance by swallowing, breathing, or touching the skin or eyes. Exposure may 
be short-term [acute exposure], of intermediate duration, or long-term [chronic exposure].  
Exposure assessment 
The process of finding out how people come into contact with a hazardous substance, how often 
and for how long they are in contact with the substance, and how much of the substance they are 
in contact with.  
Exposure-dose reconstruction 
A method of estimating the amount of people's past exposure to hazardous substances. Computer 
and approximation methods are used when past information is limited, not available, or missing.  
Exposure investigation 
The collection and analysis of site-specific information and biologic tests (when appropriate) to 
determine whether people have been exposed to hazardous substances.  
Exposure pathway  
The route a substance takes from its source (where it began) to its end point (where it ends), and 
how people can come into contact with (or get exposed to) it. An exposure pathway has five 
parts: a source of contamination (such as an abandoned business); an environmental media and 
transport mechanism (such as movement through groundwater); a point of exposure (such as a 
private well); a route of exposure (eating, drinking, breathing, or touching), and a receptor 
population (people potentially or actually exposed). When all five parts are present, the exposure 
pathway is termed a completed exposure pathway.  
Exposure registry 
A system of ongoing followup of people who have had documented environmental exposures.  
Feasibility study  
A study by EPA to determine the best way to clean up environmental contamination. A number 
of factors are considered, including health risk, costs, and what methods will work well.  
Geographic information system (GIS)  
A mapping system that uses computers to collect, store, manipulate, analyze, and display data. 
For example, GIS can show the concentration of a contaminant within a community in relation to 
points of reference such as streets and homes.  
Grand rounds 
Training sessions for physicians and other health care providers about health topics.  
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Groundwater  
Water beneath the earth's surface in the spaces between soil particles and between rock surfaces 
[compare with surface water].  
Half-life (t½)  
The time it takes for half the original amount of a substance to disappear. In the environment, the 
half-life is the time it takes for half the original amount of a substance to disappear when it is 
changed to another chemical by bacteria, fungi, sunlight, or other chemical processes. In the 
human body, the half-life is the time it takes for half the original amount of the substance to 
disappear, either by being changed to another substance or by leaving the body. In the case of 
radioactive material, the half life is the amount of time necessary for one half the initial number 
of radioactive atoms to change or transform into another atom (that is normally not radioactive). 
After two half lives, 25% of the original number of radioactive atoms remain.  
Hazard  
A source of potential harm from past, current, or future exposures.  
Hazardous Substance Release and Health Effects Database (HazDat)  
The scientific and administrative database system developed by ATSDR to manage data 
collection, retrieval, and analysis of site-specific information on hazardous substances, 
community health concerns, and public health activities.  
Hazardous waste  
Potentially harmful substances that have been released or discarded into the environment.  
Health consultation 
A review of available information or collection of new data to respond to a specific health 
question or request for information about a potential environmental hazard. Health consultations 
are focused on a specific exposure issue. Health consultations are therefore more limited than a 
public health assessment, which reviews the exposure potential of each pathway and chemical 
[compare with public health assessment].  
Health education 
Programs designed with a community to help it know about health risks and how to reduce these 
risks. 
Health investigation 
The collection and evaluation of information about the health of community residents. This 
information is used to describe or count the occurrence of a disease, symptom, or clinical 
measure and to evaluate the possible association between the occurrence and exposure to 
hazardous substances. 
Health promotion 
The process of enabling people to increase control over, and to improve, their health.  
Health statistics review 
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The analysis of existing health information (i.e., from death certificates, birth defects registries, 
and cancer registries) to determine if there is excess disease in a specific population, geographic 
area, and time period. A health statistics review is a descriptive epidemiologic study.  
Indeterminate public health hazard 
The category used in ATSDR's public health assessment documents when a professional 
judgment about the level of health hazard cannot be made because information critical to such a 
decision is lacking. 
Incidence 
The number of new cases of disease in a defined population over a specific time period [contrast 
with prevalence]. 
Ingestion 
The act of swallowing something through eating, drinking, or mouthing objects. A hazardous 
substance can enter the body this way [see route of exposure].  
Inhalation 
The act of breathing. A hazardous substance can enter the body this way [see route of exposure].  
Intermediate duration exposure  
Contact with a substance that occurs for more than 14 days and less than a year [compare with 
acute exposure and chronic exposure]. 
In vitro 
In an artificial environment outside a living organism or body. For example, some toxicity 
testing is done on cell cultures or slices of tissue grown in the laboratory, rather than on a living 
animal [compare with in vivo].  
In vivo 
Within a living organism or body. For example, some toxicity testing is done on whole animals, 
such as rats or mice [compare with in vitro].  
Lowest-observed-adverse-effect level (LOAEL)  
The lowest tested dose of a substance that has been reported to cause harmful (adverse) health 
effects in people or animals. 
Medical monitoring  
A set of medical tests and physical exams specifically designed to evaluate whether an 
individual's exposure could negatively affect that person's health.  
Metabolism 
The conversion or breakdown of a substance from one form to another by a living organism.  
Metabolite 
Any product of metabolism. 
229 

mg/kg 
Milligram per kilogram.  
mg/cm2 
Milligram per square centimeter (of a surface).  
mg/m3 
Milligram per cubic meter; a measure of the concentration of a chemical in a known volume (a 
cubic meter) of air, soil, or water.  
Migration 
Moving from one location to another. 
Minimal risk level (MRL)  
An ATSDR estimate of daily human exposure to a hazardous substance at or below which that 
substance is unlikely to pose a measurable risk of harmful (adverse), noncancerous effects. 
MRLs are calculated for a route of exposure (inhalation or oral) over a specified time period 
(acute, intermediate, or chronic). MRLs should not be used as predictors of harmful (adverse) 
health effects [see reference dose]. 
Morbidity 
State of being ill or diseased. Morbidity is the occurrence of a disease or condition that alters 
health and quality of life. 
Mortality 
Death. Usually the cause (a specific disease, a condition, or an injury) is stated.  
Mutagen 
A substance that causes mutations (genetic damage).  
Mutation 
A change (damage) to the DNA, genes, or chromosomes of living organisms.  
National Priorities List for Uncontrolled Hazardous Waste Sites (National Priorities List or 
NPL) 
EPA's list of the most serious uncontrolled or abandoned hazardous waste sites in the United 
States. The NPL is updated on a regular basis. 
National Toxicology Program (NTP) 
Part of the Department of Health and Human Services. NTP develops and carries out tests to 
predict whether a chemical will cause harm to humans.  
No apparent public health hazard  
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A category used in ATSDR's public health assessments for sites where human exposure to 
contaminated media might be occurring, might have occurred in the past, or might occur in the 
future, but where the exposure is not expected to cause any harmful health effects.  
No-observed-adverse-effect level (NOAEL)  
The highest tested dose of a substance that has been reported to have no harmful (adverse) health 
effects on people or animals. 
No public health hazard 
A category used in ATSDR's public health assessment documents for sites where people have 
never and will never come into contact with harmful amounts of site-related substances.  
NPL [see National Priorities List for Uncontrolled Hazardous Waste Sites] 
Physiologically based pharmacokinetic model (PBPK model) 
A computer model that describes what happens to a chemical in the body. This model describes 
how the chemical gets into the body, where it goes in the body, how it is changed by the body, 
and how it leaves the body. 
Pica 
A craving to eat nonfood items, such as dirt, paint chips, and clay. Some children exhibit pica-
related behavior. 
Plume 
A volume of a substance that moves from its source to places farther away from the source. 
Plumes can be described by the volume of air or water they occupy and the direction they move. 
For example, a plume can be a column of smoke from a chimney or a substance moving with 
groundwater. 
Point of exposure  
The place where someone can come into contact with a substance present in the environment 
[see exposure pathway]. 
Population 
A group or number of people living within a specified area or sharing similar characteristics 
(such as occupation or age). 
Potentially responsible party (PRP)  
A company, government, or person legally responsible for cleaning up the pollution at a 
hazardous waste site under Superfund. There may be more than one PRP for a particular site.  
ppb 
Parts per billion. 
ppm 
Parts per million.  
231 

Prevalence 
The number of existing disease cases in a defined population during a specific time period 
[contrast with incidence]. 
Prevalence survey 
The measure of the current level of disease(s) or symptoms and exposures through a 
questionnaire that collects self-reported information from a defined population.  
Prevention 
Actions that reduce exposure or other risks, keep people from getting sick, or keep disease from 
getting worse. 
Public availability session  
An informal, drop-by meeting at which community members can meet one-on-one with ATSDR 
staff members to discuss health and site-related concerns. 
Public comment period 
An opportunity for the public to comment on agency findings or proposed activities contained in 
draft reports or documents. The public comment period is a limited time period during which 
comments will be accepted.  
Public health action 
A list of steps to protect public health. 
Public health advisory 
A statement made by ATSDR to EPA or a state regulatory agency that a release of hazardous 
substances poses an immediate threat to human health. The advisory includes recommended 
measures to reduce exposure and reduce the threat to human health.  
Public health assessment (PHA) 
An ATSDR document that examines hazardous substances, health outcomes, and community 
concerns at a hazardous waste site to determine whether people could be harmed from coming 
into contact with those substances. The PHA also lists actions that need to be taken to protect 
public health [compare with health consultation].  
Public health hazard  
A category used in ATSDR's public health assessments for sites that pose a public health hazard 
because of long-term exposures (greater than 1 year) to sufficiently high levels of hazardous 
substances or radionuclides that could result in harmful health effects.  
Public health hazard categories  
Public health hazard categories are statements about whether people could be harmed by 
conditions present at the site in the past, present, or future. One or more hazard categories might 
be appropriate for each site. The five public health hazard categories are no public health hazard, 
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no apparent public health hazard, indeterminate public health hazard, public health hazard, and 
urgent public health hazard. 
Public health statement 
The first chapter of an ATSDR toxicological profile. The public health statement is a summary 
written in words that are easy to understand. The public health statement explains how people 
might be exposed to a specific substance and describes the known health effects of that 
substance. 
Public health surveillance 
The ongoing, systematic collection, analysis, and interpretation of health data. This activity also 
involves timely dissemination of the data and use for public health programs. 
Public meeting  
A public forum with community members for communication about a site.  
Radioisotope 
An unstable or radioactive isotope (form) of an element that can change into another element by 
giving off radiation. 
Radionuclide 
Any radioactive isotope (form) of any element.  
RCRA [see Resource Conservation and Recovery Act (1976, 1984)]  
Receptor population 
People who could come into contact with hazardous substances [see exposure pathway].  
Reference dose (RfD)  
An EPA estimate, with uncertainty or safety factors built in, of the daily lifetime dose of a 
substance that is unlikely to cause harm in humans.  
Registry 
A systematic collection of information on persons exposed to a specific substance or having 
specific diseases [see exposure registry and disease registry].  
Remedial investigation 
The CERCLA process of determining the type and extent of hazardous material contamination at 
a site. 
Resource Conservation and Recovery Act (1976, 1984) (RCRA) 
This Act regulates management and disposal of hazardous wastes currently generated, treated, 
stored, disposed of, or distributed. 
RFA 
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RCRA Facility Assessment. An assessment required by RCRA to identify potential and actual 
releases of hazardous chemicals.  
RfD [see reference dose] 
Risk 
The probability that something will cause injury or harm.  
Risk reduction 
Actions that can decrease the likelihood that individuals, groups, or communities will experience 
disease or other health conditions. 
Risk communication 
The exchange of information to increase understanding of health risks.  
Route of exposure  
The way people come into contact with a hazardous substance. Three routes of exposure are 
breathing [inhalation], eating or drinking [ingestion], or contact with the skin [dermal contact].  
Safety factor [see uncertainty factor]  
SARA [see Superfund Amendments and Reauthorization Act]  
Sample 
A portion or piece of a whole. A selected subset of a population or subset of whatever is being 
studied. For example, in a study of people the sample is a number of people chosen from a larger 
population [see population]. An environmental sample (for example, a small amount of soil or 
water) might be collected to measure contamination in the environment at a specific location.  
Sample size 
The number of units chosen from a population or an environment.  
Solvent 
A liquid capable of dissolving or dispersing another substance (for example, acetone or mineral 
spirits). 
Source of contamination 
The place where a hazardous substance comes from, such as a landfill, waste pond, incinerator, 
storage tank, or drum. A source of contamination is the first part of an exposure pathway.  
Special populations 
People who might be more sensitive or susceptible to exposure to hazardous substances because 
of factors such as age, occupation, sex, or behaviors (for example, cigarette smoking). Children, 
pregnant women, and older people are often considered special populations.  
Stakeholder 
234 

A person, group, or community who has an interest in activities at a hazardous waste site.  
Statistics 
A branch of mathematics that deals with collecting, reviewing, summarizing, and interpreting 
data or information. Statistics are used to determine whether differences between study groups 
are meaningful.  
Substance 
A chemical.  
Substance-specific applied research 
A program of research designed to fill important data needs for specific hazardous substances 
identified in ATSDR's toxicological profiles. Filling these data needs would allow more accurate 
assessment of human risks from specific substances contaminating the environment. This 
research might include human studies or laboratory experiments to determine health effects 
resulting from exposure to a given hazardous substance.  
Superfund [see Comprehensive Environmental Response, Compensation, and Liability Act of 
1980 (CERCLA) and Superfund Amendments and Reauthorization Act (SARA)  
Superfund Amendments and Reauthorization Act (SARA)  
In 1986, SARA amended the Comprehensive Environmental Response, Compensation, and 
Liability Act of 1980 (CERCLA) and expanded the health-related responsibilities of ATSDR. 
CERCLA and SARA direct ATSDR to look into the health effects from substance exposures at 
hazardous waste sites and to perform activities including health education, health studies, 
surveillance, health consultations, and toxicological profiles.  
Surface water  
Water on the surface of the earth, such as in lakes, rivers, streams, ponds, and springs [compare 
with groundwater]. 
Surveillance [see public health surveillance]  
Survey 
A systematic collection of information or data. A survey can be conducted to collect information 
from a group of people or from the environment. Surveys of a group of people can be conducted 
by telephone, by mail, or in person. Some surveys are done by interviewing a group of people 
[see prevalence survey]. 
Synergistic effect 
A biologic response to multiple substances where one substance worsens the effect of another 
substance. The combined effect of the substances acting together is greater than the sum of the 
effects of the substances acting by themselves [see additive effect and antagonistic effect].  
Teratogen 
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A substance that causes defects in development between conception and birth. A teratogen is a 
substance that causes a structural or functional birth defect.  
Toxic agent 
Chemical or physical (for example, radiation, heat, cold, microwaves) agents that, under certain 
circumstances of exposure, can cause harmful effects to living organisms.  
Toxicological profile 
An ATSDR document that examines, summarizes, and interprets information about a hazardous 
substance to determine harmful levels of exposure and associated health effects. A toxicological 
profile also identifies significant gaps in knowledge on the substance and describes areas where 
further research is needed. 
Toxicology 
The study of the harmful effects of substances on humans or animals.  
Tumor 
An abnormal mass of tissue that results from excessive cell division that is uncontrolled and 
progressive. Tumors perform no useful body function. Tumors can be either benign (not cancer) 
or malignant (cancer).  
Uncertainty factor  
Mathematical adjustments for reasons of safety when knowledge is incomplete. For example, 
factors used in the calculation of doses that are not harmful (adverse) to people. These factors are 
applied to the lowest-observed-adverse-effect-level (LOAEL) or the no-observed-adverse-effect-
level (NOAEL) to derive a minimal risk level (MRL). Uncertainty factors are used to account for 
variations in people's sensitivity, for differences between animals and humans, and for 
differences between a LOAEL and a NOAEL. Scientists use uncertainty factors when they have 
some, but not all, the information from animal or human studies to decide whether an exposure 
will cause harm to people [also sometimes called a safety factor]. 
Urgent public health hazard  
A category used in ATSDR's public health assessments for sites where short-term exposures 
(less than 1 year) to hazardous substances or conditions could result in harmful health effects that 
require rapid intervention. 
Volatile organic compounds (VOCs) 
Organic compounds that evaporate readily into the air. VOCs include substances such as 

benzene, toluene, methylene chloride, and methyl chloroform.  

Other glossaries and dictionaries: 

Environmental Protection Agency (http://www.epa.gov/OCEPAterms/) 

National Center for Environmental Health (CDC) 
(http://www.cdc.gov/nceh/dls/report/glossary.htm) 
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National Library of Medicine (NIH) 
(http://www.nlm.nih.gov/medlineplus/mplusdictionary.html) 
For more information on the work of ATSDR, please contact: 
Office of Policy and External Affairs 

Agency for Toxic Substances and Disease Registry 

1600 Clifton Road, N.E. (MS E-60) 

Atlanta, GA 30333 

Telephone: (404) 498-0080 
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Appendix E 

Response to Public Comments on

“Evaluation of Environmental Concerns and Cancer Incidence in Belmont and 

Surrounding Communities, Middlesex County, Massachusetts, 1982–1999” 

Listed below are comments received from the public regarding the Public Health 
Assessment (PHA) for Cambridge Plating Company in Belmont, Massachusetts.  The 
public comment period ended on December 15, 2005.  MDPH and ATSDR received 
written comments from two residents of Belmont.  In addition, a number of comments 
were received from individuals who attended the October 20, 2005 public meeting.  All 
comments received are summarized with responses provided below.  Where possible, 
these comments were listed together and a single response has been provided.   
Comment 1: Due to limited surface soil sampling data available for Cambridge Plating, 
it is unknown whether past emissions of chromium to air could have resulted in elevated 
levels of chromium in surface soils in other areas surrounding the facility.  Without this 
data, it was not possible for you to evaluate this potential surface soil exposure pathway.  
Please define the specific sample data MA DEP.  The sample needs to include depth, 
location, and number of samples. Also, would soil samples from residents north of the 
facility be useful? 
Comment 2: Purecoat has caused the release of chromium in to the air from vents on or 
near the roof of the facility. Chromium has been determined to be a human carcinogen.  
In the air, chromium compounds are present mostly as fine dust particles, which 
eventually settle over land and water.  There is the potential that chromium could be on 
nearby properties, even if the Purecoat property appears to be clean.  There is a known 
chromium contaminated site at the north side of the facility that is not fenced in.  
Children who have unique vulnerabilities to toxic emissions have been observed on the 
site. It is not yet known if this area has been fully cleaned up.  We still do not know how 
much contamination is in the ground, and how it got there.  This is why additional studies 
should be done. 
Comment 3: Airborne chromium may have been dispersed and contamination may not 
necessarily be near the plant. Off-site sampling for chromium should be done to evaluate 
dispersal of airborne emissions from the roof.   
Comment 4: Was the chromium found on site and near the railroad tracks hexavalent 
chromium? 
Response: 
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In November 2005, Cambridge Plating submitted additional soil sampling results for both 
total and hexavalent chromium (chromium VI) in response to a requirement by the 
Massachusetts Department of Environmental Protection (MDEP) (OHI 2005a).  Ten on-
site locations were sampled to meet the MDEP requirement including three locations 
along Hittinger Street, three along the MBTA railroad tracks, two along the fence 
adjacent to the baseball field, and two along Brighton Street.  These locations were 
required by MDEP based on air emissions modeling results indicating that areas of 
maximum impact would be located on the site; this modeling was done in order to 
determine whether off-site sampling would be necessary (J. Miano, MDEP, personal 
communication, 2006). All OHI samples were collected from surface soils at depths 
between 0 and 6 inches and analyzed for both total and hexavalent forms of chromium.  
Total chromium was detected in each of the ten samples at concentrations ranging from 
23 to 220 milligrams per kilogram (mg/kg) (OHI 2005a).  The maximum detected 
concentration of total chromium was below the Reference Dose Media Evaluation Guide 
(RMEG) value for adult exposure to chromium VI (2,000 mg/kg) and similar to the 
RMEG value for childhood exposure to chromium VI (200 mg/kg).  RMEGs are 
developed by the Agency for Toxic Substances and Disease Registries (ATSDR) and 
represent the concentration in soil at which daily human exposure is unlikely to result in 
adverse noncarcinogenic effects.  ATSDR comparison values for total chromium were 
not available, so comparison values for chromium VI were used.  Chromium VI was 
detected in one of the ten samples at 1.2 mg/kg (OHI 2005a), well below both the adult 
and child RMEG values for chromium VI.   
To evaluate community concerns about potential exposure to chromium that might be 
present in off-site surface soils, exposure estimates were calculated for incidental soil 
ingestion using the maximum total chromium (220 mg/kg) and maximum chromium VI 
(1.2 mg/kg) concentrations detected in on-site surface soils samples collected at 
Cambridge Plating at depths of 0 to 6 inches.  As previously mentioned, the highest 
concentrations in soil would be on the site itself.  Therefore, the use of the highest 
measured concentration in on-site soil represents a conservative assumption for 
evaluating off-site health risks. 
Assuming an older child trespassed on the site, incidentally ingested 200 mg/kg of soil 
per day, 1 day per week for 26 weeks of the year for 5 years, the exposure doses would 
be below the United States Environmental Protection Agency (EPA) Chronic Reference 
Doses for both chromium III and chromium VI 4, 5. The EPA reference dose is defined as 
4 ATSDR Minimal Risk Levels and EPA cancer slope factors were not available for total chromium 
240 

an estimate, with uncertainty or safety factors built in, of the daily lifetime dose of a 
substance that is unlikely to cause harm in humans.  Therefore, the chromium present in 
the soil is unlikely to cause adverse health effects in nearby residents.   
Because true on-site surface soil samples were previously unavailable and samples 
collected from 0 to 4 feet and presented in the 2005 PHA report included soil samples 
with higher concentrations of total chromium and chromium VI, the same exposure 
assumptions listed above were also used to evaluate the previous chromium 
concentrations measured in soil.  Specifically, using the maximum concentrations of total 
(3,900 mg/kg) and hexavalent chromium (4.6 mg/kg) detected in all on-site surface soil 
samples collected at depths of 0 to 4 feet below ground surface, the estimated exposures 
are also below the EPA Chronic Reference Doses for both chromium III and chromium 
VI.6  In addition, other considerations suggest that these exposure estimates would be 
even lower. First, it is unlikely that the trespasser would be exposed to the maximum 
concentration of chromium 1 day each week for 26 weeks of each year for 5 years.  
Second, soil containing the maximum concentration of total chromium (3,900 mg/kg) 
was excavated and removed from the site in 2004 (OHI 2005b).  Finally, more recent soil 
samples taken around the perimeter of the property confirm that levels of chromium in 
5 Calculation using the maximum total chromium value in surface soil: 
(1day/week) (26 weeks/year) (5 years) 
(max contaminant concentration) (ingestion rate) (exposure factor) (1kg/10 mg) 
Noncancer Effects Exposure Factor = 
(5 years) (365 days/year) 
= 0.07 
6 
Noncancer Effects Exposure Dose(Older Child) = 
body weight 
(220 mg/kg) (200 mg/day) (0.07) (1kg/106 mg) − 5 = = 8.8x10 mg / kg / day
35 kg 
EPA Chronic Rfd for Chromium VI = 0.003mg / kg / day 
EPA Chronic Rfd for Chromium III =1.5mg / kg / day 
6 Calculation using the maximum hexavalent chromium value in surface soil: 
(max contaminant concentration) (ingestion rate) (exposure factor) (1kg/106 mg)
Noncancer Effects Exposure Dose(Older Child) = 
body weight 
= (1.2 mg/kg) (200 mg/day) (0.07) (1kg/10
6 mg) = 4.8x10− 7 mg / kg / day
35 kg 
EPA Chronic Rfd for Chromium VI = 0.003mg / kg / day 
EPA Chronic Rfd for Chromium III =1.5mg / kg / day 
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surface soil, soil that residents may come in contact with, are unlikely to cause adverse 
health effects for nearby residents.  
Based on air emissions modeling results, MDEP predicted that the areas with the highest 
concentrations of chromium would likely be located on-site.  Therefore, given that 
adverse health effects are unlikely for trespassers exposed to on-site surface soil, based 
on both reasonable and conservative exposure estimates, it appears unlikely that exposure 
through incidental ingestion to chromium potentially present in off-site surface soil 
would result in adverse health effects for residents living in close proximity to Cambridge 
Plating. 
In June 2007, in response to the MDPH recommendation in the 2005 public comment 
release of the Cambridge Plating Public Health Assessment, the MDEP sampled surface 
soil at off-site locations near Cambridge Plating to confirm the results of air emissions 
modeling and to determine if elevated levels of chromium were present in off-site soil 
(MDEP 2007). The seven samples were located near the tennis courts and ball field east 
of the facility, near residences north of the facility, near the intersection of Hittinger and 
Baker Streets south of the facility, and at three locations along Brighton Street northwest, 
west, and southwest of the facility.  Hexavalent chromium was not detected in any of the 
seven surface soil samples (Figure 4).  Total chromium measurements ranged from 12–46 
mg/kg (Table 1). These concentrations of chromium were lower than ATSDR 
comparison values of 200 mg/kg for hexavalent chromium and are not likely to pose a 
health threat to nearby residents.  These concentrations are also below levels of 
chromium considered typical for soil in the eastern United States (Shacklette and 
Boerngen 1984). 
Table 1: Off-Site Surface Soil Sampling Results (June 2007) 
Sample Name 
Hexavalent 
Chromium (mg/kg) 
Total Chromium 
(mg/kg) 
1-Ball Field 
2-Tennis Courts 
3-Residences - North 
4-Brighton St - Vale Rd 
5-Condos - End of Vale 
6-Brighton St - Flanders Rd 
7-Hittinger St - Baker St - South 
Not Detected 
Not Detected 
Not Detected 
Not Detected 
Not Detected 
Not Detected 
Not Detected 
26 
44 
20 
19 
12 
46 
14 
This additional information was incorporated as part of the final Cambridge Plating 
Public Health Assessment report (see sections IV and V).    
Comment 5: Some neighbors have vegetable gardens – could this be another exposure 
pathway? 
Response: 
Studies of chromium uptake into plants have shown that only a small fraction of 
chromium present in soils typically reaches the above ground portion of edible plants 
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(ATSDR 2000). However, to evaluate community concerns about potential exposure to 
chromium through ingestion of fruits and vegetables grown in nearby gardens, exposure 
estimates were calculated using the maximum total chromium value measured during 
recent off-site surface soil sampling discussed in the response above (exposure estimates 
shown below under Calculations). Sampling conducted during June 2007 at several off-
site locations indicated no detectable levels of hexavalent chromium and a maximum 
total chromium concentration of 46 mg/kg.   
Conservative estimates for consumption of fruits and vegetables by households in the 
northeast region of the United States were used to calculate exposure estimates (EPA 
1997). The EPA suggests the use of a bioconcentration factor to represent the amount of 
chromium in soil that is actually taken up by the roots of the plant and the use of a dry 
weight to wet weight conversion factor to determine the concentration of chromium in a 
typical garden plant (EPA 1999).  Calculations can be seen below and show that the 
human exposure dose of chromium from fruits and vegetables is well below levels 
thought by the EPA to cause harm in humans.  This indicates that regular ingestion of 
fruits and vegetables grown in the vicinity of Cambridge Plating would be unlikely to 
result in adverse health effects for residents. 
Equation for uptake of chromium from soil to plants 
Hexavalent Chromium in Plants = C x BCF x CF 
where: 
C = Contaminant Concentration in soil (mg/kg) 
BCF = Bioconcentration Factor (unitless) 
CF = Dry weight to wet weight conversion factor (unitless) 
Equation for exposure dose from ingestion of homegrown fruits or vegetables 
D = CL x CR x EF x PH / BW 
where: 
D = Exposure Dose (mg/kg/day) 
CL = Contaminant Concentration in plant (mg/g) 
CR = Consumption Rate of Food Group (g/day) 
EF = Exposure Factor (unitless) 
PH = Percentage of food that is homegrown 
BW = Body weight (kg) 
Calculations 
Hexavalent Chromium in Plants = C x BCF x CF 
    = 46 mg/kg x 0.0075 x 0.12 
    = 0.0414 mg/kg or 0.0000414 mg/g 
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Calculation for ingestion of homegrown fruits: 
(Contaminant concentration) (Consumption rate) (Exposure Factor) (% of food that is homegrown)
Exposure Dose(Adult) = 
body weight 
(0.0000414 mg/g) (129.6 g/day) (1) (0.5%)= = 0.0000004mg / kg − day
70 kg 
Calculation for ingestion of homegrown vegetables: 
(Contaminant concentration) (Consumption rate) (Exposure Factor) (% of food that is homegrown)
Exposure Dose(Adult) = 
body weight 
(0.0000414 mg/g) (469.2 g/day) (1) (3.8%)= = 0.00001mg / kg − day
70 kg 
The total human exposure dose of chromium from contaminated garden produce is equal 
to the sum of the exposure dose from homegrown fruit and the exposure dose from 
homegrown vegetables.  Therefore, the total human exposure dose from chromium in 
garden produce is 0.00001 mg/kg-day based on levels measured in recent off-site soil 
samples.  The EPA Chronic Reference Dose (Rfd) is 0.003 mg/kg-day.  Because the total 
exposure dose of chromium present in garden fruits and vegetables is well below the EPA 
Rfd, it is unlikely to cause adverse health effects in residents. 
Comment 6: People spend a lot of time at the softball field and at Clay Pit Pond.  Is it 
safe to be playing softball or walking around the pond?  Has soil been tested at the ball 
field and near the pond? 
Response: 
As discussed in the responses above, two of the ten soil samples taken in November 2005 
were located along the fence adjacent to the baseball field.  Surface soil samples CR-1 
and CR-3 were located along the fence that borders the right outfield of the field adjacent 
to Cambridge Plating.  These soil samples had no detectable levels of hexavalent 
chromium and had concentrations of total chromium of 51 mg/kg and 24 mg/kg, 
respectively.   A surface soil sample taken at the ball field in June 2007 also had no 
detectable level of hexavalent chromium and had a low total chromium concentration of 
26 mg/kg.  These concentrations are all below concentrations of chromium considered 
typical for soil in the eastern United States (Shacklette and Boerngen 1984).   
Incidental ingestion and dermal contact with soils near Clay Pit Pond could be possible 
for children or adults who may walk or play around the pond.  However, MDEP 
modeling based on air emissions indicated higher concentrations on-site and lower 
concentrations at points off-site, such as at Clay Pit Pond.  The off-site soil sampling 
confirmed the modeling and indicated that soil samples from points nearest to Clay Pit 
Pond, such as samples taken near the tennis courts and from the ball field, show levels of 
chromium are below comparison values.  Contaminant levels below these comparison 
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 values are not likely to pose a health threat to residents (see further discussion in Section 
IV of the PHA). 
A majority of the contaminants measured on-site were below comparison values or were 
within the range of concentrations considered typical for soil of this area and are not 
likely to pose a health threat. A small number of contaminants were measured above 
comparison values.  However, in addition to the likelihood that site-related contaminant 
concentrations are lower at Clay Pit Pond than in on-site soil, it is important to consider 
that comparison values are based on a residential exposure scenario, and it is unlikely that 
a visitor to Clay Pit Pond would have had contact with surface soil for a comparable 
frequency and duration of time. 
Comment 7: What about children who have been seen playing in puddles that could be 
contaminated by rooftop drainage and/or sump pump discharge?   
Response: 
It is possible that individuals who trespassed on the property could have or have had 
infrequent contact with rooftop drainage or with sump pump discharge.  Because data are 
not available for rooftop water or sump pump discharge, it is not possible to 
quantitatively evaluate this scenario. Reports in the Belmont Health Department files 
indicate that young adults have trespassed on the Cambridge Plating property in the past; 
specifically, there was an incidence of youth climbing on the roof of the building 
(Belmont Department of Health 2003a, 2003b).  However, because this is a working 
industrial facility it is not expected that these individuals would be trespassing on a 
regular basis or for an extended period of time. Therefore, it is unlikely that children who 
might trespass on the site would have contact with rooftop drainage or sump pump 
discharge for a sufficient frequency and duration of time to result in health effects.   
Comment 8: On page 10, paragraph 3, it refers to a chromating process still in 
operation. Is this hexavalent chromium? What is the process and what fugitive 
emissions would be expected?   
Response: 
According to MDEP, there is still a chromating process in operation at Cambridge 
Plating. This process is operated at ambient conditions and uses hexavalent chromium 
(C. Buttaro, MDEP, personal communication, 2007).  However, as stated in the 2005 
public comment release of the public health assessment titled “Evaluation of 
Environmental Concerns and Cancer Incidence in Belmont and Surrounding 
Communities, Middlesex County, Massachusetts, 1982–1999,” the chromating process is 
not heated and air emissions are not expected (R. Crystal, U.S. EPA Region 1, personal 
communication, 2005). 
Comment 9: Purecoat has caused the release of TCE to the soil and groundwater on its 
property. TCE has been identified as a probable human carcinogen.  TCE breaks down 
into more hazardous compounds such as vinyl chloride.  Groundwater does leave the 
Purecoat facility.  All the testing to date has only been conducted on the Purecoat 
property. No testing has occurred in the neighborhoods adjacent to the facility, the ball 
field, or the tennis courts. At some superfund sites, TCE has been found to volatilize from 
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the groundwater and soils and accumulate in the basements of properties neighboring the 
site. 
Comment 10:  Preventing further exposure should be very important, as we do not yet 
know what kind of contaminants are in the ground, if it has spread off-site, or if vapor 
intrusion to indoor air of nearby homes has occurred.  Further assessment should be a 
priority, to ensure the health and safety of our community.   
Response: 
To evaluate whether the levels of TCE detected in groundwater at the site could 
contaminate indoor air in nearby residences, MDPH asked ATSDR to run a model 
incorporating site-specific information on groundwater, soil, and housing for the area 
surrounding the facility (ATSDR 2003). On the basis of the Johnson-Ettinger modeling 
results provided by ATSDR and soil gas and groundwater investigations at Cambridge 
Plating required by MDEP, high levels of VOCs, including TCE, detected in groundwater 
near the building (monitoring wells MW-03 and CC-105) do not appear to have migrated 
south toward the site boundary at sufficient concentrations to raise health concerns 
related to VOCs in indoor air in nearby homes along Hittinger Street. 
In November 2005, Cambridge Plating submitted additional groundwater characterization 
and groundwater sampling results in response to a requirement by the MDEP (OHI 
2005a). This additional investigation was performed in response to an MDPH 
recommendation to conduct “additional characterization of VOCs in groundwater in the 
northern portion of the site…to ensure elevated levels of TCE detected in monitoring 
wells located close to the Cambridge Plating building are not presenting a health concern 
for indoor air in homes north of the site (MDPH 2005).”  Three on-site deep monitoring 
wells were installed and sampled to meet the MDEP requirement.  Three existing 
groundwater monitoring wells on the property were also sampled in 2005.  In addition to 
groundwater sampling locations around the property, a groundwater sample was taken 
from beneath the facility to meet MDEP’s requirement for the investigation of TCE 
sources in the vicinity of the degreasing area or boiler room.  Of the seven new 
groundwater samples taken on-site, three sampled deep groundwater (30-35 feet below 
ground surface) and four sampled shallower groundwater. 
Review of all available shallow groundwater data for TCE and its breakdown products 
indicates that TCE concentrations measured in the area of the loading dock (the location 
previously determined to contain the highest levels of VOCs on-site) are lower than 
levels measured in 2004, concentrations of cis-1,2-dichloroethene are similar to levels 
measured in 2004, and concentrations of vinyl chloride are greater than levels measured 
in 2004 (OHI 2005a). 
The new information also clarified groundwater conditions and allowed the MDEP to 
better determine potential health risks to residents living in the vicinity of Cambridge 
Plating, including those living in homes north of the facility.   
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MDEP determined that the new data confirmed that shallow groundwater flow is 
generally in a south-southwest direction across the site.  According to the MDEP, it is 
unlikely that VOCs found at high concentrations near the loading dock would flow 
upgradient (i.e., against the flow of groundwater) and be present at concentrations that 
could present a health hazard to residents in homes north of the site. 
Additionally, in an Interim Deadline letter dated May 20, 2005, MDEP required that 
Cambridge Plating Company obtain a groundwater sample from beneath the floor of the 
facility in the TCE degreasing area or boiler room to investigate the source of elevated 
levels of VOCs in the area of the loading dock on the southern side of the building.  The 
groundwater sample was taken 10 feet below the floor of the degreasing area by OHI 
Engineering, Inc. The groundwater sample showed low levels of TCE (15 ug/L) and 
other VOCs. Therefore, OHI Engineering, Inc. concluded and MDEP concurred that 
there did not appear to be an ongoing source of VOC contamination beneath the building. 
This additional information was incorporated as part of the revised PHA report (see 
Section V). 
Comment 11: The purpose of the public health action plan is to ensure that this health 
assessment is not only a definite potential public health hazard, but to provide a plan of 
action. Who will implement your recommendations?   
Response: 
As suggested in the first three recommendations in the 2005 PHA report, MDEP required 
additional characterization of groundwater and of groundwater flow patterns, and 
additional surface soil sampling at the Cambridge Plating facility.  In November 2005, 
Cambridge Plating Company submitted results for all of the MDEP requirements.  The 
additional environmental data were reviewed by MDPH and are summarized in Response 
to Comments 1-4, 6, 9, and 10.  The fourth recommendation related to the review of 
additional environmental data on historical air emissions or ambient air quality related to 
Cambridge Plating, if available.  No additional historical data have become available.  
The final recommendation suggested a collaboration of efforts to reduce odor and 
nuisance concerns. Correspondence with the Belmont Department of Health indicates 
that “odors from the company have subsided and the complaints greatly decreased 
(Belmont Department of Health 2007).”   
Comment 12: Purecoat has potassium cyanide at the facility.  This material can be used 
to make hydrogen cyanide by merely mixing it with acid.  Hydrogen cyanide is what is 
used in gas chambers, and also listed as a chemical warfare agent.  They also store acid. 
If there were another fire, or accident at the facility, these materials mixed together could 
cause a cloud of deadly gas. Purecoat should be required to do a consequence analysis 
of such a release since we have a company, which has release potentially cancer causing 
substances, and store materials, which could lead to release of a chemical warfare agent, 
right in the middle of a residential neighborhood, next to a public school, and little 
league field. 
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Response: 
The Emergency Planning and Community Right-to-Know Act (EPCRA) of 1986 was 
passed in response to concerns regarding the environmental and safety hazards posed by 
the storage and handling of toxic chemicals.  EPCRA requires that those facilities storing 
hazardous chemicals, such as potassium cyanide, submit an annual inventory report for 
those chemicals to the State Emergency Response Commission (SERC), the Local 
Emergency Planning Committee (LEPC) and local fire department by March 1 of each 
year. The LEPC must then develop an annually reviewed emergency response plan and 
provide information about chemicals in the community to residents.  In Belmont, the 
LEPC By-Laws state that members of this committee shall include representatives from 
the following categories: fire, police, health, transportation, public works, school 
departments, Hazmat Team, Belmont Emergency Management Agency, hospitals, 
Emergency Medical Services (EMS), covered facilities (such as Cambridge Plating), 
media, and community groups.  Residents seeking further information on the emergency 
response plan in the Town of Belmont should contact the LEPC at 617-993-2203 or see 
http://www.town.belmont.ma.us/Public_Documents/BelmontMA_EMS/LEPC. 
Comment 13: What did childhood cancer look like near Cambridge Plating? 
Response: 
Cancer incidence data (i.e., reports of new cancer diagnoses) for the years 1982–2003 
were obtained for Belmont census tracts (CTs) 3571 and 3572 from the Massachusetts 
Cancer Registry (MCR). Cambridge Plating is located in CT 3572 close to the border of 
CT 3571. During the 22-year time period from 1982–2003, there were four diagnoses of 
cancer among children under 19 years of age living in Belmont census tracts (CT) 3571 
and 3572. As discussed below, no apparent geographic or temporal concentrations of 
cancer diagnoses were observed in any one area of Belmont CTs 3571 and 3572.  
Standardized incidence ratios (SIRs) and 95% confidence intervals were not calculated 
for childhood cancer types due to small numbers of observed diagnoses.  
Address at the time of diagnosis for each child diagnosed with cancer was mapped using 
a computerized geographic information system (GIS) (ESRI 2005).  This allowed for an 
evaluation of the spatial distribution of individual diagnoses at a smaller geographic level 
within a census tract (e.g., neighborhoods).  The geographic distribution was determined 
using a qualitative evaluation of the point pattern of cancer diagnoses in Belmont CTs 
3571 and 3572. In instances where the address information from the MCR was 
incomplete (i.e., did not include specific streets or street numbers), efforts were made to 
research those cases using Registry of Motor Vehicle records and telephone books issued 
within 2 years of a child’s diagnosis.  In accordance with Massachusetts laws aimed at 
protecting the confidentiality of patients (M.G.L. c.111. s 24A), maps of the locations of 
individuals with cancer cannot be provided. 
The addresses at the time of diagnosis for each child ranged from 0.3 to 0.6 miles away 
from the Cambridge Plating facility.  Based on a review of address at the time of 
diagnosis for each child and given that each child was diagnosed with a different type of 
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cancer during different years, no apparent geographic or temporal concentrations of 
cancer diagnoses (of any type) were observed in any one area of Belmont CTs 3571 and 
3572. 
Comment 14:  Why have you not looked at trends in cancer incidence over the past five 
years? 
Response: 
After the release of the 2005 PHA, the MDPH conducted additional analyses of cancer 
incidence in Belmont, Cambridge, Arlington, and Watertown in order to incorporate 
newly available MCR data. (The 2005 PHA contained cancer incidence data covering 
1982 through 1999.) Due to the volume of information received by the MCR, the large 
number of reporting facilities, and the 6-month period between diagnosis and required 
reporting, the most current registry data that are complete will inherently be a minimum 
of 2 years prior to the current date. At the time of this analysis, the years 2000-2003 
constituted the period for which the most recent and complete cancer incidence data were 
available from the MCR. The updated analysis for 2000–2003 focused on the CTs 
immediately surrounding the facility.  Town-wide cancer incidence rates for 2000–2003 
and a summary of results are also provided for Arlington, Belmont, Cambridge, and 
Watertown. This information was incorporated as part of the revised PHA report (see 
Appendix F). 
Comment 15: Since the year 2000, there seems to be elevated cancer trends with specific 
occurrences in the following types: Breast, Brain, Bladder, and Stomach.  Why have 
these cancers been overlooked?   
Response: 
For 2005 PHA report, the MDPH selected six cancer types (i.e., kidney, leukemia, liver, 
lung and bronchus, NHL, and pancreas) for evaluation based on available environmental 
data for Cambridge Plating and information in the scientific literature on known or 
suspected associations with contaminants of concern (e.g., TCE, chromium).  In order to 
address community concerns about breast, brain, bladder and stomach cancers, cancer 
incidence rates and a summary of results are provided as part of the revised PHA report 
(see Appendix F).  The additional analysis for these cancer types focused on the CTs 
immediately surrounding the facility.   
Comment 16:  Breast cancer is the most common form of cancer in females nationally.  
Both genetic and environmental factors are believed to play a role in a woman’s risk of 
developing breast cancer.  This cancer has a variety of risk factors that may not make it 
easy to evaluate in your study.  However, it appears that breast cancer levels are 
elevated in specific areas of town that may warrant a closer look. All the known risk 
factors for breast cancer, family history, early menstruation, and having children late in 
life, to name a few, account for less than half of all breast cancer cases.   
Response: 
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To address community concerns about breast cancer, cancer incidence rates and a 
summary of results are provided as part of the revised PHA report (see Appendix F). 
Comment 17: Many teachers employed at Belmont High School have been diagnosed 
with cancer, but do not live in the town; they are exposed to Cambridge Plating on a 
daily basis, were they included in the study?  What about residents who relocated, and 
were diagnosed out of the area? 
Response: 
The cancer incidence evaluation included all individuals diagnosed with the types of 
cancer evaluated while living in the communities of Belmont, Cambridge, Arlington, and 
Watertown during 1982–2003.  While some of the teachers and staff at Belmont High 
School with cancer may live or have lived in one of these four communities, individuals 
with cancer are reported to the MCR according to place of residence at the time of 
diagnosis. The MCR contains some information on a person’s occupation (e.g., job title); 
however, it is not possible from the MCR to determine the exact location of employment 
for each individual diagnosed with cancer.  In addition, age group and gender-specific 
population data are required to calculate expected rates and SIRs.  Because of the need 
for age group and gender-specific population data, the census tract is the smallest 
geographic area for which cancer rates can be accurately calculated.   
Although residents might move in and out of the area evaluated during the 22–year 
period of the study, presumably these migrations balance one another over the course of 
time. 
Comment 18: What about individuals who are not treated in hospitals, where they are 
required to report cancer incidences? 
Response: 
The MDPH was able to look at the patterns of cancer in Belmont and the surrounding 
communities by using data collected by the MCR.  The MCR is a population-based 
surveillance system that collects information on all Massachusetts residents diagnosed 
with cancer, and state law requires that all new cancer diagnoses be reported to the MCR 
within 6 months of diagnosis, regardless of where the diagnoses occur.  According to 
state regulations, all health care facilities, including but not limited to hospitals and health 
care providers who provide diagnosis, evaluation, treatment, medical support or palliative 
services to patients with malignant disease or benign brain-related tumor disease shall 
report to the MCR.  A health care facility means “any facility or institution, whether 
public or private, proprietary or not for profit, including but not limited to hospitals, 
including general hospitals, free-standing radiation therapy and outpatient oncology 
centers, nursing homes, hospices, all pathology and cytology laboratories, including 
hospital laboratories, health maintenance organizations and other outpatient facilities 
such as free-standing surgical centers, which diagnose, evaluate or provide cancer 
treatment to cancer patients (105 CMR 301).” 
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Estimates of MCR completeness in reporting have increased steadily since the registry 
was established in 1982. In its early years, the MCR was estimated to include 90-95% of 
all reportable cancer cases in Massachusetts.  More recently, efforts to improve case 
ascertainment have increased completeness to more than 95%, and the MCR is 
considered by the North American Association of Central Cancer Registries to have 
achieved the gold standard for certification in recent years (MDPH 2006).   
Comment 19: The Massachusetts Department of Environmental Protection (MDEP) 
recommended a wording change in the recommendation regarding future 
characterization of groundwater conditions and flow patterns in the event of construction 
or development of the Cambridge Plating property, specifically they recommended the 
citation of the applicable regulations. 
Response: 
MDPH changed the text from “…should be required by MDEP…” to “…should be 
conducted in accordance with MDEP regulations, the MCP 310 CMR 40.000…” 
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Additional Analyses in Response to Public Comments 

Assessment of Cancer Incidence in Belmont, Massachusetts, and Surrounding 
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 I. Introduction and Background 
On October 20, 2005, the Community Assessment Program (CAP) of the Massachusetts 
Department of Public Health (MDPH), Bureau of Environmental Health (BEH) released 
for public comment the Public Health Assessment (PHA) report titled Evaluation of 
Environmental Concerns and Cancer Incidence in Belmont and Surrounding 
Communities, Middlesex County, Massachusetts, 1982–1999 (MDPH 2005). This 
investigation was conducted in response to requests by the Belmont Department of 
Health, community residents, and in response to a legislative directive, to address 
concerns about suspected increases in cancer incidence in the vicinity of the Cambridge 
Plating Company and a possible relationship to environmental contamination.  The 2005 
report describing that investigation provided an evaluation of six cancer types in the town 
of Belmont and the surrounding communities of Cambridge, Arlington, and Watertown.  
Cancers of the kidney, liver, lung and bronchus, and pancreas as well as leukemia and 
non-Hodgkin’s lymphoma (NHL) were evaluated based on potential associations with 
contaminants of concern at the Cambridge Plating site and/or residents’ concerns over 
suspected elevations in some cancer types. 
The findings of the 2005 PHA report indicated that, in general, the six cancer types 
evaluated occurred near or below the expected rates for Belmont census tracts (CTs) 
3572, where Cambridge Plating is located, and the adjacent CT 3571 and for the town of 
Belmont as a whole during the 18-year time period, 1982–1999.  Similar trends were 
observed in the surrounding communities of Cambridge, Arlington, and Watertown.   
In addition to calculating cancer incidence rates, analysis of the geographic distribution 
of place of residence for individuals diagnosed with cancer did not reveal any atypical 
spatial patterns that would suggest a common factor (environmental or 
nonenvironmental) in Belmont as a whole, CTs 3571 and 3572, or the surrounding 
communities of Cambridge, Arlington, and Watertown is related to the incidence of 
cancer. No unusual concentrations of individuals diagnosed with cancer were observed 
in the vicinity of the Cambridge Plating site or in any other area of Belmont, Cambridge, 
Arlington, or Watertown. 
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This current assessment contains additional analyses requested by concerned residents 
and received during the public comment period for the report released on October 20, 
2005 (MDPH 2005). Public comments on the October 20, 2005 report were accepted 
through December 15, 2005.  Two additional analyses were performed in response to 
public comments and results are provided below.  Requests for additional analyses 
included further evaluation of the six cancer types analyzed in the public comment 
release report for the most recent time period, 2000-2003, and well as requests for 
analyses of bladder, brain and central nervous system (CNS) cancer, breast cancer and 
stomach cancer in Belmont. 
II.	 Cancer Incidence, 2000–2003, for Six Cancer Types Analyzed in 2005 Public 
Health Assessment (PHA) for Belmont and Surrounding Communities  
Cambridge Plating is located in CT 3572 close to the border of CT 3571 (see Figure 1 in 
the main report).  This section presents cancer incidence rates for the town of Belmont, 
with particular focus on Belmont CTs 3571 and 3572, during the most recent time period 
for which data were available at the time of this writing, 2000–2003.  A summary of the 
cancer experience in the communities of Cambridge, Arlington, and Watertown is also 
provided. Cancer incidence results for Belmont as a whole and the census tracts 
immediately surrounding Cambridge Plating are presented in Tables 1-3, while results for 
Cambridge, Arlington, and Watertown are presented in Tables 4, 5, and 6, respectively.  
Standardized Incidence Ratios (SIRs) were not calculated for some cancer types due to 
the small number of observed cases (less than five).  However, the expected number of 
cases was calculated during each time period, and the observed and expected numbers of 
cases were compared to determine whether more cancer cases were occurring than 
expected. 
A. Results 
1.	 Town of Belmont 
The cancer types evaluated in this section generally occurred approximately near or 
below expected rates in the town of Belmont as a whole during the 4-year time period, 
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2000–2003, although one statistically significant elevation was observed (i.e., NHL 
among females) (Table 1). 
NHL occurred more often than expected in Belmont during 2000–2003 (32 diagnoses 
observed vs. 23.6 expected, SIR = 136, 95% CI = 93-191).  Eleven males were diagnosed 
with NHL during 2000–2003 compared to about 12 males expected.  The elevation was 
due to approximately nine additional diagnoses among females (21 diagnoses observed 
versus 11.7 expected, SIR = 180, 95% CI = 111-275) and was statistically significant. 
This statistically significant elevation among females diagnosed with NHL is discussed 
later, when risk factor information is summarized for these females diagnosed with NHL. 
Overall, kidney cancer, liver cancer, and lung and bronchus cancer occurred less often 
than expected during 2000–2003. Kidney cancer occurred statistically significantly less 
often than expected in Belmont during 2000–2003 (7 diagnoses observed vs. 16.1 
expected, SIR = 44, 95% CI = 17–90).  Three males were diagnosed with kidney cancer 
compared to about ten expected.  Among females, there were four diagnoses observed 
compared to about seven diagnoses expected.  Liver cancer occurred slightly less often 
than expected in Belmont during 2000–2003 (4 diagnoses observed vs. 5.8 expected).  
Lung and bronchus cancer occurred statistically significantly less often than expected in 
Belmont (56 diagnoses observed vs. 87.5 expected, SIR = 64, 95% CI = 48–83) during 
the 4-year time period, 2000–2003.  
Leukemia occurred at approximately the expected rate for males and females evaluated 
together during 2000–2003. Fifteen diagnoses of leukemia were observed in Belmont 
versus about 14 expected. Males in Belmont experienced fewer diagnoses of leukemia 
than expected during 2000–2003 (4 observed vs. 7.2 expected).  However, among 
females, more diagnoses occurred during 2000–2003 than expected (11 diagnoses 
observed vs. 6.5 expected), but this elevation was not statistically significant. 
Pancreatic cancer occurred more often than expected during 2000–2003 based on the 
statewide cancer experience. Nineteen diagnoses of pancreatic cancer were observed in 
Belmont during 2000–2003 versus about 15 expected.  The increase was based on 
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approximately one additional diagnosis for males and approximately three additional 
diagnoses for females over the expected number and was not statistically significant. 
2. Belmont CTs 3571 and 3572 
Rates of kidney cancer, leukemia, liver, lung and bronchus cancer, and pancreatic cancer 
were approximately near or below the expected rates among males and females combined 
in Belmont CT 3571 during the 4-year time period, 2000–2003 (Table 2).  Lung and 
bronchus cancer occurred statistically significantly less often than expected among males 
and females combined during this time (8 diagnoses observed vs. 19.3 expected, SIR = 
42, 95% CI = 18-82). 
Of the six cancer types evaluated in this section, one statistically significant elevation was 
observed (i.e., NHL) during the time period 2000–2003 in Belmont CT 3571.  NHL 
occurred statistically significantly more often than expected (12 diagnoses observed 
versus 5.1 expected, SIR = 237, 95% CI = 123-415). This elevation was due to 
approximately one additional diagnosis among males in CT 3571, and approximately five 
additional diagnoses among females in CT 3571.  The elevation observed among females 
in CT 3571 was statistically significant and is further discussed below in section B.1 (see 
page 261). 
Rates of kidney cancer, leukemia, liver, lung and bronchus cancer, and NHL were 
approximately near or below the expected rates among males and females combined in 
Belmont CT 3572, where Cambridge Plating is located, during the 4-year time period 
2000–2003 (Table 3). 
Pancreatic cancer occurred statistically significantly more often among males and 
females in Belmont CT 3572 during 2000–2003.  Six individuals were diagnosed with 
pancreatic cancer among males and females combined while approximately 1.8 would 
have been expected. About one excess case occurred among males (2 diagnoses 
observed vs. 0.9 expected), while about 3 excess cases of pancreatic cancer occurred 
among females (4 diagnoses observed vs. 0.9 expected).  Cancer risk factor information 
related to pancreatic cancer is discussed below in section B.2 (see page 263). 
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3. City of Cambridge 
Cancer incidence rates were evaluated for the city of Cambridge.  The results of these 
analyses are summarized for each of the six cancer types in Table 4.  The evaluation 
indicates that rates during the 2000–2003 time period were very similar to rates in the 
previously evaluated time period, 1982–1999.  Citywide incidence rates in Cambridge 
during 2000–2003 were lower than expected for kidney cancer, leukemia, lung and 
bronchus cancer, and NHL.  Rates were about as expected for pancreatic cancer and 
higher than expected for liver cancer. Overall, 21 individuals were diagnosed with liver 
cancer compared to 15.3 expected (SIR = 137, 95% CI = 85-209).  The elevation in liver 
cancer was not statistically significant for males and females evaluated together.  
However, among females in Cambridge, nine individuals were diagnosed with liver 
cancer, compared to about four expected and the elevation was statistically significant. 
4. Town of Arlington 
In general, residents of Arlington experienced the six cancer types evaluated 
approximately at or below the rates expected during 2000–2003 (Table 5).  Leukemia, 
liver cancer, lung and bronchus cancer, and pancreatic cancer all occurred less often than 
expected during 2000–2003. Overall, the incidence of lung and bronchus cancer in 
Arlington continued to be statistically significantly decreased with respect to the state rate 
during 2000–2003 (117 diagnoses observed vs. 150.5 expected, SIR = 78, 95% CI = 64– 
93). Kidney cancer occurred near expected rates during this time period (29 diagnoses 
observed vs. 27.5 expected, SIR = 105, 95% CI = 71–151), while NHL was diagnosed at 
slightly higher rates than expected during 2000–2003.  Overall, 45 individuals were 
diagnosed with NHL compared to 40.8 expected (SIR = 110, 95% CI = 80-148).  The 
elevation in NHL was not statistically significant. 
5. Town of Watertown 
With one exception, Watertown residents experienced the six cancer types approximately 
at or below the rates expected during 2000–2003 (Table 6).  Specifically, the incidence of 
leukemia, liver cancer, lung and bronchus cancer, NHL, and pancreatic cancer were all 
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lower than expected during the time period 2000–2003.  A slight elevation in kidney 
cancer continued to be observed during this time period, however the elevation was not 
statistically significant.  The incidence of kidney cancer among males and females 
combined was slightly higher than expected based on the state rate (23 diagnoses 
observed vs. 20.1 expected, SIR = 114, 95% CI = 72-171). 
B. Review of Cancer Risk Factor Information 
As previously mentioned in the report, cancer is not just one disease, but is a term used to 
describe a variety of different diseases.  As such, studies have generally shown that 
different cancer types have different causes, patterns of incidence, risk factors, latency 
periods (the time between exposure and development of disease), characteristics, and 
trends in survival.  Available information from the Massachusetts Cancer Registry 
(MCR) related to age and gender, as well as other factors related to the development of 
cancer such as smoking and occupation, was reviewed for individuals diagnosed with 
cancer in Belmont.  Information for the two cancer types (i.e., NHL and pancreatic 
cancer) that were statistically significantly elevated was compared to known or 
established incidence trends to assess whether any unexpected patterns exist among these 
cases. It is important to note, however, that personal risk factors such as family history, 
pre-existing medical conditions, hormonal events, diet, and other factors also influence 
the development of these cancer types.  This information is not collected by the MCR or 
any other readily accessible source.  Therefore, it was not possible to evaluate the role 
these types of risk factors may have played in the incidence of cancer in Belmont in this 
investigation. 
Age and gender are risk factors in many types of cancers, including kidney cancer, liver 
cancer, lung and bronchus cancer, leukemia, NHL, and pancreatic cancer.  Therefore, a 
review of age-group specific SIRs was conducted for the cancer types with statistically 
significant elevations.  Where numbers of cases in each age group were too small to 
calculate SIRs, the distribution of cases by age was reviewed. 
Tobacco use is also a known or suggested causal risk factor in several types of cancer, 
including kidney cancer, lung and bronchus cancer, and pancreatic cancer.  The smoking 
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history of individuals diagnosed with pancreatic cancer was reviewed to assess the role 
tobacco smoking may have played in the development of this cancer among residents of 
Belmont.  However, results of smoking history analysis should be interpreted with 
caution because of the number of individuals for which smoking status was unknown. 
In some studies, an association has been found between specific occupational exposures 
and an increase in the incidence of kidney cancer, leukemia, liver cancer, lung and 
bronchus cancer, NHL, and pancreatic cancer.  Therefore, occupational information as 
reported to the MCR at the time of diagnosis was reviewed for individuals diagnosed 
with statistically significantly elevated cancer types to determine the role that 
occupational factors may have played in the development of these cancers in Belmont.  It 
should be noted, however, that occupational data reported to the MCR are generally 
limited to job title and often do not include specific job duty information that could 
further define exposure potential for individual cases.  In addition, these data are often 
incomplete as occupational information can be reported as unknown, at home, or retired. 
1. Non-Hodgkin’s Lymphoma (NHL) 
Non-Hodgkin’s lymphoma (NHL) can occur at all ages; however, the average age at 
diagnosis is the early 60s, and the incidence of this disease generally increases with age.  
The American Cancer Society estimates that approximately 63,190 Americans will be 
diagnosed with NHL in 2007, making it the fifth most common cancer in the United 
States among both men and women, excluding nonmelanoma skin cancers (ACS 2006a).  
Although the primary factors related to the development of NHL include viral infections 
and conditions that suppress the immune system, certain exposures related to occupations 
involving chemicals or agriculture have been associated with an increased risk of 
developing NHL. Farmers, herbicide and pesticide applicators, and grain workers appear 
to have the most increased risk (Zahm et al. 1990 and 1993; Tatham et al. 1997).  An 
elevated risk for NHL development has also been noted among fence workers, orchard 
workers, and meat workers.  High-dose exposure to benzene has been associated with 
NHL (ACS 2006a); however, a recent international cohort study indicated that petroleum 
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workers exposed to benzene were not at an increased risk of NHL (Wong and Raabe 
2000). 
a. Age and Gender 
In the town of Belmont as a whole, a statistically significant elevation in the incidence of 
NHL was noted for females only, during the 4-year time period 2000–2003.  During this 
time period males were diagnosed about as expected in Belmont.  Among the 32 
individuals diagnosed in the town of Belmont, the average age at diagnosis was 71 years, 
which is consistent with that seen in the general population.  Among males, NHL 
occurred about as expected with 82% of the diagnoses occurring in males age 60 and 
older. Among females, NHL occurred statistically significantly more often than expected 
with 15 of the 21 diagnoses (71%) occurring in females age 60 and older.   
Among individuals diagnosed with NHL in Belmont CT 3571, a statistically significant 
elevation was noted for the 4-year time period 2000–2003.  The average age at diagnosis 
for individuals diagnosed with NHL in Belmont CT 3571 during this time period was 67 
years, which is consistent with that seen in the general population. The average age for 
individuals diagnosed with NHL in the state of Massachusetts was 65 years.  Among 
males, NHL occurred about as expected with 75% of the diagnoses occurring in males 
age 60 and older. Among females, NHL occurred statistically significantly more often 
than expected with four of the eight diagnoses occurring in females age 60 and older.   
b. Occupation 
On the basis of a review of job title information as reported to the MCR for individuals in 
Belmont diagnosed with NHL during 2000–2003, occupational exposures do not appear 
likely for the majority of those diagnosed.  However, two individuals reported working in 
an occupation in which occupational exposures may have been possible.  Information 
regarding specific job duties that could help to further define exposure potential for these 
individuals was not available.  Occupation was reported as retired, unknown, or at home 
for 38% of individuals (n = 12). 
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Review of occupational information for individuals diagnosed with NHL in Belmont CT 
3751 revealed that two individuals may have worked jobs in which occupational 
exposures potentially related to the development of NHL may have been possible.  
However, information regarding specific job duties that could help to further define 
exposure potential for these individuals was not available.  Occupation was reported as 
retired, unknown, or at home for 25% of individuals (n = 3).  The occupations reported 
for the remaining seven individuals are not likely related to an increased risk of this 
cancer type. 
c. Previous Cancer Diagnosis 
According to the American Cancer Society, individuals treated with radiation therapy for 
some other cancers have a slightly increased risk of developing NHL later in life (ACS 
2006a). Individuals treated with some chemotherapy drugs for other cancers may also 
have an increased risk of developing NHL later in life; however, a direct cause and effect 
relationship has not yet been definitely established (ACS 2006a).  Among the 12 
individuals diagnosed with NHL in Belmont CT 3571, five individuals (42%) had a 
previous cancer diagnosis. Unfortunately, the data reported to the MCR does not include 
information regarding specific treatments for the individuals’ previous cancer diagnoses. 
However, it is possible that treatment related to previous cancer diagnoses may have 
played a role in NHL incidence in this census tract.  
2. Pancreatic Cancer in Belmont CT 3572 
The risk of developing pancreatic cancer increases with age, and the majority of cases 
occur between ages 60 and 80. Besides age, the most consistent risk factor for pancreatic 
cancer is cigarette smoking.  According to the American Cancer Society, approximately 
30% of all pancreatic cancer cases are thought to result directly from cigarette smoking 
(ACS 2006b). Studies have estimated that the risk of pancreatic cancer is two to six 
times greater in heavy smokers than in nonsmokers (Anderson et al. 1996). 
Numerous occupations have been investigated for their potential role in the development 
of pancreatic cancer, but studies have not produced consistent results.  Heavy exposure to 
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certain pesticides (including DDT and its derivatives) may increase the risk of pancreatic 
cancer (ACS 2006b; Ji et al. 2001; Porta et al. 1999).  Exposure to certain dyes and to 
certain chemicals related to gasoline, in addition to exposure to asbestos and ionizing 
radiation, have also been associated with the development of pancreatic cancer in some 
studies. Other studies, however, have found no link between these agents and pancreatic 
cancer (Anderson et al. 1996). A recent evaluation of data from several studies has 
implicated organic solvents (e.g., chlorinated hydrocarbons and polycyclic aromatic 
hydrocarbons), nickel compounds, and chromium compounds in the development of 
pancreatic cancer, but further studies are needed to corroborate this finding (Ojajarvi et 
al. 2000). 
a. Age and Gender 
A review of individuals diagnosed with pancreatic cancer in Belmont CT 3572 from 
2000–2003 revealed that more females (67%) than males (33%) were diagnosed.  A 
review of individuals diagnosed with pancreatic caner in the state of Massachusetts 
revealed that only slightly more females (54%) than males (46%) were diagnosed.  The 
average age at diagnosis for individuals with pancreatic cancer in Belmont CT 3572 
during 2000–2003 was 69 years, consistent with the statewide average age at diagnosis of 
71 years. Eighty-three percent of those diagnosed were age 65 or older at the time of 
diagnosis. 
b. Smoking History 
Of the six individuals diagnosed with pancreatic cancer in Belmont CT 3572 during 
2000–2003, 33% (n = 2) reported being current or former smokers at the time of 
diagnosis. Another 33% (n = 2) were nonsmokers, and smoking history was unknown 
for the remaining 33% (n =2).  In the state as a whole, 41% of those diagnosed with 
pancreatic cancer during 2000–2003 were current or former smokers at the time of 
diagnosis, 30% were nonsmokers, and smoking history was unknown for 29%. 
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c. Occupation 
On the basis of a review of occupational information as reported to the MCR, two of the 
individuals diagnosed with pancreatic cancer in Belmont CT 3572 during 2000–2003 
indicated working in a job likely to be associated with occupational exposures related to 
an increased risk of pancreatic cancer.  However, information regarding specific job 
duties that could help to further define exposure potential for these individuals was not 
available. The occupations reported for three individuals are not likely related to an 
increased risk of this cancer type. Occupation was reported as retired, unknown, or at 
home for the remaining individual. 
C. Analysis of Geographic Distribution of Cancer Incidence 
In addition to determining incidence rates for the six cancer types, a qualitative 
evaluation of the geographic pattern of cancer diagnoses was conducted for the town of 
Belmont and surrounding communities.  Place of residence at the time of diagnosis was 
mapped for each individual diagnosed with the cancer types evaluated in this report to 
assess any possible geographic concentrations of cases in relation to each other or in the 
vicinity of Cambridge Plating.  As previously mentioned, cancer is one word that 
describes many different diseases.  Therefore, for the purposes of this evaluation, the 
geographic distribution of each cancer type was evaluated separately to determine 
whether an atypical pattern of any one type was occurring.  The geographic distributions 
of some specific types of cancer were also evaluated together because they may have 
similar etiologies (e.g., leukemia and NHL in children). 
Based on a review of address at the time of diagnosis for each individual diagnosed with 
a cancer type considered in this section, no apparent concentrations of cancer diagnoses 
(of any type) were observed in the vicinity of the Cambridge Plating site.   
No other unusual spatial patterns or concentrations of cases at the neighborhood level that 
would suggest a common factor (environmental or nonenvironmental) related to cancer 
diagnoses among residents were apparent for any cancer type.  Any patterns that were 
observed were consistent with what would be expected based on the population 
distribution and areas of higher population density.  For example, in Belmont, the 
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majority of individuals with each type of cancer tended to be located in areas of the town 
where population and housing density are greater.  Although elevations in the incidence 
of some cancer types were noted in Belmont or Belmont census tracts, in general, the 
geographic distribution of diagnoses for these cancer types seemed to coincide closely 
with the pattern of population density. Specifically, in Belmont CTs 3571 and 3572 
where elevations in NHL and pancreatic cancer were observed, respectively, there were 
no apparent spatial patterns at the neighborhood level that could not be attributed to 
factors such as areas of higher population density (e.g., the presence of multi-unit housing 
complexes or nursing homes).  Further, no apparent concentrations of cancer diagnoses 
(of any type) were observed in any of the three surrounding communities that would 
suggest a potential relationship to Cambridge Plating.  Thus, it does not appear that 
exposures to environmental contamination associated with Cambridge Plating are likely 
to have played a role in the development of cancer among residents of Belmont or 
surrounding communities. 
D. Discussion 
In general, the six cancer types (e.g., kidney cancer, leukemia, liver cancer, lung and 
bronchus cancer, Non-Hodgkin’s Lymphoma (NHL), and pancreatic cancer) evaluated 
during 2000–2003 occurred approximately near or below expected rates in the town of 
Belmont and the surrounding communities of Cambridge, Arlington, and Watertown.  
However, some elevations were observed.  In Belmont, the incidence of NHL among 
females was statistically significantly elevated in census tract (CT) 3571 during 2000– 
2003. Pancreatic cancer was also statistically significantly elevated among males and 
females evaluated together in Belmont CT 3572 during 2000–2003.  This elevation in 
pancreatic cancer was due to three additional diagnoses among females during this period 
of study. Citywide incidence ratios for liver cancer among females in Cambridge were 
statistically significantly elevated during 2000–2003.   
Available risk factor information for individuals diagnosed with NHL or pancreatic 
cancer in Belmont was compared to known or established trends to assess whether any 
unexpected patterns exist in the town.  In general, risk factor trends observed in Belmont 
were similar to those seen in the general population.  Further evaluation of the pattern of 
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cancer diagnoses revealed that individuals diagnosed with NHL in Belmont CT 3571 
during 2000–2003 were diagnosed with histology types of the disease that are consistent 
with the distribution observed statewide during the same time period.  Of the 12 
individuals diagnosed with NHL in Belmont CT 3571, 50% were diagnosed with the 
most common type of NHL diagnosed in the state.  The remaining individuals were 
diagnosed with ## different histology types of NHL.  Among the eight females diagnosed 
with NHL, four were diagnosed with the most common type of NHL diagnosed in the 
state. Analysis of the geographic distribution of place of residence for individuals 
diagnosed with cancer, with particular focus on NHL diagnoses in Belmont CT 3571 and 
pancreatic cancer diagnoses in Belmont CT 3572, did not reveal any atypical spatial 
patterns that would suggest a common factor (environmental or nonenvironmental) 
related to the incidence of cancer in Belmont or in surrounding communities.   
To evaluate possible trends in cancer incidence over time, data from 1982–1999 was 
evaluated alongside data from the more recent time period, 2000–2003.  Appendix A of 
this report entitled “Assessment of Cancer Incidence in Belmont, Massachusetts, and 
Surrounding Communities: 1982–1999” provides a detailed review of the pattern of 
cancer incidence in Belmont and adjacent communities for the years 1982–1999 and for 
three smaller time periods, 1982–1987, 1988–1993, 1994–1999.  By including the results 
from the most recent time period, 2000–2003, as discussed above, patterns or trends in 
cancer incidence over four time periods can be evaluated.   
In the town of Belmont, an evaluation of cancer incidence over time indicates that kidney 
cancer rates decreased from 1982 through 2003. Lung and bronchus cancer and liver 
cancer occurred approximately at or below expected rates across previously evaluated 
time periods during 1982–1999 and during 2000–2003.  Pancreatic cancer and NHL 
occurred approximately at or below expected rates during three of the four time periods.   
Rates of pancreatic cancer and NHL were elevated during the 2000–2003 time period.  
Neither elevation was statistically significant.  Incidence of leukemia in the town of 
Belmont occurred approximately at or below expected rates in two time periods: 1982– 
1987 and 2000–2003; and occurred slightly above expected rates in two time periods: 
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 1988–1993 and 1994–1999. The slight elevation was not statistically significant and is 
discussed further in Appendix A. 
In Belmont CT 3571, kidney cancer, leukemia, liver cancer, and lung and bronchus 
cancer occurred approximately at or below expected rates across time periods evaluated 
in Appendix A of this report, 1982-1999, and during 2000-2003.  NHL occurred 
approximately at or below expected rates during three of the four time periods and was 
elevated during the 2000-2003 time period.  This elevation was statistically significant, 
however, an evaluation of risk factors (e.g., age, gender, occupation, previous cancer 
diagnoses), histology types, and spatial and temporal patterns did not reveal any atypical 
patterns that would suggest a common factor (environmental or nonenvironmental) 
related to the incidence of NHL in Belmont CT 3571.  Pancreatic cancer occurred below 
expected rates in two time periods, 1988-1993 and 2000-2003, and occurred slightly 
above expected rates in two time periods, 1982-1987and 1994-1999.  No clear trend was 
apparent in pancreatic cancer over time and no single time period showed a statistically 
significant elevation. 
In Belmont CT 3572, the census tract where Cambridge Plating is located, kidney cancer, 
leukemia, liver cancer, lung and bronchus cancer, and NHL occurred approximately at or 
below expected rates across previously evaluated time periods during 1982–1999 and 
during 2000–2003. Pancreatic cancer occurred approximately at or below expected rates 
during 1982–1999. However, pancreatic cancer occurred statistically significantly above 
expected rates during 2000–2003 and is discussed in Sections IIA (see page 2) and IIB 
(see page 6) of this appendix. 
In the city of Cambridge, an evaluation of cancer incidence over time indicates that rates 
during the 2000–2003 time period were very similar to rates in the previously evaluated 
time period, 1982–1999.  Citywide incidence rates in Cambridge during 1982–1999 and 
2000–2003 were approximately at or below expected rates for kidney cancer, leukemia, 
lung and bronchus cancer, NHL and pancreatic cancer.  Liver cancer occurred slightly 
more often than expected in previously evaluated time periods during 1982–1999 and 
during 2000–2003. 
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In the town of Arlington, kidney cancer, leukemia, and lung and bronchus cancer 
occurred approximately at or below expected rates across previously evaluated time 
periods during 1982–1999 and during 2000–2003. Liver cancer and pancreatic cancer 
showed elevations during the 1982–1987 time period and are discussed in Appendix A of 
this PHA. Rates of liver and pancreatic cancer in the most recent time period evaluated, 
2000–2003, are approximately at or below expected.  Rates of NHL were approximately 
at or below expected during the two earlier time periods, 1982–1987, 1988–1993 and 
were slightly elevated across the two latter time periods, 1994–1999 and 2000–2003.  
The slight elevation in NHL in Arlington was not statistically significant. 
In Watertown, an evaluation of cancer incidence over time indicates that lung and 
bronchus cancer and pancreatic cancer occurred approximately at or below expected rates 
across previously evaluated time periods during 1982-1999 and during 2000-2003.  
Kidney cancer in Watertown occurred below expected rates during 1994–1999, and 
slightly above expected rates in other time periods evaluated.  The slight elevations in 
kidney cancer were not statistically significant for males and females combined.  
However, a statistically significant elevation occurred in males during 1988–1993 and is 
discussed in Appendix A. Rates of leukemia were below expected during two time 
periods: 1982–1987, 2000–2003; and were slightly elevated across two time periods: 
1988–1993 and 1994–1999. Liver cancer occurred approximately at or below expected 
rates during three of the four time periods.  Liver cancer occurred more often than 
expected during 1994–1999 and is discussed in Appendix A.  The slight elevation in 
leukemia in Watertown was not statistically significant.  An evaluation of NHL rates over 
time indicated that incidence of NHL has been decreasing over time.   
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III.	 Cancer Incidence for Four Cancer Types in Belmont Census Tracts 3571 and 3572 
in Response to Community Concern  
The MDPH selected the six cancer types (e.g., kidney cancer, leukemia, liver cancer, 
lung and bronchus cancer, NHL, and pancreatic cancer) for evaluation in the 2005 Public 
Health Assessment (PHA) report based on available environmental data for Cambridge 
Plating and information in the scientific literature on known or suspected associations 
with contaminants of concern (e.g., trichloroethylene, chromium).  However, due to 
community concerns about bladder cancer, brain and central nervous system (CNS) 
cancer, breast cancer, and stomach cancer, the MDPH reviewed cancer incidence data 
from 1982–2003 for each of these types.  To evaluate possible trends over time, cancer 
incidence data were also analyzed by four smaller time periods, 1982–1987, 1988–1993, 
1994–1999, and 2000–2003. 
Because the six cancer types evaluated in the 2005 PHA in relation to Cambridge Plating 
generally occurred near or below the expected rates for the census tracts surrounding the 
facility (Belmont CTs 3571 and 3572) and the town of Belmont as a whole during the 18-
year time period 1982–1999, this evaluation will focus on diagnoses of the four types 
within census tracts immediately surrounding Cambridge Plating.   
The following section presents the results of the cancer incidence analyses for the 
Belmont CTs 3571 and 3572 during the 22-year time period 1982–2003.  Although SIRs 
and 95% confidence intervals were not calculated for some cancer types in smaller time 
periods due to small numbers of observed diagnoses (i.e., fewer than five), the expected 
number of diagnoses was calculated to determine whether excess numbers of diagnoses 
were occurring. These data are summarized in Tables 7a through 7e and 8a through 8e. 
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A. Results 
1. Belmont Census Tract 3571 
Of the cancer types evaluated in this section, three types (bladder cancer, brain/CNS 
cancer, and stomach cancer) occurred approximately near or below expected rates, while 
one (breast cancer) occurred slightly more than expected rates in Belmont CT 3571 
during the 22-year time period 1982–2003 as well as smaller time periods (i.e., 1982– 
1987, 1988–1993, 1994–1999, and 2000–2003). No statistically significant elevations 
were noted during the 22-year time period or during any of the smaller time periods in 
Belmont CT 3571.  
Bladder cancer occurred approximately near expected rates during 1982–2003 based on 
the statewide cancer experience.  Twenty-nine diagnoses of bladder cancer were observed 
in Belmont during 1982–2003 versus about 27 expected.  When examined by smaller 
time periods, no clear trends emerged among males or females over time.  During 1982– 
1987 and 1994–1999, males were diagnosed with bladder cancer slightly less than 
expected, while females were diagnosed slightly more often than expected.  During 
1988–1993, males and females were diagnosed slightly more often than expected based 
on statewide incidence of bladder cancer.  During the most recent time period, 2000– 
2003, bladder cancer rates were near or below the expected rates for males and females in 
Belmont CT 3571.  None of the slight elevations noted during the earlier time periods 
were statistically significant. 
Brain and CNS cancer occurred generally as expected during the overall time period 
1982–2003 and during each of the smaller time periods evaluated.  While brain and CNS 
cancer occurred at about the rate expected based on statewide rates during the three time 
periods, 1982–1987, 1994–1999, and 2000–2003, one additional diagnosis was noted 
during the time period 1988–1993. 
Females in Belmont CT 3571 were diagnosed with breast cancer more often than 
expected during the overall time period 1982–2003, and during the first three smaller 
time periods evaluated.  The increases observed during the smaller time periods were 
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based on approximately four to five additional diagnoses over the expected number 
among females and were not statistically significant.  During the most recent time period, 
2000–2003, females were diagnosed with breast cancer less than the expected rates in 
Belmont CT 3571.   
Stomach cancer occurred less often than expected during 1982–2003 and during each of 
the smaller time periods.  The incidence of stomach cancer appears to have remained 
consistent over time among both male and female residents of Belmont CT 3571, with a 
slight decrease in incidence in the most recent time period evaluated, 2000–2003.  During 
the most recent time period evaluated, no individuals were diagnosed with stomach 
cancer compared to about two diagnoses expected.  Both males and females experienced 
lower than expected incidence of stomach cancer during all time periods. 
Refer to Tables 7a– 7e for bladder, brain and CNS, breast, and stomach cancer incidence 
rates in Belmont CT 3571. 
2. Belmont Census Tract 3572 
Rates of bladder cancer and stomach cancer were near or below the expected rates among 
males and females combined in Belmont CT 3572 during the 22-year time period, 1982– 
2003. Slightly more brain and CNS cancer diagnoses were observed during the overall 
time period; however, the elevation was not statistically significant.  Statistically 
significant elevations in breast cancer were observed among females during the 22-year 
time period, as well as during two of the smaller time periods, 1988–1993 and 2000– 
2003. 
When examined by smaller time periods, incidence of bladder cancer was generally near 
or below the expected rates for males and females combined and no clear patterns 
emerged when males and females were evaluated separately.  During 1988–1993, about 
one additional diagnosis was observed for males and females combined.  This was due to 
fewer diagnoses than expected among males (2 diagnoses observed vs. 2.9 expected) and 
more diagnoses than expected among females (3 diagnoses observed vs. 1.1 expected). 
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 Brain and CNS cancer occurred slightly more often than expected during the 22-year 
time period from 1982–2003 (9 diagnoses observed vs. 6.3 expected).  The elevation was 
based on approximately one additional diagnosis for females during 1982–1987 and one 
additional diagnosis for males during 1994–1999. 
Evaluation of breast cancer showed statistically significant elevations from 1988–1993 
and 2000–2003 and a higher than expected number of diagnoses during 1994–1999.  
Breast cancer during 1982–1987 occurred approximately as expected, with 15 diagnoses 
observed compared to 15.2 diagnoses expected based on statewide cancer incidence. 
Stomach cancer was diagnosed approximately near or below the expected rate for three 
of the four smaller time periods.  During the most recent time period, 2000–2003, 
approximately one additional diagnosis was noted for males and approximately one 
additional diagnosis was noted for females.  This elevation was not statistically 
significant. 
Refer to Tables 8a– 8e for bladder, brain and CNS, breast, and stomach cancer incidence 
rates in Belmont CT 3572. 
B. Review of Risk Factor Information 
1. Breast Cancer in Belmont Census Tract 3572 
Breast cancer is the most frequently diagnosed cancer among women in both the United 
States and in Massachusetts and accounts for almost 30% of all newly diagnosed cancers 
among females (Henderson et al. 1996).  Breast cancer has the highest incidence rate of 
all cancers among women ages 35 and above, with higher incidence rates in the older age 
groups (Devesa et al. 1995). According to the American Cancer Society, about 17% of 
new breast cancer diagnoses are among women in their 40s, while approximately 78% 
occur in women over age 50 (ACS 2006c).  Breast cancer incidence and age have been 
shown to be related because incidence increases from age 35 to 45, increases at a slower 
rate from age 45 to 50, and at a steeper rate in post-menopausal women after age 50 
(Kessler 1992). 
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The risk of developing breast cancer can be influenced by a number of factors.  
Epidemiological studies have determined some well-established risk factors for this 
cancer type. The most well-established risk factors for breast cancer are related to 
genetic and specific reproductive events in a woman’s life, such as age at first pregnancy, 
number of births, and age at menopause (Kessler 1992).  Other factors such as a woman’s 
age and demographic characteristics (e.g., socioeconomic status) are known to increase 
breast cancer risk. More recent research on breast cancer has included evaluation of the 
possible contributions of occupation or environmental factors in breast cancer 
development.  
a. Age and Gender 
A review of individuals diagnosed with breast cancer in Belmont CT 3572 from 1982– 
2003 revealed that approximately 17% were in their 40s at time of diagnosis.  An 
additional 75% were age 50 or older at time of diagnoses.  This is consistent with 
established prevalence patterns reported by the American Cancer Society (ACS 2006c).  
The average age at diagnosis for individuals with breast cancer in Belmont CT 3572 
during 1982–2003 was 61 years, which is consistent with established trends of this 
disease. The majority of the individuals diagnosed with breast cancer in Belmont CT 
3572 were women.  Two men were diagnosed with breast cancer in Belmont CT 3572 
during this time.  This gender pattern is also consistent with general prevalence patterns 
of breast cancer. 
C. Analysis of Geographic Distribution of Cancer Incidence 
In addition to determining incidence rates for each cancer type, a qualitative evaluation of 
the geographic pattern of cancer diagnoses was conducted, particularly as it relates to 
areas of environmental concern.  The place of residence for individuals diagnosed with 
bladder cancer, brain and CNS cancer, breast cancer, and stomach cancer in Belmont CTs 
3571 and 3572 was evaluated to identify any geographic concentrations of cases that 
might be present within the community.   
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Based on a review of address at the time of diagnosis for each individual diagnosed with 
the cancer types evaluated in this section, no atypical spatial patterns that would suggest a 
common factor (environmental or nonenvironmental) related to the incidence of cancer in 
the surrounding communities were noted.  In general, any patterns observed were 
consistent with what would be expected based on the population distribution and areas of 
higher population density. Further, no apparent concentrations of cancer diagnoses (of 
any type) were observed in Belmont CTs 3571 or 3572 that would suggest a potential 
relationship to Cambridge Plating. 
D. Discussion 
The MDPH selected six cancer types (e.g., kidney cancer, leukemia, liver cancer, lung 
and bronchus cancer, NHL, and pancreatic cancer) for evaluation in the 2005 PHA report 
based on available environmental data for Cambridge Plating and information in the 
scientific literature on known or suspected associations with the contaminants of concern.  
However, to address community concerns about breast, brain, bladder and stomach 
cancers, cancer incidence rates for these four types were calculated and presented as 
additional analyses in this report. 
The MDPH reviewed cancer incidence data for the Belmont CTs surrounding the facility 
for the four cancer types. The overall time period, 1982–2003, as well as four smaller 
time periods were analyzed to evaluate possible trends over time.  Three of the four 
cancer types evaluated during 1982–2003 occurred approximately near expected rates in 
Belmont CTs 3571 and 3572.  Breast cancer occurred statistically significantly more 
often than expected in Belmont CT 3572 during the overall time period, 1982–2003, and 
during two smaller time periods, 1988–1993 and 2000–2003.   
To better understand the pattern of breast cancer in Belmont CT 3572, the stage of cancer 
at the time of diagnosis was also reviewed.  The staging of breast cancer categorizes the 
extent of the disease and its spread at the time of diagnosis.  Communities in which many 
women receive routine breast cancer screening are expected to have a greater number of 
women diagnosed at the early stages of the disease.  Conversely, communities with low 
screening rates would be expected to have more diagnoses occurring at the later stages of 
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disease. Invasive breast cancer is typically classified as one of four stages of disease: 
localized, regional, distant, and unknown. Localized breast cancer represents a diagnosis 
in which the tumor is invasive but the cancer is confined to the breast.  Regional refers to 
a tumor that has spread beyond the organ of origin (breast), including spread to adjacent 
tissues and organs, lymph nodes, or both.  Distant stage breast cancer is a cancer that has 
metastasized or spread to organs other than those adjacent to the organ of origin, to 
distant lymph nodes, or both (MCR 1996).  Some diagnoses are reported to the 
Massachusetts Cancer Registry (MCR) with an unknown stage meaning that, at the time 
of reporting by a hospital or other facility (e.g., physician's office), the tumor had not 
been staged. 
Since the inception of the MCR in 1982, breast cancer staging has changed over time in 
Massachusetts. Prior to 1995, the MCR did not require the use of a standardized staging 
system, so hospital registrars used different staging systems when reporting diagnoses to 
the MCR. In 1995, the MCR adopted one staging system and required all hospital 
registrars to report staging information using this system.  Due to the variability of 
staging data for diagnoses prior to 1995, this analysis examined the more reliable staging 
data (for both Belmont residents and the state as a whole) that was available for the 1995-
2003 time period1. 
From 1995-2003, approximately 61% of breast cancer diagnoses among individuals in 
Belmont CT 3572 were diagnosed at the local stage of disease, approximately 34% were 
diagnosed at the regional stage, and just fewer than 3% were diagnosed at either the 
distant stage or with an unknown stage. The combined earlier stages are similar to the 
distribution observed statewide during this time period (65.7% local, 26.4% regional, 
4.4% distant, and 3.5% unknown). 
1 Breast cancer staging information is based on the staging systems in use at the time of diagnosis and/or 
reporting.  For pre-1995 staging data, in most cases, the American Joint Committee on Cancer’s TNM 
(Tumor, Node, Metastasis) staging system was used.  For post-1995 staging data (through 2003), the SEER 
(Surveillance, Epidemiology and End Results) Summary Stage system was used.  Regardless of the time 
period, for the purposes of this report, breast cancer stages were categorized as local, regional, distant, or 
unknown.  These categories are more general than currently used by physicians and tumor registrars, but 
are appropriate for descriptive epidemiological investigations. 
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Despite the vast number of studies on the causation of breast cancer, known risk factors 
are estimated to account for slightly more than half of all diagnoses in the general 
population (Madigan et al. 1995). Researchers are continuing to examine other potential 
genetic, hormonal, and environmental (e.g., pesticides or PCBs) risk factors for breast 
cancer. Nonetheless, it is known that a female’s risk for developing breast cancer can 
change over time due to many factors, some of which are dependent upon well-
established risk factors for this cancer type.  Females with a family history of breast 
cancer, those who have never had children, or have had their first child after the age of 
30, are at an increased risk for developing this disease (ACS 2006c).  Women who take 
menopausal hormone therapy (estrogen plus progestin) for 5 or more years after 
menopause also appear to have an increased risk of developing breast cancer (National 
Cancer Institute 2005). Information related to family history of breast cancer, 
reproductive factors, and use of hormone replacement therapy after menopause is not 
included in the MCR database. 
Although the number of reported diagnoses of breast cancer exceeded the number of 
expected diagnoses during the 22-year time period evaluated, no unusual patterns were 
noted. From the available data, it does not appear that a common factor (environmental 
or nonenvironmental) played a major role in the incidence of breast cancer in Belmont 
CTs 3571 or 3572. The MDPH will continue to monitor the incidence of all cancer types 
in the town through city/town cancer incidence reports published by the MCR. 
IV. Conclusions 
•	 With two exceptions, the cancer types evaluated in relation to Cambridge Plating 
occurred near or below the expected rates for Belmont CTs 3571 and 3572 and the 
town of Belmont as a whole during the 4-year time period, 2000–2003.  Similar 
trends were observed in the surrounding communities of Cambridge, Arlington, and 
Watertown. The incidence of NHL among females in Belmont and among females in 
CT 3571 was statistically significantly elevated during this time period, as was the 
incidence of pancreatic cancer among males and females in CT 3572.  A review of 
available risk factor information and spatial and temporal patterns for individuals 
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diagnosed with NHL or pancreatic cancer in Belmont showed that patterns observed 
in Belmont are similar to those seen in the general population.  No unusual 
concentrations of individuals diagnosed with cancer (including those cancer types 
with a potential association with exposure to TCE and chromium) were observed in 
the vicinity of the Cambridge Plating site or in any other area of Belmont, Cambridge, 
Arlington, or Watertown. 
•	 With one exception, the cancer types (bladder, brain and CNS, breast, stomach) 
evaluated at the request of the community occurred near or below expected rates for 
Belmont CTs 3571 and 3572.  Breast cancer among females in Belmont CT 3572 was 
statistically significantly elevated, however, review of the geographic distribution of 
individuals diagnosed with breast cancer in CTs surrounding Cambridge Plating 
revealed no apparent spatial patterns at the neighborhood level that would suggest a 
common factor (environmental or nonenvironmental) related to cancer diagnoses 
among residents.  Review of available risk factor information for individuals 
diagnosed with breast cancer (e.g., age, gender) suggests that the trends observed in 
Belmont CTs are similar to those seen in the general population.   
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TABLE 1

Cancer Incidence

Belmont, Massachusetts

2000-2003

Cancer Type Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
Kidney 7 16.1 44 * 17 90 -- 3 9.6 NC NC  -- NC 4 6.5 NC NC  -- NC 
Leukemia 15 13.7 109 61 180 -- 4 7.2 NC NC  -- NC 11 6.5 169 84  -- 302 
Liver 4 5.8 NC NC NC -- 2 4.3 NC NC  -- NC 2 1.5 NC NC  -- NC 
Lung & Bronchus 56 87.5 64 * 48 83 -- 22 44.7 49 * 31  -- 75 34 42.8 79 55  -- 111 
NHL 32 23.6 136 93 191 -- 11 11.9 92 46  -- 165 21 11.7 180 * 111  -- 275 
Pancreatic 19 14.9 127 77 199 -- 8 6.8 117 51  -- 231 11 8.1 136 68  -- 243 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
NHL = Non-Hodgkin's Lymphoma 
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 2

Cancer Incidence

Census Tract 3571, Belmont, Massachusetts

2000-2003

Cancer Type Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
Kidney 1 3.4 NC NC NC -- 0 2.0 NC NC  -- NC 1 1.4 NC NC  -- NC 
Leukemia 4 2.9 NC NC NC -- 2 1.5 NC NC  -- NC 2 1.4 NC NC  -- NC 
Liver 1 1.2 NC NC NC -- 1 0.9 NC NC  -- NC 0 0.3 NC NC  -- NC 
Lung & Bronchus 8 19.3 42 * 18 82 -- 3 9.7 NC NC  -- NC 5 9.6 52 17  -- 121 
NHL 12 5.1 237 * 123 415 -- 4 2.5 NC NC  -- NC 8 2.6 312 * 134  -- 614 
Pancreatic 2 3.4 NC NC NC -- 1 1.5 NC NC  -- NC 1 1.9 NC NC  -- NC 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
NHL = Non-Hodgkin's Lymphoma 
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 3

Cancer Incidence

Census Tract 3572, Belmont, Massachusetts

2000-2003

Cancer Type Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
Kidney 1 2.1 NC NC NC -- 1 1.3 NC NC  -- NC 0 0.8 NC NC  -- NC 
Leukemia 1 1.7 NC NC NC -- 0 0.9 NC NC  -- NC 1 0.7 NC NC  -- NC 
Liver 0 0.8 NC NC NC -- 0 0.6 NC NC  -- NC 0 0.2 NC NC  -- NC 
Lung & Bronchus 7 10.9 64 26 132 -- 4 5.8 NC NC  -- NC 3 5.1 NC NC  -- NC 
NHL 3 2.9 NC NC NC -- 2 1.5 NC NC  -- NC 1 1.3 NC NC  -- NC 
Pancreatic 6 1.8 337 * 123 733 -- 2 0.9 NC NC  -- NC 4 0.9 NC NC  -- NC 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
NHL = Non-Hodgkin's Lymphoma 
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 4

Cancer Incidence

Cambridge, Massachusetts

2000-2003

Cancer Type Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
Kidney 40 42.8 94 67 127 -- 23 25.2 91 58  -- 137 17 17.6 97 56  -- 155 
Leukemia 36 38.1 95 66 131 -- 21 20.3 103 64  -- 158 15 17.8 84 47  -- 139 
Liver 21 15.3 137 85 209 -- 12 11.4 105 54  -- 184 9 4.0 227 * 104  -- 432 
Lung & Bronchus 174 221.1 79 * 67 91 -- 84 110.1 76 * 61  -- 94 90 111.0 81 65  -- 100 
NHL 50 65.5 76 57 101 -- 21 33.7 62 * 39  -- 95 29 31.8 91 61  -- 131 
Pancreatic 39 36.8 106 75 145 -- 16 16.7 96 55  -- 155 23 20.0 115 73  -- 172 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
NHL = Non-Hodgkin's Lymphoma 
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 5

Cancer Incidence

Arlington, Massachusetts

2000-2003

Cancer Type Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
Kidney 29 27.5 105 71 151 -- 19 15.8 120 72  -- 187 10 11.7 86 41  -- 157 
Leukemia 22 23.5 94 59 142 -- 13 11.9 109 58  -- 187 9 11.6 77 35  -- 147 
Liver 9 9.8 92 42 175 -- 5 7.1 70 23  -- 164 4 2.7 NC NC  -- NC 
Lung & Bronchus 117 150.5 78 * 64 93 -- 49 73.2 67 * 50  -- 88 68 77.3 88 68  -- 111 
NHL 45 40.8 110 80 148 -- 22 19.8 111 70  -- 168 23 21.0 110 70  -- 165 
Pancreatic 20 25.6 78 48 121 -- 5 11.1 45 15  -- 106 15 14.6 103 58  -- 170 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
NHL = Non-Hodgkin's Lymphoma 
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 6

Cancer Incidence

Watertown, Massachusetts

2000-2003

Cancer Type Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
Kidney 23 20.1 114 72 171 -- 16 11.4 140 80  -- 227 7 8.7 80 32  -- 165 
Leukemia 15 17.7 85 47 139 -- 3 8.9 NC NC  -- NC 12 8.8 136 70  -- 237 
Liver 4 7.1 NC NC NC -- 3 5.1 NC NC  -- NC 1 2.0 NC NC  -- NC 
Lung & Bronchus 106 112.0 95 77 114 -- 57 54.0 106 80  -- 137 49 58.0 84 62  -- 112 
NHL 29 30.8 94 63 135 -- 13 14.8 88 47  -- 150 16 16.0 100 57  -- 163 
Pancreatic 15 19.3 78 43 128 -- 9 8.1 110 50  -- 210 6 11.2 54 20  -- 117 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
NHL = Non-Hodgkin's Lymphoma 
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 7a

Cancer Incidence

Census Tract 3571, Belmont, Massachusetts

1982-2003

Cancer Type Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
Bladder 29 27.2 107 71 153 -- 15 18.9 79 44  -- 131 14 8.3 168 92  -- 282 
Brain and CNS 12 10.0 120 62 209 -- 4 4.7 NC NC  -- NC 8 5.3 150 65  -- 296 
Breast 121 112.7 107 89 128 -- 0 0.8 NC NC  -- NC 121 111.9 108 90  -- 129 
Stomach 9 14.8 61 28 115 -- 6 8.3 72 26  -- 157 3 6.5 NC NC  -- NC 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
CNS = Central Nervous System 
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 7b

Cancer Incidence

Census Tract 3571, Belmont, Massachusetts

1982-1987

Cancer Type Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
Bladder 10 8.2 121 58 223 -- 4 5.8 NC NC  -- NC 6 2.5 243 89  -- 529 
Brain and CNS 3 2.8 NC NC NC -- 1 1.3 NC NC  -- NC 2 1.6 NC NC  -- NC 
Breast 34 28.5 119 82 166 -- 0 0.2 NC NC  -- NC 34 28.4 120 83  -- 167 
Stomach 3 4.6 NC NC NC -- 2 2.6 NC NC  -- NC 1 2.0 NC NC  -- NC 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
CNS = Central Nervous System 
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 7c

Cancer Incidence

Census Tract 3571, Belmont, Massachusetts

1988-1993

Cancer Type Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
Bladder 9 7.7 117 53 222 -- 6 5.3 112 41  -- 244 3 2.3 NC NC  -- NC 
Brain and CNS 4 3.0 NC NC NC -- 2 1.3 NC NC  -- NC 2 1.7 NC NC  -- NC 
Breast 37 31.8 116 82 161 -- 0 0.2 NC NC  -- NC 37 31.5 117 83  -- 162 
Stomach 3 4.1 NC NC NC -- 2 2.3 NC NC  -- NC 1 1.9 NC NC  -- NC 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
CNS = Central Nervous System 
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 7d

Cancer Incidence

Census Tract 3571, Belmont, Massachusetts

1994-1999

Cancer Type Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
Bladder 7 7.2 97 39 200 -- 3 5.0 NC NC  -- NC 4 2.2 NC NC  -- NC 
Brain and CNS 3 2.5 NC NC NC -- 1 1.3 NC NC  -- NC 2 1.2 NC NC  -- NC 
Breast 35 30.7 114 79 159 -- 0 0.2 NC NC  -- NC 35 30.4 115 80  -- 160 
Stomach 3 3.6 NC NC NC -- 2 2.1 NC NC  -- NC 1 1.5 NC NC  -- NC 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
CNS = Central Nervous System 
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 7e

Cancer Incidence

Census Tract 3571, Belmont, Massachusetts

2000-2003

Cancer Type Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
Bladder 3 3.8 NC NC NC -- 2 2.7 NC NC  -- NC 1 1.1 NC NC  -- NC 
Brain and CNS 2 1.6 NC NC NC -- 0 0.8 NC NC  -- NC 2 0.8 NC NC  -- NC 
Breast 15 18.8 80 45 132 -- 0 0.2 NC NC  -- NC 15 18.6 81 45  -- 133 
Stomach 0 2.3 NC NC NC -- 0 1.3 NC NC  -- NC 0 1.0 NC NC  -- NC 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
CNS = Central Nervous System 
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 8a

Cancer Incidence

Census Tract 3572, Belmont, Massachusetts

1982-2003

Cancer Type Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
Bladder 13 14.0 93 50 159 -- 8 10.1 79 34  -- 156 5 3.9 129 42  -- 302 
Brain and CNS 9 6.3 143 65 271 -- 4 3.2 NC NC  -- NC 5 3.1 163 53  -- 381 
Breast 87 60.9 143 * 114 176 -- 2 0.4 NC NC  -- NC 85 60.4 141 * 112  -- 174 
Stomach 8 7.4 108 46 212 -- 6 4.5 133 48  -- 289 2 2.9 NC NC  -- NC 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
CNS = Central Nervous System 
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 8b

Cancer Incidence

Census Tract 3572, Belmont, Massachusetts

1982-1987

Cancer Type Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
Bladder 3 4.4 NC NC NC -- 3 3.2 NC NC  -- NC 0 1.2 NC NC  -- NC 
Brain and CNS 3 1.7 NC NC NC -- 1 0.8 NC NC  -- NC 2 0.9 NC NC  -- NC 
Breast 15 15.2 99 55 163 -- 0 0.1 NC NC  -- NC 15 15.1 99 56  -- 164 
Stomach 2 2.4 NC NC NC -- 1 1.4 NC NC  -- NC 1 0.9 NC NC  -- NC 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
CNS = Central Nervous System 
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 8c

Cancer Incidence

Census Tract 3572, Belmont, Massachusetts

1988-1993

Cancer Type Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
Bladder 5 3.9 127 41 295 -- 2 2.9 NC NC  -- NC 3 1.1 NC NC  -- NC 
Brain and CNS 1 1.9 NC NC NC -- 0 0.9 NC NC  -- NC 1 1.0 NC NC  -- NC 
Breast 29 16.6 174 * 117 250 -- 1 0.1 NC NC  -- NC 28 16.5 169 * 113  -- 245 
Stomach 2 2.0 NC NC NC -- 2 1.2 NC NC  -- NC 0 0.8 NC NC  -- NC 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
CNS = Central Nervous System 
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 8d

Cancer Incidence

Census Tract 3572, Belmont, Massachusetts

1994-1999

Cancer Type Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
Bladder 3 3.7 NC NC NC -- 1 2.7 NC NC  -- NC 2 1.0 NC NC  -- NC 
Brain and CNS 3 1.6 NC NC NC -- 2 0.9 NC NC  -- NC 1 0.7 NC NC  -- NC 
Breast 22 17.2 128 80 193 -- 0 0.1 NC NC  -- NC 22 17.1 129 81  -- 195 
Stomach 1 1.8 NC NC NC -- 1 1.2 NC NC  -- NC 0 0.7 NC NC  -- NC 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
CNS = Central Nervous System 
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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TABLE 8e

Cancer Incidence

Census Tract 3572, Belmont, Massachusetts

2000-2003

Cancer Type Total Males Females 
Obs Exp SIR 95% CI Obs Exp SIR 95% CI Obs Exp SIR 95% CI 
Bladder 2 2.0 NC NC NC -- 2 1.5 NC NC  -- NC 0 0.5 NC NC  -- NC 
Brain and CNS 2 1.1 NC NC NC -- 1 0.6 NC NC  -- NC 1 0.5 NC NC  -- NC 
Breast 21 11.3 186 * 115 285 -- 1 0.1 NC NC  -- NC 20 11.2 179 * 109  -- 276 
Stomach 3 1.2 NC NC NC -- 2 0.8 NC NC  -- NC 1 0.4 NC NC  -- NC 
Note: SIRs are calculated based on the exact number of expected cases. 
Expected number of cases presented are rounded to the nearest tenth. 
SIRs and 95% CI are not calculated when observed number of cases < 5. 
Obs = Observed number of cases 95% CI = 95% Confidence Interval 
Exp = Expected number of cases NC = Not calculated 
SIR = Standardized Incidence Ratio * = Statistical significance 
CNS = Central Nervous System 
Data Source: Massachusetts Cancer Registry, Bureau of Health Information, Statistics, Research and Evaluation, Massachusetts Department of Public Health. 
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Risk Factor Summary for Bladder Cancer 
The American Cancer Society estimates that bladder cancer will affect 61,420 people in 
the U.S. in 2006, accounting for 6% of all cancers diagnosed in the United States among 
men and 2% among women.  In Massachusetts, bladder cancer accounts for 
approximately 5% of all cancers diagnosed among males and females combined (ACS 
2006a). Males are four times more likely to develop bladder cancer than females and 
whites are two times more likely to develop this disease than blacks.  The risk of bladder 
cancer increases with age and nearly 90% of people with this cancer are over the age of 
55 at the time of diagnosis (ACS 2006b). 
The greatest risk factor for bladder cancer is cigarette smoking.  Smokers are more than 
twice as likely to develop bladder cancer compared to nonsmokers (ACS 2006a).  The 
risk of developing bladder cancer increases with the number of packs smoked per day and 
with duration of smoking.  Further, the risk of bladder cancer may be higher in women 
than in men who smoke comparable numbers of cigarettes (Castelao et al. 2001).  
Approximately 25-60% of all bladder cancers can be attributed to tobacco use (Johansson 
and Cohen 1997). Smoking cessation has been found to reduce the risk of developing 
bladder cancer by 30% to 60% (Silverman et al. 1996). 
Studies have also revealed a number of occupations that are associated with bladder 
cancer. In fact, exposures to chemicals in the workplace account for an estimated 20-
25% of all bladder cancers diagnosed among men in the U.S. (Johansson and Cohen 
1997). Occupational exposure to aromatic amines, such as benzidine and beta-
naphthylamine, increases the risk of bladder cancer (ACS 2006b).  These chemicals were 
common in the dye industry in the past. A higher risk of bladder cancer has also been 
observed among aromatic amine manufacturing workers as well as among workers in the 
rubber, leather, textiles, printing, and paint products industries (ACS 2006a; Silverman et 
al. 1996). The development of new chemicals, changed worker exposures, and the 
elimination of many known bladder carcinogens in the workplace have caused shifts in 
those occupations considered to be high risk.  For example, risks among dye, rubber, and 
leather workers have declined over time, while other occupations such as motor vehicle 
operation (e.g., drivers of trucks, buses, and taxis) and the aluminum industry have 
emerged as potential high-risk occupations (Silverman et al. 1996).  However, specific 
Source: Community Assessment Program, Bureau of Environmental Health, Massachusetts Department of Public Health 
May 2006 
299 
Risk Factor Summary for Bladder Cancer 
occupational exposures in these occupations have not been confirmed and study findings 
are not consistent. Further, the risk of bladder cancer from occupational exposures may 
be increased among smokers (ACS 2006b). 
Dietary factors such as consumption of fried foods as well as foods high in fat and 
cholesterol have been found to be associated with increased bladder cancer risk 
(Silverman et al. 1996).  Use of some anti-cancer drugs (e.g., cyclophosphamide and 
chlornaphazine), use of phenacetin, and infection with Shistosoma haematobium (a 
parasite found in Africa) are thought to be associated with the development of bladder 
cancer. However, not all epidemiological studies have produced convincing findings 
(Silverman et al. 1996). 
Other risk factors for bladder cancer include a personal history of bladder cancer, certain 
rare birth defects involving the bladder, and exposure to ionizing radiation (ACS 2006a; 
Silverman et al. 1996).  Long term exposure to chlorinated by-products in drinking water 
has also been suggested to increase the risk of developing bladder cancer, particularly 
among men (Villanueva 2003). 
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Brain and central nervous system (CNS) tumors can be either malignant (cancerous) or 
benign (non-cancerous). Primary brain tumors (i.e., brain cancer) comprise two main 
types: gliomas and malignant meningiomas.  Gliomas are a general classification of 
malignant tumors that include a variety of types, named for the cells from which they 
arise: astrocytomas, oligodendrogliomas, and ependymomas.  Meningiomas arise from 
the meninges, which are tissues that surround the outer part of the spinal cord and brain.  
Although meningiomas are not technically brain tumors, as they occur outside of the 
brain, they account for about 25% of all reported primary brain tumors and the majority 
of spinal cord tumors.  The majority of meningiomas (about 85%) are benign and can be 
cured by surgery. In addition to these main types, there are a number of rare brain 
tumors, including medulloblastomas, which develop from the neurons of the cerebellum 
and are most often seen in children.  Also, the brain is a site where both primary and 
secondary malignant tumors can arise; secondary brain tumors generally originate 
elsewhere in the body and then metastasize, or spread, to the brain (ACS 2006a).  The 
American Cancer Society estimates that 18,820 Americans (10,730 men and 8,090 
women) will be diagnosed with primary brain cancer (including cancers of the central 
nervous system, or spinal cord) and approximately 12,820 people (7,260 men and 5,560 
women) will die from this disease in 2006 (ACS 2006). 
Brain and spinal cord cancers account for over 20% of malignant tumors diagnosed 
among children aged 0-14 (ACS 2006b).  About half of all childhood brain tumors are 
astrocytomas and 25% are primitive neuroectodermal tumors (PNET), which spread 
along the spinal cord and the meninges (ACS 2006b).  After a peak in childhood 
(generally under 10 years of age), the risk of brain cancer increases with age from age 25 
to age 75. In adults, the most frequent types of brain tumors are astrocytic tumors 
(mainly astrocytomas and glioblastoma multiforme). Incidence rates are higher in males 
than in females for all types.  In general, the highest rates of brain and nervous system 
cancer tend to occur in whites.  However, this varies somewhat by type; the incidence of 
gliomas is lower among black men and women than whites, but for meningiomas, the 
reverse is true (Preston-Martin and Mack 1996). 
Source: Community Assessment Program, Bureau of Environmental Health, Massachusetts Department of Public Health 
May, 2006 
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Despite numerous scientific and medical investigations, and analyses, the causes of brain 
cancer are still largely unknown.  Among the possible risk factors investigated in relation 
to this type of cancer are ionizing radiation, electromagnetic fields, occupational 
exposures, exposure to N-nitroso compounds, head trauma, and genetic disorders. 
The most established risk factor (and only established environmental risk factor) for brain 
tumors (either cancerous or non-cancerous) is high-dose exposure to ionizing radiation 
(i.e., x-rays and gamma rays).  Most radiation-induced brain tumors are caused by 
radiation to the head from the treatment of other cancers (ACS 2006a).  Meningiomas are 
the most common type of tumors that occur from this type of exposure, but gliomas may 
also occur (Preston-Martin and Mack 1996).  Among adults, the risk of developing 
meningiomas has been associated with full-mouth dental x-rays taken decades ago when 
radiation doses were higher than today. Although the relationship between low-dose 
radiation exposure and increased risk of brain tumors has been debated in several studies, 
prenatal exposure from diagnostic x-rays has been related to an increase in childhood 
brain tumors (Preston-Martin and Mack 1996). 
In recent years, there has been increasing public concern and scientific interest regarding 
the relationship of electromagnetic fields (EMF) to brain cancer.  However, results from 
recent epidemiological investigations provide little or no evidence of an association 
between residential EMF exposure (e.g., from power lines and home appliances) and 
brain tumors (Kheifets 2001).  Studies also suggest that the use of handheld cellular 
telephones is not associated with an increased risk of primary brain cancer (Muscat et al. 
2000). However, given the relatively recent use of cellular phones, evidence is 
preliminary and few studies have been conducted. 
Other environmental factors such as exposure to vinyl chloride (used in the 
manufacturing of some plastics) and aspartame (a sugar substitute) have been suggested 
as possible risk factors for brain cancer but no conclusive evidence exists implicating 
these factors (ACS 2006a). Although some occupational studies have suggested that 
electrical and electric utility workers may be at a slightly increased risk of brain cancer, 
these studies have important limitations, such as exposure misclassifications and a lack of 
Source: Community Assessment Program, Bureau of Environmental Health, Massachusetts Department of Public Health 
May, 2006 
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dose-response relationships (Kheifets 2001). Some researchers have also reported an 
increased risk of brain tumors in adults among veterinarians and farmers.  Exposures to 
farm animals and pets have been considered as possible risk factors because of their 
association with bacteria, pesticides, solvents, and certain animal oncogenic (cancer-
related) viruses (Yeni-Komshian and Holly 2000).  However, the relationship between 
farm life and brain cancer remains controversial. 
Recent reports have proposed a link between occupational exposure to lead and brain 
cancer risk, but further analytic studies are warranted to test this hypothesis (Cocco et al. 
1998). In a case-control study, the concentrations of metal and non-metal compounds in 
brain biopsies from patients with primary brain tumors were compared to results from an 
analysis of tumor-free brain tissue.  Statistically significant associations were observed 
between the presence of brain tumors and the concentrations of silicon, magnesium, and 
calcium (Hadfield et al. 1998).  However, further research using a larger sample size is 
needed to determine whether exposure to these elements plays a role in the development 
of brain cancer. Other occupations that may be associated with elevated risks include 
workers in certain health professions (e.g., pathologists and physicians), agricultural 
workers, workers in the nuclear industry, and workers in the rubber industry, although 
specific exposures have not been established (Preston-Martin and Mack 1996).  Studies 
investigating the possible association between occupational exposure of parents (in 
particular, paper or pulp-mill, aircraft, rubber, metal, construction, and electric workers) 
and the onset of brain tumors in their children have provided inconsistent results 
(Preston-Martin and Mack 1996). 
The association between the development of brain cancer and nitrites and other N-nitroso 
compounds, among the most potent of carcinogens, has been heavily researched.  N-
nitroso compounds have been found in tobacco smoke, cosmetics, automobile interiors, 
and cured meats.  A study concluded that an increased risk of pediatric brain tumor may 
be associated with high levels of nitrite intake from maternal cured meat consumption 
during pregnancy (Pogoda and Preston-Martin 2001).  However, the role of nitrites and 
cured meats in the development of brain cancer remains controversial (Blot et al. 1999; 
Bunin 2000). Because most people have continuous, low level exposure to N-nitroso 
Source: Community Assessment Program, Bureau of Environmental Health, Massachusetts Department of Public Health 
May, 2006 
303 
Risk Factor Information for Brain and Central Nervous System Cancers 
compounds throughout their lives, further studies, especially cohort studies, are needed to 
determine if this exposure leads to an increased risk of brain tumors (Preston-Martin 
1996). 
Injury to the head has been suggested as a possible risk factor for later development of 
brain tumors but most researchers agree that there is no conclusive evidence for an 
association (ACS 2006a). Head trauma is most strongly associated with the development 
of meningiomas compared with other types of brain tumor.  Several studies have found 
an increased risk in women with histories of head trauma; in men who boxed; and in men 
with a previous history of head injuries.  Gliomas are the most common type of childhood 
brain tumor and have been positively associated with trauma at birth (e.g., Cesarean 
section, prolonged labor, and forceps delivery).  However, other studies have found no 
association (Preston-Martin and Mack 1996). 
In addition, rare cases of brain and spinal cord cancer run in some families.  Brain tumors 
in some persons are associated with genetic disorders such as neurofibromatosis types I 
and II, Li-Fraumeni syndrome, and tuberous sclerosis.  Neurofibromatosis type I (von 
Recklinghausen’s disease) is the most common inherited cause of brain or spinal cord 
tumors and occurs in about one out of every 3,000 people (Preston-Martin and Mack 
1996). The disease may be associated with optic gliomas or other gliomas of the brain or 
spinal cord (ACS 2006b).  Of those afflicted with the disease, about 5-10% will develop a 
central nervous system tumor (Preston-Martin and Mack 1996).  In addition, von Hippell-
Lindau disease is associated with an inherited tendency to develop blood vessel tumors of 
the cerebellum (ACS 2006b).  However, malignant (or cancerous) brain tumors are rare 
in these disorders; inherited syndromes that predispose individuals to brain tumors appear 
to be present in fewer than 5% of brain tumor patients (Preston-Martin and Mack 1996). 
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Breast cancer is the most frequently diagnosed cancer among women in both the United 
States and in Massachusetts.  According to the American Cancer Society, female breast 
cancer incidence in Massachusetts is the fourth highest among all states (ACS 2006).  
The breast cancer incidence rate has been rising in the United States since the 1980s.  
However, the rate of increase slowed in the 1990s compared to the 1980s.  Most recently, 
breast cancer incidence has only increased in women over 50 years of age (ACS 2006a).  
A similar trend occurred in Massachusetts and there was even a significant decrease in 
incidence (2.5%) between 1998 and 2002 (MCR 2005). 
In the year 2006, approximately 212,920 women in the U.S. will be diagnosed with breast 
cancer (ACS 2006). Worldwide, female breast cancer incidence has increased, mainly 
among women in older age groups whose proportion of the population continues to 
increase as well (van Dijck et al. 1997).  A woman’s risk for developing breast cancer can 
change over time due to many factors, some of which are dependent upon the well-
established risk factors for breast cancer.  These include increased age, an early age at 
menarche (menstruation) and/or late age at menopause, late age at first full-term 
pregnancy, family history of breast cancer, and high levels of estrogen.  Other risk factors 
that may contribute to a woman’s risk include benign breast disease and lifestyle factors 
such as diet, body weight, lack of physical activity, consumption of alcohol, and exposure 
to cigarette smoke. Data on whether one’s risk may be affected by exposure to 
environmental chemicals or radiation remains inconclusive.  However, studies are 
continuing to investigate these factors and their relationship to breast cancer.   
Family history of breast cancer does affect one’s risk for developing the disease.  
Epidemiological studies have found that females who have a first-degree relative with 
premenopausal breast cancer experience a three-fold greater risk.  However, no increase 
in risk has been found for females with a first degree relative with postmenopausal breast 
cancer. If women have a first-degree relative with bilateral breast cancer (cancer in both 
breasts) at any age, then their risk increases five-fold.  Moreover, if a woman has a 
mother, sister or daughter with bilateral premenopausal breast cancer, their risk increases 
nine-fold (Broeders and Verbeek 1997).  In addition, twins have a higher risk of breast 
cancer compared to non-twins (Weiss et al. 1997).  
Source: Community Assessment Program, Bureau of Environmental Health, Massachusetts Department of Public Health 
May 2006 
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A personal history of benign breast disease is also associated with development of 
invasive breast cancer. Chronic cystic or fibrocystic disease is the most commonly 
diagnosed benign breast disease. Women with cystic breast disease experience a 2-3 fold 
increase in risk for breast cancer (Henderson et al. 1996). 
According to recent studies, approximately 5 to 10% of breast cancers can be attributed 
to inherited mutations in breast cancer-related genes.  Most of these mutations occur in 
the BRCA1 and BRCA2 genes.  Women who inherit BRCA1 or BRCA2 gene mutations 
have up to an 80% chance of developing breast cancer at some point in their lifetimes 
(ACS 2006). 
Cumulative exposure of the breast tissue to estrogen and progesterone hormones may be 
one of the greatest contributors to risk for breast cancer (Henderson et al. 1996).  
Researchers suspect that early exposures to a high level of estrogen, even during fetal 
development, may add to one’s risk of developing breast cancer later in life.  Other 
studies have found that factors associated with increased levels of estrogen (i.e., neonatal 
jaundice, severe prematurity, and being a fraternal twin) may contribute to an elevated 
risk of developing breast cancer (Ekbom et al. 1997).  Conversely, studies have revealed 
that women whose mothers experienced toxemia during pregnancy (a condition 
associated with low levels of estrogen) had a significantly reduced risk of developing 
breast cancer. Use of estrogen replacement therapy is another factor associated with 
increased hormone levels and it has been found to confer a modest (less than two-fold) 
elevation in risk when used for 10-15 years or longer (Kelsey 1993).  Similarly, more 
recent use of oral contraceptives or use for 12 years or longer seems to confer a modest 
increase in risk for bilateral breast cancer in premenopausal women (Ursin et al. 1998). 
Cumulative lifetime exposure to estrogen may also be increased by certain reproductive 
events during one’s life. Women who experience menarche at an early age (before age 
12) have a 20% increase in risk compared to women who experience menarche at 14 
years of age or older (Broeders and Verbeek 1997; Harris et al. 1992; ACS 2006).  
Women who experience menopause at a later age (after the age of 55) have a slightly 
elevated risk for developing the disease (ACS 2006). Furthermore, the increased 
Source: Community Assessment Program, Bureau of Environmental Health, Massachusetts Department of Public Health 
May 2006 
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cumulative exposure from the combined effect of early menarche and late menopause has 
been associated with elevated risk (Lipworth 1995).  In fact, women who have been 
actively menstruating for 40 or more years are thought to have twice the risk of 
developing breast cancer than women with 30 years or less of menstrual activity 
(Henderson et al. 1996). Other reproductive events have also shown a linear association 
with risk for breast cancer (Wohlfahrt 2001).  Specifically, women who gave birth for the 
first time before age 18 experience one-third the risk of women who have carried their 
first full-term pregnancy after age 30 (Boyle and Leake 1988). The protective effect of 
earlier first full-term pregnancy appears to result from the reduced effect of circulating 
hormones on breast tissue after pregnancy (Kelsey 1993).  
Diet, and particularly fat intake, is another factor suggested to increase a woman’s risk 
for breast cancer. Currently, a hypothesis exists that the type of fat in a woman's diet 
may be more important than her total fat intake (ACS 2006; Wynder et al. 1997).  
Monounsaturated fats (olive oil and canola oil) are associated with lower risk while 
polyunsaturated (corn oil, tub margarine) and saturated fats (from animal sources) are 
linked to an elevated risk. However, when factoring in a woman’s weight with her 
dietary intake, the effect on risk becomes less clear (ACS 1998).  Many studies indicate 
that a heavy body weight elevates the risk for breast cancer in postmenopausal women 
(Kelsey 1993), probably due to fat tissue as the principal source of estrogen after 
menopause (McTiernan 1997).  Therefore, regular physical activity and a reduced body 
weight may decrease one’s exposure to the hormones believed to play an important role 
in increasing breast cancer risk (Thune et al. 1997).  
Aside from diet, regular alcohol consumption has also been associated with increased risk 
for breast cancer (Swanson et al. 1997; ACS 2006).  Women who consumed one 
alcoholic beverage per day experienced a slight increase in risk (approximately 10%) 
compared to non-drinkers, however those who consumed 2 to 5 drinks per day 
experienced a 1.5 times increased risk (Ellison et al. 2001; ACS 2006).  Despite this 
association, the effects of alcohol on estrogen metabolism have not been fully 
investigated (Swanson et al. 1997). 
Source: Community Assessment Program, Bureau of Environmental Health, Massachusetts Department of Public Health 
May 2006 
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To date, no specific environmental factor, other than ionizing radiation, has been 
identified as a cause of breast cancer.  The role of cigarette smoking in the development 
of breast cancer is unclear. Some studies suggest a relationship between passive smoking 
and increased risk for breast cancer; however, confirming this relationship has been 
difficult due to the lack of consistent results from studies investigating first-hand smoke 
exposure (Laden and Hunter 1998). 
Studies on exposure to high doses of ionizing radiation demonstrate a strong association 
with breast cancer risk. These studies have been conducted in atomic bomb survivors 
from Japan as well as patients that have been subjected to radiotherapy in treatments for 
other conditions (i.e., Hodgkin’s Disease and non-Hodgkin’s Lymphoma) (ACS 2006).  
However, it has not been shown that radiation exposures experienced by the general 
public or people living in areas of high radiation levels from industrial accidents or 
nuclear activities are related to an increase in breast cancer risk (Laden and Hunter 1998). 
Investigations of electromagnetic field exposures in relation to breast cancer have been 
inconclusive as well. 
Occupational exposures associated with increased risk for breast cancer have not been 
clearly identified. Experimental data suggest that exposure to certain organic solvents 
and other chemicals (e.g., benzene, trichloropropane, vinyl chloride, polycyclic aromatic 
hydrocarbons (PAHs)) causes the formation of breast tumors in animals and thus may 
contribute to such tumors in humans (Goldberg and Labreche 1996).  In particular, a 
significantly elevated risk for breast cancer was found for young women employed in 
solvent-using industries (Hansen 1999). Although risk for premenopausal breast cancer 
may be elevated in studies on occupational exposures to a combination of chemicals, 
including benzene and PAHs, other studies on cigarette smoke (a source of both 
chemicals) and breast cancer have not shown an associated risk (Petralia et al. 1999).  
Hence, although study findings have yielded conflicting results, evidence does exist to 
warrant further investigation into the associations. 
Other occupational and environmental exposures have been suggested to confer an 
increased risk for breast cancer in women, such as exposure to polychlorinated biphenyls 
Source: Community Assessment Program, Bureau of Environmental Health, Massachusetts Department of Public Health 
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(PCBs), chlorinated hydrocarbon pesticides (DDT and DDE), and other endocrine-
disrupting chemicals.  Because these compounds affect the body’s estrogen production 
and metabolism, they can contribute to the development and growth of breast tumors 
(Davis et al. 1997; Holford et al. 2000; Laden and Hunter 1998). However, studies on this 
association have yielded inconsistent results and follow-up studies are ongoing to further 
investigate any causal relationship (Safe 2000). 
When considering a possible relationship between any exposure and the development of 
cancer, it is important to consider the latency period.  Latency refers to the time between 
exposure to a causative factor and the development of the disease outcome, in this case 
breast cancer. It has been reported that there is an 8 to 15 year latency period for breast 
cancer (Petralia et al. 1999; Aschengrau et al. 1998; Lewis-Michl et al. 1996).  This 
means that if an environmental exposure were related to breast cancer, it may take 8 to 15 
years after exposure to a causative factor for breast cancer to develop. 
Socioeconomic differences in breast cancer incidence may be a result of current 
screening participation rates.  Currently, women of higher socioeconomic status (SES) 
have higher screening rates, which may result in more of the cases being detected in these 
women.  However, women of higher SES may also have an increased risk for developing 
the disease due to different reproductive patterns (i.e., parity, age at first full-term birth, 
and age at menarche).  Although women of lower SES show lower incidence rates of 
breast cancer, their cancers tend to be diagnosed at a later stage (Segnan 1997).  Hence, 
rates for their cancers may appear lower due to the lack of screening participation rather 
than a decreased risk for the disease. Moreover, it is likely that SES is not in itself the 
associated risk factor for breast cancer.  Rather, SES probably represents different 
patterns of reproductive choices, occupational backgrounds, environmental exposures, 
and lifestyle factors (i.e., diet, physical activity, cultural practices) (Henderson et al. 
1996). 
Despite the vast number of studies on the causation of breast cancer, known factors are 
estimated to account for less than half of breast cancers in the general population 
Source: Community Assessment Program, Bureau of Environmental Health, Massachusetts Department of Public Health 
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(Madigan et al. 1995). Researchers are continuing to examine potential risks for 
developing breast cancer, especially environmental factors.   
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According to the American Cancer Society, approximately 21,260 Americans (13,000 
men and 8,260 women) will be diagnosed with stomach cancer in 2007 (ACS 2007).      
Approximately 90-95% of these cases will suffer from an adenocarcinoma, a cancer 
which develops within the epithelial cells of the stomach’s innermost lining, the mucosa.  
Less common types of stomach cancer include lymphoma of mucosa-associated 
lymphoid tissue, gastrointestinal stromal tumors, and carcinoid tumors.  The majority of 
stomach cancers tend to occur in people over the age of 50, with most diagnoses 
happening after the age of 70. This type of cancer is more common in men than women, 
and is found more frequently among Asian, Pacific Islander, Hispanic, and African 
populations than in non-Hispanic white Americans (Shibata and Parsonnet 1996).      
Stomach, or gastric, cancer is an increasingly rare form of cancer in the United States.  It 
was once the leading cause of cancer deaths in the United States, yet since the mid-
twentieth century, its prevalence has been drastically reduced.  It is currently the seventh-
leading cause of cancer deaths in the U.S. (NCI 2007).  This reduction can be attributed 
to many factors, including increased refrigeration of foods and decreased consumption of 
salted and smoked meats.  Some physicians feel that it can also be attributed to the 
widespread use of antibiotics to kill infections, such as h. pylori, which may increase 
one’s risk for developing stomach cancer (NCI 2007).  Stomach cancer is a much larger 
problem globally, particularly in underdeveloped nations.  It is the second-leading cause 
of cancer deaths worldwide, with approximately 700,000 deaths in 2002 (ACS 2007). 
While the exact cause of stomach cancer is unknown, many risk factors for the disease 
have been identified. Risk factors for stomach cancer include h. pylori infection, which 
can lead to chronic atrophic gastritis, a possible pre-cancerous change in the lining of the 
stomach (ACS 2007).  H. pylori infection can also lead to the formation of peptic ulcers.  
The majority of people who carry the h. pylori bacterium do not develop cancer, but it 
has been confirmed as increasing one’s risk for stomach cancer.  This risk may be 
increased when someone is taking medicines known as histamine antagonists and proton-
pump inhibitors (PPIs) to inhibit acid production in the stomach, which may, in turn, 
allow for increased bacterial growth. Many researchers now suggest eradication of h. 
pylori before beginning these medicines (Shibata and Parsonnet 1996).   
Source: Community Assessment Program, Bureau of Environmental Health, Massachusetts Department of Public Health 
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Dietary factors may also affect one’s risk for developing stomach cancer.  Increased risk 
is associated with higher levels of consumption of smoked and salted fish and meats and 
pickled vegetables. Diets high in whole grains, fruits, and vegetables which contain 
vitamins A and C have been shown to reduce the risk of stomach cancer.  Recent studies 
have also found that certain chemicals in barbequed and grilled muscle meats may 
increase cancer risk. These chemicals, known as heterocyclic amines (HCAs) are formed 
when muscle meats (beef, pork, fowl, and fish) are cooked at high temperatures for an 
extended period of time (to a medium-well or well-done temperature).  Frying, boiling, 
and grilling cause the formation of most HCAs, but this effect can be somewhat negated 
by microwaving meats before cooking them. 
Other notable causes for increased risk for stomach cancer include tobacco use.  Smoking 
increases risk for cancers of the upper portion of the stomach closest to the esophagus, 
and the rate of stomach cancer is approximately doubled for smokers over nonsmokers 
(ACS 2007). Obesity has also emerged as a factor contributing to cancer in this area of 
the stomach.   
Medical and familial history may also contribute to one’s risk for developing stomach 
cancer. People who have had previous stomach surgery, such as a gastric bypass or 
removal of an ulcer, have an increased risk for stomach cancer due to a higher 
concentration of bacteria in the stomach and potential for reflux of bile from the small 
intestine, as well as a change in the pH balance of the stomach.  According to the 
American Cancer Society, people with Type A blood have a higher risk for stomach 
cancer, for unknown reasons (ACS 2007). Pernicious anemia is also noted as a risk 
factor for stomach cancer.  Inherited genetic disorders, such as hereditary nonpolyposis 
colorectal cancer and familial adenomatous polyposis cause a slightly increased risk for 
stomach cancer in individuals affected by the inherited gene mutations.  Also, people 
with several first-degree relatives with stomach cancer are more likely to develop the 
disease. 
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